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Background: Tumour necrosis factor (TNF)-α inhibitors (anti-TNFs) are typically used when the
inflammatory rheumatologic diseases ankylosing spondylitis (AS) and non-radiographic axial
spondyloarthritis (nr-AxSpA) have not responded adequately to conventional therapy. Current National
Institute for Health and Care Excellence (NICE) guidance recommends treatment with adalimumab,
etanercept and golimumab in adults with active (severe) AS only if certain criteria are fulfilled but it does
not recommend infliximab for AS. Anti-TNFs for patients with nr-AxSpA have not previously been
appraised by NICE.
Objective: To determine the clinical effectiveness, safety and cost-effectiveness within the NHS of
adalimumab, certolizumab pegol, etanercept, golimumab and infliximab, within their licensed indications,
for the treatment of severe active AS or severe nr-AxSpA (but with objective signs of inflammation).
Design: Systematic review and economic model.
Data sources: Fifteen databases were searched for relevant studies in July 2014.
Review methods: Clinical effectiveness data from randomised controlled trials (RCTs) were synthesised
using Bayesian network meta-analysis methods. Results from other studies were summarised narratively.
Only full economic evaluations that compared two or more options and considered both costs and
consequences were included in the systematic review of cost-effectiveness studies. The differences in the
approaches and assumptions used across the studies, and also those in the manufacturer’s submissions,
were examined in order to explain any discrepancies in the findings and to identify key areas of
uncertainty. A de novo decision model was developed with a generalised framework for evidence synthesis
that pooled change in disease activity (BASDAI and BASDAI 50) and simultaneously synthesised
information on function (BASFI) to determine the long-term quality-adjusted life-year and cost burden of
the disease in the economic model. The decision model was developed in accordance with the NICE
reference case. The model has a lifetime horizon (60 years) and considers costs from the perspective of the
NHS and personal social services. Health effects were expressed in terms of quality-adjusted life-years.
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Results: In total, 28 eligible RCTs were identified and 26 were placebo controlled (mostly up to 12 weeks);
17 extended into open-label active treatment-only phases. Most RCTs were judged to have a low risk of
bias overall. In both AS and nr-AxSpA populations, anti-TNFs produced clinically important benefits to
patients in terms of improving function and reducing disease activity; for AS, the relative risks for ASAS
40 ranged from 2.53 to 3.42. The efficacy estimates were consistently slightly smaller for nr-AxSpA than
for AS. Statistical (and clinical) heterogeneity was more apparent in the nr-AxSpA analyses than in the AS
analyses; both the reliability of the nr-AxSpA meta-analysis results and their true relevance to patients seen
in clinical practice are questionable. In AS, anti-TNFs are approximately equally effective. Effectiveness
appears to be maintained over time, with around 50% of patients still responding at 2 years. Evidence for
an effect of anti-TNFs delaying disease progression was limited; results from ongoing long-term studies
should help to clarify this issue. Sequential treatment with anti-TNFs can be worthwhile but the drug
survival response rates and benefits are reduced with second and third anti-TNFs. The de novo model,
which addressed many of the issues of earlier evaluations, generated incremental cost-effectiveness ratios
ranging from £19,240 to £66,529 depending on anti-TNF and modelling assumptions.
Conclusions: In both AS and nr-AxSpA populations anti-TNFs are clinically effective, although more so
in AS than in nr-AxSpA. Anti-TNFs may be an effective use of NHS resources depending on which
assumptions are considered appropriate.
Future work recommendations: Randomised trials are needed to identify the nr-AxSpA population who
will benefit the most from anti-TNFs.
Study registration: This study is registered as PROSPERO CRD42014010182.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Adverse effect An abnormal or harmful effect caused by, and attributable to, exposure to a chemical
(e.g. a drug), which is indicated by some result such as death, a physical symptom or visible illness. An
effect may be classed as adverse if it causes functional or anatomical damage, causes irreversible change in
the homeostasis of the organism or increases the susceptibility of the organism to other chemical or
biological stress.
Ankylosing spondylitis A rheumatic disease that affects the spine and may lead to some degree of
stiffness in the back. As the inflammation reduces and healing takes place, bone grows out from both
sides of the vertebrae and may join the two together; this stiffening is called ankylosis. If definite, changes
to spinal and/or pelvic joints are present on plain radiographs.
Articular Of or relating to the joints.
Axial spondyloarthritis Refers to a form of arthritis in which the predominant symptom is back pain due
to inflammation of spinal and/or pelvic joints. If definite changes on plain radiographs are present, the
disease is classified as ankylosing spondylitis, but if they are absent the disease is classified as
non-radiographic axial spondyloarthritis. Further tests may indicate that in some patients it is very likely
that non-radiographic axial spondyloarthritis is ankylosing spondylitis, only at an earlier stage of disease.
Between-study variance Between-study variance is a measure of statistical heterogeneity that depends
on the scale of the outcome measured. It represents the variation in reported study effects over and above
the variation expected given the within-study variation.
Biologic therapies (synonym: biological) Medical preparations derived from living organisms. Includes
anti-tumour necrosis factor drugs and other new drugs which target pathologically active T cells.
Biosimilar An imitation biological medical product (such as an anti-tumour necrosis factor) usually
marketed by a different manufacturer to the original biological product, once a patent has expired.
The biosimilar should be similar to the original licensed product in terms of safety and efficacy.
C-reactive protein Concentrations of this protein in the blood can be measured as a test of inflammation
or disease activity, for example in ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Corticosteroid A synthetic hormone, similar to that produced naturally by the adrenal glands, which is
available in pill, topical and injectable forms.
Cost–benefit analysis An economic analysis that converts the effects or consequences of interventions
into the same monetary terms as the costs and compares them using a measure of net benefit or a
cost–benefit ratio.
Cost-effectiveness analysis An economic analysis that expresses the effects or consequences of
interventions on a single dimension. This would normally be expressed in ‘natural’ units (e.g. cases cured,
life-years gained or additional strokes prevented). The difference between interventions in terms of costs
and effects is typically expressed as an incremental cost-effectiveness ratio (e.g. the incremental cost per
life-year gained).
Cost–utility analysis The same as a cost-effectiveness analysis but the effects or consequences of
interventions are expressed in generic units of health gain, usually quality-adjusted life-years.
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Credible interval In Bayesian statistics, a credible interval is a posterior probability interval estimation
which incorporates problem-specific contextual information from the prior distribution. Credible intervals
are used for the purposes similar to those of confidence intervals in frequentist statistics.
Disease-modifying antirheumatic drugs Disease-modifying antirheumatic drugs are drugs capable of
modifying the progression of rheumatic disease. The term is, however, applied to what are now
considered to be traditional disease-modifying drugs, in particular sulphasalazine, methotrexate and
ciclosporin, as well as azathioprine, cyclophosphamide, antimalarials, penicillamine and gold. The newer
agent leflunomide may be included as a disease-modifying antirheumatic drug. The biologics such as
etanercept and infliximab are not generally referred to as disease-modifying antirheumatic drugs.
Erythrocyte sedimentation rate One of the tests designed to measure the degree of inflammation.
Fixed-effect model A statistical model that stipulates that the units under analysis (e.g. people in a trial
or study in a meta-analysis) are the ones of interest, and thus constitute the entire population of units.
Only within-study variation is taken to influence the uncertainty of results (as reflected in the confidence
interval) of a meta-analysis using a fixed-effect model.
Heterogeneity In systematic reviews heterogeneity refers to variability or differences between studies in
the estimates of effects. A distinction is sometimes made between ‘statistical heterogeneity’ (differences
in the reported effects), ‘methodological heterogeneity’ (differences in study design) and ‘clinical
heterogeneity’ (differences between studies in key characteristics of the participants, interventions or
outcome measures).
I-squared (I2) A measure of ‘statistical heterogeneity’ (differences in the reported effects). It varies
between 0 and 1, for which 0 indicates that the differences in reported effects are entirely consistent with
the within-study uncertainty and 1 indicates that the differences in reported effects are entirely explained
by study characteristics that vary across studies.
Intention to treat An intention-to-treat analysis is one in which all the participants in a trial are analysed
according to the intervention to which they were allocated, whether or not they received it.
Monoclonal antibody An antibody produced in a laboratory from a single clone that recognises only
one antigen.
Non-radiographic axial spondyloarthritis Axial spondyloarthritis for which definite changes to spinal
and/or pelvic joints on plain radiographs are not present. Further tests may indicate that in some patients it
is very likely that non-radiographic axial spondyloarthritis ankylosing spondylitis, only at an earlier stage
of disease.
Non-steroidal anti-inflammatory drugs Consists of a large range of drugs of the aspirin family,
prescribed for different kinds of arthritis which reduce inflammation and control pain, swelling
and stiffness.
Open-label study A type of study in which both participants and researchers know which treatment is
being administered.
Placebo An inactive substance or procedure administered to a patient, usually to compare its effects with
those of a real drug or other intervention but sometimes for the psychological benefit to the patient
through a belief that s/he is receiving treatment.
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Quality-adjusted life-year An index of health gain in which survival duration is weighted or adjusted by
the patient’s quality of life during the survival period. Quality-adjusted life-years have the advantage of
incorporating changes in both quantity (mortality) and quality (morbidity) of life.
Quality of life A concept incorporating all the factors that might impact on an individual’s life, including
factors such as the absence of disease or infirmity as well as other factors which might affect their physical,
mental and social well-being.
Random-effects model A statistical model sometimes used in meta-analysis in which both within-study
sampling error (variance) and between-studies variation are included in the assessment of the uncertainty
(confidence interval) of the results of a meta-analysis.
Randomised controlled trial (synonym: randomised clinical trial) An experiment in which
investigators randomly allocate eligible people into intervention groups to receive, or not to receive, one or
more interventions that are being compared.
Relative risk (synonym: risk ratio) The ratio of risk in the intervention group to the risk in the control
group. The risk (proportion, probability or rate) is the ratio of people with an event in a group to the total
in the group. A relative risk of one indicates no difference between comparison groups. For undesirable
outcomes, a relative risk that is less than one indicates that the intervention was effective in reducing the
risk of that outcome.
Sensitivity analysis An analysis used to determine how sensitive the results of a study or systematic
review are to changes in how it was done. Sensitivity analyses are used to assess how robust the results
are to uncertain decisions or assumptions about the data and the methods that were used.
Tumour necrosis factor One of the cytokines, or messengers, known to be involved in the process of
systemic inflammation.
Weighted mean difference (in meta-analysis) A method of meta-analysis used to combine measures
on continuous scales, where the mean, standard deviation and sample size in each group are known.
The weight given to each study is determined by the precision of its estimate of effect and is equal to the
inverse of the variance. This method assumes that all of the trials have measured the outcome on
the same scale.
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AE adverse event
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NRI non-responder imputation
NSAID non-steroidal anti-inflammatory
drug
OASIS Outcomes in Ankylosing Spondylitis
International Study
OMERACT Outcome Measures in Rheumatology
OR odds ratio
PAS patient access scheme
PCS physical component summary
PSA probabilistic sensitivity analysis
PSS personal social services
PSSRU Personal Social Services Research
Unit
QALY quality-adjusted life-year
RCT randomised controlled trial
RLDQ Revised Leeds Disability
Questionnaire
SAE serious adverse event
SD standard deviation
SE standard error
SF-36 Short Form questionnaire-36 items
SIRAS Scotland and Ireland Registry for
Ankylosing Spondylitis
SMART St Mary RheumaToid Arthritis
SMR standardised mortality ratio
SpA spondyloarthritis
TA technology appraisal
TNF tumour necrosis factor
VAS visual analogue scale
Note
This monograph is based on the Technology Assessment Report produced for NICE. The full
report contained a considerable number of data that were deemed academic-in-confidence
and commercial-in-confidence. The full report was used by the Appraisal Committee at NICE
in their deliberations. The full report with each piece of academic-in-confidence data and
commercial-in-confidence removed and replaced by the statement ‘academic-in-confidence
and/or commercial-in-confidence information (or data) removed’ is available on the NICE
website: www.nice.org.uk.
The present monograph presents as full a version of the report as is possible while retaining
readability, but some sections, sentences, tables and figures have been removed. Readers
should bear in mind that the discussion, conclusions and implications for practice and research
are based on all the data considered in the original full NICE report.
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Plain English summary
Axial spondyloarthritis is a progressive form of arthritis which causes severe back pain because ofinflammation of spinal and/or pelvic joints. If definite changes on plain radiographs are present, the
disease is classified as ankylosing spondylitis (AS), but if they are absent the disease is classified as
non-radiographic axial spondyloarthritis (nr-AxSpA). Usual therapy includes anti-inflammatory drugs,
exercise and physiotherapy. Tumour necrosis factor inhibitors (also known as anti-TNFs) are typically used
when the disease has not responded adequately to this.
This project systematically reviewed the evidence on five anti-TNF treatments (adalimumab, certolizumab
pegol, etanercept, golimumab and infliximab), for treating severe active AS or nr-AxSpA. The objective of
this project was to assess the benefits and adverse effects of these anti-TNFs and to run an economic
model using both response to treatment and the impact of disease progression, to evaluate if their use to
treat these patients is a cost-effective use of NHS resources.
In total, 28 eligible randomised controlled trials were identified and 26 were placebo controlled (most of
the trials which used a placebo did so for no more than 12 weeks); the majority were good quality and 17
were extended into active treatment-only phases. In both AS and nr-AxSpA populations, anti-TNFs
produced clinically important benefits to patients in terms of improving function and reducing disease
activity. The benefit of treatment was consistently slightly smaller for nr-AxSpA than for AS. In AS the
different anti-TNFs are approximately equally effective and effectiveness appears to be maintained over
time. The results of the economic model indicated that anti-TNFs may be an effective use of NHS resources
depending on which assumptions are considered appropriate.
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Scientific summary
Background
Spondyloarthritis encompasses a heterogeneous group of inflammatory rheumatologic diseases.
Spondyloarthritis can be categorised as having predominantly axial or peripheral involvement. In people
with axial spondyloarthritis (axSpA), the predominant symptoms are back pain and stiffness developed
before age 45 years. For axSpA patients to be classified as having ankylosing spondylitis (AS), imaging
evidence of joint damage using radiography is required. Patients with non-radiographic axial
spondyloarthritis (nr-AxSpA) may, or may not, have signs of sacroiliac joint inflammation on a magnetic
resonance image. The use of magnetic resonance imaging allows for earlier detection of axSpA, as joint
damage may not become evident on radiographs for many years. Progression of axSpA is difficult
to predict.
Tumour necrosis factor (TNF)-α inhibitors (anti-TNFs) are typically used when the disease has not responded
adequately to conventional therapy. Current National Institute for Health and Care Excellence (NICE)
guidance recommends treatment with adalimumab, etanercept and golimumab in adults with active
(severe) AS only if certain criteria are fulfilled, but it does not recommend infliximab for AS. Anti-TNFs for
patients with nr-AxSpA have not previously been appraised by NICE.
Objectives
To determine the clinical effectiveness, safety and cost-effectiveness within the NHS of adalimumab,
certolizumab pegol, etanercept, golimumab and infliximab, within their respective licensed indications,
for the treatment of severe active AS or severe nr-AxSpA (but with objective signs of inflammation).
Methods
For the systematic review of clinical efficacy, randomised controlled trials (RCTs) were eligible, including any
open-label extensions. Adverse events data were sought from existing reviews of anti-TNFs used in any
disease and from other appropriately large studies. For studies of natural history, long-term effectiveness,
adherence and sequential use, published analyses based on large and long-term data sets (registry data)
were eligible. Eligible studies were of adults with either severe active AS or severe nr-AxSpA but with
objective signs of inflammation. The treatments of interest were adalimumab, certolizumab pegol,
etanercept, golimumab, infliximab or any of their biosimilars. The relevant comparators were conventional
management strategies (either with or without placebo) and alternative anti-TNFs. Key outcomes included
multiple domain response criteria [such as Assessment in Ankylosing Spondylitis (ASAS) 40] and measures of
disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] and function [Bath Ankylosing
Spondylitis Functional Index (BASFI)].
Fifteen databases were searched for relevant studies in July 2014. Clinical effectiveness data from RCTs
were synthesised using Bayesian network meta-analysis methods. Sensitivity analyses were performed in
which trials at risk of bias were excluded. Results from other studies were summarised narratively.
A systematic review of cost-effectiveness studies was undertaken to assess the relevance of existing data
from the perspective of the NHS. Three databases were searched. Only full economic evaluations that
compared two or more options and considered both costs and consequences were included. The
DOI: 10.3310/hta20090 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 9
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxxiii
differences in the approaches and assumptions used across the studies were examined in order to explain
any discrepancies in the findings and to identify key areas of uncertainty. A separate review of the
manufacturer’s submissions was also undertaken and the findings were compared with those found in the
review of previously published studies.
The findings from the clinical effectiveness and cost-effectiveness reviews were used to inform the
development of a de-novo decision model to assess the cost-effectiveness of the alternative anti-TNFs in
accordance with their licences for the separate indications. We developed a generalised framework for
evidence synthesis that pools evidence on the change in BASDAI by considering those studies that report
this measure directly and also those that report the proportion of patients achieving a BASDAI 50 response
(a ≥ 50% improvement in BASDAI score). We expressed BASDAI 50 as a function of the absolute change
in BASDAI and we used this relationship in the extended synthesis. We also aimed to simultaneously
synthesise information on BASFI (function) score, a measure that is used together with the BASDAI score to
determine the long-term quality-adjusted life-year (QALY) and cost burden of the disease in the economic
model. The decision model was a cohort model structured as a modified decision tree tracking response at
12 weeks and treatment failure at subsequent time points within the time horizon. These events determine
changes in BASDAI and BASFI scores, which are further used to define costs and utilities. The model
considers the independent effects on BASFI as a result of disease activity (BASDAI) and the extent and
progression of radiographic disease (as measured by the modified Stoke Ankylosing Spondylitis Spinal
Score). The model was developed in accordance with the NICE reference case. The model has a lifetime
horizon (60 years) and considers costs from the perspective of the NHS and personal social services. Health
effects were expressed in terms of QALYs.
Results
Clinical efficacy from randomised controlled trials
Twenty-eight eligible RCTs were identified, with 24 being suitable for data synthesis. All but seven of the
trials were extended into open-label active treatment-only phases. Most RCTs were judged to have a low
risk of bias overall.
For the AS population, the 10- to 16-week data showed consistent effects across the different anti-TNFs
when compared with placebo: for ASAS 20 the pooled relative risks ranged from 1.80 (certolizumab
pegol) to 2.45 (infliximab); for the ASAS 40 data the relative risks ranged from 2.53 (certolizumab pegol)
to 3.42 (adalimumab) and for BASDAI 50 the relative risks ranged from 3.16 (adalimumab) to 4.86
(infliximab). Adalimumab, certolizumab pegol, etanercept and infliximab produced statistically significant
and clinically important reductions in disease activity, with BASDAI reductions ranging from 1.46 units
(certolizumab pegol) to 2.28 units (infliximab), and function, with BASFI reductions ranging from 1.1 units
(certolizumab pegol) to 2.16 units (infliximab).
When analysed as a class, anti-TNFs were statistically significantly more likely than placebo to result in
patients with AS achieving an ASAS 20 response (relative risk 2.21), an ASAS 40 response (relative risk
3.06), and a BASDAI 50 response (relative risk 3.37). They also produced statistically significant
improvements (calculated using mean difference in change from baseline) in disease activity (BASDAI mean
difference –1.66 units) and in function (BASFI mean difference –1.38 units). There was little evidence of
statistical heterogeneity for the key outcomes (ASAS outcomes, BASFI, BASDAI and BASDAI 50) but
substantial heterogeneity was seen for other outcomes. Results of the sensitivity analyses performed for
the AS studies were very similar to the main analyses.
For the nr-AxSpA population, five RCTs were included. When anti-TNFs were considered as a class,
statistically significant improvements were found for ASAS 20 (relative risk 1.65); ASAS 40 (relative risk
2.74); BASDAI 50 (relative risk 2.31); BASDAI (mean difference –1.32 units); and BASFI (mean difference
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–0.99 units). For the disease activity, function and responder outcomes, these common class efficacy
estimates were consistently slightly smaller for nr-AxSpA than for AS, most noticeably for BASFI and
BASDAI 50. Statistical heterogeneity (when such estimates could be calculated) was apparent in the
nr-AxSpA analyses.
Long-term efficacy
For AS, across all the anti-TNFs, after around 2 years and 5 years of treatment, roughly half of patients
were still achieving a good level of response to therapy. However, the long-term studies produced less
reliable data than the RCTs. Fewer studies were available of nr-AxSpA patients, although the results were
broadly similar to those of the AS studies.
Evidence for an effect of anti-TNFs on radiographic disease progression was limited; the relatively
short-term follow-up available to date and the insensitivity of radiography as an imaging tool precluded
the drawing of firm conclusions regarding the role of anti-TNFs in preventing or delaying the progression
of AS. There are some data to suggest an identifiable benefit from around 4 years, but results from
ongoing long-term studies should help to clarify this issue.
Registry data demonstrate that around 60% of patients with AS treated with a first anti-TNF will still be on
treatment at 2 years. Sequential treatment with anti-TNFs can be worthwhile but the drug survival
response rates and benefits are reduced with second and third anti-TNFs, with the proportion of BASDAI
50 responders falling approximately 10% with each subsequent anti-TNF and the median BASDAI and
BASFIs achieved increasing (worsening).
Adverse effects
Data from large systematic reviews, which included patients with a wide range of diseases, suggest that,
in the short term, anti-TNFs as a group are associated with significantly higher rates of serious infections,
tuberculosis reactivation, non-melanoma skin cancer, total adverse events (AEs) and withdrawals because
of AEs than control treatments. Specifically, infliximab is associated with significantly higher rates of total
AEs and withdrawals because of AEs and certolizumab pegol is associated with significantly higher rates of
serious infections and serious AEs. The available open-label data on AEs were limited by the small sample
sizes and non-randomised study designs.
Cost-effectiveness reported in existing published studies and
manufacturer’s submissions
A total of six UK studies reporting on the cost-effectiveness of anti-TNFs were identified, all for the
treatment of AS. There appear marked differences between the results of the previously published
industry-funded assessments in AS and the results reported in a previous independent assessment.
Although all models reviewed used changes in BASDAI and/or BASFI to quantitatively model the short- and
longer-term costs and quality-of-life effects, there appeared significant variation in the assumptions
employed. We identified important conceptual issues with all existing models relating to the subsequent
projection of BASDAI and BASFI scores over a longer time horizon.
Manufacturers submitted de novo analyses for both AS (AbbVie, UCB, Pfizer, Merck Sharp & Dohme) and
nr-AxSpA (AbbVie, UCB, Pfizer) populations. Despite the different model structures and assumptions
applied across the various manufacturer’s submissions, the incremental cost-effectiveness ratios (ICERs)
reported for the anti-TNFs versus conventional care (CC) appeared consistent in AS. Across the separate
base-case analyses, the ICERs ranged from £16,391 to £44,448 for the alternative anti-TNFs compared
with CC alone. Infliximab was routinely reported to have the highest ICER. When infliximab was excluded
from consideration, the ICERs ranged from £16,391 to £21,972 for the other anti-TNFs.
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The differences in structural and parameter assumptions appear more evident in the cost-effectiveness
results for the nr-AxSpA population. The ICERs for adalimumab, certolizumab and etanercept ranged
between £12,866 and £50,692 per QALY. Importantly, when the results in the separate populations were
compared, no consistent relationship appeared to emerge across the manufacturer’s submissions regarding
the cost-effectiveness on anti-TNFs in AS compared with the nr-AxSpA population. In addition, many of
the same conceptual concerns identified from the review of published cost-effectiveness studies were also
still evident.
An independent model was developed to address the conceptual concerns and areas of remaining
uncertainty. Although it shared several of the assumptions and parameter estimates from the manufacturer
models, it has a different conceptual structure (linking BASFI progression to evidence from radiographic
assessments) and applies a more generalised framework for the synthesis of clinical-effectiveness data.
The extended synthesis approach showed the effectiveness of the different anti-TNFs to be similar.
Consequently, the treatment effects for the anti-TNFs were assumed to come from a ‘common’
distribution, that is a ‘class effect’. We developed a simulation model that allowed prediction of the
conditional change scores for responders/non-responders to BASDAI 50 at 12 weeks and to explore
differences in the baseline BASDAI/BASFI scores according to response status.
Base-case cost-effectiveness results were presented for two alternative ‘rebound’ assumptions. In the
rebound equal to gain scenario, the ICER of the alternative anti-TNFs varied between £19,240
[certolizumab with the proposed patient access scheme (PAS)] to £40,467 per additional QALY (infliximab)
in AS patients. In the rebound to CC scenario, the ICER of the alternative anti-TNFs varied between
£33,762 (certolizumab with the proposed PAS) to £66,529 per additional QALY (infliximab) in AS patients.
In the rebound equal to gain scenario, the ICER of the alternative anti-TNFs for nr-AxSpA patients varied
between £28,247 (certolizumab with the proposed PAS) to £29,784 per additional QALY (etanercept) in
AS patients. In the rebound to CC scenario, the ICER of the alternative anti-TNFs for nr-AxSpA patients
varied between £32,528 (certolizumab with the proposed PAS) to £34,232 (etanercept) per
additional QALY.
Discussion
The key strengths of the systematic review are the rigorous methods used and the extensive breadth of the
types of study included. The York model confers several advantages over current cost-effectiveness studies
by linking changes in function to a more explicit clinical/biological process and facilitating a more formal
consideration of the potential impact of anti-TNFs on function, via the specific effects these drugs have on
the different processes which independently relate to this parameter.
The meta-analysis results derived from a substantial and generally high-quality evidence base demonstrated
that anti-TNFs produce clinically important benefits to AS patients in terms of improved function and
reduced disease activity following around 3 months of treatment with an anti-TNF. Smaller benefits were
seen across outcomes in patients with nr-AxSpA, which was a more heterogeneous population. Less
reliable data were available on long-term efficacy, although it appears that around half of patients still
achieve a good level of response after around 2 years of treatment.
Although there are a number of important differences in approaches both among the different
manufacturer models and compared with the York model, the comparison of ICERs based on the York
rebound equal to gain scenario appears broadly consistent with that reported by the manufacturers in
both populations.
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Conclusions
l In both AS and nr-AxSpA populations anti-TNFs produce clinically important benefits to patients in
terms of improving function and reducing disease activity. The efficacy estimates were consistently
slightly smaller for nr-AxSpA than for AS.
l Statistical (and clinical) heterogeneity was more apparent in the nr-AxSpA analyses than in the AS
analyses; both the reliability of the nr-AxSpA meta-analysis results and their true relevance to patients
seen in clinical practice are questionable.
l In AS anti-TNFs can be assumed to have a class effect, with the treatments being equally effective.
l Effectiveness appears to be maintained over time in about 50% of patients at 2 years.
l Evidence for an effect of anti-TNFs delaying disease progression was limited; results from ongoing
long-term studies should help to clarify this issue.
l Sequential treatment with anti-TNFs can be worthwhile but the drug survival response rates and
benefits are reduced with second and third anti-TNFs.
l The de novo model, which had addressed many of the issues of earlier evaluations, generated ICERs
ranging from £19,240 to £66,529 depending on anti-TNF and modelling assumptions.
Suggested research priorities
Randomised trials are needed to identify the nr-AxSpA population that will benefit the most from
anti-TNFs. Long-term studies are needed to clarify the effect of anti-TNFs on the progression of structural
damage in AS and to help clarify the characteristics of nr-AxSpA patients who go on to develop AS.
Studies are also needed to better inform the efficacy estimates relating to sequential use of anti-TNFs.
Study registration
This study is registered as PROSPERO CRD42014010182.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of health problem
Spondyloarthritis (SpA) encompasses a heterogeneous group of inflammatory rheumatologic diseases
including ankylosing spondylitis (AS), reactive arthritis, psoriatic arthritis, inflammatory bowel disease-related
arthritis and undifferentiated SpA.1 SpA can be categorised as having predominantly axial (sacroiliac joints
or spine) or peripheral involvement. In people with axial spondyloarthritis (axSpA), the predominant
symptom is back pain (due to inflammation of the sacroiliac joints, the spine, or both) but there may also be
extra-articular and peripheral joint manifestations.
In practice, and in clinical trials, AS is commonly diagnosed using the modified New York criteria (Box 1);
sometimes in practice radiography may not be performed routinely (because of the radiation doses involved)
or magnetic resonance imaging (MRI) may be preferred as a diagnostic tool. The recently developed
Assessment of SpondyloArthritis International (ASAS) Society classification criteria encompass a broad
range of patients with axSpA, including patients with AS and patients with non-radiographic axial
spondyloarthritis (nr-AxSpA).3 All axSpA patients will have developed chronic back pain (≥ 3 months) before
age 45 years. Classifications can be made using the imaging or clinical arms of the criteria. The imaging arm
requires evidence of joint damage (erosions or fusion) due to sacroiliitis, using either radiography (when the
disease is classified as AS) or MRI (when the disease is classified as nr-AxSpA);4 additionally, at least one of the
following SpA features is also required: inflammatory back pain, arthritis, enthesitis (heel), uveitis, dactylitis,
psoriasis, Crohn’s/colitis, good response to non-steroidal anti-inflammatory drugs (NSAIDs), family history of
SpA, human leucocyte antigen (HLA)-B27 genetic marker, and elevated C-reactive protein (CRP). People with
axSpA often have the genetic marker HLA-B27. To be classified as having axSpA via the clinical arm of the
criteria, patients must be HLA-B27 positive and also have at least three of the aforementioned SpA features.
The use of MRI allows for earlier detection of axSpA, as joint damage may not become evident on radiography
for many years. Patients with nr-AxSpA may, or may not, have signs of sacroiliac joint inflammation on a
magnetic resonance image. There may be other objective signs of inflammation such as an abnormally raised
erythrocyte sedimentation rate (ESR) or CRP level, although these are less sensitive and specific for AS. A MRI
diagnosis may therefore provide the opportunity for treatment to reduce the possibility of long-term structural
damage (and associated burden of symptoms).5 However, there is some concern that the diagnostic criteria for
nr-AxSpA may be too liberal and may include patients who do not have axSpA and will never progress to AS,
particularly with respect to patients who are diagnosed without evidence of imaging (MRI) changes.6–8
The differences between AS and nr-AxSpA are explored further in Chapter 3.
BOX 1 Modified New York criteria for AS (1984)2
Clinical criteria
l Low back pain and stiffness for more than 3 months that improves with exercise but is not relieved by rest.
l Limitation of motion of the lumbar spine in the sagittal and frontal planes.
l Limitation of chest expansion relative to normal values correlated for age and sex.
Radiological criterion
l Sacroiliitis grade > 2 bilaterally or grade 3–4 unilaterally.
l Definite AS if the radiological criterion is associated with at least one clinical criterion.
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Prognosis
Axial spondyloarthritis is a painful, progressive form of inflammatory arthritis. It mainly affects the spine but can
also affect other joints, tendons and ligaments. Other areas such as the eyes and bowel can also sometimes be
involved in non-radiographic and radiographic (AS) forms of axSpA.9 The pain and stiffness of axSpA adversely
affects optimal daily functioning. These symptoms are a result of a combination of reversible components of
the disease, such as inflammation and flares, and irreversible components, such as syndesmophytes and
vertebral bridging (bony deposition).10 Most patients with AS develop the first symptoms at 25–45 years of
age.11 Progression of the disease is variable and difficult to predict.12 There is often a delay of many years
between patients first noticing symptoms and the diagnosis of axSpA being received. Many people with axSpA
have AS, with evidence of bony deposition as well as inflammation. In later-stage AS, joints and bones may
fuse together, a process that can occur over a long period of time and cause restricted movement. The
functional impairment because of inflammation and/or bony deposition can have a profound effect on health
and quality of life, and lead to withdrawal from active employment, with resultant adverse financial
consequences; the burden of disease is greater in more socially deprived patients.13 The prognosis is poor,
although there is some evidence that deterioration plateaus in well-established AS.14 Paradoxically, early disease
(nr-AxSpA) may be less readily diagnosed and patients offered fewer treatment options even though it can be
as, or even more, debilitating that established AS.15
Ankylosing spondylitis is associated with an increased risk of death; it is estimated that patients have a
standardised mortality ratio (SMR) of ≥ 1.5. The increased risk appears to be greater in men, with one
study reporting a statistically significant increase in SMR of 1.63 in men but no significant increase in
women (SMR 1.38) with AS.16 This study found that, after correcting for age, sex, disease duration and
pre-existing cardiovascular disease, independent predictors of increased mortality were elevated CRP level,
diagnostic delay, not using NSAIDs and work disability. According to British Society for Rheumatology (BSR)
guidelines, the excess mortality is mainly accounted for by cardiac valvular disease, amyloidosis and
fractures.17 nr-AxSpA affects approximately equal numbers of men and women, but it is more likely that
men will develop AS.18
Epidemiology
Currently, only limited epidemiological data are available for axSpA defined according to ASAS criteria.
For AS, the prevalence is thought to be around 0.25% in European populations.19 It is around three times
more common in men than in women.20 A recent study published in the USA reported an estimated AS
prevalence of 0.52–0.55%, and the prevalence of axSpA as approximately 1.0–1.4%.21 The proportion of
nr-AxSpA among patients with axSpA is estimated to be between 20% and 80%.22 Each year in the UK an
estimated 2% of patients in a general practice will present with back pain and up to 5% of these will
show features of AS.23
Measurement of disease
There are a number of components and measures of disease activity in axSpA;24 a patient’s health-related
quality of life (HRQoL) is determined by both by physical functioning and by disease activity. In turn, physical
function is determined by spinal mobility and disease activity, and spinal mobility is determined by structural
damage and inflammation of the spine.24 In nr-AxSpA, a patient may have significant inflammation but no
detectable structural damage; in AS, a patient may have both significant inflammation and structural damage;
and in late AS, there may be less inflammation but extensive structural damage.
The main tools used for the assessment of various components of the disease are listed in Table 1.
Placebo response
The term ‘placebo effect’ can be used to describe different types of ‘effect’ but it generally encompasses
one or more of three different meanings. First, there is the temporal (before–after) change after placebo
medication, in which the effects of a placebo intervention cannot be distinguished from the natural course
of the disease or regression to the mean. Second, there is the causal effect of placebo intervention
associated with the treatment ritual, and, finally, there is the effect of all the psychological processes
BACKGROUND
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TABLE 1 Disease assessment tools
Assessment measures
Tool
Disease
component Description
BASDAI Disease activity Consists of a 1–10 scale (1 being no problem and 10 being the worst problem)
which is used to answer six questions pertaining to the five major symptoms of AS:
l fatigue
l spinal pain
l joint pain/swelling
l areas of localised tenderness (also called enthesitis or inflammation of tendons
and ligaments)
l morning stiffness duration
l morning stiffness severity
BASFI Functional ability Patient assesses difficulty on a 10-point scale (1 is easy and 10 is impossible)
for each of 10 items:
l putting on your socks or tights without help or aids (e.g. sock aid)
l bending from the waist to pick up a pen from the floor without aid
l reaching up to a high shelf without help or aids (e.g. helping hand)
l getting up from an armless chair without your hands or any other help
l getting up off the floor without help from lying on your back
l standing unsupported for 10 minutes without discomfort
l climbing 12–15 steps without using a handrail or walking aid
l looking over your shoulder without turning your body
l doing physically demanding activities (e.g. physiotherapy exercises, gardening
or sports)
l doing a full day’s activities whether it be at home or at work
BASMI Disease activity,
spinal mobility
Clinician assessment of cervical rotation, tragus-to-wall distance, lumbar side
flexion, modified Schober’s, intermalleolar distance
ASDAS Disease activity Calculated from BASDAI questions on spinal pain, peripheral arthritis and duration
of morning stiffness, patients global assessment of disease activity and CRP level
(or ESR if CRP level not available)
mSASSS Structural
damage
In the mSASSS the anterior vertebral corners of the cervical (lower border of C2 to
upper border of T1) and lumbar (lower border of T12 to upper border of S1)
segments (a total of 24 VCs) are scored at a lateral view, for the presence of erosion
and/or sclerosis and/or squaring (1 point), syndesmophyte (2 points) and bridging
syndesmophyte (3 points). The total score ranges from 0 to 72. The mSASSS has
shown better reliability and sensitivity to change than other radiographic scoring
methods25
continued
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involved in the interaction between doctor and patient.26 For the placebo-controlled trials in AS and nr-AxSpA
these non-pharmacological components can be assumed to act equally in the anti-tumour necrosis factor (TNF)
and placebo arms. Results from the placebo arms measure the non-pharmacological effects and the difference
between the anti-TNF and placebo arms measures the pharmacological effect. All three components of the
placebo effect could be important to consider when evaluating trials in this assessment, although once the trial
treatment periods have ended, it is likely that the effect of the natural course of the disease becomes the most
important factor of any ‘placebo’ effect. Estimated cost-effectiveness ratios and associated policy decisions
may be sensitive to assumptions regarding the mechanism underlying placebo responses.27
The natural course of disease activity in AS is known to vary over time with exacerbations, or flares, being
common. In a study of flares in patients with AS, clinically relevant changes in Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI; but not in function) were noted during minor/localised flares (which occurred
in 59% of patients in any given week). Although major/generalised flares were less common (reported in
12% of patients in any given week) they were associated with clinically relevant changes in both disease
activity and function.28 Pain is a key component of BASDAI and the ASAS responder outcomes; a Cochrane
systematic review of placebos for all clinical conditions found that placebo interventions can influence
patient-reported outcomes, especially pain (and nausea).29 The authors also concluded that it was difficult to
distinguish patient-reported effects of placebo from biased reporting, and that the effect on pain varied from
negligible to clinically important, even among trials with low risk of bias.
Current service provision
Management of disease
Short- and long-term treatment goals for axSpA include minimising pain and stiffness, maintaining
function and posture, arresting disease progression and maintaining quality of life and ability to work.
Current conventional therapy for axSpA includes acute anti-inflammatory treatment with NSAIDs and
physiotherapy and exercise.
MRI assessments
Measures of response
BASDAI 50 Response
criterion
≥ 50% improvement in BASDAI
ASAS 20 Response
criterion
≥ 20% improvement and ≥ 1 unit absolute improvement (range 1–10) in three of
four domains with no worsening of ≥ 20% improvement and ≥ 1 unit absolute
in the fourth domain: BASFI, spinal pain, patient GDA and inflammation
(BASDAI Q5 and 6)
ASAS 40 Response
criterion
≥ 40% improvement and ≥ 2 units absolute improvement (range 1–10) in three of
four domains with no worsening at all in the fourth domain: BASFI, spinal pain,
patient GDA and inflammation (BASDAI Q5 and 6)
ASAS partial
remission
Response
criterion
A value of ≥ 2 units absolute improvement (range 1–10) in each of four domains:
ASFI, spinal pain, patient GDA and inflammation (BASDAI Q5 and 6)
ASAS 5/6 Response
criterion
Improvement in five out of six domains (using pre-defined % improvements)
without deterioration in the sixth domain: pain, patient global assessment, function,
inflammation, spinal mobility, CRP level
ASDAS major
improvement
Response
criterion
≥ 2 units improvement in ASDAS
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index;
BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; GDA, Global
Disease Activity; mSASSS, modified Stroke Ankylosing Spondylitis Spinal Score; VC, vertebral corner.
TABLE 1 Disease assessment tools (continued)
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Conventional therapy for AS is limited to NSAIDs (despite very limited supporting clinical trial evidence)30 and
recommendations regarding appropriate physical activity. Other statements in the ASAS/EULAR (European
League Against Rheumatism) recommendations for the management of AS include analgesics such as
paracetamol and opioid-like drugs that may be considered for residual pain. Glucocorticoid injections into the
direct site of inflammation (but not systemic) may be of benefit. The use of disease-modifying antirheumatic
drugs (DMARDs, such as methotrexate and sulfasalazine) has been all but abandoned after evidence of lack of
benefit. The cornerstone of non-pharmacological treatment of patients with AS is patient education and
regular exercise; home exercises are effective. Physical therapy with supervised exercises, land- or water-based,
individually or in a group, should be preferred, as these are more effective than home exercises. Patient
associations and self-help groups may be useful. A Cochrane review of 11 trials concluded that the current
best available evidence suggests that physiotherapy is beneficial for people with AS, but that it is still not clear
which treatment protocol, duration and intensity should be recommended in the management of AS.31
Physiotherapy is universally recommended32 but variable in practice.
Biologic drugs are the only treatment shown to be efficacious in the treatment of symptoms and signs of
disease activity in axSpA and AS. Current National Institute for Health and Care Excellence (NICE) and BSR
guidance recommends treatment with the anti-TNFs adalimumab, etanercept and golimumab in adults
with active (severe) AS only if certain criteria are fulfilled, but it does not recommend infliximab for AS.17,33
Description of technology under assessment
Tumour necrosis factor-α inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab and
infliximab), also referred to as anti-TNFs, are typically used when the disease has not responded adequately
to conventional therapy. They target the activation of TNF-α and its subsequent activation of downstream
inflammatory processes, and as such have the potential to offer symptom control as well as alter disease
progression. Adalimumab, certolizumab pegol, golimumab and infliximab are monoclonal antibodies,
whereas etanercept is a recombinant human TNF receptor fusion protein.
Adalimumab, etanercept, golimumab and infliximab are licensed in the UK for the treatment of adults with
severe active AS that has responded inadequately to conventional therapy. Certolizumab pegol is licensed
for the treatment of adults with severe active AS whose disease has responded inadequately to, or who
are intolerant of, NSAIDs.
Adalimumab, etanercept and certolizumab pegol are also licensed for the treatment of adults with severe
nr-AxSpA with objective signs of inflammation (including elevated CRP level and/or positive MRI), whose
disease has responded inadequately to, or who are intolerant of, NSAIDs. Golimumab and infliximab do
not currently have a UK marketing authorisation for nr-AxSpA. Current NICE guidance recommends
treatment with adalimumab, etanercept or golimumab in adults with active (severe) AS only if certain
criteria are fulfilled (including a stipulation that patients must have tried at least two different NSAIDs,
which have failed to control symptoms), but it does not recommend infliximab for AS.17,33 Anti-TNFs for
patients with nr-AxSpA have not previously been appraised by NICE.
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Chapter 2 Definition of decision problem
Decision problem in terms of Population, Intervention,
Comparator, Outcome, Study design and other key issues
The decision problem relates to the optimal use of adalimumab, certolizumab pegol, etanercept,
golimumab and infliximab, within their licensed indications, for the treatment of severe/active AS or severe
axSpA without radiographic evidence of AS (but with objective signs of inflammation).
Previous National Institute for Health and Care
Excellence appraisals
In the previous NICE technology appraisal (TA) 143, adalimumab, etanercept and infliximab were evaluated
for AS, while in TA23333 golimumab was evaluated for AS. A number of key areas of uncertainty and
potential limitations of the evidence base were identified from these appraisals. These include:
1. a lack of direct head-to-head trial evidence evaluating the relative efficacy and safety of the
TNF-α inhibitors
2. a lack of evidence on the efficacy and safety of the sequential use of TNF-α inhibitors
3. the long-term effectiveness of TNF-α inhibitors in controlling disease activity
4. the rate of disease progression in responders and non-responders to treatment, and in those
on placebo
5. the proportion of patients who may experience a significant improvement in their condition without
TNF-α inhibitor treatment
6. the rate of treatment withdrawal on TNF-α inhibitors and the degree to which a patient’s condition
might be expected to rebound if therapy is withdrawn
7. the adverse effects associated with the long-term use of TNF-α inhibitors
8. the impact of TNF-α inhibitors on the progression of structural damage in the spine and functional
disability associated with ankylosis
9. the time horizon appropriate for considering the cost-effectiveness of TNF-α inhibitors
10. a lack of registry data of patients receiving TNF-α inhibitors for severe active AS.
This assessment would consider each of these areas of uncertainty and identify the relevant evidence
available to inform the limitations of the previous appraisals.
Overall aims and objectives of assessment
The aim of the study is to determine the clinical effectiveness, safety and cost-effectiveness within the NHS
of adalimumab, certolizumab pegol, etanercept, golimumab and infliximab, within their licensed
indications, for the treatment of severe active AS or severe axSpA without radiographic evidence of AS
(but with objective signs of inflammation). If evidence allows, the clinical effectiveness and
cost-effectiveness of sequential use of these treatments will also be evaluated.
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Chapter 3 Assessment of clinical effectiveness
Methods for reviewing effectiveness
Inclusion criteria
Two reviewers independently screened all titles and abstracts. Full manuscripts of any titles/abstracts that
were relevant were obtained where possible and the relevance of each study assessed by two reviewers
according to the criteria below. Any discrepancies were resolved by consensus and, when necessary, a
third reviewer was consulted. Studies available only as abstracts were included.
Study design
For the review of clinical efficacy randomised controlled trials (RCTs) were eligible, including any open-label
extensions of RCTs. Adverse event (AE) data were sought from existing reviews and other appropriately
large studies. For studies of natural history, long-term effectiveness, adherence and sequential use,
published analyses based on large and long-term data sets (including studies of registry data) were eligible.
Interventions
Adalimumab, certolizumab pegol, etanercept, golimumab, infliximab or any of their biosimilars
were eligible.
Comparators
Relevant comparators were conventional management strategies (either with or without placebo) and also
the different TNF-α inhibitors listed above (i.e. head-to-head trials).
Participants
Studies of adults with either severe active AS or severe axSpA without radiographic evidence of AS but
with objective signs of inflammation (such as elevated CRP levels or a positive MRI) were eligible. Patients
with predominantly peripheral spondyloarthritis were excluded. Data relating to serious adverse effects
associated with anti-TNF agents used in other indications were also considered.
Outcomes
Studies reporting the following outcomes were eligible:
l multiple domain response criteria: (e.g. ASAS 20, ASAS 40, ASAS 5/6 and ASAS partial remission)
l disease activity (e.g. BASDAI)
l functional capacity [e.g. Bath Ankylosing Spondylitis Functional Index (BASFI)]
l disease progression [e.g. modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS)]
l pain [e.g. visual analogue scale (VAS) scores]
l peripheral symptoms (including enthesitis, peripheral arthritis and dactylitis)
l symptoms of extra-articular manifestations (including anterior uveitis, inflammatory bowel disease
and psoriasis)
l HRQoL [e.g. European Quality of Life-5 Dimensions (EQ-5D)]
l rates of treatment discontinuation and withdrawal
l AEs.
For AEs the evaluation specifically focused on known possible AEs of anti-TNFs, such as reactivation of
latent tuberculosis, malignancies, non-melanoma skin cancer, severe infections, congestive heart failure,
and injection site reactions. Withdrawals because of AEs and events categorised as serious adverse events
(SAEs) were also evaluated.
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Searches
The following databases were searched for relevant clinical effectiveness and cost-effectiveness research:
l MEDLINE
l EMBASE
l Cumulative Index to Nursing and Allied Health Literature Plus
l Science Citation Index
l ClinicalTrials.gov
l Cochrane Central Register of Controlled Trials
l Cochrane Database of Systematic Reviews
l Database of Abstracts of Reviews of Effects
l International Prospective Register of Systematic Reviews (PROSPERO)
l Health Technology Assessment Database
l Conference Proceedings Citation Index – Science
l National Guidelines Clearinghouse
l NHS Evidence
l NHS Clinical Knowledge Summaries
l NHS Economic Evaluation Database (NHS EED).
The terms for search strategies were identified through discussion within the research team, by scanning the
background literature and browsing the MEDLINE medical subject headings. No date or language limits were
applied. As several databases were searched, some degree of duplication resulted. To manage this issue, the
titles and abstracts of bibliographic records were imported into EndNote bibliographic management software
(version X7, Thomson Reuters, CA, USA) to remove duplicate records. Databases were searched from
inception, with most of the searches being performed in June or July 2014. The full search strategies used in
each database, together with the search dates, are listed in Appendix 1.
Data extraction
Data relating to study design, outcome results and quality were extracted by one reviewer using a
standardised data extraction form and independently checked for accuracy by a second reviewer.
Disagreements were resolved through consensus, and, when necessary, a third reviewer was consulted.
Data from studies with multiple publications were extracted and reported as a single study. Data were also
extracted from the manufacturer’s submissions when they were not available from other sources.34–37
Clinicaltrials.gov records and relevant US Food and Drug Administration (FDA) or European Medicines
Agency reports were also used to extract any missing data. When data could only be estimated from
graphs, the estimates used in the previous assessment report38 were used when available. In the light of
the multidomain outcomes which incorporated pain scores (the ASAS and BASDAI outcomes), it was
decided that pain scores on their own would not be extracted.
This report contains reference to confidential information provided as part of the NICE appraisal process.
This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
Critical appraisal
The quality of RCTs was assessed using the Cochrane risk of bias tool,39 with additional assessments made
for baseline imbalance of important prognostic indicators.40 The relevant prognostic and treatment
response indicators were identified from both published research and clinical advice. The risk of bias
assessments were performed by one reviewer, and independently checked by a second. Disagreements
were resolved through consensus, and, when necessary, a third reviewer was consulted. Open-label
extension studies were evaluated based on the imputation methods and patient withdrawal criteria used.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Methods of data synthesis
This section describes the data set construction and meta-analyses conducted for the different outcomes
individually. Chapter 5 provides detailed evidence synthesis methods that incorporate different outcomes
within one analysis and presents clinical outcome estimates appropriate for the economic model.
Results of the data extraction in terms of study characteristics and quality assessment are presented in
tables and summarised narratively. Results of open-label studies, drug survival and switching studies and
natural history studies were also summarised narratively. As several of the RCTs were placebo-controlled
up to 24 weeks, only time points beyond 24 weeks were evaluated in the open-label studies. AE data from
the RCTs were pooled when enough data were identified; otherwise, the AE data and the other studies
relating specifically to AEs were summarised narratively.
Clinical effectiveness data were synthesised using Bayesian meta-analysis methods. The main analysis was
of outcomes reported from 10 to 16 weeks. A sensitivity analysis was done of outcomes reported from
24 to 30 weeks.
Dosage and pooling of trial arms
The doses included in the analyses were:
l adalimumab – 40mg every other week
l certolizumab pegol – 200mg every 2 weeks, 400mg every 4 weeks
l etanercept – 25mg twice weekly, 50mg weekly
l golimumab – 50mg every month
l infliximab – 5mg/kg at 0, 2 or ≥ 6 weeks.
Golimumab of 100mg every 4 weeks was excluded when it was not used according to its licence.
Data from active treatment arms were pooled in trials which studied different doses. This occurred for
certolizumab pegol 200mg every 2 weeks and 400mg every 4 weeks and for etanercept 25mg twice
weekly and 50mg weekly.
Data imputation and assumptions
Medians were treated as means. Although the median may not be exactly the same as the mean, the
median was considered to give sufficiently accurate information. Standard deviations (SDs) were estimated
from interquartile ranges, the method of which is described in Appendix 2. Where no SD was reported,
the highest SD from the other trials was used as a conservative estimate.
In the meta-analyses, ‘change from baseline’ outcomes were used in the analysis for continuous outcomes.
Where these were not reported, but adequate baseline and final value outcomes were reported, the
change from baseline and its SD were derived from the baseline and final values and their SDs.
The detailed methods are described in Appendix 2.
The imputation of change from baseline or final values required a within-trial correlation estimate, and
trials that reported the SDs of baseline, change from baseline and final values were used to estimate the
within-trial correlation. For BASDAI the within-study correlation varied from 0.33 to 0.67 across four trials.
Given the small samples of some trials, the within-study correlation can vary significantly from trial to trial.
For the base-case analysis, a correlation estimate of 0.3 was used and an estimate of 0.7 was tested in
sensitivity analysis. For the calculation of final values, the lowest possible correlation was used when 0.3 or
0.7 were not feasible solutions (see Appendix 2).
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Change from baseline was imputed for three trials for BASDAI, five trials for BASFI, one trial for Bath
Ankylosing Spondylitis Metrology Index (BASMI), two trials for Short Form questionnaire-36 items (SF-36)
physical component summary (PCS), and one trial for SF-36 mental component summary (MCS). For each
of these outcomes, one of the imputations was for a trial with a non-radiographic population.
Binary event outcomes
Odds ratios (ORs) were derived for binary event outcomes. Relative risks were also derived from the ORs
using the placebo absolute risks estimated from all the trials measuring the relevant outcome within
weeks 10 to 16. The relative risk estimates are therefore based on the population distribution of the trials
across the interventions. As the placebo absolute risk was based on more trials than those informing the
ORs for some outcomes, the 95% credible interval (CrI) estimates of the relative risk were narrower than
the CrI estimates of the OR. The placebo absolute risk was estimated using both fixed- and random-effect
models within WinBUGS (Medical Research Council Biostatistics Unit, Cambridge, UK). As the
random-effect model for the placebo absolute risk was a better fit than the fixed effect model according
to the deviance information criterion (DIC) statistic, the placebo absolute risks from the random-effect
models were used. For the ASAS outcomes, fewer trials reported the greater response outcomes, so a prior
distribution was used for the between-study SD based on the closest ASAS outcome (see Appendix 2).
Analyses
Analyses were conducted in WinBUGS version 1.4.3. See Chapter 5 for more details on the models. For
each outcome, multiple-treatment meta-analyses were conducted assuming that the treatments had
independent effects [related to models A1 (fixed effect) and A2 (random effects) in Chapter 5]. They were
also run assuming that they had a common class effect [related to models A3 (fixed effect) and A4
(random effects) in Chapter 5] and that the DIC statistic was used to determine the model that best fitted
the data. The random-effect models with independent treatment effects were assumed to have a common
between-study variance across the comparisons in the network.
The sensitivity of random-effect models to the between-study SD priors was tested. I2 statistics for
heterogeneity were calculated for random-effect models that were insensitive to change in the prior
distribution for the between-study SD. Results were only presented for random-effect models.
Clinical effectiveness results
Quantity and quality of research available
The electronic database searches identified 2284 references. After screening titles and abstracts, full copies
of 198 papers were assessed for inclusion in the review. Three trials of axSpA populations were excluded
because results were not available separately for the AS and nr-AxSpA populations.41–43 One study of
adalimumab appeared likely to be eligible but was excluded as it was only available as a ClinicalTrials.gov
record, without any results or further study details.44 One excluded study was an ongoing trial of
golimumab (called GO-AHEAD).45
Twenty-eight eligible RCTs were identified, with 24 being suitable for data synthesis. Three etanercept
trials were not suitable for data synthesis because the study durations were only 6 weeks,46–48 and
one infliximab trial was unsuitable because a (currently) unlicensed dose (3 mg/kg) had been studied.49 The
Barkham 2009 trial50,51 of infliximab in nr-AxSpA patients (see Table 2) was included in the clinical efficacy
section because, even though infliximab is not currently licensed for patients with nr-AxSpA, the dose used
in this trial was the same as that licensed for AS. Furthermore, there was no reason to think it could not be
considered in the same class as the other anti-TNFs when treating a nr-AxSpA population. The results of
the trial therefore had the potential to be useful to help inform the relative efficacy of anti-TNFs for
nr-AxSpA.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Of the 17 RCTs in which participants were studied beyond the randomised phase (i.e. in open-label
studies), 71 additional full publications or conference abstracts were identified. Figure 1 illustrates the flow
of studies through the review process.
Study characteristics
Table 2 lists the 24 eligible RCTs (and all the RCT-related references) which were eligible for inclusion in
the network meta-analysis. Six trials compared adalimumab versus placebo, one compared certolizumab
pegol versus placebo, seven compared etanercept versus placebo, three compared golimumab versus
placebo, five compared infliximab versus placebo, one compared etanercept with infliximab and one
compared infliximab with an infliximab biosimilar (CT-P13). Most placebo-controlled phases lasted for
12 weeks. All but seven of the trials were extended into open-label (unblinded) phases, with 11 studies
having a total duration of at least 1 year.
Of the trials suitable for analysis, most were conducted in Europe and/or North America; four were
conducted in China. Four studies recruited a nr-AxSpA population, 19 an AS population and one recruited
both populations.64 Table 3 details the baseline characteristics of the populations studied. In the nr-AxSpA
studies around half of the participants were male, whereas in the AS studies around three-quarters were
male. All trials recruited participants with active disease; half the trials specified that participants had to
have failed one or more NSAID, and a BASDAI score of ≥ 4 was used as an entry requirement in most,
with the exception of six early trials in which a BASDAI criterion was not stated.72,79,83,86,100 Notwithstanding
these entry criteria, the recruited participants mostly still took a NSAID (around between 80% and 90% of
participants, although reported in only 12 trials) and had quite high mean (or median) BASDAI scores:
most were between 5.5 and 6.5 (the range across all trial arms was 5.3–7.0). BASFI scores varied more
widely, ranging between 3.2 and 6.7. Variation in CRP levels was also apparent, with lower values in the
nr-AxSpA trials being evident. Trials which reported both mean and median CRP showed skewed
distributions, with means being higher than medians.58,64,95 The upper limits of normal used for defining
elevated CRP level in the nr-AxSpA trials were either unclear58 or varied, being 3mg/l,76 6mg/l51 or
7.9 mg/l.64 One nr-AxSpA study recruited only MRI-positive patients.50 In the remaining nr-AxSpA trials the
proportion of MRI-positive patients ranged from 51%58 to 81%.76
Records identified from
searches (n = 2284)
Full papers screened (n = 198)
Excluded on
title/abstract (n = 2086)
Excluded (n = 62)
Eligible RCTs (n = 28)
(65 RCT references and 71 open-label
study references)
RCTs excluded from analyses (n = 4)
• Short trial duration, n = 3
• Unlicensed dose, n = 1
FIGURE 1 Flow chart showing the number of studies identified and included.
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TABLE 2 General trial characteristics
Study Interventions Anti-TNF dose Country/continent Population
Duration of
placebo-controlled
phase (weeks)
Total duration of
study, including
any open-label
extension phase
Haibel 200852–54 Adalimumab; placebo 40mg every other week Germany nr-AxSpA with inflammation,
inadequate response/intolerance
to NSAIDs
12 1 year
Hu 201255 Adalimumab; placebo 40mg every other week China AS, inadequate response/
intolerance to NSAIDs
12 24 weeks
Huang 201456 Adalimumab; placebo 40mg every other week China AS, inadequate response/
intolerance to NSAIDs
12 24 weeks
Lambert 200757 Adalimumab; placebo 40mg every other week Canada AS, inadequate response to a
NSAID or DMARD
12 1 year
ABILITY-1 201358–60 Adalimumab; placebo 40mg every other week Australia, Europe,
North America
nr-AxSpA with inflammation,
inadequate response/
contraindication to NSAIDs
12 3 years
ATLAS 200661–63 Adalimumab; placebo 40mg every other week USA, Europe AS, inadequate response to a
NSAID or DMARD
12 5 years
RAPID-axSpA
201464–70
Certolizumab pegol;
placebo
200mg every 2 weeks or
400mg every 4 weeks
Europe, North America,
Latin America
AS, nr-AxSpA with inflammation,
inadequate response/intolerance
to NSAIDs
12 96 weeks
Barkham 201071 Etanercept; placebo 25mg twice weekly UK AS 12 12 weeks
Davis 200372,73 Etanercept; placebo 25mg twice weekly North America, Europe AS 24 168 weeks
Dougados
201174,75
Etanercept; placebo 50mg weekly Europe AS, inadequate response to
NSAIDs
12 24 weeks
Dougados
201476–78
Etanercept; placebo 50mg weekly Europe, Asia, South
America
nr-AxSpA, inadequate response
to NSAIDs
12 48 weeks
Gorman 200279–82 Etanercept; placebo 25mg twice weekly USA AS 16 40 weeks
Calin 200483–85 Etanercept; placebo 25mg twice weekly Europe AS 12 5 years
van der Heijde
200686,87
Etanercept; placebo 25mg twice weekly or
50mg weekly
Europe AS 12 12 weeks
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Study Interventions Anti-TNF dose Country/continent Population
Duration of
placebo-controlled
phase (weeks)
Total duration of
study, including
any open-label
extension phase
Giardina 201088,89 Etanercept; infliximab 50mg weekly; 5mg/kg
(at week 0, 2, 6 and
every 6 weeks)
Italy AS, inadequate response to
NSAIDs
N/A 12 weeks
GO-RAISE
200890–94
Golimumab; placebo 50mg or 100mg every
4 weeks
North America,
Europe, Asia
AS 16 4 years
Bao 201495,96 Golimumab; placebo 50mg every 4 weeks China AS 14 1 year
Tam 201497 Golimumab; placebo 50mg every 4 weeks China (Hong Kong) AS, inadequate response to
NSAIDs
24 1 year
Barkham 200950,51 Infliximab; placebo 5mg/kg (at 0, 2, 6 and
12 weeks)
UK nr-AxSpA with inflammation 16 16 weeks
Braun 200298,99 Infliximab; placebo 5mg/kg (at weeks 0, 2
and 6)
Germany AS 12 8 years
Marzo-Ortega
2005100
Infliximab+methotrexate;
placebo+methotrexate
5mg/kg (at weeks 0, 2,
6, 14 and 22)
UK AS 30 30 weeks
Van den Bosch
2002101
Infliximab; placebo 5mg/kg (at weeks 0, 2
and 6)
Belgium AS 12 12 weeks
ASSERT102–109 Infliximab; placebo 5mg/kg (at weeks 0, 2,
6, 12 and 18)
North America, Europe AS, inadequate response/
intolerance to NSAIDs
24 2 years
PLANETAS
2013110,111
CT-P13 biosimilar;
infliximab
Both 5mg/kg Europe, Asia, Latin
America
AS N/A 2 years (using
randomised
interventions up to
54 weeks)
ASSERT, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy; ATLAS, Adalimumab Trial Evaluating Long-term Efficacy and Safety for Ankylosing Spondylitis;
DMARD, disease-modifying antirheumatic drugs; PLANETAS, Programme evaluating the Autoimmune disease iNvEstigational drug cT-p13 in Ankylosing Spondylitis; N/A, not applicable.
All RCT-related references have been included for each study.
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TABLE 3 Baseline characteristics of trial populations
Trial
Patient
group Trial arm n % male Age (years)
% on a
NSAID
Symptom
duration
(years)
BASDAI
score
BASFI
score
BASMI
score
CRP level
mg/l, (SD)
% HLA-B27
positive
SF-36 MCS
score
SF-36 PCS
score
ASQoL
score
Haibel 2008
52
nr-AxSpA Adalimumab 22 41 Mean 38 NR Mean 7 Mean 6.5
(SD 1.2)
Mean 5.4
(SD 2)
Mean 1.3
(SD 1.2)
Mean 6.2
(SD 5.8)
59 Mean 41.3
(SD 12.5)
Mean 28.8
(SD 7.6)
Mean 10.8
(SD 3.7)
nr-AxSpA Placebo 24 50 Mean 37 NR Mean 8 Mean 6.2
(SD 1.3)
Mean 4.9
(SD 1.6)
Mean 1.3
(SD 1.6)
Mean 7.8
(SD 7.0)
75 Mean 43.6
(SD 11.1)
Mean 30.7
(SD 6)
Mean 9.5
(SD 3)
Hu 201255 AS Adalimumab 26 92 Mean 28.2
(SD 6.9)
NR Mean 7.4 Mean 5.9
(SD 1.4)
Mean 3.7
(SD 2.1)
– Mean 24.6 96 – – –
AS Placebo 20 100 Mean 27.4
(SD 7.2)
NR Mean 7.6 Mean 6.2
(SD 1.1)
Mean 3.9
(SD 2)
– Mean 32.1 95 – – –
Huang 2014
56
AS Adalimumab 229 81 Mean 30.1
(SD 8.7)
80 Mean 8.1 Mean 6.0
(SD 1.4)
Mean 4.3
(SD 2.3)
Mean 3.4
(SD 1.4)
Mean 22.4
(SD 24)
96 Mean 36.2
(SD 10.7)
Mean 33.8
(SD 7)
–
AS Placebo 115 83 Mean 29.6
(SD 7.5)
78 Mean 7.7 Mean 6.2
(SD 1.4)
Mean 4.4
(SD 2.3)
Mean 3.4
(SD 1.5)
Mean 23
(SD 30)
95 Mean 35
(SD 10.6)
Mean 32.2
(SD 6.7)
–
Lambert
2007
57
AS Adalimumab 38 76 Mean 41.9
(SD 11.1)
NR Mean 14.5 Mean 6.2
(SD 1.7)
Mean 5.3
(SD 2)
– Mean 18 87 – – –
AS Placebo 44 82 Mean 40
(SD 10.9)
NR Mean 12.1 Mean 6.5
(SD 1.6)
Mean 5.6
(SD 2.2)
– Mean 23 82 – – –
a
ABILITY-1
201358
nr-AxSpA Adalimumab 69 46 Mean 38.3
(SD 11.7)
NR Mean 10.7 Mean 6.4
(SD 1.6)
Mean 4.5
(SD 2.1)
Mean 2.7 Mean 8.6
(SD 13.1)
NR – Mean 33.3
(SD 7.8)
–
nr-AxSpA Placebo 73 45 Mean 38.3
(SD 10.5)
NR Mean 10.5 Mean 6.4
(SD 1.5)
Mean 4.8
(SD 2.3)
Mean 2.7 Mean 9.3
(SD 10.9)
NR – Mean 33.2
(SD 8.2)
–
ATLAS 2006
61
AS Adalimumab 208 76 Mean 41.7
(SD 11.7)
80 Mean 11.3 Mean 6.3
(SD 1.7)
Mean 5.2
(SD 2.2)
Mean 3.8
(SD 2.2)
Mean 18 78 Mean 43.4
(SD 12)
Mean 32.9
(SD 8)
Mean 10.2
(SD 4)
AS Placebo 107 74 Mean 43.4
(SD 11.3)
79 Mean 10 Mean 6.3
(SD 1.7)
Mean 5.6
(SD 2.2)
Mean 4.2
(SD 2.1)
Mean 22 79 Mean 44.4
(SD 12)
Mean 31.8
(SD 8)
Mean 10.6
(SD 4)
RAPID-axSpA
201464
AS Certolizumab
pegol 200mg
65 72 Mean 41
(SD 10.8)
91 Median 8.8 Mean 6.5
(SD 1.7)
Mean 5.6
(SD 2.3)
Mean 4.2
(SD 1.6)
Median 14 82 – – –
AS Certolizumab
pegol 400mg
56 73 Mean 41.9
(SD 11.5)
91 Median 8.8 Mean 6.2
(SD 1.3)
Mean 5.7
(SD 2.3)
Mean 4.3
(SD 1.8)
Median
12.9
79 – – –
AS Placebo 57 72 Mean 41.6
(SD 12.8)
90 Median 10.2 Mean 6.4
(SD 1.9)
Mean 6.0
(SD 2)
Mean 4.7
(SD 1.6)
Median
16.6
84 – – –
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Trial
Patient
group Trial arm n % male Age (years)
% on a
NSAID
Symptom
duration
(years)
BASDAI
score
BASFI
score
BASMI
score
CRP level
mg/l, (SD)
% HLA-B27
positive
SF-36 MCS
score
SF-36 PCS
score
ASQoL
score
RAPID-axSpA
201464
nr-AxSpA Certolizumab
pegol 200mg
46 44 Mean 36.6
(SD 13)
83 Median 4.8 Mean 6.5
(SD 1.4)
Mean 4.8
(SD 2.2)
Mean 3.1
(SD 1.4)
Median 10 74 – – –
nr-AxSpA Certolizumab
pegol 400mg
51 53 Mean 37.5
(SD 10.8)
86 Median 7.3 Mean 6.6
(SD 1.6)
Mean 5.1
(SD 2.4)
Mean 3.3
(SD 1.5)
Median
12.1
73 – – –
nr-AxSpA Placebo 50 48 Mean 38
(SD 11.8)
82 Median 4.5 Mean 6.4
(SD 1.5)
Mean 4.9
(SD 2.2)
Mean 3.1
(SD 1.6)
Median
13.5
78 – – –
Barkham
201071
AS Etanercept 20 75 Mean 40.8
(SD 9.7)
NR Median 11 Mean 6.1
(SD 1.7)
Mean 5.6
(SD 2.0)
– – NR – – –
AS Placebo 20 85 Mean 39.4
(SD 10.1)
NR Median 20 Mean 5.5
(SD 1.7)
Mean 5.3
(SD 1.8)
– – NR – – –
Davis 200372 AS Etanercept 138 76 Mean 42.1 91 Mean 10.1 Mean 5.8
(SE 0.15)
Mean 5.2 – Mean 19 84 – – –
AS Placebo 139 76 Mean 41.9 92 Mean 10.5 Mean 6.0
(SE 0.14)
Mean 5.6 – Mean 20 84 – – –
Dougados
201174
AS Etanercept 39 95 Mean 46
(SD 11)
NR Mean 19 Mean 6.4
(SD 1.2)
Mean 6.3
(SD 2.0)
Mean 5.7
(SD 1.4)
Mean 25
(31)
79 – – –
AS Placebo 43 91 Mean 48
(SD 10)
NR Mean 23 Mean 5.8
(SD 1.5)
Mean 5.7
(SD 1.9)
Mean 5.8
(SD 1.3)
Mean 17
(19)
86 – – –
b
Dougados
2014
76
nr-AxSpA Etanercept 106 64 Mean 31.9
(SD 7.8)
CiC
information
has been
removed
Mean 2.4 CiC
information
has been
removed
CiC
information
has been
removed
Mean 1.4
(SD 1.3)
Mean 6.8 67 – CiC
information
has been
removed
CiC
information
has been
removed
nr-AxSpA Placebo 109 57 Mean 32
(SD 7.8)
CiC
information
has been
removed
Mean 2.5 CiC
information
has been
removed
CiC
information
has been
removed
Mean 1.2
(SD 1.3)
Mean 6.4 76 – CiC
information
has been
removed
CiC
information
has been
removed
Gorman
2002
79
AS Etanercept 20 65 CiC
information
has been
removed
80 CiC
information
has been
removed
– Mean 4.5
(SD 2.1)
– Mean 20 95 – – –
AS Placebo 20 90 CiC
information
has been
removed
95 CiC
information
has been
removed
– Mean 3.2
(SD 2.5)
– Mean 15 90 – – –
continued
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TABLE 3 Baseline characteristics of trial populations (continued )
Trial
Patient
group Trial arm n % male Age (years)
% on a
NSAID
Symptom
duration
(years)
BASDAI
score
BASFI
score
BASMI
score
CRP level
mg/l, (SD)
% HLA-B27
positive
SF-36 MCS
score
SF-36 PCS
score
ASQoL
score
Calin 200483 AS Etanercept 45 80 Mean 45.3
(SD 9.5)
89 Mean 15.0 Mean 6.1 Mean 6.0 – Median
154
NR – – –
AS Placebo 39 77 Mean 40.7
(SD 11.4)
85 Mean 9.7 Mean 5.9 Mean 5.7 – Median 97 NR – – –
van der
Heijde 200686
AS Etanercept
25mg
150 76 Mean 39.8
(SD 10.7)
85 Mean 10.0 Mean 5.9
(SD 1.7)
Mean 5.8
(SD 2.0)
– Mean 19.8
(SD 20.8)
NR – – –
AS Etanercept
50mg
155 70 Mean 41.5
(SD 11)
80 Mean 9.0 Mean 6.2
(SD 1.7)
Mean 6.1
(SD 2.0)
– Mean 21.7
(SD 24.6)
NR – – –
AS Placebo 51 78 Mean 40.1
(SD 10.9)
78 Mean 8.5 Mean 6.1
(SD 1.4)
Mean 6.0
(SD 1.9)
– Mean 22
(SD 22.9)
NR – – –
Giardina
2010
88
AS Etanercept 25 80 Mean 32.6
(SD 6.8)
NR Mean 15.7 Mean 6.6
(SD 1.1)
Mean 6.5
(SD 1.1)
Mean 3.9
(SD 1.7)
Mean 22.9 96 – – –
AS Infliximab 25 76 Mean 31.9
(SD 9.2)
NR Mean 15.4 Mean 6.5
(SD 1.2)
Mean 6.1
(SD 0.9)
Mean 3.7
(SD 1.6)
Mean 25 92 – – –
GO-RAISE
200890
AS Golimumab
50mg
138 74 Median 38 90 Median 11 Median 6.6
(IQR 5.6–7.6)
Median 5
(IQR 3.2–6.7)
Median 3
(IQR 2–4)
Mean 11 82 Median
46.5 (IQR
36.8–54.1)
Median
29.7 (IQR
22.5–35.3)
–
AS Golimumab
100mg
140 70 Median 38 88 Median 9.5 Median 7
(IQR 6.0–7.9)
Median 5.4
(IQR 3.4 to
7.3)
Median 3
(IQR 2–5)
Mean 9 84 Median
43.1 (IQR
33.5–53.5)
Median
29.8 (IQR
25.2–35.5)
–
AS Placebo 78 71 Median 41 92 Median 16.0 Median 6.6
(IQR 5.7–7.7)
Median 4.9
(IQR 3.5–6.8)
Median 4
(IQR 2–5)
Mean 11.5 85 Median
46.2 (IQR
37.1–54.8)
Median
28.3 (IQR
23.8–34.1)
–
Bao 2014
95
AS Golimumab 108 83 Mean 30.5
(SD 10.3)
67 Mean 6.8 Mean 6.6
(1.3)
Mean 5
(SD 2.4)
Mean 4
(SD 1.9)
Mean 20.6 – Mean 36.5
(SD 10.5)
Mean 33.2
(SD 7.8)
–
AS Placebo 105 83 Mean 30.6
(SD 8.6)
72 Mean 7.5 Mean 6.5
(1.5)
Mean 5
(SD 2.4)
Mean 3.8
(SD 1.6)
Mean 18.6 – Mean 36.2
(SD 11.5)
Mean 33.9
(SD 7.7)
–
Tam 201497 AS Golimumab 20 90 Mean 35.6
(SD 9.9)
85 Mean 8.0 Mean 6.2
(1.0)
Mean 4.6
(SD 1.9)
Median 5.0
(IQR 4.0–7.0)
Mean 23.9
(SD 18.6)
– – – –
AS Placebo 21 90 Mean 34.2
(SD 10)
100 Mean 11.0 Mean 6.2
(1.5)
Mean 4.1
(SD 2.3)
Median 3
(IQR 2.0–5.5)
Mean 19.9
(SD 14.0)
– – – –
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Trial
Patient
group Trial arm n % male Age (years)
% on a
NSAID
Symptom
duration
(years)
BASDAI
score
BASFI
score
BASMI
score
CRP level
mg/l, (SD)
% HLA-B27
positive
SF-36 MCS
score
SF-36 PCS
score
ASQoL
score
Barkham
200950
nr-AxSpA Infliximab 20 75 Mean 29.5 90 Mean 13.4 Mean 5.9 Mean 4.4 – Median 5 100 – – Mean 10
nr-AxSpA Placebo 20 75 Mean 28.2 90 Mean 17.2 Mean 5.8 Mean 4.1 – Median
11.5
100 – – Mean 11
Braun 200298 AS Infliximab 34 68 Mean 40.6
(SD 8)
NR Mean 16.4 Mean 6.5
(1.2)
Mean 5.4
(SD 1.8)
Mean 3.7
(SD 2.0)
Mean 24 91 Mean 51.5
(SD 22.6)
Mean 46.5
(SD 22.6)
-
AS Placebo 35 63 Mean 39
(SD 9.1)
NR Mean 14.9 Mean 6.3
(1.4)
Mean 5.1
(SD 2.2)
Mean 3.7
(SD 2.2)
Mean 18 88 Mean 65.4
(SD 18.4)
Mean 47.6
(SD 23.4)
–
Marzo-Ortega
2005
100
AS Infliximab 28 82 Mean 41 89 Median 8 Mean 6.5
(1.9)
Median 6.7 – Median
30.5
96 – – Median 14
AS Placebo 14 79 Mean 39 86 Median 10 Mean 6.6
(2.1)
Median 6 – Median 30 86 – – Median
13.5
Van den
Bosch 2002
101
AS Infliximab 9 78 Mean 44.3 NR Mean 10 Median 5.9 Median 4.7 Median 5 Mean 41.0 89 – – –
AS Placebo 12 83 Mean 46.4 NR Mean 17 Median 5.3 Median 5.9 Median 4 Mean 25.7 75 – – –
ASSERT
2005102
AS Infliximab 201 78 Median 40 NR Mean 7.7 Median 6.6
(IQR 5.2–
7.1)
Median 5.7
(IQR 4.5–
7.1)
– Mean 15 87 Median
47.6 (IQR
37.6–54.9)
Median
28.8 (IQR
23.8–33.7)
–
Park 2013
110
AS Placebo 78 87 Median 41 NR Mean 13.2 Median 6.5
(IQR 5.3–
7.6)
Median 6
(IQR 4.1–
7.2)
– Mean 17 89 Median 45
(IQR 33.7–
55.5)
Median
30.1 (IQR
24.9–36.2)
–
PLANETAS
2013
110
AS CT-P13 125 79 Median 38 NR – Mean 6.7
(SD 1.4)
Mean 6.2
(SD 1.9)
Mean 4 (SD
2.1)
Median 11 – – – –
AS Infliximab 125 82 Median 38 NR – Mean 6.6
(SD 1.6)
Mean 6.2
(SD 2.2)
Mean 4.1
(SD 2.1)
Median 14 – – – –
ASQoL, Ankylosing Spondylitis Quality of Life; ASSERT, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy; ATLAS, Adalimumab Trial Evaluating Long-term
Efficacy and Safety for Ankylosing Spondylitis; CER, certolizumab pegol; CiC, commercial-in-confidence; IQR, interquartile range; NR not reported; SE, standard error.
a Licensed population.
b Includes a small proportion (12%) of unlicensed patients.
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Risk of bias
Results of the risk of bias judgements are presented in Table 4. Further details, including judgement
reasons and the prognostic indicators of important baseline imbalance, are available in Appendix 3. Most
trials were judged to have a low risk of bias overall; when possible bias was detected, there was little
indication to suggest that this varied across the different anti-TNF trials.
Over half the trials did not report adequate details about methods of randomisation and allocation
concealment, although in the majority of those trials (8 out of 14) an assessment could be made of
whether or not groups were balanced in all five of the important prognostic indicators of treatment
response. Using both randomisation method details and a baseline assessment to judge the risk of
selection bias, 15 trials were judged as having a low risk of selection bias, five trials were judged as having
an unclear risk51,71,86,96,112 and four as having a high risk;50,79,83,101 in one of these four trials the risk was
deemed likely to be a result of a chance effect.79
The risk of performance bias arising from lack of blinding of participants and personnel was low in
20 trials, unclear in three trials55,57,64 and high in the one head-to-head trial, in which blinding would have
been difficult to achieve because of the different modes and timings of delivery (weekly injection for
etanercept vs. 6-weekly infusion for infliximab).88 All except one of the trials were at low risk of detection
bias, as they were all adequately placebo controlled (except the head-to-head trial), with nearly all the key
outcomes being self-reported by patients (a notable exception being BASMI). The blinded patients were
the outcome assessors, and the effect of any unblinded study personnel on patient questionnaire
responses was likely to be minimal at most. The proportion of patients withdrawing or dropping out of
trials was generally low; most trials received low risk judgements for attrition bias. In two of the trials with
unclear risk judgements, there were nevertheless reasons to suspect the possibility of important bias (see
Appendix 3).55,71 Of the studies with missing data which also reported details on the populations and
imputations used in analyses, ‘last observation carried forward’ (LOCF) was used; this was done using a
modified intention-to-treat (mITT) approach in just over half the trials (in which patients had to have
received at least one dose of treatment) and an intention-to-treat (ITT) approach in the remaining trials
(see Appendix 3). There was no evidence of reporting bias in any of the trials with all being judged as low
risk, except for one trial with an unclear risk of bias.55
Clinical effectiveness results: efficacy results from randomised
controlled trials
Individual results for all 24 trials are presented in Appendix 4.
Exclusions from the meta-analyses
Of the trials with results at between 10 and 16 weeks, one small head-to-head trial (n= 50) comparing
etanercept with infliximab was excluded, as it was redundant in a class-effect model (in addition, blinding
was not feasible in this trial).88 One trial110 was excluded because it compared infliximab and CT-P13, and
therefore did not include any of the relevant comparators needed for meta-analysis. The maximum number
of studies included for any one outcome was 16.
Exclusions from the sensitivity analyses
Five studies were excluded in the sensitivity analyses because of risk of bias judgements.55,71,79,83,101 Further
details can be found in Appendix 3. A sensitivity analysis of the nr-AxSpA trials was not performed, as the one
trial judged to have a high risk of bias had only 40 patients;50 any effect arising from the removal of such a
small study would have been likely to have been minimal.
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TABLE 4 Risk of bias assessment results
Trial
Bias domain
1. Sequence
generation
2. Allocation
concealment
3. Important
baseline
imbalance
Selection bias
based on 1, 2,
and 3
4. Blinding of
participants
and personnel
5. Blinding
of outcome
assessment
6. Incomplete
outcome data
7. Selective
reporting
Risk of bias judgement
Adalimumab vs. placebo
Haibel 200852 Unclear Unclear Unclear Unclear Low Low Low Low
Hu 201255 Unclear Unclear Low Low Unclear Low Unclear Unclear
Huang 201456 Low Low Low Low Low Low Low Low
Lambert 200757 Unclear Unclear Low Low Unclear Low Low Low
ABILITY-1 201358 Low Low Low Low Low Low Low Low
ATLAS 200661 Unclear Unclear Low Low Low Low Low Low
Certolizumab pegol vs. placebo
RAPID-axSpA 201464 Low Low Low Low Unclear Low Low Low
Etanercept vs. placebo
Barkham 201071 Unclear Unclear Unclear Unclear Low Low Unclear Low
Davis 200372 Unclear Unclear Low Low Low Low Low Low
Dougados 201174 Unclear Unclear Low Low Low Low Low Low
Dougados 201476 Low Low Low Low Low Low Low Low
Gorman 200279 Low Low Higha Higha Low Low Low Low
Calin 200483 Unclear Unclear High High Low Low Low Low
van der Heijde 200686 Unclear Unclear Unclear Unclear Low Low Low Low
continued
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TABLE 4 Risk of bias assessment results (continued )
Trial
Bias domain
1. Sequence
generation
2. Allocation
concealment
3. Important
baseline
imbalance
Selection bias
based on 1, 2,
and 3
4. Blinding of
participants
and personnel
5. Blinding
of outcome
assessment
6. Incomplete
outcome data
7. Selective
reporting
Risk of bias judgement
Etanercept vs. infliximab
Giardina 201088 High High Low Low High High Low Low
Golimumab vs. placebo
GO-RAISE 200890 Low Low Low Low Low Low Low Low
Bao 201495 Unclear Unclear Unclear Unclear Low Low Unclear Low
Tam 201497 Low Unclear Unclear Unclear Low Low Low Low
Infliximab vs. placebo
Barkham 200950 Unclear Unclear High High Low Low Low Low
Braun 200298 Low Low Low Low Low Low Low Low
Marzo-Ortega 2005100 Low Low Unclear Low Low Low Unclear Low
Van den Bosch 2002101 Unclear Unclear High High Low Low Low Low
ASSERT102 Unclear Unclear Low Low Low Low Low Low
Infliximab vs. biosimilar infliximab (InflectraCT-P13)
PLANETAS 2013110 Low Low Unclear Low Low Low Low Low
ASSERT, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy; ATLAS, Adalimumab Trial Evaluating Long-term Efficacy and Safety for Ankylosing Spondylitis.
a Judged to be likely to be because of chance.
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The best model
Models were run when it was assumed that:
l there were different independent treatment effects
l there was just one treatment class effect.
In addition, fixed-effect and random-effects models were run when there were sufficient data. These
models relate to models A1, A2, A3 and A4 in Chapter 5. For the non-radiographic population, there were
very few studies and therefore only fixed-effect analyses were conducted.
The DIC and I2 results for each outcome (other than injection site reactions) are shown for the AS
population in Table 5 and for the nr-AxSpA population in Table 6. The lower the DIC for a given outcome,
the better the model fit. I2 varies between 0% and 100%, with 0% representing no heterogeneity in the
results and 100% indicating that all of the variation in the results can be explained by heterogeneity.
The greater the value of I2, the more likely it is that a random-effects model would be a better fit. But this
is not always the case, as if there are few studies then there will be significant uncertainty around the
between-study variance and therefore the I2 also. Random-effect model results and I2 results are not
presented for some outcomes because of sensitivity to prior distributions in the model.
Overall, assuming a class effect for the treatments produced a better-fitting model than assuming
independent treatment effects. In addition, a fixed-effect analysis was more often than not appropriate.
The mean and median effects of the two analyses were also similar. Hence the fixed-effect results are
reported in this chapter; these represent a common class effect.
For AS, the common class-effect model was found to be a much better fit than the independent treatment
effect model. As described in Chapter 5 the exchangeable class-effect model, not explored here, also fitted
the data well, although not so well as the common class-effect model. It should be noted here that the
common class-effect model may possibly underestimate the uncertainty around the treatment effect
estimate. As explained in Chapter 5, if the differences between treatments are a result of systematic
TABLE 5 The AS population model DIC statistics
Outcome
Independent effects Class effect
I2 (%)Fixed effect Random effects Fixed effect Random effects
Related model in Chapter 5 A1 A2 A3 A4 –
BASDAI 50 16.82 – 10.86 12.71 21
BASDAI 16.76 18.22 13.53 15.12 21
BASFI 18.96 20.87 14.79 16.80 10
ASAS 20 10.68 17.05 9.98 8.73 16
ASAS 40 10.36 14.07 8.50 10.29 27
ASAS 50 8.38 – 6.68 8.11 52
ASAS 70 2.92 – – – –
BASMI –0.87 – 0.12 –3.01 77
SF-36 PCS 19.64 – 20.20 17.71 76
MASES 5.99 – 4.17 – –
SF-36 MCS 19.20 – 16.67 18.26 47
MASES, Maastricht Ankylosing Spondylitis Enthesitis Score.
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differences in study design between treatments, then an exchangeable class-effect model may be
appropriate. However, if in fact there is a true difference between treatments, such as between infliximab
and the other TNF-inhibitors, then an exchangeable class-effect model may overestimate the uncertainty
around the effect estimates. As the common class-effect model had a lower DIC than the exchangeable
class-effect model, this is the model evaluated in this chapter. The economic model explores the
assumption that treatment effect differences are in fact because of systematic differences in study design
between treatments.
As there was very little difference between the results in which change from baseline was imputed
assuming a within-study correlation of 0.3 or 0.7, only the results assuming a within-study correlation of
0.3 are reported here. A comparison of the results assuming different within-study correlations is
presented in Appendix 5.
Individual anti-tumour necrosis factors compared with placebo
Binary responder outcomes at between 10 and 16 weeks
The results of the analyses of the responder outcomes between 10 and 16 weeks for patients with AS are
presented in Table 7.
Assessment in Ankylosing Spondylitis improvement criteria: Assessment in Ankylosing
Spondylitis 20, Assessment in Ankylosing Spondylitis 40, Assessment in
Ankylosing Spondylitis 50 and Assessment in Ankylosing Spondylitis 70
For the AS population ASAS 20 data were available for all five anti-TNFs, although the number of
participants studied varied considerably, ranging from 839 patients in five etanercept trials to 111 patients
in two infliximab trials. A consistent effect was evident across the treatments with the pooled relative risks
ranging from 1.80 (certolizumab pegol) to 2.45 (infliximab). ASAS 40 data were available for four
anti-TNFs (no data were available for infliximab); the number of data available ranged from 178 patients in
one certolizumab trial to 659 patients in two adalimumab trials. Again, a consistent effect was found, with
relative risks ranging from 2.53 (certolizumab pegol) to 3.42 (adalimumab); all the relative risks were
TABLE 6 The nr-AxSpA population model DIC statistics
Outcome
Independent effects Class effect
I2 (%)Fixed effect Random effects Fixed effect Random effects
Related model in Chapter 5 A1 A2 A3 A4 –
BASDAI 50 6.74 – 4.85 – –
BASDAI 10.80 – 11.07 11.51 69
BASFI 11.45 – 13.74 10.70 83
ASAS 20 6.72 – 5.23 – –
ASAS 40 11.17 – 7.96 9.30 49
ASAS 50 – – – – –
ASAS 70 – – – – –
BASMI 1.80 – 4.74 2.42 89
SF-36 PCS 16.67 – 20.18 – –
MASES – – – – –
SF-36 MCS 14.61 – 14.08 – –
MASES, Maastricht Ankylosing Spondylitis Enthesitis Score.
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TABLE 7 Results versus placebo for AS population: response outcomes at between 10 and 16 weeks
Intervention
Type of
analysis
ASAS 20 ASAS 40 ASAS 50 BASDAI 50
Number
of trials
(number of
patients)
Relative
risk
(95% CrI)
OR
(95% CrI)
Number
of trials
(number of
patients)
Relative
risk
(95% CrI)
OR
(95% CrI)
Number
of trials
(number of
patients)
Relative
risk
(95% CrI)
OR
(95% CrI)
Number
of trials
(number of
patients)
Relative
risk
(95% CrI)
OR
(95% CrI)
Adalimumab Main 3 (741) 2.28 (1.98
to 2.62)
4.52 (3.23
to 6.33)
2 (659) 3.42 (2.57
to 4.55)
5.67 (3.56
to 8.97)
1 (82) 2.75 (1.11
to 5.45)
3.58 (1.12
to 11.17)
2 (659) 3.16 (2.40
to 4.16)
4.68 (3.14
to 7.03)
Sensitivity 3 (741) 2.27 (1.97
to 2.62)
4.52 (3.23
to 6.33)
2 (659) 3.34 (2.53
to 4.40)
5.67 (3.56
to 8.97)
As in the main analysis 2 (659) 3.11 (2.37
to 4.09)
4.68 (3.14
to 7.03)
Certolizumab
pegol
Main 1 (178) 1.80 (1.24
to 2.39)
2.61 (1.37
to 5.01)
1 (178) 2.53 (1.47
to 3.98)
3.38 (1.59
to 7.15)
– – – 1 (178) 3.60 (2.02
to 5.74)
5.97 (2.39
to 15.03)
Sensitivity 1 (178) 1.80 (1.24
to 2.39)
2.61 (1.37
to 5.01)
1 (178) 2.49 (1.46
to 3.87)
3.38 (1.59
to 7.15)
– – – 1 (178) 3.53 (2.00
to 5.58)
5.97 (2.39
to 15.03)
Etanercept Main 5 (839) 2.23 (1.93
to 2.55)
4.23 (3.05
to 5.88)
3 (478) 2.75 (1.88
to 3.88)
3.86 (2.21
to 6.72)
2 (359) 3.43 (2.40
to 4.90)
5.04 (2.98
to 8.51)
3 (478) 3.17 (2.20
to 4.49)
4.74 (2.71
to 8.28)
Sensitivity 3 (715) 2.17 (1.84
to 2.53)
3.98 (2.78
to 5.73)
2 (436) 2.65 (1.80
to 3.72)
3.72 (2.11
to 6.53)
As in the main analysis 2 (436) 3.03 (2.08
to 4.31)
4.50 (2.52
to 8.01)
Golimumab Main 2 (429) 2.14 (1.75
to 2.53)
3.82 (2.47
to 5.86)
2 (429) 3.11 (2.24
to 4.26)
4.77 (2.85
to 7.98)
– – – 2 (429) 3.57 (2.51
to 5.00)
5.85 (3.31
to 10.28)
Sensitivity 2 (429) 2.13 (1.74
to 2.53)
3.82 (2.47
to 5.86)
2 (429) 3.05 (2.21
to 4.13)
4.77 (2.85
to 7.98)
– – 2 (429) 3.50 (2.48
to 4.88)
5.85 (3.31
to 10.28)
Infliximab Main 2 (111) 2.45 (1.73
to 3.06)
5.54 (2.41
to 12.71)
– – – 1 (69) 5.59 (2.44
to 9.81)
14.71
(3.07 to
72.69)
1 (69) 4.86 (2.41
to 7.82)
12.07
(3.09 to
46.37)
Sensitivity 2 (111) 2.44 (1.72
to 3.06)
5.54 (2.41
to 12.71)
– – – As in the main analysis 1 (69) 4.72 (2.38
to 7.54)
12.07
(3.09 to
46.37)
Anti-TNFs as
a class
Main 13 (2298) 2.21 (2.01
to 2.43)
4.12 (3.40
to 4.99)
8 (1744) 3.06 (2.52
to 3.76)
4.61 (3.51
to 6.05)
4 (510) 3.51 (2.55
to 4.86)
5.23 (3.31
to 8.27)
9 (1813) 3.37 (2.75
to 4.16)
5.22 (4.00
to 6.79)
Sensitivity 11 (2174) 2.18 (1.97
to 2.42)
4.04 (3.32
to 4.92)
7 (1702) 2.99 (2.47
to 3.66)
4.57 (3.48
to 6.02)
As in the main analysis 8 (1771) 3.29 (2.68
to 4.07)
5.16 (3.94
to 6.72)
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5
greater than the corresponding ASAS 20 estimates. For ASAS 50 there were two trials of etanercept
(totalling 359 participants) and small single trials in adalimumab (n= 82) and infliximab (n= 69). A wider
range of relative risks and CrIs resulted, ranging from 2.75 (adalimumab) to 5.59 (infliximab), which may
be a consequence of the smaller numbers of patients studied. Only two trials, both of etanercept
(n= 359), reported actual numbers of ASAS 70 responders. The pooling of these data showed that
patients taking etanercept were more than three times more likely to be ASAS 70 responders than patients
taking placebo (relative risk 3.59, 95% CrI 2.18 to 5.87).
For the nr-AxSpA population, each of the relative risks for certolizumab pegol and etanercept were based
on single, quite large trials; the estimate for adalimumab was based on a similar number of patients (to
etanercept and certolizumab) across two trials, whereas infliximab was represented by a single small trial
(n= 40). ASAS 20 results were similar across treatments but for ASAS 40 heterogeneity of effect appeared
evident; the smallest estimate was for etanercept and the largest estimate was seen in the small infliximab
trial (Table 8). However, this infliximab trial was the only nr-AxSpA trial judged to be at high risk of bias.
Only one trial (ABILITY-158) reported ASAS 50 or ASAS 70 results. For ASAS 50 the relative risk was 4.23
(95% CrI 1.84 to 9.72; OR 5.96, 95% CrI 2.40 to 14.80). For ASAS 70 the relative risk was 4.58 (95% CrI
1.37 to 15.40; OR 5.42, 95% CrI 1.54 to 19.11).
Bath Ankylosing Spondylitis Disease Activity Index 50
For the AS population BASDAI 50 data were available for all five anti-TNFs; the number of participants
studied varied widely, ranging from 69 patients in one infliximab trial to 659 patients in two adalimumab
trials. Although a consistent beneficial effect was evident across treatments, some heterogeneity of effect
could be seen with the relative risks ranging from 3.16 (adalimumab) to 4.86 (infliximab).
For the nr-AxSpA population the relative risks were lower than for the AS population being 2.52 (95% CrI
1.65 to 3.83, two trials) for adalimumab, 2.80 (95% CrI 1.71 to 4.47, one trial) for certolizumab and
1.92 (95% CrI 1.27 to 2.82, one trial) for etanercept (see Table 8).
Results of the AS sensitivity analyses were very similar to those of the main analyses (see Table 7).
Continuous outcomes at between 10 and 16 weeks
The results of the analyses of the continuous efficacy outcomes for patients with AS are presented in
Table 9.
For the AS population, when compared with placebo, adalimumab (n= 705), certolizumab pegol (n= 178),
etanercept (n= 483) and infliximab (n= 132) produced statistically significant reductions in disease activity,
when assessed using BASDAI. The magnitude of the reductions in change from baseline BASDAI score
ranged from 1.46 units (certolizumab pegol) to 2.28 units (infliximab). None of the three golimumab trials
reported BASDAI as a continuous outcome. The number of data available for BASFI in patients with AS
ranged from 132 patients in three infliximab trials, to 523 patients in five etanercept trials. When
compared with placebo, all five anti-TNFs produced statistically significant improvements in function. The
magnitude of the reductions in change from baseline BASFI score ranged from 1.1 units (certolizumab
pegol) to 2.16 units (infliximab). When compared with placebo, statistically significant improvements in
BASMI scores were found for AS patients taking adalimumab (mean difference in change from baseline
–0.37 units, 95% CrI –0.50 to –0.23 units) and etanercept (mean difference in change from baseline
–0.37 units, 95% CrI –0.65 to –0.09 units) but not for certolizumab pegol (mean difference in change
from baseline –0.26 units, 95% CrI –0.55 to 0.03 units) and golimumab (mean difference in change from
baseline –0.11 units, 95% CrI –0.26 to 0.04 units). Results for SF-36 MCS, SF-36 PCS and ethesitis
[Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)] are presented in Table 9.
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TABLE 8 Results vs. placebo for nr-AxSpA population: response outcomes at 10–16 weeks
Intervention
ASAS 20 ASAS 40 BASDAI 50
Number of
trials (number
of patients)
Relative risk
(95% CrI)
OR
(95% CrI)
Number of
trials (number
of patients)
Relative risk
(95% CrI)
OR
(95% CrI)
Number of
trials (number
of patients)
Relative risk
(95% CrI)
OR
(95% CrI)
Adalimumab 2 (188) 1.92
(1.47 to 2.56)
3.71
(2.02 to 6.75)
2 (188) 3.14
(1.99 to 4.68)
5.04
(2.44 to 10.32)
2 (188) 2.52
(1.65 to 3.83)
3.97
(1.97 to 7.86)
Certolizumab pegol 1 (147) 1.59
(1.10 to 2.21)
2.32
(1.15 to 4.67)
1 (147) 3.04
(1.74 to 4.81)
4.75
(2.01 to 11.17)
1 (147) 2.80
(1.71 to 4.47)
4.92
(2.09 to 11.58)
Etanercept 1 (215) 1.46
(1.08 to 1.94)
1.94
(1.13 to 3.37)
1 (215) 2.07
(1.26 to 3.20)
2.55
(1.32 to 4.92)
1 (215) 1.92
(1.27 to 2.82)
2.45
(1.37 to 4.43)
Infliximab – – – 1 (40) 3.63
(1.41 to 6.44)
6.85
(1.52 to 31.03)
– – –
Anti-TNFs as a class 4 (550) 1.65
(1.37 to 2.04)
2.52
(1.78 to 3.59)
5 (590) 2.74
(2.08 to 3.62)
3.92
(2.61 to 5.91)
4 (550) 2.31
(1.76 to 3.10)
3.33
(2.24 to 4.96)
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TABLE 9 Results vs. placebo for AS population: continuous outcomes at 10–16 weeks
Intervention
Type of
analysis
BASDAI score BASFI score
Number of trials
(number of patients)
Mean difference
in change from
baseline (95% CrI)
Number of trials
(number of patients)
Mean difference
in change from
baseline (95% CrI)
Adalimumab Main 3 (705) –1.55 (–1.88
to –1.22)
2 (390) –1.25 (–1.63
to –0.87)
Sensitivity 2 (659) –1.55 (–1.89
to –1.21)
1 (344) –1.28 (–1.68
to –0.88)
Certolizumab
pegol
Main 1 (178) –1.46 (–2.17
to –0.74)
1 (178) –1.10 (–1.83
to –0.37)
Sensitivity Same as the main analysis Same as the main analysis
Etanercept Main 4 (483) –1.75 (–2.14
to –1.37)
5 (523) –1.43 (–1.82
to –1.04)
Sensitivity 2 (359) –1.72 (–2.16
to –1.29)
2 (359) –1.29 (–1.76
to –0.84)
Golimumab Main – – 2 (429) –1.45 (–1.84
to –1.05)
Sensitivity – – Same as the main analysis
Infliximab Main 3 (132) –2.28 (–3.18
to –1.38)
3 (132) –2.16 (–3.18
to –1.12)
Sensitivity 2 (111) –2.18 (–3.14
to –1.21)
2 (111) –1.94 (–3.07
to –0.80)
Anti-TNFs as
a class
Main 11 (1498) –1.66 (–1.88
to –1.43)
13 (1652) –1.38 (–1.59
to –1.18)
Sensitivity 7 (1305) –1.63 (–1.88
to –1.39)
8 (1419) –1.34 (–1.57
to –1.12)
MASES, Maastricht Ankylosing Spondylitis Enthesitis Score.
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BASMI score SF-36 PCS score SF-36 MCS score MASES
Number
of trials
(number of
patients)
Mean
difference
in change
from
baseline
(95% CrI)
Number
of trials
(number of
patients)
Mean
difference
in change
from
baseline
(95% CrI)
Number
of trials
(number of
patients)
Mean
difference
in change
from
baseline
(95% CrI)
Number
of trials
(number of
patients)
Mean
difference
in change
from
baseline
(95% CrI)
2 (659) –0.37 (–0.50
to –0.23)
2 (659) 3.53 (2.37
to 4.68)
2 (659) 1.41 (–0.19
to 3.02)
2 (659) –0.50 (–0.89
to –0.11)
Same as the main analysis Same as the main analysis Same as the main analysis Same as the main analysis
1 (178) –0.26 (–0.55
to 0.03)
1 (178) 5.64 (3.64
to 7.66)
1 (178) 1.25 (–2.08
to 4.61)
– –
Same as the main analysis Same as the main analysis Same as the main analysis – –
1 (82) –0.37 (–0.65
to –0.09)
– – – – –
Same as the main analysis – – – – –
2 (429) –0.11 (–0.26
to 0.04)
2 (429) 5.06 (3.71
to 6.40)
2 (429) 2.75 (1.08
to 4.40)
1 (216) –0.70 (–1.53
to 0.11)
Same as the main analysis Same as the main analysis Same as the main analysis Same as the main analysis
– – – – – – – –
– – – – – – – –
6 (1348) –0.27 (–0.36
to –0.18)
5 (1266) 4.40 (3.60
to 5.21)
5 (1266) 1.93 (0.12
to 3.72)
3 (875) –0.54 (–0.89
to –0.19)
Same as the main analysis Same as the main analysis Same as the main analysis Same as the main analysis
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For the nr-AxSpA population, a heterogeneity of effect on BASDAI and BASFI appears evident from the
relative risks of the individual anti-TNFs. The smallest estimates were for etanercept and the largest
estimates were seen in the small infliximab trial, although this trial was the only nr-AxSpA trial judged to
be at high risk of bias (Table 10).
Results of the AS sensitivity analyses were very similar to those of the main analyses (see Table 9).
When the mean baseline BASDAI and BASFI are presented by treatment response at week 12 (or 14 for
golimumab) for three of the five anti-TNFs (see Appendix 6), it can be seen that in patients with AS and
patients with nr-AxSpA, on average baseline BASDAI does not differ greatly between responders and
non-responders to either placebo or active anti-TNF therapy. In patients with AS or nr-AxSpA from the
trials of adalimumab [ATLAS (Adalimumab Trial Evaluating Long-term Efficacy and Safety for Ankylosing
Spondylitis)61 and ABILITY-158] and golimumab (GO-RAISE90) on average baseline BASFI was higher in
non-responders compared with responders. However, this was not seen in the etanercept trials.
Individual anti-tumour necrosis factors compared with each other
For efficacy outcomes, all of the comparisons that could be made between different anti-TNFs at 10–16 weeks
resulted in no statistically significant differences between treatments. For the full results see Appendix 7.
One small trial, which could not be included in the meta-analysis (see Study characteristics), compared
infliximab with etanercept in a 2-year unblinded randomised study of 50 AS patients.88 At 12 weeks there
were statistically significant differences between groups in terms of BASDAI score (3.5 vs. 5.6; p< 0.005)
and BASFI score (3.5 vs. 5; p< 0.005), favouring treatment with infliximab. By week 48, the BASDAI and
BASFI scores were almost identical across the treatment groups (data were only presented graphically).
In addition, at 12 weeks 19 of 25 infliximab patients were ASAS 20 responders compared with 15 of
25 etanercept patients (not a statistically significant difference). This study concluded that infliximab
produces a more rapid clinical improvement, but, at the end of the study, treatment with both etanercept
and infliximab was effective and safe. The results of this trial may explain why at 10–16 weeks the
meta-analysis results for infliximab were a little better than those of the other anti-TNFs.
Another trial which could not be included in the meta-analysis compared infliximab with an infliximab
biosimilar called CT-P13 in 250 AS patients.110 The ASAS 40 response rates at week 14 were 42% for
CT-P13 and 46% for infliximab [OR 0.85; 95% confidence interval (CI) 0.51 to 1.42] and at week 30 they
were 52% for CT-P13 and 47% for infliximab (OR 1.19, 95% CI 0.70 to 2.00). At week 14 BASDAI
median change from baseline scores were identical (–2.7) and at week 30 they differed slightly (–3.1
CT-P13 vs. –2.5 infliximab). For BASFI the median change from baseline scores were –2.2 CT-P13 versus
–2.4 infliximab at week 14 and –2.6 CT-P13 versus –2.2 infliximab at week 30. The study concluded that
CT-P13 had a comparable efficacy and safety profile with that of infliximab.
Anti-tumour necrosis factors as a class compared with placebo
Within this section the class effect, calculated as a common effect across all the TNF-inhibitors under
consideration, assumes a single treatment effect for all the TNF-inhibitors. It is calculated as the pooled
treatment effect using a fixed effect model. The common class-effect model may possibly underestimate
the uncertainty around the treatment effect estimate. As explained in Chapter 5, if the differences
between treatments is a result of systematic differences in study design between treatments then an
exchangeable class-effect model may be appropriate. However, if in fact there is a true difference between
treatments, such as between infliximab and the other TNF-inhibitors, then an exchangeable class-effect
model may overestimate the uncertainty around the mean class-effect estimates. As the common
class-effect model had a lower DIC than the exchangeable class-effect model, this is the model evaluated
in this chapter. The economic model in Chapter 6 explores the assumption that treatment effect
differences are because of differences in study design between treatments.
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TABLE 10 Results vs. placebo for nr-AxSpA population: continuous outcomes at between 10 and 16 weeks
Intervention
BASDAI score BASFI score BASMI score SF-36 PCS score SF-36 MCS score
Number
of trials
(number of
patients)
Mean
difference in
change from
baseline
(95% CrI)
Number
of trials
(number of
patients)
Mean
difference in
change from
baseline
(95% CrI)
Number
of trials
(number of
patients)
Mean
difference in
change from
baseline
(95% CrI)
Number
of trials
(number of
patients)
Mean
difference in
change from
baseline
(95% CrI)
Number
of trials
(number of
patients)
Mean
difference in
change from
baseline
(95% CrI)
Adalimumab 2 (188) –1.23 (–1.83
to –0.62)
2 (188) –0.90 (–1.44
to –0.36)
2 (188) –0.02 (–0.24
to 0.20)
2 (188) 4.98 (2.74
to 7.20)
2 (188) 1.13 (–1.86
to 4.13)
Certolizumab pegol 1 (147) –1.85 (–2.83
to –0.88)
1 (147) –1.90 (–2.87
to –0.94)
1 (147) –0.55 (–0.89
to –0.20)
1 (147) 6.99 (4.23
to 9.76)
1 (147) 4.01 (0.44
to 7.53)
Etanercept 1 (215) –0.70 (–1.54
to 0.12)
1 (215) –0.60 (–1.16
to –0.06)
– – – – – –
Infliximab 1 (40) –2.67 (–4.21
to –1.13)
1 (40) –2.24 (–3.67
to –0.80)
1 (40) 0.00 (–0.44 to
0.44)
1 (40) 2.10 (–0.21
to 4.37)
– –
Anti-TNFs as a class 5 (590) –1.32 (–1.74
to –0.90)
5 (590) –0.99 (–1.34
to –0.64)
4 (375) –0.15 (–0.32
to 0.02)
4 (375) 4.41 (3.04
to 5.81)
3 (335) 2.33 (0.07
to 4.62)
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Binary responder outcomes at between 10 and 16 weeks
Assessment in Ankylosing Spondylitis improvement criteria – ASAS 20, ASAS 40, ASAS 50 and
ASAS 70 When compared with placebo, anti-TNFs as a common class were more than twice as likely to
result in patients with AS achieving an ASAS 20 response (relative risk 2.21, 95% CrI 2.01 to 2.43;
13 trials, see Table 7). Anti-TNFs were also around three times as likely to result in patients achieving an
ASAS 40 response (relative risk 3.06, 95% CrI 2.52 to 3.76; eight trials) and three and a half times as likely
to result in patients achieving an ASAS 50 response (relative risk 3.51, 95% CrI 2.55 to 4.86; four trials).
Only two trials, both of etanercept, reported data suitable for the ASAS 70 analysis; the results are
presented in Individual anti-TNFs compared with placebo. There was little evidence of heterogeneity for
ASAS 20 (I2= 16%) and ASAS 40 (I2= 27%) but heterogeneity was evident for ASAS 50 (I2= 52%).
For ASAS 50, three of the four trials were small (i.e. fewer than 100 participants), which may partly explain
the heterogeneity estimate.
For the nr-AxSpA population anti-TNFs as a common class were statistically significantly more effective
than placebo, although the relative risks being lower than for the AS population. For ASAS 20 the relative
risk was 1.65 (95% CrI 1.37 to 2.04; four trials) and for ASAS 40 the relative risk was 2.74 (95% CrI 2.08
to 3.62; five trials). Only one trial presented ASAS 50 and ASAS 70 results (see Clinical effectiveness results:
efficacy results from randomised controlled trials). A heterogeneity estimate could be calculated for only
ASAS 40 (I2= 49%).
BASDAI 50 Anti-TNFs as a common class resulted in patients with AS being more than three times more
likely to achieve a BASDAI 50 response than patients taking placebo (relative risk 3.37, 95% CrI 2.75 to
4.16; nine trials). There was little evidence of heterogeneity (I2= 21%).
For the nr-AxSpA population, anti-TNFs as a common class were also statistically significantly more
effective than placebo in terms of achieving a BASDAI 50, although the relative risk was lower than for the
AS population (relative risk 2.31, 95% CrI 1.76 to 3.10; four trials). Results of the AS sensitivity analyses
were very similar to the main analyses (see Table 7).
Binary responder outcomes at between 24 and 30 weeks
Four AS trials reported outcomes at between 24 and 30 weeks (see Table 2). Anti-TNFs as a common class
were statistically significantly more effective than placebo at 24–30 weeks; for ASAS 20 the relative risk
was 1.69 (95% CrI 1.30 to 2.14; four trials). No studies reported BASDAI 50 or ASAS 70 results, and only
single studies reported on ASAS 40 (relative risk 4.01, 95% CrI 2.13 to 7.55)102 and ASAS 50 (relative risk
4.17, 95% CrI 2.45 to 7.12).72
Continuous outcomes at between 10 and 16 weeks
When considered together as a group compared with placebo (see Table 9), treatment with an anti-TNF in
patients with AS produced statistically significant improvements (calculated using mean difference in
change from baseline) in the following areas: disease activity (BASDAI mean difference –1.66 units,
95% CrI –1.88 to –1.43 units; 11 trials); function (BASFI mean difference –1.38 units, 95% CrI –1.59 to
–1.18 units; 13 trials); spinal mobility (BASMI mean difference –0.27 units, 95% CrI –0.36 to –0.18 units);
physical health (SF-36 PCS mean difference 4.40 units, 95% CrI 3.60 to 5.21 units; five trials); mental
health (SF-36 MCS mean difference 1.96 units, 95% CrI 0.87 to 3.05 units; five trials); and enthesitis
(MASES mean difference –0.54 units, 95% CrI –0.89 to –0.19 units; three trials). There was little evidence
of heterogeneity for BASDAI (I2= 21%) and BASFI (I2= 10%), but evidence of substantial heterogeneity for
BASMI (I2= 77%), SF-36 PCS (I2= 76%), SF-36 MCS (I2= 47%) and MASES (I2= 91%).
In the nr-AxSpA population the mean differences achieved with anti-TNFs (see Table 10) were also
statistically significant, although slightly lower than for the AS population. For BASDAI the mean difference
was –1.32 units (95% CrI –1.74 to –0.90; I2= 69%) and for BASFI the mean difference was –0.99 units
(95% CrI –1.34 to –0.64 units; I2= 83%) but there was evidence of substantial heterogeneity. The results
for SF-36 MCS and SF-36 PCS were similar to those for AS (see Table 10).
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Results of the AS sensitivity analyses were very similar to the main analyses (see Table 9). As the results of the
independent treatment effects showed a trend that infliximab had a greater, although not statistically significant,
effect on the change in BASDAI and BASFI from baseline, an additional sensitivity analysis was conducted for
which infliximab was assumed to be different from the rest of the anti-TNFs. The results are presented in
Table 11. The low weight of evidence available for infliximab ensures that the class effect for the other anti-TNFs
does not change greatly. Although it is possible that infliximab has a greater effect than the other anti-TNFs at
least at 12 weeks, there is no strong evidence from these analyses to suggest that it does.
Continuous outcomes at between 24 and 30 weeks
Four AS trials reported outcomes at between 24 and 30 weeks (see Table 2). The mean differences in
change from baseline were –1.98 units (95% CrI –2.27 to –1.68 units, four trials) for BASDAI, –0.87 units
(95% CrI –1.11 to –0.62 units; three trials)72,100,102 for BASFI, and –1.00 unit (95% CrI –1.19 to –0.81 units;
two studies)97,102 for BASMI. One study reported SF-36 outcomes, with differences of 9.40 units (95% CrI
7.88 to 10.92 units) for SF-36 PCS and 0.70 units (95% CrI –1.36 to 2.76 units) for SF-36 MCS.102
Outcomes not included in the meta-analyses
Very few data were available on peripheral symptoms (other than enthesitis, see the MASES results in
Table 9) or symptoms of extra-articular manifestations. One trial reported five cases of inflammatory bowel
disease flare up to the 24-week time point: three occurred in patients on etanercept and two in patients
on placebo.72 Another study reported that there were no cases of inflammatory bowel disease at
12 weeks.86 Incidence of uveitis was also reported in one trial; up to the 24-week time point there were
three cases in the etanercept arm and eight cases in the placebo arm.72
One trial (ABILITY-158) reported statistically significantly improved quality of life, using EQ-5D index scores,
in patients taking adalimumab [change from baseline 0.15 units (SD 0.30 units)] when compared with
those taking placebo [change from baseline 0.06 units (SD 0.28 units)]. A study of adalimumab reported
no statistically significant difference in EQ-5D between groups at 12 weeks (0.78 units for adalimumab vs.
0.72 units for placebo; p= 0.32).51
For Ankylosing Spondylitis Quality of Life (ASQoL), a quality of life instrument specific to AS, ATLAS61 was
the only trial which reported results together with SDs or standard errors (SEs); significant improvements
were found favouring treatment with adalimumab at week 12 [mean change from baseline –3.2 units
(SD 0.3 units) for adalimumab vs. –1 unit (SD 0.4 units) for placebo].62 Similar statistically significant results
were reported in an etanercept trial at 12 weeks (mean change from baseline –3.3 units for etanercept vs.
–0.1 units for placebo; p= 0.02)71 and in an infliximab trial at 16 weeks (mean change from baseline
–6.2 units for infliximab vs. –1 unit for placebo; p= 0.007).50 Another small study of infliximab did not find
a significant difference between groups at 30 weeks (p= 0.14).100
TABLE 11 The difference in change from baseline for BASDAI and BASFI scores assuming all TNFs have the same
effect and assuming infliximab may be different
Category of intervention
BASDAI score BASFI score
Mean 95% CrI Mean 95% CrI
All TNFs –1.66 –1.88 to –1.43 –1.38 –1.59 to –1.18
TNFs other than infliximab –1.62 –1.85 to –1.38 –1.35 –1.56 to –1.14
Infliximab –2.28 –3.18 to –1.38 –2.15 –3.18 to –1.11
DOI: 10.3310/hta20090 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 9
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
33
‘Placebo’ response in ankylosing spondylitis and non-radiographic
axial spondyloarthritis
To inform insight into the extent of any ‘placebo’ effects (outlined in Chapter 1, Description of health
problem), Table 12 compares the placebo response rates in trials which reported ASAS 20 results and at
least one of ASAS 40 or BASDAI 50 results. These data highlight the relatively high rates of ASAS 20
response (median 31%, range 21–40%) when compared with ASAS 40 response (median 15%, range
10–23%) and BASDAI 50 response (median 16%, range 5–24%).
However, the extent of the ‘placebo’ response on the ASAS 20 results might result in an underestimation
of anti-TNF efficacy, notably when ASAS 20 is the only ASAS improvement outcome reported in a trial.
An increase in the likelihood of being a responder (i.e. the relative risks when compared with placebo)
when moving up the ASAS thresholds seems apparent from the results in Clinical effectiveness results:
efficacy results from randomised controlled trials. This might be explained by considering the subset of
patients who achieve an ASAS 20 response largely because of regression to the mean (i.e. because of
natural variation in repeated data measurements, such as patients transitioning from flare at randomisation
to no flare at 12 weeks). For those patients who experience regression to the mean after taking an
anti-TNF, the true benefit of treatment may be hidden in the ASAS 20 outcome for some patients, and the
proportion of ASAS 20 responders might therefore differ only moderately between the anti-TNF and
placebo groups. As the bar for response is raised, from ASAS 20 through to ASAS 70, this difference in
the proportion of responders between active treatment and placebo groups is likely to increase as an
effect because regression to the mean becomes less probable. The diluting effect of a placebo response on
the relative risks therefore diminishes as the ASAS thresholds increase (and more informative estimates of
treatment benefit can be seen). Regardless of the reason, these results highlight the limited applicability of
ASAS 20 as a clinically informative outcome measure. ASAS 20 was nevertheless the most commonly
reported responder outcome across the trials.
Summary of the randomised controlled trial clinical efficacy results
For both the AS and nr-AxSpA populations the results of the meta-analyses demonstrated that anti-TNFs
produce statistically significant and clinically relevant benefits to patients in terms of improving function
and reducing disease activity. The common class-effect model used may have underestimated the
uncertainty in the effect estimates. Although there is a possibility that infliximab is more effective than
other TNF inhibitors, at least at 12 weeks, there is no strong evidence to support this. For the disease
activity, function and responder outcomes, the class-efficacy estimates were consistently slightly smaller for
nr-AxSpA than for AS, most noticeably for BASFI and BASDAI 50.
The included RCTs were generally subject to low risks of bias and no important variation in baseline
characteristics was evident, with the exception of CRP levels: in the nr-AxSpA trial populations CRP levels
were much lower than in the AS populations. Although heterogeneity of CRP levels was evident across
both the AS trials and the nr-AxSpA trials, in almost all the AS trials the CRP levels were higher than the
14mg/l threshold identified as being a key predictor of treatment response (in AS, higher CRP levels
are associated with an increased likelihood of BASDAI 50 response).112 In the nr-AxSpA trials only the
RAPID-axSpA64 population came close to this cut-off point. These lower CRP levels may therefore have had
an impact on the efficacy estimates for the nr-AxSpA population.
Statistical heterogeneity was more apparent in the nr-AxSpA analyses than in the AS analyses. This may be
a result of both clinical heterogeneity in the nr-AxSpA trials (such as variation in CRP thresholds, or the
proportion of MRI positive patients) and the fact that fewer studies were available for analysis. In the light
of the statistical heterogeneity across the nr-AxSpA trials, both the reliability of the nr-AxSpA-pooled
estimates and their true relevance to patients seen in clinical practice are questionable.
The clinical relevance of the efficacy of anti-TNFs can be evaluated in part by considering the literature on
minimum clinically important differences (MCIDs) or minimum clinically important improvements. In a study
of 125 AS patients, Pavy et al.113 reported a MCID of 1 unit (or a 20% relative change) for BASDAI and
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TABLE 12 Comparison of placebo response rates in trials reporting ASAS 20 results together with ASAS 40 or BASDAI 50 results
Population
and study
Placebo
compared
with
Time point
(weeks)
Number of
patients
on placebo
Number of responders % of responders Difference in response (%)
ASAS 20 ASAS 40 BASDAI 50 ASAS 20 ASAS 40 BASDAI 50
ASAS 20 vs.
ASAS 40
ASAS 20 vs.
BASDAI 50
ASAS 40 vs.
BASDAI 50
Nr-axSpA51 Adalimumab 12 24 6 3 5 25 13 21 13 4 –8
AS56 Adalimumab 12 115 35 11 19 30 10 17 21 14 –7
Nr-axSpA58 Adalimumab 12 73 23 10 10 32 14 14 18 18 0
AS61 Adalimumab 12 107 22 14 17 21 13 16 7 5 –3
AS64 Certolizumab 12 57 21 11 6 37 19 11 18 26 9
Nr-axSpA64 Certolizumab 12 50 20 8 8 40 16 16 24 24 0
AS74 Etanercept 12 43 14 10 10 33 23 23 9 9 0
Nr-axSpA76 Etanercept 12 109 39 17 26 36 16 24 20 12 –8
AS86 Etanercept 12 51 19 11 10 37 22 20 16 18 2
AS90 Golimumab 14 78 17 12 12 22 15 15 6 6 0
AS95 Golimumab 14 105 26 10 5 25 10 5 15 20 5
AS98 Infliximab 12 35 10 – 3 29 – 9 – 20 –
Any minor discrepancies in the difference in response columns are because of rounding.
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5
0.7 units (17.5% relative change) for BASFI. All the effect estimates from this review for both BASDAI
and BASFI were considerably higher than these MCIDs. The small effect on spinal mobility (a group effect
reduction of around 0.3 BASMI units) appears unlikely to be clinically important.
Summary of some key issues arising from the Food and Drug Administration
assessments of the ABILITY-158 and RAPID-axSpA64 trials
The FDA Arthritis Advisory Committee met in July 2013 to discuss licence applications for adalimumab for
patients with active nr-AxSpA (with objective signs of inflammation) and certolizumab pegol for patients
with active axSpA, including patients with AS.114 An important issue which arose in both trials was the
differences in diagnoses arising from radiograph images evaluated centrally compared with images being
evaluated locally. The implications for efficacy were explored via further analyses.
RAPID-axSpA64 trial (certolizumab pegol)
This trial aimed to recruit both AS and nr-AxSpA patients.64 The nr-AxSpA patients had to have a positive
MRI or an elevated CRP level; the definition used for CRP level elevation was 7.9mg/l.
Comparison of ankylosing spondylitis and non-radiographic axial spondyloarthritis population
characteristics In AS males predominated (72%), whereas in nr-AxSpA the male-to-female ratio was roughly
equal. The AS population had a mean age of 41.5 years, which was around four years older than the nr-AxSpA
population. Baseline BASFI, BASMI and CRP levels suggested more functional and mobility impairment and
more inflammation in the AS group when compared with the nr-AxSpA group. However, baseline back pain
severity and BASDAI scores were similar between the AS and nr-AxSpA subgroups (Table 13).
Methods used to evaluate radiograph images In the trial, many patients had their disease reclassified
when radiographs were evaluated centrally, rather than being evaluated locally. Two readers were involved
in the central evaluation of the radiographs, they were blinded to both the assigned subgroup and the
treatment group; a third reader was used in cases of disagreement. Twenty-one per cent of locally
classified AS patients were reclassified as nr-AxSpA by central readers and 51% of locally classified
nr-AxSpA patients were reclassified as AS by the central readers. Based on the central assessments
184 patients had AS and 98 patients had nr-AxSpA. Central reads could not be made for 43 patients as
radiographs were not available (37 AS patients and six nr-AxSpA patients).
ABILITY-158 trial (adalimumab)
This trial intended to recruit only nr-AxSpA patients, although this included patients (n= 43) who had
nr-AxSpA but neither a positive MRI nor an elevated CRP level.58 The population with these 43 patients
excluded is referred to as the ‘adalimumab target population’ (ATP). As in the RAPID-axSpA64 trial, central
rereading of radiographs was performed (in addition to local evaluation), although this was only done for
per-protocol patients who also reached week 104 [n= 102 (out of 185) patients]. Thirty-eight of the
102 patients were identified as having AS rather than nr-AxSpA. The FDA statistician analysed the results in
these 38 patients and compared them to those for patients with centrally confirmed nr-AxSpA. The FDA
document reported results for the subpopulations based on local or central diagnosis, including ATP analyses.
Comparison of ankylosing spondylitis and non-radiographic axial spondyloarthritis
results and impact of reclassification in the trials
For certolizumab pegol the FDA statistical review stated that ‘efficacy findings were consistent in both AS
and nr-AxSpA subpopulations regardless of the discrepancy in pelvic X-ray readings at local or central lab
for modified New York criteria’115 (Table 14).
For ABILITY-158 a notably higher proportion of patients in the AS subgroup responded to adalimumab
(ASAS 40) than placebo compared with patients with confirmed nr-AxSpA. This suggests that the
treatment benefit in the whole trial population may be driven by benefit in AS patients rather than in
nr-AxSpA patients, skewing the results for the ATP (see Table 14). It should be noted, however, that this
may be an atypical AS population; the trial had intended to recruit only nr-AxSpA patients.
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TABLE 13 Baseline characteristics of trials analysed by the FDA
Trial and population
Characteristic
Age (years),
mean % male
Duration (years)
of symptoms
Weight (kg),
mean
% HLA-B27
positive
% on
NSAIDs CRP level
% MRI
positive
BASDAI
score, mean
BASFI score,
mean
ABILITY-1,58 nr-AxSpA
(n= 142)
38 46 Median 8,
mean 11
80 80 81 Median ≈4,
mean 9
51 6 4.7
RAPID-axSpA,64
nr-AxSpA (n= 147)
37 48 Median 5.5,
mean 8.6
82 75 84 Median 11.9,
mean 16
54 6.5 4.9
RAPID-axSpA,64 AS
(n= 178)
42 73 Median 9.1,
mean 11.9
82 82 91 Median 14.3,
mean 21.3
N/A 6.4 5.7
N/A, not applicable.
TABLE 14 Food and Drug Administration analyses: percentage differences from placebo, by method of diagnosis
Outcomes
at week 12
ABILITY-158 ATP population RAPID-axSpA64
Local
laboratory
nr-AxSpAa
Central
laboratory
nr-AxSpAb
Local laboratory
nr-AxSpAc
Central laboratory
nr-AxSpAd Local laboratory ASe Central laboratory ASf
Adalimumab,
40mg, %
(95% CI)
Adalimumab,
40mg, %
(95% CI)
Certolizumab,
200mg, %
(95% CI)
Certolizumab,
400mg, %
(95% CI)
Certolizumab,
200mg, %
(95% CI)
Certolizumab,
400mg, %
(95% CI)
Certolizumab,
200mg, %
(95% CI)
Certolizumab,
400mg, %
(95% CI)
Certolizumab,
200mg, %
(95% CI)
Certolizumab,
400mg, %
(95% CI)
ASAS 20 28 (12 to 44) 15 (–14 to 44) 19 (1 to 38) 23 (4 to 42) 23 (2 to 44) 23 (1 to 44) 20 (3 to 37) 27 (10 to 45) 17 (1 to 33) 23 (7 to 39)
ASAS 40 27 (13 to 41) 11 (–16 to 38) 32 (14 to 49) 31 (14 to 48) 18 (0 to 36) 27 (8 to 47) 21 (5 to 36) 31 (14 to 47) 28 (13 to 43) 33 (17 to 48)
BASDAI 50 25 (11 to 39) 19 ( –8 to 46) – – – – – – – –
a Adalimumab n= 69, placebo n= 73.
b Adalimumab n= 25, placebo n= 20.
c Certolizumab 200mg, n= 46; certolizumab 400mg, n= 51; placebo, n= 50.
d Certolizumab 200mg, n= 39; certolizumab 400mg, n= 35; placebo, n= 39.
e Certolizumab 200mg, n= 65; certolizumab 400mg, n= 56; placebo, n= 57.
f Certolizumab 200mg, n= 74; certolizumab 400mg, n= 71; placebo, n= 67.
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Owing to the fact that only a select group of patients could be subject to central confirmation of their
nr-AxSpA status, the FDA statistician explored assumptions around the proportion of true nr-AxSpA patients
in the whole trial population. Given that the treatment difference in the non-centrally read patients was 23%:
l Assuming that all non-centrally read patients were true negatives and therefore including them in the
analysis with the centrally read negatives, the treatment difference for the centrally read and
non-centrally read negatives was 15%.
l Assuming that a fraction (i.e. 63%) of non-centrally read patients were true negatives and including
only this fraction of non-centrally read patients with the centrally read negatives, the treatment
difference was 14%.
The FDA document stated that:
Because there was a differential treatment effect between the centrally-read positive and centrally-read
negative, it is safe to assume that the difference of 23% is an overestimate of the treatment effect
because this includes both positive and negative x-ray groups. If there is a fraction of patients who
are negative in the non-centrally-read group, treatment difference among this negative group
would be smaller. Therefore, the treatment difference for negative x-rays (i.e. centrally-read and
non-centrally-read) should be at most 15%. Based on the data provided, the estimate of the treatment
effect in ASAS40 response for nr-AxSpA should be no bigger than 15%
FDA Briefing Package116
Overall, the results suggest reduced efficacy of anti-TNFs in the centrally diagnosed nr-AxSpA population
compared with the locally diagnosed population. Nevertheless, there was noticeable variation across the
two trials. In RAPID-axSpA64 (certolizumab) the difference between the central and local populations
appears small (and is not evident for 400-mg vs. placebo results). Conversely, in ABILITY-158 (adalimumab)
the locally diagnosed population had notably more responders than the centrally diagnosed population,
although the treatment group sample sizes were small.
Long-term efficacy results from open-label extensions of randomised
controlled trials
Of the 24 included RCTs, 17 reported data from an open-label extension phase. Results for all studies are
presented in Appendix 8. Considerable effort has been put into patient follow-up in anti-TNF trials with
the result that data up to 5 years are available (there are data up to 8 years for infliximab but these
included an involuntary treatment break which is not discussed further). The longest follow-up durations in
patients with AS by anti-TNF are adalimumab 260 weeks, etanercept 264 weeks, infliximab 156 weeks,
golimumab 268 weeks and certolizumab pegol 96 weeks. However, the data were reported across
numerous publications and in various formats. Results were reported as observed, as completer analyses,
using imputation (and rarely LOCF) for non-responders and LOCF for missing continuous data, but these
related to differing populations (at varying time points): all patients randomised, all patients who took
active drug at any point in the study or all patients who took active drug just during the open-label phase.
The follow-up protocols were not clearly reported, with stopping rules unclear, but it appears that not all
non-responders discontinued therapy. Therefore, the results may not reflect clinical practice should
response be required for treatment continuation.
Table 15 presents the results based on non-responder imputation (NRI) analyses for the main studies when
these results could be extracted. For AS the results show that across all the anti-TNFs after approximately
2 years of treatment, around half of patients are still achieving a good level of response to therapy. The
results for golimumab look particularly strong with around 60% of all randomised patients achieving
ASAS 40 and BASDAI 50 after 5 years. However, this is probably not reflective of clinical practice, as many
of the normal weight patients took the 100-mg dose of golimumab rather than the 50-mg dose: the
licence permits the use of 100-mg dose only in patients with a body weight of more than 100 kg who do
not achieve an adequate clinical response after three or four doses. The equivalent results for adalimumab
and etanercept are approximately 30% and 50%, although it is unknown if the difference may be
because of variations in follow-up protocols rather than true treatment difference.
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TABLE 15 Treatment effect over time (AS only) (results calculated using non-responder imputation)
Outcome Trial
52 weeks,
n/N (%)
104 weeks,
n/N (%)
156 weeks,
n/N (%)
5 years
(approximately
264 weeks),
n/N (%)
Adalimumab
ASAS 20 ATLAS61 193/311 (62)a 135/311 (43)a – 111/311 (36)a
ASAS 40 ATLAS61 138/311 (44)a 109/311 (35)a – 88/311 (28)a
BASDAI 50 ATLAS61 167/311 (54)a 122/311 (39)a – 96/311 (31)a
Certolizumab
ASAS 20 RAPID-axSpA64
(AS)
(48 weeks)
89/121 (74)b
(96 weeks)
78/121 (64)b
– –
ASAS 40 RAPID-axSpA64
(AS)
(48 weeks)
70/121 (58)b
(96 weeks)
61/121 (50)b
– –
BASDAI 50 – – – – –
Etanercept
ASAS 20 Calin 200483 – (108 weeks)
52/81 (64)c
– –
ASAS 40 Calin 200483 – (108 weeks)
44/81 (54)c
– 40/81 (49)c
BASDAI 50 Calin 200483 – (108 weeks)
42/81 (52)c
– 39/81 (48)c
Golimumab
ASAS 20 GO-RAISE90 – 235/356 (66)b (160 weeks)
246/356 (69)b
235/356 (66)b
ASAS 40 GO-RAISE90 – 203/356 (57)b (160 weeks)
208/356 (58)b
203/356 (57)b
BASDAI 50 GO-RAISE90 – 199/356 (58)b – 199/356 (58)b
Infliximab
ASAS 20 PLANETAS
2013110
(78 weeks)
125/174 (72)c,d
(102 weeks)
127/174 (73)c,d
– –
ASAS 40 – (78 weeks)
93/174 (53)c,d
(102 weeks)
101/174 (58)c,d
– –
ASAS 40 ASSERT 2005102 (102 weeks) 33/78 (42)b,e – –
BASDAI 50 Braun 200298 (54 weeks)
33/69 (48)b
(102 weeks)
30/69 (43)b
– –
ASSERT, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy; NRI, non-responder
imputation.
a NRI imputed result calculated using number of patients who had received at least one dose of active as denominator.
b NRI imputed result calculated using number of patients randomised as denominator.
c NRI imputed result calculated using number of patients who had received active during open-label phase
as denominator.
d CT-P13 and infliximab combined.
e Only the subset of patients who took the 5-mg dose of infliximab (remaining patients took 5 or 7.5mg).
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The long-term follow-up for nr-AxSpA patients (Table 16) shows continued high proportions of responders.
At 1 year around half of patients are achieving an ASAS 40 or BASDAI 50 level response and with
certolizumab this is maintained at 2 years and with adalimumab at 3 years.
When the long-term data are presented as observed or completer analyses, the long-term results are
similarly good; withdrawal rates are not high and a high proportion of those who remain on treatment
continue to achieve a good response, see the example data available from one trial of adalimumab and
one of certolizumab pegol (Table 17).
At long-term follow-up mean final values or mean change from baseline for BASDAI, BASFI and BASMI,
when reported, were generally maintained at clinically meaningful levels.
For adalimumab, data from the large ATLAS trial61 showed that mean changes from baseline at 1, 2 and
3 years remain stable and clinically meaningful at around –3.7 units for BASDAI and at around –2.9 units
for BASFI. Similarly, the mean final value for BASMI remains at a level indicative of clinically significant
TABLE 16 Treatment effect over time (nr-AxSpA only)
Outcome Trial
52 weeks,
n/N (%)
104 weeks,
n/N (%)
156 weeks,
n/N (%)
5 years
(approximately
264 weeks),
n/N (%)
Adalimumab
ASAS 20 ABILITY-158 – – 83/142 (58)a –
ASAS 40 Haibel 200852 23/46 (50)b – – –
ASAS 40 ABILITY-158 (68 weeks)
77/142 (54)a
– 67/142 (47)a –
BASDAI 50 Haibel 200852 24/46 (52) – – –
BASDAI 50 ABILITY-158 (68 weeks)
74/142 (52)a
– 70/142 (49)a –
Certolizumab
ASAS 20 RAPID-axSpA64 (AS) (48 weeks)
68/97 (70)b
(96 weeks)
59/97 (61)b
– –
ASAS 40 RAPID-axSpA64 (AS) (48 weeks)
56/97 (58)b
(96 weeks)
49/97 (51)b
– –
BASDAI 50 – – – – –
Etanercept
ASAS 20 Dougados 201476 (48 weeks) (CiC
information has
been removed)
– – –
ASAS 40 – (48 weeks)
108/205 (53)b
– – –
BASDAI 50 – (48 weeks) (CiC
information has
been removed)
– – –
CiC, commercial-in-confidence.
a NRI imputed result calculated using number of patients at week 12 as denominator.
b NRI imputed result calculated using number of patients randomised as denominator.
Results calculated using NRI.
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treatment benefit (3.1 to 3.7 units). At 5 years the mean final values are BASDAI 1.8 units, BASFI 2.1 units,
and BASMI 3.7 units. Clearly these results relate only to those patients who have remained on adalimumab
in the long-term (40% of those who started adalimumab). They do, however, demonstrate continued
benefit in a significant proportion of patients.
For certolizumab, results for these outcomes are available up to 96 weeks. At this time point the mean
BASDAI and BASFI are indicative of clinically significant treatment benefit (both around 3 units).
The long-term data from Calin et al.83 for etanercept, with 81 patients at 2 years and 59 (73%) remaining
at 5 years also report mean BASDAI and BASFI scores of around 3.
From GO-RAISE90 at 2 years for those who took golimumab throughout the trial and follow-up (n= 138),
median BASDAI score was around 3 and median BASFI score was around 2. These values are from a LOCF
analysis of all patients randomised to golimumab 50mg.
For infliximab, the Braun et al.98 and follow-up studies found, from 1 to 3 years, a stable mean BASDAI
score of around 2.6, a stable mean BASFI score of around 3 and a stable mean BASMI score of
around 2.7.
Overall, the reported data (although not particularly robust) do indicate that significant proportions of
patients continue to derive real benefit from continued use of anti-TNFs. There is nothing to indicate any
difference between them.
Almost no data were available regarding radiographic progression of bony disease in patients with AS.
Furthermore, it should be noted that radiographic changes and progression of these take many years to
appear and radiography is an insensitive tool by which to evaluate the progression of AS. Therefore,
evidence, particularly that from relatively short-term studies, has to be interpreted with caution. The limited
evidence includes mSASSS change from baseline, reported for golimumab from the GO-RAISE90 study at
4 years (208 weeks): 1.3 units (SD 4.1 units) based on the 111 of 138 patients randomised to 50mg.
As results from untreated cohorts suggest a progression rate of 2 units/2 years, a rate of 1.3 units (or even
2 units) over 4 years seems beneficial. For further discussion of this issue see Effect of anti-tumour necrosis
factors on radiographic progression. MASES was reported only for adalimumab from ATLAS;61 in patients
remaining on therapy at 2 years the mean change from baseline was 2.2 units (n= 217).
TABLE 17 Observed or completer analysis results
Trial, anti-TNF (population) Time point
Type of
analysis
ASAS 20,
n/N (%)
ASAS 40,
n/N (%)
BASDAI 50,
n/N (%)
ATLAS 2006,61 adalimumab (AS) 52 weeks Observed 193/276 (70) 138/276 (50) 167/276 (61)
104 weeks Observed 135/173 (78) 109/173 (63) 122/173 (71)
5 years Completer 111/125 (89) 88/125 (70) 96/124 (77)
RAPID-axSpA,64 certolizumab
pegol; all (AS)
96 weeks Observed 78/93 (84) 61/93 (66) –
RAPID-axSpA,64 certolizumab
pegol; all (nr-AxSpA)
96 weeks Observed 59/74 (80) 49/74 (66) –
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For nr-AxSpA patients long-term data for the continuous outcomes was limited to 1 year’s follow-up.
For adalimumab, data were available from only one small study (Haibel 2008,52 n= 46): BASDAI change
from baseline 2.8 units (95% CI 2.1 to 3.6 units); BASFI change from baseline 2 units (95% CI 1.4 to
2.6 units); BASMI change from baseline –0.4 units (95% CI –0.7 to –0.04 units); and MASES change from
baseline of 0.9 units (95% CI –0.02 to 1.9 units). In addition, of 26 patients with magnetic resonance
images at baseline and 52 weeks’ follow-up, none showed a change in sclerosis or in erosions. For
etanercept, data were available on 205 patients randomised to etanercept or placebo and then on
long-term etanercept (Dougados 201476): [commercial-in-confidence (CiC) information has been removed].
For certolizumab, LOCF analysis at 96 weeks (n= 97) gave a BASDAI final value score of 3.0, and a BASFI
score of 2.4. Overall, the 1-year results in nr-AxSpA patients are similar to each other and also reflect those
seen in AS patients. Again, the short-term nature of this follow-up relative to the 8–10 years over which
radiographic changes develop must be borne in mind.
Findings from anti-tumour necrosis factor patient registry studies
Effect of anti-tumour necrosis factors on radiographic progression
A total of seven studies were identified that provided some comparative results on the effect of anti-TNFs
on radiographic progression (Table 18).
TABLE 18 Effect of anti-TNFs on radiographic progression
Study Methods Results
van der Heijde
et al. 2009117
Study used 2-year data from active
treatment arms of two adalimumab trials
(total n= 397) and compared them with
OASIS cohort118 (186 with radiographs at
2 years). Note: primary analysis set= 307
adalimumab (minimum of 1.5 years
exposure to drug) and 169 anti-TNF naive
(OASIS)
There were significant differences between adalimumab
and OASIS118 patients at baseline for BASDAI, BASFI and
other measures. Increase in mSASSS was very similar in
the two groups: adalimumab mean 0.8 (SD 2.6) and
OASIS mean 0.9 (SD 3.3). When only patients who would
have qualified for the adalimumab trials were included in
the OASIS cohort (n= 77) the results were not changed.
Note: in the light of these van der Heijde results, it would
have been good to test effect of baseline BASDAI (mean
6.2 in adalimumab cohort and 3.4 in OASIS), as without
treatment progression in adalimumab cohort would have
been expected to be higher than in the OASIS one, so
there might have been some effect of adalimumab
van der Heijde,
et al. 2008103
Study compared 2-year data from
infliximab trial (ASSERT102) (n= 201) with
that from OASIS118 (n= 192). OASIS
patients not treated with any anti-TNF
There were significant differences between infliximab and
OASIS118 patients at baseline for BASDAI, BASFI and other
measures (higher disease activity and worse function in
trial patients). Mean increase in mSASSS was very similar
in the two groups: infliximab 0.9 (SD 2.6) and OASIS 1.0
(SD 3.2). When only patients who would have qualified
for the infliximab trials were included in the OASIS cohort
(n= 70), the results changed very little [mean mSASSS
increase 1.2 (SD 3.9)]
van der Heijde,
et al. 2008119
Study compared 2-year data from
etanercept trial (Davis et al.72) (n= 257)
with that from OASIS118 (n= 175). OASIS
patients not treated with any anti-TNF
There were significant differences between infliximab and
OASIS118 patients at baseline for BASDAI, BASFI and other
measures (higher disease activity and worse function in
trial patients). Mean increase in mSASSS was very similar
in the two groups: etanercept 0.91 (SD 2.5) and OASIS
0.95 (SD 3.2). When only patients who would have
qualified for the etanercept trials were included in the
OASIS cohort (n= 76), the results changed very little
[mean mSASSS increase 1.3 (SD 3.6)]
Braun et al.
2014120
Long-term data on golimumab (2- and
4-year radiographic data) (n= 233). No
comparison with OASIS118 made
Mean increase in mSASSS to 2 years was 0.9 (SD 2.7)
(50mg) and 0.9 (SD 3.9) (100mg). Mean increase in
mSASSS to 4 years was 1.3 (SD 4.1) (50mg) and 2.0
(SD 5.6) (100mg). Note: 2-year results are very similar to
those with other anti-TNFs and OASIS,118 that is there is
no benefit of golimumab evident
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Four studies reported on disease progression over 2 years of follow-up in terms of mSASSS in patients
taking adalimumab,117 infliximab,103 etanercept119 and golimumab.120 All four open-label, uncontrolled
follow-up studies found that mSASSS increased by a mean of around 0.9 units over 2 years. Three of these
studies compared their rates with those from the Outcomes in Ankylosing Spondylitis International Study
(OASIS) cohort118 (of patients not taking an anti-TNF) and found no difference (mean rate over 2 years for
OASIS was 0.9 units, Table 19). As stated in the previous section, radiographic changes and progression of
these take many years to appear and, therefore, the evidence from these relatively short-term studies
should be interpreted with caution.
TABLE 18 Effect of anti-TNFs on radiographic progression (continued )
Study Methods Results
Haroon et al.
2013121
Cohort study (n= 334) with at least two
spinal radiographs at 2-year intervals
(patients with total spinal fusion at
baseline excluded). Logistic regression
analysis tested for baseline mSASSS, ESR,
BASDAI, smoking, male vs. female, age at
onset, disease duration, HLA-B27,
anti-TNF use and NSAID index. Further
analysis tested factors that could influence
exposure to anti-TNFs using propensity
matching
In total, 201 out of 334 patients had received anti-TNFs
for a mean of 2.5 years (SD 2.6 years). No radiographic
abnormality of the spine was seen at baseline in
144 patients (43%) and 102 patients (30.5%) showed no
progression (> 1 mSASSS unit/year). Mulitvariate
regression found baseline mSASSS (OR 1.06, 95% CI
1.04 to 1.08), ESR and smoking significantly increased
and anti-TNF use significantly increased odds of
radiographic progression (OR 0.47, 95% CI 0.24 to 0.94).
Further analysis using the 142 patients who could be
included post propensity matching confirmed these
findings except for ESR: baseline mSASSS (OR 1.05,
95% CI 1.02 to 1.08) and anti-TNF (OR 0.30, 95% CI 0.11
to 0.78). Note: the association with anti-TNF use is explained
by the more severe patients with radiographic changes at
baseline being treated with anti-TNFs
Barialiakos et al.
2014122
Comparison of long-term (8 years)
treatment with infliximab with historical
cohort (infliximab n= 22 and Herne
cohort n= 34)
Progression as assessed by mSASSS increased equally in
infliximab treated patients and in the Herne cohort from
baseline to 2, 4 and 6 years but while progression
increased only slightly in the infliximab group between
6 and 8 years it increased greatly in the Herne cohort so
that at 8 years there was a difference in infliximab’s
favour of 4.5 mSASSS (p= 0.047). Result was adjusted for
baseline mSASSS. Other factors (age, symptom duration,
BASDAI, BASFI) not significant confounders
Barialiakos
2007123
4-year radiographic progression in AS
patients treated with infliximab (n= 33).
Crude comparison made with OASIS
cohort118 results at 4 years
At baseline, mean mSASSS was 11.6 (15.3 SD), mean
BASDAI was 6.6 (1.4 SD) and mean BASFI was 3.5
(1.9 SD). Progression assessed by mSASSS. Mean change
over 4 years was 1.6 (SD 2.6) mSASSS units. Published
results for OASIS are 4.4 units in 4 years
ASSERT, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy; OASIS, Outcomes in
Ankylosing Spondylitis International Study.
TABLE 19 Summary of long-term results for mSASSS change
Trial, anti-TNF
Increase in mSASSS over 2 years,
patients on an anti-TNF
Increase in mSASSS over 2 years,
patients from OASIS cohort118
n Mean (SD) n Mean (SD)
van der Heijde 2009,117 adalimumab 397 0.8 (SD 2.6) 186 0.9 (SD 3.3)
van der Heijde 2008, etanercept119 257 0.91 (SD 2.45) 175 0.95 (SD 3.2)
Infliximab103 201 0.9 (SD 2.6) 192 1.0 (SD 3.2)
Golimumab120 111 50mg, 0.9 (SD 2.7) – –
122 100mg, 0.9 (SD 3.9) – –
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Comparison of the rates calculated from the OASIS cohort118 in these studies with those from the studies
by Ramiro124,125 highlight a discrepancy; the latter reported rates of 2 mSASSS units every 2 years, rather
than the 0.9 units/2 years used here to compare with individual anti-TNFs.
Two very small studies of infliximab reported some inhibiting effect on radiographic progression.122,123
The first123 compared findings in 22 infliximab patients with 34 from the HERNE cohort, over 2, 4, 6 and
8 years. Progression as assessed by mSASSS increased equally in infliximab treated patients and in the
untreated HERNE cohort from baseline to 2, 4 and 6 years but then while progression increased only
slightly in the infliximab group between 6 and 8 years it increased greatly in the HERNE cohort so that at
8 years there was a difference in infliximab’s favour of 4.5 mSASSS units. The result was adjusted for
baseline mSASSS (other factors, age, symptom duration, BASDAI, BASFI, etc., were not statistically
significant confounders). The other study of 33 patients123 found the mean progression over 4 years was
1.6 mSASSS units (SD 2.6 units), lower than the 4.4 units seen in the untreated OASIS cohort118 at 4 years.
Another study examined a cohort of 334 patients with at least two spinal radiographs at 2-year intervals
(patients with total spinal fusion at baseline were excluded).121 In this study 201 out of 334 patients had
received anti-TNFs for a mean of 2.5 years (SD 2.6 years) and no radiographic abnormality of the spine
was seen at baseline in 144 patients (43%). At follow-up 102 patients (30.5%) showed no progression
(≥ 1 mSASSS unit/year). Mulitvariate regression found baseline mSASSS (OR 1.06, 95% CI 1.04 to 1.08),
ESR and smoking significantly increased the odds of radiographic progression, but anti-TNF use was
significantly associated with a > 50% reduction in the (adjusted) odds of progression (0.47, 95% CI 0.24
to 0.94). Further analysis that tested factors that could influence exposure to anti-TNFs using propensity
matching confirmed the association with mSASSS and found a stronger association with anti-TNF use
(OR 0.30, 95% CI 0.11 to 0.78).
In conclusion, there is evidence of disease progression over time, although the disease course is highly
variable. Best estimates of yearly disease progression rates without anti-TNF therapy are around 1.0 mSASSS
units and 0.035–0.07 BASFI units. Whether or not there is any impact of anti-TNF treatment is unclear;
a beneficial effect can neither be assumed, and nor, given the short-term nature of the follow-up and the
insensitivity of radiography as a tool for the evaluation of disease progression in AS, can one be discounted.
Drug survival and anti-tumour necrosis factor switching
The EndNote Library generated by the searches for RCTs of all the anti-TNFs were separately screened to
identify patient registry studies of any or all of the anti-TNFs. This was possible because the search strategy
for RCTs was very sensitive and will have identified any clinical study including any of the named anti-TNFs.
A total of 25 potentially relevant studies were screened fully and 12 publications that reported some data
on drug survival or the efficacy of anti-TNFs after switching were identified (see Table 20 for summary
details of each). Across the 12 studies, the sources of data were either retrospective cohort studies or
prospective registers (although analysis plans may have been retrospective), from a range of regions:
USA (two studies), Canada (one study) and Europe (nine studies). No data from a UK-based cohort were
available. Most of the cohorts and registries included experience with the three oldest anti-TNFs: infliximab,
etanercept and adalimumab. One study (of the RHAPSODY cohort) included results from 326 patients
treated with adalimumab as second anti-TNF after infliximab or etanercept. Small numbers of patients
provided data on golimumab (three studies) and even smaller numbers on certolizumab (two studies).
The population in 10 of the 12 studies was AS, although the diagnostic criteria used to specify AS were
rarely given. One study provided results specifically for nr-AxSpA and one study provided results for axial
SpA (nr-AxSpA or AS).
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TABLE 20 Registry studies reporting data on drug survival and anti-TNF switching
Citation
Study/registry and
method
n (duration,
where stated) Population Anti-TNFs included Drug survival Efficacy on switching
Bonafede
2012126
Market Scan
(administrative claims
data) 2005–9, USA;
retrospective
308 (360 days) AS Etanercept, adalimumab
and infliximab
n (%) who stopped treatment
and did not switch/who
switched:
l etanercept: (n= 149) 42
(28%)/12 (8%)
l adalimumab: (n= 103) 36
(35%)/11 (11%)
l infliximab: (n= 46) 14
(30%)/6 (13%)
NR
Choquette
2013127
(abstract only)
Rhumadata register,
Canada; unknown
119 (5 years) AS, previous NSAIDs
and BASDAI score
of ≥ 4
Etanercept, adalimumab
and infliximab
n who remained on same
anti-TNF was 80% at 1 year;
70% at 2 years; and 55% at
5 years (no difference between
anti-TNFs)
NR
Gulfe 2014128 SSATG registry,
Sweden; prospective
112 (2 years) Nr-axSpA not AS,
demographic
summary available
Etanercept, adalimumab,
infliximab, golimumab
and certolizumab
Kaplan–Meier estimates drug
survival was 76% at 1 year and
65% at 2 years
NR
Nell-Duxneuner
2012129
Drug reimbursement
data, Austria;
retrospective
694 (2 years) AS Etanercept, adalimumab
and infliximab
Starting in 2007 drug survival
was:
l etanercept: 0.83 (1 year)
and 0.58 (2 years)
l adalimumab: 0.70 (1 year)
and 0.55 (2 years)
l infliximab: 0.71 (1 year)
and 0.54 (2 years)
NR
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
2
0
0
9
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
6
V
O
L
.
2
0
N
O
.
9
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
6
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
C
o
rb
e
tt
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
4
5
TABLE 20 Registry studies reporting data on drug survival and anti-TNF switching (continued )
Citation
Study/registry and
method
n (duration,
where stated) Population Anti-TNFs included Drug survival Efficacy on switching
Yeaw 2014130 LifeLink Health Plan
Claims database
2004–10, USA;
retrospective
632 AS patients who had
discontinued an
anti-TNF
Etanercept, adalimumab
and infliximab
% who restart within 360 days
after stopping:
l etanercept: 59% (n= 376)
l adalimumab: 45%
(n= 134)
l infliximab: 39% (n= 122)
NR
% who switch to another
anti-TNF or biologic:
l etanercept: 17% (n= 376)
l adalimumab: 13%
(n= 134)
l infliximab: 24% (n= 122)
% who switch to non-biologic:
l etanercept: 5% (n= 376)
l adalimumab: 8% (n= 134)
l infliximab: 6% (n= 122)
% who switch to no new
treatment:
l etanercept: 18% (n= 376)
l adalimumab: 34% (n=134)
l infliximab: 30% (n= 122)
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Citation
Study/registry and
method
n (duration,
where stated) Population Anti-TNFs included Drug survival Efficacy on switching
Scire et al.
2013131
MonitorNet database
(Italian Society of
Rhuematology) to
2012, Italy; multiple
imputation used for
missing data
498 AS Etanercept, adalimumab
and infliximab
Unadjusted Kaplan–Meier
estimates of drug survival at:
l 1 year: 0.87 (95% CI
0.83 to 0.89)
l 2 years: 0.72 (95% CI
0.67 to 0.77)
l 3 years: 0.69 (95% CI
0.63 to 0.74)
NR
Adjusted HR discontinuation
rate (median follow-up
17 months) 0.59 (95% CI 0.46
to 0.75) (adjusted for age, sex,
number of comorbidities,
disease duration, number of
previous DMARDs, concurrent
DMARDS, baseline BASDAI
score and BASFI score)
Zufferey 2014132 Single centre in
Switzerland (Centre
Hospitalier Universitaire
Vaudois) 2011–12;
retrospective
112, of whom
77 were AS
(follow-up at 12
and 24 months)
SpA (AxSpA and AS) Etanercept, adalimumab,
infliximab and
golimumab
Median drug survival across
all anti-TNFs 12 months
(IQR 7–19 months) for
AxSpA and 8 months
(IQR 6–13 months) for AS
NR
Drug survival for AS:
l 1 year 49%
l 2 years 36%
No difference between
anti-TNFs
Pavelka 2009133 ATTRA national
registry, Czech
Republic; prospective
310 (1 year) AS (note mean
BASDAI score 6.4 at
baseline)
Etanercept, adalimumab
and infliximab
Drug survival at 1 year was
84%; at 2 years was 76%;
and at 3 years was 72%
NR
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TABLE 20 Registry studies reporting data on drug survival and anti-TNF switching (continued )
Citation
Study/registry and
method
n (duration,
where stated) Population Anti-TNFs included Drug survival Efficacy on switching
Lie 2011134 NOR-DMARD register
2000–9, Norway;
prospective
514 (2 years) AS Etanercept, adalimumab
and infliximab
In total 77 patients switched
from first anti-TNF; 437 did
not. In the 77 switchers,
median drug survival on first
anti-TNF was 266 days on the
first anti-TNF (range 1–1392)
and the second anti-TNF was a
median of 77 days (range
0–1608 after the first was
stopped). Finding may just be a
consequence of the stopping
rules in Denmark (patients
given around 6 months to
achieve a response)
Non-switchers: response to first
anti-TNF at 3 months (n=362):
l BASDAI 50, n/N: 105/362
l ASAS 20, n/N: 106/202
l ASAS 40, n/N: 76/202
l Median (IQR) BASFI score: 2.3
(0.7–4.0)
Median (IQR) BASDAI score:
2.6 (1.3–4.4)
% on treatment after 1 and
2 years:
First anti-TNF: 76% and 65%
Second anti-TNF: 67% and
60%
Switchers: response to first
anti-TNF at 3 months:
l BASDAI 50, n/N: 6/63
l ASAS 20, n/N: 11/23
l ASAS 40, n/N: 7/23
Median (IQR) BASFI, score:
4.7 (1.5–6.0) (n= 63)
Median (IQR) BASDAI, score:
4.8 (3.3–7.01) (n= 63)
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TABLE 20 Registry studies reporting data on drug survival and anti-TNF switching (continued )
Citation
Study/registry and
method
n (duration,
where stated) Population Anti-TNFs included Drug survival Efficacy on switching
Glintborg
2012135
DANBIO registry,
Denmark; prospective
1436 (432
switchers;
median
2.4 years)
AS (switchers only;
had received at least
two anti-TNFs during
follow-up)
Etanercept, adalimumab,
infliximab and golimumab
(certolizumab and other
biologics had less than
1% between them and
only to first treatment
course)
Median (95% CI) years of drug
survival (n) (% on treatment
after 2 years) for sequential
anti-TNFs:
l First anti-TNF: 3.1 (2.6 to
3.7), n= 1436 (58%)
l Second anti-TNF: 1.6
(1.0 to 2.2), n= 432 (47%)
l Third anti-TNF: 1.8
(0.9 to 2.7), n= 137 (49%)
Median (IQR) BASDAI at 3 months
for sequential anti-TNFs:
l First anti-TNF (n= 1436):
2.8 (1.1–4.8)
l Second anti-TNF (n= 432):
3.6 (1.9–6.4)
l Third anti-TNF (n= 137):
5.1 (3.6–6.7)
Median (IQR) BASFI at 3 months for
sequential anti-TNFs:
l First anti-TNF (n= 1436):
2.8 (1.1–4.8)
l Second anti-TNF (n= 432):
3.6 (1.7–6.0)
l Third anti-TNF (n= 137):
5.1 (3.0–7.3)
% BASDAI 50/20mm responders
at 6 months (NR at 3 months):
l First anti-TNF: 54%
l Second anti-TNF: 37%
l Third anti-TNF: 30%
Rudwaleit
2009136
RHAPSODY, European
cohort; prospective
uncontrolled cohort of
patients treated with
adalimumab
1250 (12-week
response data
only)
AS Adalimumab NR 12-week response rates: anti-TNF
naive (n=924); BASDAI 50–63%;
ASAS 40–59%; anti-TNF exposed
(etanercept and/or infliximab,
n=326); BASDAI 50–41%; and
ASAS 40–38%
Logistic regression with backward
elimination found that younger age,
higher CRP level, HLA-B27 positive
and anti-TNF naivety all predictive of
better response (table 1134)
HR, hazard ratio; IQR, interquartile range; NR, not reported; RHAPSODY, Review of safety and effectiveness witH Adalimumab in Patients with active ankylosing SpOnDYlitis;
SSATG, Southern Sweden Anti-rheumatic Therapy Group.
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Drug survival on first anti-TNF for all anti-TNFs was around 70–80% at 1 year, around 65–75% at 2 years,
around 70% at 3 years and 55% at 5 years. Little difference between the three older anti-TNFs was
identified, although one analysis using Cox proportional hazard estimates found statistically lower rates of
discontinuation with etanercept and adalimumab compared with infliximab.131
The median drug survival in AS patients across all anti-TNFs reported varied (Table 21). Based on the
largest registry (DANBIO)135 the median drug survival for a first anti-TNF was 3.1 years (95% CI 2.6 to
3.7 years) (n= 1436), with 58% of patients remaining on treatment at 2 years. Median drug survival for a
second anti-TNF was 1.6 years (95% CI 1.0 to 2.2 years) (n= 432), with 47% of patients remaining on
treatment at 2 years, and for a third, 1.8 years (95% CI 0.9 to 2.7 years) (n= 137) (49% on treatment at
2 years).
The efficacy of second or third anti-TNFs after switching in AS patients was reported in only a small
number of studies. One analysis based on the NOR-DMARD registry134 showed how the response rate and
BASDAI and BASFI achieved at 3 months in patients who remain on their first therapy is (not surprisingly)
better than in patients who switch. Median BASDAI and BASFI achieved with a second anti-TNF were not
as low (not as good) as was achieved with a first anti-TNF in non-switchers. An analysis of the DANBIO
registry indicated that response (BASDAI 50) at 6 months reduced with subsequent anti-TNFs, as did the
median improvement in BASDAI and BASFI achieved (Table 22).135 These results are supported by the
RHAPSODY study that found higher response rates with adalimumab in anti-TNF naive patients (BASDAI
50–63%; ASAS 40–59%)(n= 924) than in anti-TNF exposed (BASDAI 50–41%; ASAS 40–38%) (n= 326).136
The registries and cohort studies provided no data on the efficacy of anti-TNFs as second or third, after
switching in nr-AxSpA patients.
TABLE 21 Drug survival results from analysis of DANBIO registry135
Anti-TNF
Drug survival for sequential anti-TNFs
Median (95% CI) % on treatment after 2 years
First (n= 1436) 3.1 (2.6 to 3.7) 58
Second (n= 432) 1.6 (1.0 to 2.2) 47
Third (n= 137) 1.8 (0.9 to 2.7) 49
TABLE 22 Efficacy results from analysis of DANBIO registry135
Anti-TNF
% BASDAI
score 50/20mm
responders
at 6 months
(at 3 NR)
BASDAI score
at 0 months
for sequential
anti-TNFs,
median (IQR)
BASDAI score
at 3 months
for sequential
anti-TNFs,
median (IQR)
BASFI score at
0 months for
sequential
anti-TNFs,
median (IQR)
BASFI score at
3 months for
sequential
anti-TNFs,
median (IQR)
First (n= 1436) 54 5.9 (4.5–7.1) 2.8 (1.1–4.8) 5.0 (3.4–6.7) 2.8 (1.1–4.8)
Second (n= 432) 37 5.6 (3.8–7.3) 3.6 (1.9–6.4) 5.2 (3.5–7.0) 3.6 (1.7–6.0)
Third (n= 137) 30 6.4 (4.8–7.9) 5.1 (3.6–6.7) 6.4 (4.2–7.9) 5.1 (3.0–7.3)
IQR, interquartile range.
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In summary, sequential treatment with anti-TNFs can be worthwhile in patients with AS but the response
rates and benefits are reduced with second and third anti-TNFs, with the proportion of BASDAI 50
responders falling approximately 10% with each subsequent anti-TNF and the median BASDAI and BASFIs
achieved increasing (worsening). The lower efficacy of a second anti-TNF relative to a first is reflected in
lower median drug survival and proportion of patients remaining on therapy at 2 years. Interestingly,
despite a further reduction in response and efficacy with a third anti-TNF, drug survival does not fall,
suggesting that at this stage in their treatment history patients may continue with a less than optimally
effective anti-TNF given any better alternative.
Clinical effectiveness results: adverse events
Randomised trials
We focused on the following outcomes, known to have possible associations with anti-TNF treatment:
serious infections, tuberculosis (including tuberculosis reactivation), injection/infusion site reactions,
congestive heart failure, cancer, non-melanoma skin cancer, SAEs and withdrawals due to SAEs. For the
randomised phases of the trials included in the review, the reporting of AE data was generally limited.
For three of the 24 trials no information on AEs was available.55,56,74 Several trials provided AE data only
at time points after which placebo patients may have switched to receive an anti-TNF (so true placebo
comparisons were not available).
Analysable data on injection/infusion site reactions were available for 10 trials, although these studies were
only of etanercept or infliximab. The data for certolizumab, golimumab and adalimumab trials either
were not reported or were only provided at time points after which placebo patients could ‘escape’ to
receive an anti-TNF; these data would not allow for an accurate comparison with placebo. Results for
injection/infusion site reactions analyses from this review for etanercept and infliximab showed a statistically
significant increase in reactions associated with etanercept (relative risk 2.69, 95% CrI 1.82 to 3.89)
compared with placebo but no significant difference between infliximab and placebo. Compared with each
other, the risk of an injection/infusion site reaction was statistically significantly higher with etanercept than
with infliximab (relative risk 2.27, 95% CrI 1.01 to 5.37). Incidence of serious infections was reported in
only eight trials, although such events were rare (nine cases in total). Of the eight trials which reported
incidence of tuberculosis, only four cases were identified; three cases were reported in the longest study,
the 54-week trial which compared infliximab with an infliximab biosimilar (CT-P13).110 Four trials reported
on congestive heart failure (no cases reported), six trials reported on cancer (one case) and three trials
reported on non-melanoma skin cancer (two cases, one in each group of the ABILITY-158 trial). In most trials
few SAEs were reported; group rates ranged from 0% to around 9%. Similarly, most trials had few
withdrawals because of AEs; rates ranged from 0% to around 12%. Full results are reported in Appendix 9.
Large systematic reviews
Overall, the number and size of trials, and the short duration of their placebo-controlled phases, were too
limited to provide enough data for meaningful analyses of AE. This common problem, of having too few
data to evaluate AEs, underpinned the rationale for a Cochrane review (and network meta-analysis) of AEs
of nine biologics in adults with any disease, except HIV/AIDS.137 In order to provide a better understanding
of toxicity, data were pooled across diseases by assuming a similar rate of AEs (across diseases). For the
present assessment, estimates of AE rates have therefore been derived from the Cochrane review, which
included 160 RCTs (n= 48,676) and 46 open-label extension studies (n= 11,954). The median durations
were 6 months for RCTs and 13 months for open-label extension studies. The biologics included were
abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituzimab and
tocilizumab. The anti-TNFs included in the present assessment were studied in 115 (72%) of the RCTs and
40 (87%) of the open-label studies included in the Cochrane review. Most studies assessed etanercept or
infliximab in cancer or rheumatoid arthritis patients; 10 RCTs were of AS (fewer than in this assessment,
as in the Cochrane review databases were searched up until January 2010). The biologics were evaluated
both as a group and as individual interventions. The results from the RCTs, what the review classified as
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‘major’ outcomes, are in Tables 23 and 24. Biologics as a group were associated with statistically
significantly higher rates of total AEs, withdrawals because of AEs, serious infections and tuberculosis
reactivation compared with control treatments. When the individual anti-TNFs were analysed separately,
compared with control treatments only infliximab and certolizumab were statistically significantly associated
with AEs: infliximab with higher rates of total AEs [number needed to harm (NNH) 13, 95% CrI 8 to 505]
and withdrawals because of AEs (NNH 10, 95% CrI 5 to 30), and certolizumab pegol with higher rates of
serious infections (NNH 12, 95% CrI 4 to 79) and SAEs (NNH 18, 95% CrI 9 to 162) (see Table 24).
For total AEs, the Cochrane review team judged the strength of evidence to be high; for SAEs, withdrawals
because of AEs and serious infections, the strength of evidence was judged to be moderate; and for
tuberculosis reactivation, lymphoma and congestive heart failure, the strength of evidence was judged to
be low. For tuberculosis reactivation, lymphoma and congestive heart failure, the network meta-analysis
statistical models did not converge (because of low numbers of events) therefore estimates for individual
anti-TNFs were not available. Outcomes which were classed in the review as ‘minor’ were not analysed
by the review authors because of the low numbers of events and the complexity of the analyses for the
major outcomes. The minor outcomes included cardiac AEs, infusion and injection site reactions, allergic
reactions, neurological outcomes, deaths, all cancers, serious lung infections or pneumonia, fungal
infections and opportunistic infections. For the purposes of the present assessment, further large studies
on cancer risk were therefore sought. An individual patient data meta-analysis of 22,904 adults (from
74 RCTs) which assessed the cancer risk of taking adalimumab, etanercept or infliximab in the short term
(median duration < 6 months) was identified.138 Although funded by manufacturers, this study was
requested by the European Medicines Agency and was planned and conducted by independent
researchers working with an independent academic steering committee. For all three anti-TNFs as a group,
there was no increase in risk of cancers excluding non-melanoma skin cancer (relative risk 0.99, 95% CI
0.61 to 1.68) but there was a doubling in the risk of non-melanoma skin cancer associated with taking an
anti-TNF (relative risk 2.02, 95% CI 1.11 to 3.95). Evaluation of drug-specific effects was hampered by
statistical precision and by differences in baseline cancer risk and reporting detail across trials.138
Another review of AE effects of etanercept, adalimumab and infliximab was based on systematic searches
for systematic reviews of the safety of biologic agents.139 Six reviews that were sufficiently rigorous to meet
the Database of Abstracts of Reviews of Effects inclusion criteria were included in the overview. This review
also included large RCTs and non-randomised studies (≥ 500 patients), and was focused on serious
potential AEs, such as serious infections, reactivation of latent tuberculosis and cancer.139 Table 25, which
summarises the rates of SAEs among the included non-randomised studies and large RCTs, indicates that
TABLE 23 Cochrane summary of findings table for biologics as a class (reproduced with permission from
Singh et al.137)
AE
Risk with comparator,
per 1000 patients
unless otherwise
stated
Risk with intervention,
per 1000 patients,
unless otherwise stated
(95% CrI) OR (95% CrI)
Number of
participants
(studies)
SAEs 118 127 (115 to 142) 1.09 (0.97 to 1.24) 21,152 (76)
Total AEs 724 770 (741 to 797) 1.28 (1.09 to 1.50) 14,959 (48)
Withdrawal due to AEs 98 137 (115 to 168) 1.47 (1.20 to 1.86) 22,636 (83)
Serious infections 26 35 (27 to 46) 1.37 (1.04 to 1.82) 21,853 (70)
Tuberculosis reactivation 4 per 10,000 20 per 10,000 4.68 (1.18 to 18.6) 30,671 (71)
Lymphoma 9 per 10,000 1 0.53 (0.17 to 1.66) 21,260 (52)
Congestive heart failure 8 6 (1 to 21) 0.69 (0.18 to 2.69) 8847 (24)
Copyright © The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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TABLE 24 Cochrane summary of findings table for individual anti-TNFs (adapted from Singh et al.137)
Anti-TNF
Risk with comparator,
per 1000 patients
unless otherwise
stated
Risk with intervention,
per 1000 patients,
unless otherwise
stated (95% CrI) OR (95% CrI)
Number of
participants
(studies)
SAEs
Adalimumab 118 114 (90 to 145) 0.96 (0.74 to 1.27) 4662 (15)
Certolizumab 118 174 (124 to 237) 1.57 (1.06 to 2.32) 2421 (6)
Etanercept 118 142 (111 to 184) 1.24 (0.93 to 1.69) 3931 (21)
Golimumab 118 123 (82 to 184) 1.05 (0.67 to 1.69) 1564 (8)
Infliximab 118 133 (102 to 174) 1.15 (0.85 to 1.57) 3403 (14)
Total AEs
Adalimumab 724 730 (637 to 802) 1.03 (0.67 to 1.54) 3266 (10)
Certolizumab 724 754 (651 to 837) 1.17 (0.71 to 1.95) 1829 (5)
Etanercept 724 784 (677 to 866) 1.38 (0.80 to 2.46) 1600 (7)
Golimumab 724 765 (672 to 839) 1.24 (0.78 to 1.98) 1187 (6)
Infliximab 724 803 (726 to 860) 1.55 (1.01 to 2.35) 2330 (9)
Withdrawal due to AEs
Adalimumab 98 128 (81 to 194) 1.35 (0.82 to 2.22) 5268 (18)
Certolizumab 98 125 (70 to 226) 1.32 (0.69 to 2.69) 2421 (6)
Etanercept 98 124 (82 to 191) 1.30 (0.82 to 2.17) 5189 (25)
Golimumab 98 127 (64 to 241) 1.34 (0.63 to 2.92) 1549 (7)
Infliximab 98 203 (132 to 310) 2.34 (1.40 to 4.14) 2973 (15)
Serious infections
Adalimumab 26 32 (17 to 60) 1.23 (0.65 to 2.40) 4847 (15)
Certolizumab 26 113 (39 to 330) 4.75 (1.52 to 18.45) 1683 (4)
Etanercept 26 33 (19 to 61) 1.29 (0.72 to 2.45) 4630 (19)
Golimumab 26 29 (12 to 65) 1.11 (0.45 to 2.59) 1334 (6)
Infliximab 26 36 (20 to 65) 1.41 (0.75 to 2.62) 2652 (13)
Tuberculosis reactivation
All nine biologics 4 per 10,000 20 per 10,000 4.68 (1.18 to 18.60) 30,671 (71)
Lymphoma
All nine biologics 9 per 10,000 1 0.53 (0.17 to 1.66) 21,260 (52)
Congestive heart failure
All nine biologics 8 6 (1 to 21) 0.69 (0.18 to 2.69) 8847 (24)
Copyright © The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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the rates of SAEs cover a broadly similar range across the three different biologic agents. However, all
estimates were derived from a highly heterogeneous group of studies in terms of participants (e.g.
inflammatory condition or disease severity), study design (e.g. length of follow-up) and treatment regimens
(e.g. dose and frequency). Consequently, reliable estimates of the relative rate of SAEs for each drug could
not be made.
Withdrawal rates due to AEs were typically < 10% for all drugs, with the highest reported single estimate
being 13.6% for one etanercept study. This suggested that the majority of patients can tolerate biologic
treatment in the medium term, although again the estimates were derived from a highly heterogeneous
group of studies; therefore, the possibility of poorer tolerability in specific patient groups was not ruled out.
Open-label extensions of randomised trials
Of the longer-term follow-up studies included in our present review we evaluated those reporting AEs after
6 months (as the Cochrane review covered events occurring up to 6 months); 13 trial cohorts had studies
which reported data after 6 months. Both the type of AEs assessed, and the periods over which they
were assessed, varied across studies. Table 26 compares results for studies with at least around 2 years of
follow-up. The ATLAS61 and GO-RAISE90 trials both had extension study publications at the 2-year and
5-year time points.140–143 Both cohorts were analysed using mITT data, in which patients had to have
received at least one dose of treatment. This amounted to 99% of the randomised patients in both studies
(311 out of 315 in ATLAS61 and 353 out of 356 in GO-RAISE90). Davis72,73 reported results for the 257 patients
who enrolled in a 168-week open-label study following week 24 of the randomised phase; 277 patients had
taken part in the earlier randomised study. All 257 patients in the open-label study had received at least one
dose of etanercept.144,145 The Calin trial83–85 randomised 84 patients, with 81 patients enrolling in the open-label
extension study. Results were presented separately for the 12-week to 2-year time points and the 2- to 5-year
time points.146,147 RAPID-axSpA64 data at 96 weeks were reported in the manufacturer’s submission. These data
related to the mITT population: 315 (97%) of the 325 originally randomised patients.
The 2-year study of the ASSERT (Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab
Therapy)102 (infliximab) cohort allowed dose escalation whereby, from week 36, patients with BASDAI
scores of ≥ 3 could increase their dose to 7.5mg/kg, which is a currently unlicensed dose. Results for the
5mg/kg group (74 patients) between weeks 24 and 102 have therefore been presented in Table 26.
The Braun cohort148 was followed up for 8 years, but it was a small study which reported only SAEs and
withdrawals due to SAEs.
Table 26 illustrates that rates of SAEs, cancer and serious infections were similar across all four anti-TNFs
when using incidence per 100 patient-years as estimates. At 5 years, SAEs appeared more prevalent with
adalimumab (45%) than golimumab (20%), although it is possible this difference is because of the way
the data were reported; it was unclear whether the ATLAS61 data related to the total number of SAEs or
to the number of patients experiencing a SAE. At 2 years, the incidence of injection site reactions was
higher in patients taking etanercept than in patients taking adalimumab, golimumab or certolizumab
pegol. Withdrawal rates due to AEs were broadly similar across treatments. The reporting of tuberculosis
and congestive heart failure was limited.
TABLE 25 Prevalence ranges of SAEs from non-randomised studies and RCTs (reproduced from Rodgers et al.139)
Drug Serious infections (%) Cancer (%) Tuberculosis (%) Mortality (%)
Withdrawals due
to AE (%)
Etanercept 0.6–13.2 1–5.7 0–1.4 0–3.1 0–13.6
Infliximab 0.8–13.8 0.16–5.1 0.06–4.6 0.06–2.0 6.4–12.8
Adalimumab 0.4–5.1 0.1–1.1 0–0.4 0.5–0.9 5.8–10.7
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TABLE 26 Studies with adverse event data at around 2 years (or later)
Event
outcome
Adalimumab Golimumab Etanercept Certolizumab Infliximab
ATLAS61 GO-RAISE90 Davis72,73 Calin83–85 RAPID-axSpA65 aASSERT102
2 years
(n= 311)
5 years
(n= 311)
2 years
(n= 353)
5 years
(n= 353)
24–192 weeks
(n= 257)b
12–108 weeks
(n= 81)b
2–5 years
(n= 59)
96 weeks
(n= 315)
24–102 weeks
(n= 74)
SAEs 48 events (15%)
10.5/100 PY
140 events (45%)
11.7/100 PY
40 events
(11%)
72 events (20%) 33 events (13%)
8/100 PY
19 events (23%) 21/100 PY AiC information
has been removed
15 events (20%)
Withdrawals
because of
AEs
24 (8%) events
4.5/100 PY
– 19 events
(5%)
32 events (9%)
2.13/100 PY
14 events (5%) 15 events (19%) 7 events (12%) AiC information
has been removed
–
Serious
infections
6 (2%) events
1.1/100 PY
17 events (5%)
1.4/100 PY
11 events
(3%)
21 events (6%)
2.1/100 PY
6 events (2%)
2/100 PY
5 events (6%) 3 events (5%)
3/100 PY
AiC information
has been removed
3 events (4%)
Cancer 4 events (1%)
0.7/100 PY
3 events (1%)
0.2/100 PY
2 events
(0.6%)
3 events (0.8%)
0.21/100 PY
– 4 events (5%) 3 events (5%) – 1 events (1%)
NMSC 0.4/100 PY – – – – – – – –
Congestive
heart failure
0 events 2 events (0.6%)
0.2/100 PY
– – – – – – –
Injection site
reactions
42 events (14%)
17.6/100 PY
– 38 events
(11%)
43 events (12%) 57 events (22%) 30 events (37%) 7 events (12%) AiC information
has been removed
9 events (12%)
Tuberculosis 0 events 0 events – – – 0 events 0 events AiC information
has been removed
–
AiC, academic-in-confidence; ASSERT, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy; NMSC, non-melanoma skin cancer; PY, person-year.
a 5 mg/kg group.
b Weeks from randomisation.
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Summary of adverse event data
Data from large systematic reviews, which included patients with a wide range of diseases, suggest that,
in the short term, anti-TNFs as a group are associated with significantly higher rates of serious infections,
tuberculosis reactivation, non-melanoma skin cancer, total AEs and withdrawals because of AEs than
control treatments. Specifically, infliximab is associated with significantly higher rates of total AEs and
withdrawals because of AEs, and certolizumab pegol is associated with significantly higher rates of serious
infections and SAEs. Analyses from the present review showed etanercept to be statistically significantly
more likely to result in an injection/infusion site reaction compared with infliximab, although analysable
data on such reactions were not reported for the three other anti-TNFs. Evaluations of longer-term data
are more scarce, although suggest similar safety profiles across anti-TNFs. Data from the open-label studies
included in this review also do not suggest that there are important differences between treatments, other
than a higher incidence of injection site reactions following treatment with etanercept. These open-label
data are, however, limited by the small sample sizes and non-randomised study designs.
Review of natural history of ankylosing spondylitis and non-radiographic
axial spondyloarthritis
In order to get some understanding of what happens to patients who, although eligible for anti-TNF
therapy for their AS or nr-AxSpA, do not receive it, we conducted a rapid review of relevant literature.
This was not a systematic review but one that started with the library of papers found by the main
searches for RCTs of the anti-TNFs and then followed relevant citations to papers on AS and axSpA in
patients not receiving an anti-TNF. Potentially relevant papers were those that reported on the pattern of
disease, AS or nr-AxSpA or axSpA, without treatment with anti-TNFs over time. This process identified
a number of relevant registries: OASIS,118 Scotland and Ireland Registry for Ankylosing Spondylitis
(SIRAS), Devenir des Spondylarthropathies Indifferenciées Récentes, Esperanza, Spanish Registry of
spondyloarthritis, German Spondyloarthritis Inception Cohort (GESPIC) and St Mary RheumaToid Arthritis
(SMART). Additional searches of MEDLINE were conducted using these specific registry names. All relevant
studies identified through this process are presented in Table 27.
The studies collectively explore the associations between the various components of axSpA: disease
activity, structural damage and spinal mobility. The exploration of the ASSERT trial baseline data24,124
reveals that HRQoL as determined by SF-36 physical and mental components, is determined by BASFI
and BASDAI; BASFI is determined by BASDAI, mSASSS and BASMI (spinal mobility); and BASMI is
independently determined both by irreversible spinal damage (mSASSS) in late disease and reversible spinal
damage (MRI) in early disease.
The studies identified that from a clinical practice and patients’ point of view disease progression in terms
of BASFI, a measure of the patient’s functional ability, is very important. A number of studies on the
disease progression of AS have been based on the European OASIS cohort118 (a consecutive cohort, started
in 1996, although there were no further specific eligibility criteria); the total cohort numbers 217 patients.
One of these, a study by Landewe et al.,10 demonstrated that physical function impairment (BASFI) is
independently affected by both disease activity (BASDAI) and bony progression, usually assessed using
mSASSS despite this being a measure of bony growth in the spine only (and not in the sacroiliac joints).
Other studies by Ramiro124,125 have demonstrated that radiographic progression, increases on average by
around 2 mSASSS units every 2 years.124,125 However, this progression is highly variable; the average patient
with inactive disease [Ankylosing Spondylitis Disease Activity Score (ASDAS) 0] would progress by 5
mSASSS units over 12 years compared with a patient with ‘very active disease’ (ASDAS 4) who would have
19 units of progression.124 In addition, of 68 patients who were followed for 12 years, 18% had no
progression on mSASSS.125 The variability is also demonstrated by the results based on a different cohort:
a single German clinic (n= 146).12 Baseline characteristics were similar to those in the OASIS cohort118
(see Table 27). Mean follow-up was 3.8 years (SD 1.7 years) and mean mSASSS change was 1.3 units/year
(SD 2.5 units/year) with a range of 0–22.8 mSASSS units. Thirty-four (23%) patients showed
no progression.
DOI: 10.3310/hta20090 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 9
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57
TABLE 27 Natural history of axSpA: relevant outcomes and impact of anti-TNFs
Study Description Population characteristics Summary of findings
Landewe
200910
Examined the relationship
between disease activity,
radiographic damage and
physical function in AS.
Based on (European) OASIS
cohort118 baseline and 2-year
data. n= 217 consecutive
(from 1996) patients with
AS (no specific criteria).
BASDAI score mean 3.4
(SD 2.1), with 38% ≥ 4
BASFI score mean 3.4
(SD 2.6), 41% ≥ 4. mSASSS
median 5, 69% > 0. Note:
does mSASSS < 0 mean
nr-AxSpA? None of the
patients in the cohort had
used anti-TNFs. Subgroup
(n= 188) baseline BASDAI
score of ≤ 6
Univariate correlation between baseline
mSASSS and BASFI score= 0.45
(Spearman’s rank correlation coefficient),
but this was modified by baseline
BASDAI:
l BASDAI score of 0–2 (n= 68)= 0.68
l BASDAI score of >2–4 (n=60)=0.58
l BASDAI score of >4–6 (n=60)=0.43
l BASDAI score of >6–8 (n=22)=0.40
l BASDAI score of >8–10 (n=7)=–0.20
Suggests a ceiling effect of BASFI. Owing
to the high level of correlation between
BASDAI and BASFI, a correlation
between mSASSS and BASFI cannot be
demonstrated at the highest level of
BASDAI. There was a multivariate
relationship between BASDAI and
mSASSS with BASFI using baseline and
2-year data (but not longitudinal?)
(n= 188, baseline BASDAI score of ≤ 6
only). Regression coefficients found that
both BASDAI and mSASSS are
statistically significant (p < 0.001)
explanatory variables for BASFI (0.73 and
0.057 units respectively)
Ramiro
2014124
Analysed long-term
relationship between disease
activity (ASDAS, BASDAI)
and radiographic damage
(mSASSS) in AS. Used OASIS
cohort118 over 12 years
Subgroup used patients
(n= 184) who had at least
two sets of radiographs.
Baseline characteristics of
this subgroup: BASDAI score
mean 3.4 (SD 2.0); mSASSS
mean 10.8 (SD 15.2), 81%
> 0. None of the patients
had used anti-TNFs
On average patients had a progression of
1.9 mSASSS units/2 years. This varied
with baseline ASDAS:
l ASDAS < 1.3 progress= 0.7 mSASSS
units/2 years
l ASDAS > 3.5 progress= 3.1 mSASSS
units/2 years
The relationship with BASDAI was similar:
l Baseline BASDAI score of < 4,
1.5 mSASSS units/2 years
l BASDAI score of ≥ 4, 2.7 mSASSS
units/2 years
l BASDAI score of > 6 units,
2.0 mSASSS units/2 years
The analysis found that the average
patient with inactive disease (ASDAS
score 1.0) would progress by 5 mSASSS
units over 12 years compared with a
patient with ‘very active disease’
(ASDAS score of 4) would have 19 units
of progression
Ramiro
2013125
Earlier analysis of OASIS
cohort118 12-year data to
describe the evolution of
radiographic abnormalities
in AS patients
Subgroup used (n= 186)
who had at least two sets
of radiographs. Baseline
characteristics of this
subgroup: BASDAI score
mean 3.4 (SD 2.0); mSASSS
mean 11.6 (SD 16.2). None
of the patients had used
anti-TNFs
Long-term radiographic progression in AS
highly variable at the patient level, but is
more severe in men who are HLA-B27
positive. Over whole follow-up, 24% of
patients (and 18% of the 68 patients who
were followed for 12 years) had no
progression on mSASSS. Duration of
disease is not relevant. At the group level,
progress is linear at 2 mSASSS units/2 years
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TABLE 27 Natural history of axSpA: relevant outcomes and impact of anti-TNFs (continued )
Study Description Population characteristics Summary of findings
Baraliakos
200912
Natural course of
radiographic progression in
AS. Retrospective cohort,
single clinic (Herne,
Germany), 1993–2005.
Mean follow-up 3.8 years
(SD 1.7 years)
n= 146 anti-TNF naive
patients. Baseline:
l mSASSS mean 20.5
(SD 14.4)
l BASDAI score mean 4.4
(SD 1.9) (range 0.5–7.3)
l BASFI score mean 3.8
(SD 2.6) (range 1.0–8.4)
Mean mSASSS change was 1.3 units/year
(SD 2.5 units/year). Note: range was
mSASSS 0–22.8. Thirty-four (23%)
patients showed no progression
Dean 2014,149
poster at BSR
meeting
SIRAS cohort. Study of
BASDAI over time
BASDAI score at diagnosis
data available for only 240
patients (out of the 1210
patient cohort). Baseline
BASDAI score (at diagnosis)
of 4.9 (SD 2.3). High disease
activity group BASDAI score
of 6.3 (SD 1.4) and low
disease activity group
BASDAI score of 2.5 (SD 1.3)
Baseline BASDAI remained fairly stable
over time: across the whole cohort and
in the high and low disease activity
groups. The subgroup treated with
anti-TNFs had higher mean BASDAI score
[5.7 (SD 2.0)] than non-biologic patients
[4.2 (SD 2.5)] and this remained so until
around a year after treatment with anti-
TNFs began, when mean BASDAI fell to
the level of the non-biologic patients
Healey 201314 Cohort study, single centre,
England. Followed patients
over 10 years [n= 69 who
provided assessments at
baseline (1998) and at
10 years (2008)]. Assessments
using RLDQ, BASDAI, ASQoL
and EQ-5D (and others)
At study entry patients were
84% male, mean age
49 years, disease duration
15.5 years, symptom
duration 21.4 years. 1.5%
on an anti-TNF at 10 years
Only RLDQ changed significantly over
time for assessment 1 (1998) and 2
(2008):
l RLDQ: mean 10.4 (SD 8.3); mean
13.6 (SD 10.9); p= 0.002
l BASDAI: mean 4.1 (SD 2.5); mean
4.4 (SD 2.7); p= 0.36
l ASQoL: mean 6.4 (SD 6.3); mean 7.5
(SD 6.4); p= 0.15
l EQ-5D: mean 0.64 (SD 0.28); mean
0.61 (SD 0.30); p= 0.45
However, as RLDQ (range 0–48) is a
measure of function (comparable with
BASFI) it does indicate progression with
time even in these AS patients whose
disease at study entry was already well
established
Stone 2007150 Analysis of longitudinal data
from SMART (Bath, UK) data
set (n=224). Regression
analysis of BASDAI score on
symptom duration and BASFI
score adjusted for BASDAI
score >4 at baseline. Duration
of follow-up was unclear
Overall, 68% had a baseline
BASDAI score of ≥ 4. Mean
symptom duration was
28.8 years
Only 20% experienced a significant
change in BASDAI score over time (13%
a decrease; 7% an increase). BASFI score
increases over time by 0.035 units/
symptom-year. In patients with baseline
BASDAI score of ≥ 4, those who would
be treated with anti-TNFs, the increase
over time is 0.039 units/symptom-year
Machado
2010151
Baseline data from
ASSERT.102 Analysis of
relation between mSASSS
and MRI inflammation and
BASMI
n= 214 AS patients (mNY
criteria). Baseline median
(IQR):
l BASMI score of
4.6 (3.6–5.8)
l BASDAI score of
6.5 (5.3–7.0)
l CRP level 1.5mg/dl
(0.7–2.9mg/dl)
l mSASSS 13.8 (4.5–29.1)
Concluded that spinal mobility (BASMI)
independently determined both by
irreversible (mSASSS) and reversible
spinal damage (MRI), the former in late
disease and the latter in early disease
continued
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TABLE 27 Natural history of axSpA: relevant outcomes and impact of anti-TNFs (continued )
Study Description Population characteristics Summary of findings
Machado
201124
Baseline data from
ASSERT.102 Analysis of
relation between SF-36 and
BASFI and BASDAI, ASDAS,
CRP level, mSASSS, MRI
inflammation and BASMI
n= 214 AS patients
(mNY criteria)
Regression coefficients for associations
reported in the publication. Briefly, SF-36
is determined by BASFI and BASDAI; and
BASFI is determined by BASDAI, mSASSS
and BASMI
Kobelt
2004152
A modelling study of
infliximab but refers to large
UK observational data set
and generates an estimate
for BASFI over time. Survey
in 2002 (n= 1413). Value
generated from patients
who were captured in two
surveys at two time points,
1992/1994 and November
2002, approximately 8 years
apart (n= 1100). Data from
a cohort of 493 patients
who had been followed up
for more than 3 years were
used as a check for the
result based on the survey
– From the whole survey (n= 1413) mean
BASDAI score 4.2 (SD 2.3) and mean
BASFI score 4.4 (SD 2.8). The population
was broader than that eligible for anti-
TNFs, with 47% having a BASDAI score
of < 4. It appears (but is unclear) that this
is the BASDAI at the later time (2002)
point not the earlier (1992/4). Estimate of
annual BASFI progression was 0.07
points. Note: progression was faster
(0.1 points) in patients with BASFI score
of < 4 at baseline, but was stable (0?) in
patients with BASFI score above 7.
(Ceiling effect of BASFI?) When only
patients with BASDAI score of ≥ 4
included BASFI progression was estimated
as 0.054. Data from the cohort study
generated similar findings; however, the
number was not actually reported for
whole survey. BASFI progression was
0.059 for patients with a BASDAI
score of ≥ 4
Nr-axSpA
Kiltz 2012153 Comparison of
characteristics of patients
with AS and nr-AxSpA.
Cohort of 100 patients seen
in 2010 in Herne clinic,
Germany. Analysis tested if
the proportion of patients
reaching pre-specified
cut-off criteria (markers of
disease severity) differed
between AS and nr-AxSpA
Consecutive, diagnosed with
axSpA. None of the patients
had used anti-TNFs. n= 100
AxSpA: n= 44 nr-AxSpA and
n= 56 AS
l Median BASDAI
score, 4.3 (AS) and 3.6
(nr-AxSpA); p= 0.2
l Median BASFI score,
2.9 (AS) and 1.5
(nr-AxSpA); p= 0.05
l Median CRP level,
8.0mg/l (AS) and
3.8mg/l (nr-AxSpA);
p<0.001
l Median mSASSS 3.0
(AS) and 1.1 (nr-AxSpA);
p< 0.007
Differences were statistically significant
for ASDAS, CRP level, mSASSS and
number of inflamed lesions. Proportion
of males also significantly different.
Results:
l % male (p-value), 31.8% (nr-AxSpA)
and 76.8% (AS); p< 0.001
l BASDAI score of ≥ 4: 43%
(nr-AxSpA) and 53.5% (AS); p= 0.1
l BASFI score of ≥ 3: 34.1%
(nr-AxSpA) and 46.4% (AS); p= 0.08
l ASDAS > 2: 54.5% (nr-AxSpA) and
78.6% (AS); p= 0.01
l CRP level >5mg/l: 29.5% (nr-AxSpA)
and 69.1% (AS); p<0.001
l mSASSS ≥ 3: 27.3%(nr-AxSpA) and
51.9% (AS); p= 0.01
l Number of inflamed lesions per
patient ≥ 3: 9.1% (nr-AxSpA) and
46.4% (AS); p= 0.01
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TABLE 27 Natural history of axSpA: relevant outcomes and impact of anti-TNFs (continued )
Study Description Population characteristics Summary of findings
Rudwaleit
200918
Cross-sectional study of
GESPIC cohort (n= 462)
patients with axSpA. Divided
into AS (n= 236) and
nr-AxSpA (with ≤ 5 years
of symptoms, n= 226)
Baseline mean:
l BASDAI score of 4.0
(SD 2.1) (AS) and 3.9
(SD 2.0) (nr-AxSpA)
l BASDAI score of ≥ 4,
48.7% (AS) and 47.7%
(nr-AxSpA)
l BASFI score of 3.1 (SD 2.5)
(AS) and 2.5 (SD 2.1)
(nr-AxSpA)
Note: mean BASFI score was
the same for patients with
AS more than or no more
than 5 years of symptoms
When AS patients were divided into
those with more than 5 years of
symptoms and those no more than
5 years, there were no differences in
characteristics at baseline. When AS
(≤ 5 years) and nr-AxSpA were compared
there were statistically significant
differences (worse for patients with AS)
in Physicians Global assessment, BASFI,
BASMI, spinal mobility, lateral spinal
flexion, CRP, ESR and all radiographic
measures (mSASSS 4.9 in AS vs. 1.4 in
nr-AxSpA). mSASSS was significantly
worse in males vs. females and in CRP
level > 6 vs. ≤ 6. Note: the AS patients
had a very short symptom duration and
must have progressed to AS rapidly. In
addition, nr-AxSpA patients had only a
short time from the start of symptoms
and may therefore not reflect patients
who remain nr-AxSpA for a longer time.
Poddubnyy
2011154
Study of radiographic
progression of sacroiliitis in
AS and nr-AxSpA.
Radiographic evidence of
sacroiliitis is a criterion in the
mNY for AS; therefore, it is
useful to see this analysis of
progression rather than only
the mSASSS
German cohort (GESPIC)
n= 210 (n= 115 AS and
n= 95 nr-AxSpA), 2 years’
follow-up. (Baseline BASDAI
score was 4 and BASFI score
was 3 across AS and
nr-AxSpA.) Overall the
cohort had a short symptom
duration of 4.2 years
(5.2 years AS and 3.2 years
nr-AxSpA). Only 3.5% had
had treatment with
anti-TNFs (3.5% AS and
1.1% nr-AxSpA)
After 2 years’ follow-up, n= 11 of the
95 nr-AxSpA patients (11.6%, 95% CI
6.6% to 19.6%) fulfilled the mNY
for AS. In addition, after 2 years
approximately 10.5% of patients in the
nr-AxSpA cohort had progressed by at
least one mNY grade, compared with
8.7% of patients in the AS group
(difference not statistically significant).
Predictors of sacroiliitis progression were
raised CRP level for both AS and
nr-AxSpA. Male sex and HLA-B27
positive predicted lower progression in
nr-AxSpA but higher progression in AS
Poddubnyy
2012155
GESPIC cohort. Radiographs
of spine and SIJ at baseline
and at 2 years
Baseline, all patients
(n= 210): of the 2.4%
patients treated with
anti-TNFs, the BASDAI score
was 4 and the BASFI
score was 3. AS (n= 115): of
the 3.5% patients treated
with anti-TNFs the BASDAI
score was 4 and the BASFI
was score 3. nr-AxSpA
(n= 95): of the 1.1%
of patients treated with
anti-TNFs, the BASDAI score
was 4 and the BASFI score
was 3
Regression analysis found syndemophytes
at baseline, elevated ESR and CRP level
and smoking were significantly associated
with spinal progression (≥mSASSS/2
years) in AS but only syndemophytes at
baseline in axSpA. In AS patients mSASSS
increased significantly from 5.86
(SD 10.30) to 6.81 (SD 11.71), mean
difference 0.95 (SD 2.78). In nr-AxSpA
patients mSASSS increased significantly
from 2.30 (SD 4.24) to 2.76 (SD 5.26),
mean difference 0.46 (SD 1.63). The
difference between mean progression in
AS and nr-AxSpA patients was not
statistically significant, and neither was
the difference between those with
symptom duration of ≤ 5 years and
> 5 years. Percentage that progressed by
> 2 mSASSS units/2 years: all axSpA
14.3%; AS 20.0% (95% CI 13.7% to
28.2%); nr-AxSpA 7.4% (95% CI 3.6%
to 14.4%). There was no difference in
mSASSS change between patients not
progressing to AS (0.49 units) and those
who progressed to AS (0.27 units);
p= 0.53
continued
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There is evidence that BASDAI is relatively constant over time. An analysis of data from a UK registry, SIRAS,
demonstrated that patients stratified into high or low disease activity (BASDAI) remain in their separate groups
over many (12) years.149 Data on the long-term pattern of patient function (BASFI) in patients not being treated
with anti-TNFs are more scarce. A cohort study, from a single centre in England, provided data on 69 patients
followed over 10 years [two data points: at baseline (1998) and at 10 years (2008)].14 The assessment of BASDAI
confirmed that it remains relatively constant [mean at baseline 4.1 units (SD 2.5 units) and after 10 years 4.4
units (SD 2.7 units) (p= 0.36)]. Patient function was assessed using the Revised Leeds Disability Questionnaire
(RLDQ) rather than BASFI, but provided evidence of deteriorating function over time: mean RLDQ at baseline
was 10.4 (SD 8.3), and after 10 years was 13.6 (SD 10.9) (p= 0.002). Analysis of longitudinal data from the
SMART (Bath, UK) data set (n= 223) found that BASFI increased over time by 0.035 units/symptom year.150 In
patients with baseline BASDAI of ≥ 4 (those that would be treated with anti-TNFs and 68% of the total cohort)
the rate of BASFI increase was 0.039 units/symptom year. Estimates of the rate of change in BASFI over time
were also reported in a cost-effectiveness modelling study.152 The data were from patients who were captured in
two surveys at two time points 1992/1994 and November 2002 approximately 8 years apart (n= 1100). The
estimate of annual BASFI progression was 0.07 points, but when only patients with BASDAI score of ≥ 4 were
included in the analysis, BASFI progression was estimated as 0.054. It was reported that data from a cohort of
493 patients who had been followed up for more than 3 years generated similar findings; the number was not
actually reported for the whole survey but was 0.059 for the BASDAI score of ≥ 4 subgroup.
TABLE 27 Natural history of axSpA: relevant outcomes and impact of anti-TNFs (continued )
Study Description Population characteristics Summary of findings
Flares
Cooksey
201028
Cohort derived from full
population of a trial
comparing probiotic and
placebo treatment in AS.
Followed up for 1216
person-weeks and recorded
localised/minor flares and
generalised/major flares, plus
BASDAI, BASFI and pain VAS
AS patients n= 134. Baseline
mean BASDAI score of 3.7
(SD 2.1); mean BASFI score
of 3.6 (SD 2.8). Mean
duration of symptoms
21 years (SD 13 years,
range 0–58 years)
The overall flare rate was 71.4 per 100
person-weeks: major flare rate of 12 per
100 person-weeks and minor flare rate
of 59.4 per 100 person-weeks. Mean
BASDAI scores were 5.5 (major flare), 3.1
(minor flare) and 2–2.5 (flare free). Mean
BASFI scores were 5.5 (major flare), 3.1
(minor flare) and 2.5–3.5 (flare free).
Note: these means are not from whole
population but only from patients who
experienced major flares plus flare-free
periods (n= 27) and minor flares plus
flare-free periods (n= 77)
Stone 2008156 A pilot study to investigate
pattern of disease and
impact of disease flares. It
used the SMART cohort
(Bath, UK). Patients were
asked about four patterns of
disease (see under Summary
of findings in this table)
AS patients, although the
diagnostic criteria was not
stated, n= 114 (although
not n= 114 for all of the
percentage). Mean BASDAI
score of 4.2 and BASFI
score of 4.0
Overall, 96% of patients reported
experiencing flares. The duration varied
by patient: days (40%), weeks (30%) and
months (30%). Of these, 83% reported
experiencing symptoms between flares.
The percentage of patients for the four
patterns of the disease were:
(a) relapsing/remitting (flares with no
symptoms between): around 20%
(b) flares on a background of symptoms:
around 50%
(c) gradually developing and resolving
flare with periods of no symptoms: 7%
(d) gradually developing and resolving
flare after which symptoms worse
than before start of flare: 26%
(a) and (d) associated with higher BASFI
score
IQR, interquartile range; mNY, modified New York criteria; RLDQ, Revised Leeds Disability Questionnaire; SIJ, sacroiliac joint.
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Natural history data from patients with nr-AxSpA are even more scarce than those for AS patients, with no
long-term data identified. A comparison of AS and nr-AxSpA patients from a cohort of 100 consecutive
patients (Herne clinic, Germany) (AxSpA n= 100, nr-AxSpA n= 44, AS n= 56) found that slightly higher
proportions of AS patients met pre-specified cut-off points of disease severity than did nr-AxSpA patients,
but the differences were statistically significant only for ASDAS, CRP level, mSASSS and the number of
inflamed lesions; the proportion of males was also statistically significantly different.153 The results are given
in Table 27. The difference for BASFI was very close to statistical significance.
A larger cross-sectional study of the GESPIC cohort [n= 462 patients with axSpA (AS or nr-AxSpA)] also
found differences between AS and nr-AxSpA patients.18 When AS (≤ 5 years) and nr-AxSpA were
compared, there were statistically significant differences in Physician Global Assessment, BASFI (3.1 in AS
vs. 2.5 in nr-AxSpA), BASMI (1.9 in AS vs. 1.1 in nr-AxSpA), spinal mobility and lateral spinal flexion, CRP
level and ESR, and all radiographic measures (mSASSS 4.9 in AS vs. 1.4 in nr-AxSpA). mSASSS was
statistically significantly worse in males versus females and between CRP level > 6 and < 6, although it is
unclear whether or not this is a meaningful cut-off point for CRP level.
In two longitudinal studies of progression in nr-AxSpA,154,155 also using the GESPIC cohort, progression in
terms of sacroiliitis and in terms of radiographic progression in the spine (mSASSS) was slightly more rapid
in AS than in nr-AxSpA but not statistically significantly so. Raised CRP level at baseline was a predictor of
both measures of progression in AS but only for sacroiliitis in nr-AxSpA. The presence of syndesmophytes
was predictive of higher progression rates as assessed by mSASSS in both AS and nr-AxSpA. Of the
95 patients with nr-AxSpA, 11 (11.6%) fulfilled the modified New York criteria for AS after 2 years of
follow-up. A review of the burden of illness in nr-AxSpA157 cited this (11.6%) progression rate along with a
10% rate over 2 years and a 24% rate over 10 years. However, the 10-year rate was derived from a
broader, more heterogeneous population than the GESPIC cohort: patients had undifferentiated
spondyloarthropathies with over half not having inflammatory low back pain.156,158 The GESPIC study
recruited only patients with axSpA (AS or nr-AxSpA).
Studies of disease progression in nr-AxSpA focus on aspects of the disease that can be assessed through
imaging techniques: radiography or MRI. This may appear reasonable given the subjective,
patient-questionnaire basis of the BASFI score.
Finally, there is evidence that as well as being progressive, the course of AS includes flares. A study based
on the population of a trial comparing probiotic and placebo treatment in AS found that the overall flare
rate was 71.4 per 100 person-weeks; the major flare rate was 12/100 person-weeks and the minor
flare rate was 59.4/100 person-weeks.28 BASDAI and BASFI varied with type of flare: mean BASDAI scores
were 5.5 (major flare), 3.1 (minor flare) and 2–2.5 (flare free), and mean BASFI scores were 5.5 (major
flare), 3.1 (minor flare) and 2.5–3.5 (flare free). A pilot study used the SMART cohort (Bath, UK) to
investigate the pattern of disease and impact of disease flares.159 Of the 114 patients, 96% reported
experiencing flares. Flare duration varied by patient: days (40%), weeks (30%) and months (30%). Fifty per
cent of patients reported flares on a background of symptoms, while 26% reported gradually developing
and resolving flares after which symptoms were worse than before the start of the flare. These patterns
were associated with higher BASFI scores. Around 20% reported flares with no symptoms between. A
small proportion (7%) reported gradually developing and resolving flare with periods of no symptoms.
In summary, the available studies indicate that in AS and nr-AxSpA disease activity (BASDAI) is fairly stable
over time and does not generally progress, although it can be at a high (severe) level early in the disease.
Patients function (as assessed by BASFI) does deteriorate over time, although the course is not constant or
predictable. BASFI is determined by both disease activity and bone neo-formation; progression of BASFI
score over time is driven by progression of bony disease as assessed by imaging scores such as mSASSS,
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or the presence of syndesmophytes. Best estimates of yearly disease progression rates without anti-TNF
therapy are around 1.0 mSASSS units and 0.035–0.07 BASFI units. Information on the natural history of
nr-AxSpA is relatively sparse. While disease progression appears to be faster in AS, patients with nr-AxSpA
can have severe disease activity and hence poor function.
Clinical effectiveness summary and conclusions
Summary of randomised controlled trial results
The quality of the trial evidence was generally high; most studies were unlikely to have produced results
which were biased. For both the AS and nr-AxSpA populations, the results of the meta-analyses
demonstrated that anti-TNFs produce statistically significant and clinically relevant benefits to patients in
terms of improving function and reducing disease activity. The common class-effect model used may have
underestimated the uncertainty in the effect estimates. Although there is a possibility that infliximab is
more effective than other TNF inhibitors at least at 12 weeks, there is no strong evidence to support this.
For the disease activity, function and responder outcomes, the class-efficacy estimates were consistently
slightly smaller for nr-AxSpA than for AS, most noticeably for BASFI and BASDAI 50. Statistical
heterogeneity was more apparent in the nr-AxSpA analyses than in the AS analyses. This may be a result
of both clinical heterogeneity in the nr-AxSpA trials (such as variation in CRP levels or the proportion of
MRI positive patients) and the fact that fewer studies were available for analysis. In the light of the
statistical heterogeneity across the nr-AxSpA trials, both the reliability of the nr-AxSpA-pooled estimates
and their true relevance to patients seen in clinical practice is questionable.
The US FDA reanalyses of two key nr-AxSpA trials further emphasised the heterogeneity in the nr-AxSpA
population. Results for an adalimumab trial in nr-AxSpA patients suggested reduced efficacy in a centrally
diagnosed nr-AxSpA population than in a locally diagnosed population and that the treatment benefit in
the whole trial population may have been driven by benefit in patients who actually had AS, not nr-AxSpA.
Conversely, in a certolizumab pegol trial which recruited both populations, the efficacy findings were
consistent across the AS and nr-AxSpA subpopulations, regardless of the discrepancy in local or central
pelvic radiograph readings.
Long-term efficacy
The longest follow-up durations in patients with AS by anti-TNF were 5 years for adalimumab, 5 years for
etanercept, 3 years for infliximab, around 5 years for golimumab and nearly 2 years for certolizumab
pegol. The results showed that across all the anti-TNFs after approximately 2 years of treatment, around
half of patients still achieved a good level of response to therapy. At 5 years around 60% of golimumab
patients, 50% of etanercept patients and 30% of adalimumab patients still achieved a good treatment
response. However, the long-term studies were not as well-reported as the RCTs, and their results were
derived from less reliable data; it is therefore unknown if these are true treatment differences or a result of
differences in follow-up protocols, and/or imputation and analysis methods.
The long-term follow-up for nr-AxSpA patients showed a continued high proportion of responders.
At 1 year around half of patients on adalimumab, etanercept or certolizumab still achieved an ASAS 40
or BASDAI 50 level response. With certolizumab this is maintained at 2 years and with adalimumab at
3 years.
When the long-term data are presented as observed or as completer analyses, the long-term results are
similarly good: withdrawal rates are not high and those patients who remain on treatment continue to
achieve a good response.
For all anti-TNFs, at long-term follow-up mean final values or mean change from baseline for BASDAI,
BASFI and BASMI, when reported, were generally maintained at levels indicative of clinically significant
treatment benefit for those patients with AS and those with nr-AxSpA.
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Four studies reported on radiographic disease progression over 2 years of follow-up in terms of mSASSS in
patients taking adalimumab, infliximab, etanercept and golimumab. All four open-label, uncontrolled
follow-up studies found that mSASSS increased by a mean of around 0.9 over 2 years. Three of these
studies compared their rates with those from the OASIS cohort118 (of patients not taking an anti-TNF) and
found no difference. In conclusion, there is no real evidence for the impact of anti-TNF treatment on
radiographic disease progression; a beneficial effect cannot be assumed, nor, given the short-term nature
of the follow-up and the insensitivity of radiography as a tool for the evaluation of disease progression in
AS, can one be discounted. There are some data to suggest an identifiable benefit from around 4 years
but results from ongoing long-term studies should help to clarify this issue.
Registry data demonstrate that around 60% of patients with AS treated with a first anti-TNF will still be
taking their therapy at 2 years, with median drug survival of 3.1 years (based on Danish registry n= 1436).
Sequential treatment with anti-TNFs can be worthwhile but the drug survival response rates and benefits
are reduced with second and third anti-TNFs, with the proportion of BASDAI 50 responders falling
approximately 10% with each subsequent anti-TNF and the median BASDAI and BASFIs achieved
increasing (worsening). The lower efficacy of a second anti-TNF relative to a first is reflected in lower
median drug survival and proportion of patients remaining on therapy at 2 years. Interestingly, despite a
further reduction in response and efficacy with a third anti-TNF, drug survival does not fall further,
suggesting that patients may be allowed to, and be prepared to, continue with a less than optimally
effective anti-TNF at this stage in their treatment history.
Adverse effects
Data from large systematic reviews, which included patients with a wide range of diseases, suggest that,
in the short term, anti-TNFs as a group are associated with significantly higher rates of serious infections,
tuberculosis reactivation, non-melanoma skin cancer, total AEs and withdrawals because of AEs, when
compared with control treatments. Specifically, infliximab is associated with significantly higher rates of
total AEs and withdrawals because of AEs, and that certolizumab pegol is associated with significantly
higher rates of serious infections and SAEs. Analyses from the present review showed etanercept to be
statistically significantly more likely to result in an injection/infusion site reaction compared with infliximab,
although analysable data on such reactions were not reported for the other three anti-TNFs. Evaluations of
longer-term data are more scarce, although they suggest similar safety profiles across anti-TNFs. Data from
the open-label studies included in this review also do not suggest that there are important differences
between treatments, other than a higher incidence of injection site reactions following treatment with
etanercept. These open-label data are, however, limited by the small sample sizes and non-randomised
study designs.
Natural history
The available studies indicate that in AS and nr-AxSpa disease activity (BASDAI) is fairly stable over time
and does not generally progress, although it can be at a high (severe) level early in the disease. Patient
function (as assessed by BASFI) does deteriorate over time, although the course is not constant or
predictable. BASFI is determined by both disease activity and bony disease; progression of BASFI over time
is driven by progression of bony disease as assessed by imaging scores such as mSASSS, or the presence of
syndesmophytes. Best estimates of yearly disease progression rates without anti-TNF therapy are around
1.0 mSASSS units and 0.035 to 0.07 BASFI units. Information on the natural history of nr-AxSpA is
relatively sparse. While disease progression appears to be faster in AS, patients with nr-AxSpA can have
severe disease activity and hence poor function.
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Overall conclusions
l For both the AS and nr-AxSpA populations the results of the meta-analyses demonstrated that
anti-TNFs produce statistically significant and clinically important benefits to patients in terms of
improving function and reducing disease activity. The efficacy estimates were consistently slightly
smaller for nr-AxSpA than for AS.
l In AS, although there is a little variation in treatment effects and it is possible that infliximab may be
more effective than other anti-TNFs at 12 weeks, the evidence for this is not strong and it is plausible
that anti-TNFs may have a common class effect, with the treatments being equally effective.
l Statistical heterogeneity was more apparent in the nr-AxSpA analyses than in the AS analyses. This may
be because of both clinical heterogeneity in the nr-AxSpA trials and the fact that fewer studies were
available for analysis. In the light of this heterogeneity, both the reliability of the nr-AxSpA-pooled
estimates and their true relevance to patients seen in clinical practice is questionable.
l Effectiveness was maintained over time. About 50% of patients maintained a benefit at 2 and 5 years.
l Evidence for an effect of anti-TNFs on radiographic disease progression was limited. The relatively
short-term follow-up available to date and the insensitivity of radiography as an imaging tool precluded
the drawing of firm conclusions regarding the role of anti-TNFs in preventing or delaying the
progression of AS; there are some data to suggest an identifiable benefit from around 4 years, but
results from ongoing long-term studies should help to clarify this issue.
l Sequential treatment with anti-TNFs can be worthwhile in patients with AS but the drug survival
response rates and benefits are reduced with second and third anti-TNFs.
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Chapter 4 Assessment of existing cost-effectiveness
evidence
Systematic review of existing cost-effectiveness evidence
The following sections provide an overview of existing cost-effectiveness evidence and an assessment of the
relevance of the data from the perspective of the UK NHS. The differences in the approaches and assumptions
used across the studies are examined in order to explain any discrepancies in the findings and to identify key
areas of remaining uncertainty. The findings from the review provide the basis for the development of a new
decision-analytic model reported in Chapter 6, Independent economic assessment: York model.
Methods
An initial systematic search was undertaken in the NHS EED using a combination of technology names and
disease terms. Further searches were undertaken in MEDLINE and EMBASE for modelling and utility studies
using disease terms only (as known references were not identified from the initial search in NHS EED). Only
full economic evaluations that compared two or more options and consider both costs and consequences
(including cost-effectiveness, cost–utility and cost–benefit analyses) were included in the review of existing
economic literature. No language and date limits were initially applied, although eligibility of studies was
subsequently restricted to those reporting results which were specific to the UK. Full details of the search
strategies used are reported in Appendix 1.
In addition, as part of the current multiple TAs process, each manufacturer submitted de novo evidence
on the cost-effectiveness of the anti-TNFs in line with their indications for the treatment of AS and
nr-AxSpA.34–37 These submissions are reviewed and the findings compared with those found in the review
of previously published studies.
Results of review of existing cost-effectiveness evidence
The combined searches retrieved 210 citations. A total of six UK studies reporting on the cost-effectiveness
of anti-TNFs for the treatment of AS were identified. No previously published studies were identified for
patients with nr-AxSpA.
Four of these studies were industry-funded assessments of the following anti-TNFs: infliximab (Kobelt et al.
2004152 and Kobelt et al. 2007160 both funded via an unrestricted grant by Schering-Plough), etanercept
(Ara et al.161 funded by Wyeth pharmaceutical P.C.) and adalimumab (Botteman et al.162 funded by Abbott
Laboratories). The three studies published in 2007 are largely based on the economic analyses originally
submitted by the manufacturers to NICE as part of the previous multiple TA (TA143).17 As the earlier
publication by Kobelt has been superseded by the 2007 publication, only the latter publication is further
considered in this review. The remaining two UK studies were publications of the assessments and/or
critiques undertaken by the independent Assessment Group/Evidence Review Group (ERG) for infliximab,
etanercept and adalimumab for TA14338 and golimumab for TA233.163 Therefore, a total of five studies
met the inclusion criteria and are included in this review.
The following sections provide a narrative discussion of each publication. The quality assessment of these
studies is shown in Appendix 10. A single critique section is used to highlight the key issues and potential
limitations of existing published cost-effectiveness evidence. These issues are then revisited with respect to the
de novo analyses submitted by the manufacturers considering how these key issues and potential limitations
have been addressed in the two separate indications. The final section highlights the remaining issues and
uncertainties and provides the basis for informing the development of a separate independent analysis of the
cost-effectiveness of anti-TNFs for AS and nr-AxSpA relevant to informing decisions for the NHS.
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Assessment of published cost-effectiveness studies
Kobelt et al.:160 Comparison of the Cost-Effectiveness of Infliximab in the
Treatment of Ankylosing Spondylitis in the UK Based on Two Different
Clinical Trials
Kobelt et al.160 estimated the cost-effectiveness of infliximab for the treatment of AS compared with
standard care over a lifetime horizon (60 years). Results were presented from both societal and
NHS/personal social services (PSS) perspectives, although only the latter are reported here in line with the
current NICE reference case. Short-term effectiveness data were derived from two separate clinical trials
(Braun et al.98 and ASSERT102,164) to inform the proportion and magnitude of initial response to treatment
expressed in terms of BASDAI 50 (or a BASDAI ≤ 4) response (12–24 weeks) and changes in BASDAI and
BASFI scores. These were combined with longer-term observational evidence on disease progression (BASFI
only) and other external sources on costs and utilities to estimate cost-effectiveness. Results were reported
separately based on each trial. Costs and benefits were discounted at 3.5% and presented at 2005 prices.
Methods
The cost-effectiveness model was based on a short-term decision tree representing the double-blind
periods of the trials (12–24 weeks) and a longer-term Markov model to estimate subsequent progression.
The Markov model comprised three states: ‘Off treatment’, ‘On treatment’ and ‘Dead’. Only patients
responding to treatment as defined by the following criteria [BASDAI ≤ 4 (scale 0–10) or a ≥ 50%
improvement in BASDAI] remain on treatment at the end of the double-blind periods. Differential BASDAI
and BASFI scores (scale 0–10) were derived from Braun [‘Off treatment’ BASDAI score= 6.3 and BASFI
score= 5.4; ‘On treatment’ (responders) BASDAI score= 1.8 and BASFI score= 2.0] and ASSERT102 [‘Off
treatment’ BASDAI score= 6.4 and BASFI score= 5.8; ‘On treatment’ (responders) BASDAI score= 1.4 and
BASFI score= 1.9]. Disease progression was expressed in terms of changes in BASFI and was estimated
from two surveys conducted 10 years apart (n= 1110).152 The mean absolute annual change in BASFI
applied was + 0.07 (scale 0–10) and this was used to characterise the natural history of progression for
patients with AS without infliximab. Three main scenarios were presented reflecting different assumptions
concerning the impact of infliximab on disease progression: (1) no progression while on treatment;
(2) 50% of natural history (0.035/year); and (3) same as natural history (0.07/year).
Fifteen per cent of patients were assumed to discontinue from infliximab annually based on data specific
to responders from the open-label extension period in the Braun trial. Interestingly, the authors noted that
the persistence rate was lower in responders compared with the entire sample in the Braun trial98 and its
extension (approximately 10% withdrawal rate per annum). The BASDAI and BASFI scores for patients
who withdrew from infliximab were assumed to return to the mean score of the non-treated group.
Mortality was modelled from general population life-tables applying a SMR of 1. Hence no additional
mortality was assumed to be related to AS and no direct or indirect benefits for mortality were assumed
for infliximab.
Disease costs and HRQoL were derived from a cross-sectional retrospective survey conducted at the
University of Bath, with the sample covering the full range of BASDAI and BASFI (1–10). The annual cost of
infliximab was based on 5mg/kg body weight (weeks 0, 2 and 6 and then every 6 weeks). An initial cost
was assigned to all patients starting treatment (£79.25) and an outpatient cost was applied to each infusion.
Results
From a NHS perspective, the cost per quality-adjusted life-years (QALYs) gained ranged from £28,332 and
£26,751 (no progression while on treatment) to £49,417 and £46,167 (no effect of treatment on
progression) as shown in Table 28. The model was also sensitive to the time horizon and the withdrawal
rate. Using a 10-year horizon resulted in incremental cost-effectiveness ratios (ICERs) between 63% and
66% higher than the base-case lifetime horizon (60 years) and a withdrawal rate of 5% resulted in ICERs
between 22% and 33% higher than the base case (15%).
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Ara et al.:161 The Cost-Effectiveness of Etanercept in Patients with Severe
Ankylosing Spondylitis in the UK
Ara et al.161 estimated the cost-effectiveness of etanercept for the treatment of severe AS in the UK in
accordance with BSR guidelines from a NHS/PSS perspective over a 25-year time horizon. Effectiveness
data were derived from individual patient data from a large multicentre European RCT to inform the
proportion and magnitude of initial response to treatment and associated changes in BASDAI and BASFI
scores. These were combined with longer-term observational evidence on disease progression (BASFI) and
other external sources on costs and utilities to estimate cost-effectiveness. Costs and benefits were
discounted at 3.5%. The price year was not formally stated.
Methods
An individual patient model was used to estimate short-term and longer-term costs and outcomes. Patients
in the model were assumed to have tried and failed at least two consecutive NSAIDs and have a BASDAI
measurement ≥ 40 (scale 0–100). Response was defined as a ≥ 50% reduction in BASDAI (or all fall of
≥ 20 units) and a reduction of the spinal VAS by ≥ 2 units. Response rates at 12 and 24 weeks were
derived from two RCTs (67% and 55% for etanercept and 24% and 16% for comparator arm at each
respective time point). Individual patient data at 12 and 24 weeks were used to estimate the magnitude of
change in BASDAI and BASFI for responders and non-responders. The mean BASDI and BASI scores at
week 12 and 24 for responders and non-responders are reported in Table 29 together with observed utility
at week 12 and the predicted utility values mapped from BASDAI and BASFI at week 24.
TABLE 28 Lifetime cost per QALY estimates reported by Kobelt et al.160 (NHS and PSS perspective)
Scenario Incremental cost QALY gain
Incremental cost-effectiveness
ratio (£/QALY)
Braun98
No progression on treatment 36,378 1.28 28,332
50% progression on treatment 35,756 1.01 35,332
Same progression on treatment 39,336 0.80 49,417
ASSERT
No progression on treatment102 33,920 1.27 26,751
50% progression on treatment102 34,408 1.01 34,067
Same progression on treatment102 39,242 0.86 46,167
TABLE 29 Bath Ankylosing Spondylitis Disease Activity Index, BASFI and EQ-5D measurements at weeks 12 and 24
Patient response
Week 12 Week 24
BASDAI BASFI EQ-5Da BASDAI BASFI EQ-5Db
Treatment non-responder 53.02 54.86 0.48 56.87 56.87 0.46
Treatment responder 19.52 25.39 0.79 18.32 21.41 0.80
Comparator non-responder 55.60 57.55 0.46 47.67 47.78 0.42
Comparator responder 22.97 29.88 0.74 25.11 20.92 0.79
a Observed values.
b Predicted values using a mapping algorithm.
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For patients who continued responding to treatment it was assumed that BASDAI and BASFI measures
remained constant at the levels observed at week 24. For patients who withdrew after week 24, it was
assumed patients would immediately revert back to their baseline values of BASDAI and BASFI. After
24 weeks in the model it was also assumed that patients with AS, not receiving anti-TNFs [conventional
care (CC) and etanercept non-responders], would experience a worsening BASFI. A mean absolute change
in BASFI of 0.7 (scale 0–100) was assumed based on a cross-sectional study of over 1000 UK patients.152
Quality-adjusted life-years were estimated using a relationship derived from BASDAI, BASFI and EQ-5D from
a single European RCT (utility= 0.9235 – 0.004 × BASFI – 0.004 × BASDAI). Disease costs were derived
from a separate costing study of 147 patients attending the Staffordshire Rheumatology Centre in
Stoke-on-trent.165 A relationship between BASDAI and BASFI measurements and costs was used to estimate
the disease costs and impact of etanercept (annual costs= 5.862+ 0.006 × BASDAI+ 0.016 × BASFI).
An annual cost of £9372 was included to reflect the acquisition and monitoring costs associated with
etanercept. An initial cost of £71 was also applied to the first 3-month period for etanercept, although no
further details were provided by the authors concerning what this cost represented. The costs and/or HRQoL
associated with AEs were not included.
The authors assumed that 10% of patients withdraw from etanercept every year. These data were derived
from external sources and no explanation was provided concerning whether or not these data specifically
applied to the post-24-week period or not and/or whether they were derived from responders to
treatment or not. Mortality was modelled from general population life-tables applying a SMR of 1.50.
No direct or indirect benefits for mortality were assumed for etanercept.
Separate scenarios were presented to explore alternative assumptions related to disease progression,
long-term annual withdrawal and the model time horizon.
Results
The main results are summarised in Table 30. From a NHS perspective, the base-case cost per QALY gained
was £22,704 for etanercept over a 25-year horizon. In contrast to the study by Kobelt et al.,160 the impact
of alternative progression assumptions appeared to have limited impact on the ICER, with alternative
scenario results ranging from between £23,625 (50% progression on treatment) and £25,679 per QALY
(same progression on treatment). The ICERs for alternative annual withdrawal rates ranged from £15,103
(5% withdrawal rate) to £29,428 per QALY (15% withdrawal rate). The ICERs for alternative time horizons
ranged between £27,594 (2 years) and £22,704 (25 years).
TABLE 30 Twenty-five-year cost per QALY estimates reported by Ara et al.161 (NHS and PSS perspective)
Scenario Incremental cost QALY gain ICER (£/QALY)
Base case 35,978 1.59 22,704
No progression for any patient 36,825 1.43 25,679
50% progression on treatment (0.035 BASFI score) 36,032 1.56 23,155
Same progression on treatment (0.07 BASFI score) 36,088 1.53 23,625
Annual withdrawal rate, 5% 33,976 2.25 15,103
Annual withdrawal rate, 15% 36,968 1.26 29,428
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Botteman et al.:162 Cost-Effectiveness of Adalimumab for the Treatment of
Ankylosing Spondylitis in the UK
Botteman et al.162 evaluated the cost-effectiveness of adalimumab versus conventional therapy in patients
with active AS from a NHS perspective over a 30-year time horizon. Effectiveness data were derived
from pooled data from two Phase III studies in patients with an inadequate response to ≥ 1 NSAID.
Micro-simulation methods were subsequently applied to these studies to simulate treatment decisions in
accordance with BSR guidelines and associated outcomes. These were combined with author assumptions
on disease progression (BASFI only), utility and cost data from the clinical trials and other external sources
to estimate cost-effectiveness. Costs and benefits were discounted at 3.5% using a 2004 price year.
Methods
Micro-simulation methods were applied to patients (n= 397) recruited into two adalimumab RCTs:
ATLAS61 and M03-606. In the adalimumab clinical trials, patients were kept on active treatment even when
response had not been achieved. Consequently, simulation methods were applied to the patients in the
clinical trial to mimic treatment decisions which more closely reflected treatment guidelines and the
requirements of the economic model. In accordance with BSR guidelines, a response in the model was
defined as a reduction of BASDAI of 50% or a decrease of ≥ 2 cm (scale 0–10) accompanied by a
reduction of spinal pain VAS of ≥ 2 cm. Assessment of initial response was assumed to take place 8 weeks
after treatment initiation. If the response criteria were not met at 8 weeks, a second response assessment
was assumed at 12 weeks. Failure to achieve response on both occasions was assumed to lead to
withdrawal of adalimumab therapy. Therapeutic responses were then assumed to be reviewed every
3 months until the end of the simulation (year 30). Failure to maintain the original response led to repeat
assessments after 6–12 weeks in the first 48 weeks. Failure to maintain response on both occasions led to
withdrawal of adalimumab. After week 48, the simulation model defined inadequate response on the
basis of BASDAI scores only. In the RCTs, patients were allowed to switch to open-label adalimumab at
week 24; for these patients, LOCF at time of switch for BASDAI, BASFI and VAS values were used in
the model.
The BASDAI, BASFI and spinal pain scores were based on directly observed trial scores (until week 48) and
additional assumptions about disease progression (after week 48). The BASDAI, BASFI and spinal pain
scores were adjusted at each time point by a fixed value equal to the average difference between
adalimumab and CC patients observed at baseline. BASDAI scores after week 48 were assumed to remain
constant at these levels for patients continuing to respond to adalimumab and for CC patients. BASFI was
assumed, for CC patients, to worsen after week 48 by 0.05 units (scale 0–10) annually. The estimate
applied to the increase in BASFI appears to be based on the authors’ own assumption but is argued to be
consistent with previous cost-effectiveness/epidemiological studies. In contrast, BASFI scores were assumed
to remain stable for adalimumab while patients remained on therapy, which was argued to be consistent
with the assumptions applied in previous published cost-effectiveness studies. It was assumed that
patients who discontinued would revert back to the BASFI scores of CC patients within 12 weeks (i.e. any
benefits in BASFI were not maintained over a longer period). This was argued by the authors to be a
conservative assumption.
Utilities were derived from the Health Utilities Index 3 (HUI-3) from data at baseline and at 24 weeks from
both adalimumab trials. A subsequent regression was estimated to predict utilities based on BASDAI,
BASFI, sex and race [utility= 0.948857 – 0.041528 × BASDAI – 0.034481 × BASFI+ 0.047080 × Gender
(1=male, 0= female) – 0.063801 × Race(1=white, 0= other)].
Estimates of disease costs were based on 2-year data from 208 patients in the OASIS study, conducted
in the Netherlands, Belgium and France.118 An ordinary least squares regression was estimated using
only BASDAI (and only BASFI in a sensitivity analysis). The regression utilised in the base-case was
£708.45+ £750 × BASDAI. Hence each increase in BASDAI of 1 unit (scale 0–10) was assumed to be
associated with an increase in costs of £750.
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Additional acquisition costs were applied to adalimumab (£357.50 per injection). No additional
administration costs were incorporated as patients were assumed to self-administer their injections.
All patients, regardless of treatment, were assumed to require at least two rheumatologist visits per year.
Routine safety monitoring costs were based on national guidance and included the cost of nursing and
physician time. The cost of a routine tuberculosis screening test via chest radiography was assumed before
and 6 months after initiation of therapy and tuberculosis skin testing before initiation of therapy. The cost
of AEs was based on data collected from the two clinical trials. A cost of £5100 was applied to an active
tuberculosis case.
An annual rate of withdrawal of 10% was applied based on a assumption by the authors. The estimate
was argued to be consistent with estimates reported in previously published cost-effectiveness analyses.
Results
The main results are summarised in Table 31. From a NHS perspective, the base-case cost per QALY gained
was £23,097 for adalimumab over a 30-year horizon. Similar to the study by Ara et al.,161 the impact of
alternative progression assumptions appeared to have limited impact on the ICER, with alternative scenario
results ranging from between £23,802 (no BASFI progression on any treatment) and £23,812 per QALY
(same BASFI progression on treatment). However, in contrast to Ara et al.,161 the ICERs appeared more
sensitive to the alternative time horizons with estimates ranging between £47,083 (48 weeks), £26,332
(5 years) and £23,097 (30 years).
McLeod et al.:38 Adalimumab, Etanercept and Infliximab for the Treatment of
Ankylosing Spondylitis: A Systematic Review and Economic Evaluation
McLeod et al.38 evaluated the clinical effectiveness and cost-effectiveness of adalimumab, etanercept and
infliximab compared with conventional treatment for AS. The publication is based on the independent
assessment undertaken by Liverpool Reviews and Implementation Group (LRiG) for NICE TA143.17 The
cost-effectiveness of these interventions over the short term (1 year) and over alternative time horizons of
up to 20 years was reported.
Methods
The authors assumed that all three interventions were of equal clinical effectiveness and analysed the
anti-TNFs as a class versus placebo. Short-term effectiveness over 1 year was modelled using individual
patient data from two RCTs (including an open-label extension from week 24) for adalimumab from
397 patients (246 adalimumab, 151 placebo). Of these, 315 of 397 patients were deemed to meet the
BSR guidelines and were included within the Abbott economic model. There is a lack of transparency
regarding the values used because of the commercial nature of the data. However, the estimates for
response rates were reported to be similar to those reported by LRiG in a separate pooled analysis at
weeks 12 and 24, which were 59% and 49.2%, respectively, for the TNF-α inhibitors (vs. 22.5% and
14%, respectively, for placebo). No information is reported on the magnitude of changes assumed. From
week 30 onwards it was assumed that spontaneous recovery without treatment (for placebo patients)
would occur at a rate of 17.1%, as estimated by LRiG from the patient-level analysis of the two
adalimumab RCTs. This assumption was explored in a separate sensitivity analyses.
TABLE 31 Thirty-year cost per QALY estimates reported by Botteman et al.162 (NHS and PSS perspective)
Scenario Incremental cost QALY gain ICER (£/QALY)
Base case 23,857 1.03 23,097
No progression for any patient NR NR 23,802
Same progression on treatment (0.05 BASFI) NR NR 23,812
NR, not reported.
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The assessment group model assumed that patients withdraw from TNF-α inhibitor treatment at a rate of
15% per year, which was considered to represent the ‘central value’ of the studies that were identified
reporting longer-term discontinuation rates. This estimate is also the same as the annual rate reported in
the open-label extension study for infliximab (Braun trial) also reported in the review undertaken by LRiG.
Rates of 7% and 24% were also explored in separate sensitivity analyses, representing the range of values
reported across the studies considered. The annual withdrawal rate (after the first 12 months, as observed
rates are used in the first 12 months) was applied to the difference in response rate between the two arms
of the evaluation, rather than the absolute number of responders. This was to account for a potential
anomaly that could arise through the assumption of a constant level (17.1%) of spontaneous recovery
without treatment.
The assessment group model took into account the cost of drug acquisition, administration, monitoring
and AEs. No administration costs were assumed for etanercept and adalimumab, as it was assumed that
both would be self-administered at home without supervision. The authors assumed an additional cost of
£267 to administer infliximab infusions based on NHS Reference Costs estimates for the regular attender
cost for chemotherapy with musculoskeletal primary diagnosis. Quarterly monitoring and testing was
assumed for all patients receiving long-term treatment with TNF-α inhibitors. However, two of these
assessments were assumed to take place at the patient’s routine follow-up outpatient visit, so only the
additional costs of tests for monitoring (£25) were applied to these assessments. The remaining two
assessments were assumed to be undertaken at a general practitioner’s surgery and an additional cost of
£25 was assumed for nurse/general practitioner time in addition to the costs of tests for monitoring (£25).
AEs costs were based on estimates reported by one manufacturer (Abbott) of £95.29 in the first year of
treatment and £47.65 per patient-year thereafter.
Disease-related costs to the NHS were estimated by fitting an exponential cost model to the weighted
aggregate data from the OASIS study; a 2-year prospective study of 208 AS patients from four centres
in France, Belgium and the Netherlands (n= 208).118 The exponential model estimated NHS
cost= £1585.30 × exp(0.1832 × BASFI). The OASIS data were considered by the authors to provide a more
reliable source than other published studies from Stoke and Bath, being prospective in design and over a
longer period. BASFI was used by the authors as the major predictor of costs because it was considered to
better reflect long-term disease progression compared with BASDAI.
Health-related quality of life was estimated using the utility model provided by Schering-Plough developed
from the Bath Survey data set on the grounds that it used a comparatively larger sample of UK AS patients
(n= 1144), and also because it incorporated age and sex variables: utility= 0.8772129 – 0.0384087 ×
BASDAI – 0.0322519 × BASFI – 0.0278913 ×Male+ 0.0016809 × Age.
The assessment group adopted a long-term increase in BASFI scores of 0.07 units per year for the
conventional treatment comparator arm of the model. This progression rate is applied for all periods after
week 20 in the model. In the base-case analysis, the same value was used in the intervention arm adjusted
pro rata to the proportion remaining of the maximal excess response seen at 12 weeks. In effect, this
assumes that patients withdrawn from anti-TNFs are assumed to return to the same trajectory as
non-responders, such that there is no ensuring benefit associated with being an initial responder.
Results
Over a 1-year time horizon, base-case ICERs for adalimumab and etanercept versus CC were essentially the
same (approximately £57,000 per QALY). In contrast, the ICER for infliximab was over £120,000 per QALY.
With respect to modelling beyond 12 months, the results for adalimumab were considered as representative of
etanercept, and only the former were provided. In contrast with other published models, the ICERs increased
steadily from year 2 onwards. At a 20-year horizon the ICERs for adalimumab/etanercept increased to £98,910
per QALY and to £175,000 per QALY for infliximab.
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Additional National Institute for Health and Care Excellence Decision Support
Unit analyses
Given the discrepancy between the results reported by McLeod et al.38 and the manufacturer’s
submissions34–37 (largely reflected in the three industry-funded publications previously discussed in this
section)160–162 also submitted as part of TA143,17 additional work was undertaken by NICE’s Decision
Support Unit (DSU) to reconcile the different models and to explore whether or not differences were a
result of different parameter inputs or alternative structural assumptions.
A common set of parameter values were applied by the DSU to the three manufacturer models and the
LRiG model. The purpose of this was to attempt to identify whether or not differences between the results
of the models persisted once this common set of values were used. The specific parameter values which
were implemented were:
1. no improvement in BASFI or BASDAI for patients not on anti-TNFs
2. BASFI progression prevented while on anti-TNFs
3. BASFI progresses at 0.07 per annum when patients are not on anti-TNFs
4. annual withdrawal rate of 7% from anti-TNFs
5. baseline BASDAI/BASFI score averages 6.5/5.6
6. utility model as in the Schering-Plough submission
7. assessment group parameters for cost parameters (drug costs only)
8. a 20-year time horizon.
These parameter values were reported to have been the values agreed at a separate NICE committee meeting
and consequently the rationale for these values and assumptions is not formally stated by the NICE DSU.
The results of the DSU analysis found that the manufacturer models all gave relatively consistent results for
each of the drugs. For Schering-Plough, the ICERs over 20 years for etanercept/adalimumab were £27,000
or £24,000 and for infliximab were £58,000 and £50,000. Two figures were presented because
Schering-Plough presented two different versions of the model which reflected two different trials. The
Wyeth model gave results of £20,000 for etanercept and £39,000 for infliximab. Abbott gave results of
£17,000 for adalimumab and £43,000 for infliximab (over a 30-year time horizon). These ICERs were
markedly different from those reported by the independent assessment group. Using a similar set of
parameters the results for etanercept/adalimumab using the LRiG model were £42,000 and for
infliximab £82,000.
Further work by the DSU revealed that the differences appeared largely driven by two key assumptions
which differed between the LRiG and industry models relating to:
1. the modelling of a ‘placebo’ effect
2. the longer-term functions fitted to BASDAI and BASFI for responders to anti-TNFs.
The LRiG model applied a 17.1% rate of spontaneous recovery without treatment from week 30 onwards
(i.e. akin to assuming a long-term ‘placebo’ response for CC) in contrast to the manufacturers who either
assumed there would be no response with CC or that any response would be transient and dissipate
quickly after the 12-week period.
The LRiG model also applied a quadratic function to the BASDAI and BASFI scores of responders over a
longer-time horizon, compared with the linear functions used by the manufacturers. The use of a quadratic
function assumes that that the difference compared with CC was decreasing (initially) with time; that is,
over time, the differences in BASDAI/BASFI would slowly reduce in responders and eventually be the same
as for CC. However, the logical problem of applying a quadratic function is clear. While the scores are
reducing for a period, at longer-time periods the function starts to increase again. The issues were
addressed by LRiG by using various assumptions and logical constraints (i.e. BASDAI/BASFI score not
allowed to be higher than CC).
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To further reconcile the models, the DSU incorporated a series of alternative structural assumptions within
the LRiG model. These assumptions included removing the 17.1% rate of spontaneous improvement
applied to CC and assuming constant BASDAI/BASFI scores after 1 year for responders. Applying these
assumptions resulted in an ICER for etanercept/adalimumab of £30,100 per QALY (estimates for infliximab
not reported) which were considered to be more consistent with the manufacturer results.
Importantly, the DSU highlighted that, although these analyses helped to reconcile the different model
results, any progression in terms of BASDAI or BASFI over time while on treatment would cause the ICER
to increase beyond £30,100. Similarly, the DSU concluded that the exclusion of the 17.1% spontaneous
recovery, without a comparable adjustment made to the intervention group was favourable towards
the cost-effectiveness of TNF-α inhibitors and any adjustment for this issue would similarly lead to a
higher ICER.
Armstrong et al.:163 Golimumab for the Treatment of Ankylosing Spondylitis:
a National Institute for Health and Care Excellence Single
Technology Appraisal
Armstrong et al.163 summarises the report undertaken by the ERG on the clinical effectiveness and
cost-effectiveness of golimumab for AS for a NICE single technology appraisal (TA233).33 The ERG provided
a critique of the manufacturer’s submission (Merck Sharp & Dohme)37 and undertook additional
exploratory analyses. The manufacturer’s model applied a 20-year time horizon in the base-case and a
separate lifetime analysis (60.1 years) was presented in a separate sensitivity analysis. The discount rate
applied was 3.5% for utilities and costs, and costs are considered from a NHS and PSS perspective.
Methods
The manufacturer’s submission for golimumab37 was based on a single trial versus placebo (GO-RAISE90).
A total of seven additional placebo controlled trials were included of other anti-TNFs; five RCTs for
etanercept and two for adalimumab. In the absence of head-to-head studies directly comparing the
relative effectiveness of the alternative anti-TNFs, the manufacturer undertook a Bayesian random-effects
mixed-treatment comparison (MTC) including BASDAI 50 response, discontinuations and SAEs. All
treatments were reported by the manufacturer to be statistically significantly more effective than placebo
in terms of BASDAI 50 response. No statistically significant differences were reported between each of the
alternative anti-TNFs in terms of discontinuations and SAEs. When the alternative anti-TNFs were compared
with each other, no significant differences between golimumab, adalimumab and etanercept were
identified for BASDAI 50. A higher risk of discontinuation was reported for golimumab versus etanercept
(relative risk 4.30, 95% CrI 1.01 to 18.50), although golimumab was associated with significant
improvements in BASDAI versus etanercept (mean difference –0.88, 95% CrI –1.58 to –0.14) and BASMI
versus adalimumab (mean difference 0.52, 95% CrI 0.23 to 0.80).
The manufacturer cost-effectiveness model37 was based on a short-term decision tree (12 weeks) and a
longer-term Markov model. The short-term tree was used to characterise response to each TNF-α inhibitor
treatment based on the MTC results for BASDAI 50. After the short-term tree, patients entered a separate
Markov model with a cycle length of 12 weeks and time horizon of 20 years. If patients were already
receiving a TNF-α inhibitor, they either stayed on therapy (‘on TNF inhibitor’ state) or discontinued therapy
because of lack of efficacy or AEs (‘not on TNF-inhibitor’ state). It was assumed that discontinuations
occurred at a rate of 15% per year in line with NICE TA143.17 To model the lower disease activity just
after discontinuation of TNF-α inhibitor therapy, two 12-week tunnel states (‘just discontinued’ and
‘discontinued’) were also incorporated into the model. Patients who are in the health state ‘on TNF-α
inhibitor’ are assumed to have at least a 50% improvement in BASDAI (BASDAI 50) during the first
12 weeks of treatment and do not discontinue. Treatment is discontinued in patients whose condition
does not respond to treatment and they are switched to conventional therapy. Patients in the CC arm
enter the Markov model in the ‘not on TNF-α inhibitor’ state. Patients could die at any point in the model.
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Disease progression was incorporated in the model using BASDAI and BASFI scores. Data from the
GO-RAISE90 trial and the open-label extension period were used to develop predictive equations of mean
change from baseline in BASDAI and BASFI scores over time. Two separate equations were developed
based on the 24-week data for all patients and post-24-week data from GO-RAISE90 for responders only.
These equations were used for all anti-TNFs and the manufacturer assumed that the scores followed the
GO-RAISE90 data for 2 years before they either levelled off (BASDAI) or started to deteriorate [BASFI at
50% of the rate of CC, equivalent to an increase of 0.035 (scale 0–10) units per year].
Although the equations are critical to the model structure and parameter estimates, these are not reported
in the paper by Armstrong et al.163 A separate examination of the full ERG report33 revealed that these
were reported as CiC by the manufacturer and hence it is not possible to report the assumptions made in
relation to the magnitude of change in BASDAI and BASFI over the initial 24-week period and subsequent
post-24-week period for the anti-TNFs (responders, non-responders) and CC. BASFI scores for CC were
reported to deteriorate according to the GO-RAISE trial (short-term equations were available only) after
which they were assumed to deteriorate at a rate of 0.07 units per year. The assumptions related to
the impact of discontinuation of anti-TNFs are not formally stated in the paper by Armstrong et al.163
However, the structure of the model implies that patients will revert back to the subsequent trajectories of
CC for both BASDAI and BASFI after 2 cycles (24 weeks).
Utilities were derived from the previous NICE TA (TA14317) and incorporated age, sex, BASFI and BASDAI.
Costs included in the model comprised drug acquisition, short-term (12-week) costs, longer-term disease
costs and AEs. Longer-term disease costs were based on BASFI scores from the GO-RAISE90 trial using
the same regression equation used for NICE TA guidance 143. Mortality was included in the model and
was considered to be a constant across the comparator treatments at a relative risk of 1.47.
Results
The main base-case results from the manufacturer are summarised in Table 32. From a NHS perspective,
the base-case cost per QALY gained was £26,597 for golimumab compared with CC over a 20-year
horizon. Both etanercept and adalimumab were reported to be extendedly dominated by golimumab.
The ERG undertook a limited validation of the model and reported various errors which were corrected.
However, they concluded that questions remained concerning the integrity of the manufacturer model.
The ERG subsequently presented results based on an exploratory reanalysis of the manufacturer’s
submission, using results from a separate MTC analysis and employing a lifetime horizon. The results of the
ERG reanalysis are reported in in Table 33. The results of this re-analysis resulted in golimumab being
extendedly dominated by the other two anti-TNFs.
There is no discussion by Armstrong et al.163 of the appropriateness of the assumptions applied to BASFI
progression, despite this being a critical structural assumption. However, a separate sensitivity analysis was
presented in the full ERG report which uses the same rate of disease progression for BASFI (0.07 units per
year) for all patients after 2 years. As part of this analysis, the ERG corrected errors identified in the way
the BASFI regression equations were incorporated by the manufacturer.
TABLE 32 Manufacturer cost-effectiveness results: 20-year horizon37
Technology Costs (£) QALYs Incremental costs Incremental QALYs ICER (£)
CC 88,667 6.6581 – – –
Adalimumab 93,601 6.8426 4934 0.1845 N/A (extendedly dominated)
Etanercept 93,782 6.8504 5115 0.1923 N/A (extendedly dominated)
Golimumab 93,786 6.8506 5119 0.1925 26,597
N/A, not applicable.
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Table 34 reports the ERG results based only on correcting the error identified and Table 35 reports the
results of also applying a common rate of disease progression for all patients after 2 years as well as
correcting for the error. Golimumab was reported to be extendedly dominated by the other two anti-TNFs
in both scenarios. It is also worth noting that the ICER for etanercept versus CC exceeded £30,000 per
QALY in both scenarios.
Summary and critique of published cost-effectiveness studies
No previously published studies were identified which assessed the cost-effectiveness of anti-TNFs for
nr-AxSpA. Consequently, the de novo submissions provided by the manufacturers provide the only
existing evidence which can be considered to inform decisions for the NHS. Of the previously published UK
cost-effectiveness study identified, there appear marked differences between the results of the industry-funded
assessments and the results from the independent assessment by LRiG. Importantly, the results of the
independent critique and exploratory reanalysis by the ERG for TA23333 also appear potentially less favourable
than the industry-funded published assessments. Although the DSU review of models submitted as part of
TA14317 has reconciled many of the key differences and highlighted the key assumptions, a number of key
TABLE 33 Evidence Review Group exploratory cost-effectiveness results: lifetime horizon
Technology Costs (£) QALYs Incremental costs Incremental QALYs ICER (£)
CC 95,227 7.8762 – – –
Golimumab 99,361 8.0296 4134 0.1534 N/A (extendedly dominated)
Adalimumab 108,295 8.3683 8934 0.3387 N/A (extendedly dominated)
Etanercept 108,347 8.3712 52 0.0029 26,505
N/A, not applicable.
TABLE 35 Evidence Review Group exploratory cost-effectiveness results: correction for BASFI error and common
BASFI progression after 2 years (from NICE TA23333)
Technology Costs (£) QALYs Incremental costs Incremental QALYs ICER (£)
CC 74,980 6.8267 – – –
Golimumab 79,330 6.9675 4350 0.1408 N/A (extendedly dominated)
Adalimumab 88,994 7.2567 9664 0.2892 N/A (extendedly dominated)
Etanercept 89,055 7.2600 61 0.0033 32,483
N/A, not applicable.
TABLE 34 Evidence Review Group exploratory cost-effectiveness results: correction for BASFI error
(from NICE TA23333)
Technology Costs (£) QALYs Incremental costs Incremental QALYs ICER (£)
CC 77,505 6.7336 – – –
Golimumab 81,849 6.8746 4334 0.1410 N/A (extendedly dominated)
Adalimumab 91,340 7.1703 9491 0.2937 N/A (extendedly dominated)
Etanercept 91,408 7.1734 68 0.0031 31,612
N/A, not applicable.
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uncertainties remain. The remainder of this section provides an overview of the issues and uncertainties
identified based on existing published studies and the DSU reports. This summary provides an important basis
for considering the extent to which the de novo submissions provided by the manufacturers for this appraisal
have adequately addressed these.
All existing models are based on similar two part structures:
l initial-response period (short-term model used to determine initial response rate)
l post-response period (longer-term model used to characterise natural history of disease (i.e. without
anti-TNFs) and impact of anti-TNFs (while on therapy and when therapy is stopped).
All models use changes in BASDAI and/or BASFI to quantitatively model the short- and longer-term costs
and quality-of-life implications (using QALYs) of the use of anti-TNFs versus CC alone.
Although there are differences between the modelling of the initial response period, existing models are
broadly comparable being based on an assessment around 12 weeks (and potentially at 24 weeks as well)
using a particular variant of existing BSR guidelines. Patients receiving anti-TNFs who meet the response
criteria at the 12-/24-week assessment are continued on anti-TNFs. Anti-TNFs are withdrawn in
non-responders at the 12-/24-week assessment point and patients subsequently receive CC alone.
However, there are marked differences between existing studies in relation to the modelling of the
post-response period and the assumptions used. This period is often separated into different time intervals
allowing different assumptions to be made regarding the effect of anti-TNFs (i.e. initially improving with
time in responders but then later ‘levelling off’ or even deteriorating over a longer-term time horizon
relative to CC). An important difference between existing models is the timing of this ‘levelling off’ period
and assumptions employed over a longer time horizon. The differences in approaches and the timing of
this ‘flattening off’ period are also closely linked to the data used, that is whether or not the changes in
BASDAI/BASFI used in the model are restricted to the 12- to 24-week data from RCT evidence reported
during the double-blind phase (Kobelt et al. 2007160 and Ara et al. 2007161) or also incorporate longer-term
data from the open-label extensions. Studies which use change in BASDAI/BASFI data directly in the
model, from the double-blind phase, appear to use shorter ‘levelling off’ periods than studies using
data from the open-label extension phase (Botteman et al. 2007,162 McLeod et al. 200738 and Armstrong
et al. 2007163).
Those studies incorporating an open-label extension typically assume continuing changes in BASDAI/BASFI
for responders to anti-TNFs versus non-responders/CC beyond the initial 12/24-week period. Importantly,
none of the studies using open-label extension data appear to provide any discussion of the potential
for selection bias (e.g. related to the initial consent for patients to participate and/or agree to switch
treatments as well as ongoing selection issues concerning retention over a longer period) and how these
should be considered and/or adjusted for in the economic model. However, the implication of this is
important, as the assumption being made by several models appears to incorporate an assumption of
an increasing effect of anti-TNFs in responders over time (i.e. in terms of continuing improvements in
BASDAI/BASFI), which does not appear to be adequately justified or related to any underlying clinical/
pharmacological mechanism. In the absence of the counter-factual (i.e. comparable data in patients who
did not participate or were subsequently withdrawn from the open-label study) it is unclear whether the
apparent increasing effect is simply a function of the selection issue or is a real effect of the anti-TNFs.
Importantly, those studies which only use data from the double-blind periods of RCTs often cite the
open-label data as providing supportive evidence regarding the maintenance of the effects observed at
12/24 weeks but do not use it to support an assumption of an increasing effect over time.
ASSESSMENT OF EXISTING COST-EFFECTIVENESS EVIDENCE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
The longer-term impact on costs and utilities beyond the initial response period are subsequently
quantified by estimating separate BASDAI/BASFI ‘trajectories’ for different patient categories. The three
main categories are:
1. CC
2. non-responder to anti-TNFs at 12-/24-week assessment
3. initial responder to anti-TNFs at 12-/24-week assessment.
The ‘trajectory’ for patients who are responders to anti-TNFs at the initial 12-/24-week assessment are
further separated into (1) the period up to the point that anti-TNFs are subsequently withdrawn
(i.e. because of loss of efficacy or AEs) and (2) the period post TNF-α inhibitor withdrawal.
After the ‘levelling off’ period for BASDAI, the majority of existing studies assume BASDAI is constant over the
longer term, that is the BASDAI of responders to anti-TNFs is assumed to be lower than the equivalent BASDAI
value (lower disease activity) applied to CC/non-responders and a constant difference is assumed to be retained
until patients discontinue. At the point of discontinuation of anti-TNFs, patients subsequently revert back
to the same value assumed for CC/placebo and non-responders to anti-TNFs at 12/24 weeks. Hence, any
improvement in BASDAI is assumed to dissipate immediately or within a short period (3–6 months) after
discontinuation of anti-TNFs.
All existing studies model BASFI as a linearly increasing function over the longer term for non-responders/CC,
that is a constant rate of change is subsequently applied which is used to characterise the impact of disease
progression on functional ability, typically a worsening of 0.07 (0–10 scale) units per annum. Again, the
same assumptions applied to BASDAI for non-responders to anti-TNFs are applied to BASFI, that is beyond
12/24 weeks non-responders are assumed to follow an identical BASFI ‘trajectory’ as that of CC/placebo
patients. By contrast, patients who respond to anti-TNFs are typically assumed not to ‘progress’ further in
terms of functional disability, or progress at a lower rate than CC patients, while continuing to receive
anti-TNFs. Hence the difference in individual mean BASFI scores increases over time in existing economic
models between patients who continue to receive anti-TNFs and non-responders/CC.
The only study which employs a markedly different approach to the modelling of BASDAI and BASFI for
responders is the study undertaken by the previous independent assessment group (LRiG) for TA143.17
Instead, LRiG applied a quadratic function to the BASDAI and BASFI scores of responders. This approach
assumed that the difference compared with CC was decreasing (initially) with time, that is, over time,
the differences in BASDAI/BASFI would slowly reduce in responders and eventually be the same as for CC.
While the logical problems of applying a quadratic function over a longer period were recognised by the
authors (i.e. function begins to increase after a particular period) and was addressed using a series of
logical restrictions (i.e. BASDAI/BASFI score constrained to be the same or better than CC), the clinical
‘face’ validity of this approach also appears questionable in the context of longer-term projections which
are required for appropriate assessments of cost-effectiveness.
Another key difference between existing studies relates to the assumptions made concerning the
subsequent trajectory of BASFI for patients who withdraw from active treatment. Given that BASFI is
linearly increasing with time for CC, the assumption of the subsequent BASFI trajectory is potentially an
important driver of cost-effectiveness. This is often referred to as ‘rebound’. Typically, two scenarios
are used:
l Rebound equal to gain: when patients fail therapy (after initially responding), their BASFI deteriorates
by the same amount by which it improves when they responded to therapy.
l Rebound back to natural history/CC: when patients fail therapy (after initially responding), their BASFI
deteriorates to the level and subsequent trajectory it would have been had they not initially responded
to therapy.
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In the absence of evidence on the magnitude of any rebound, these alternative scenarios represent the
‘best-case’ and ‘worst-case’ scenarios possible. In other words, the reality regarding rebound is likely to be
somewhere between these two scenarios which should, therefore, be seen as the limits.
The implications of the different rebound scenarios are clearly illustrated in Figures 2 and 3. Studies which
are based on assumptions of rebound equal to gain incorporate an ongoing benefit of anti-TNFs in
patients in whom therapy is subsequently withdrawn after an initial response. Hence, such an assumption
is more optimistic than assuming no continuing benefit at the point treatment is withdrawn.
Although the impact of discontinuation in patients who initially respond is clearly an important issue, the
assumptions underpinning the subsequent trajectories of patients who are non-responders at 12/24 weeks
to anti-TNFs are rarely explicitly justified. The most common assumption applied is that non-responders
during the initial period follow the same subsequent trajectory for BASDAI/BASFI as CC/placebo patients
beyond the 12-/24-week assessment point. However, the appropriateness of this assumption does not
appear to have been discussed in existing studies. Essentially, for this assumption to hold, the initial
response to anti-TNFs has to be independent of baseline patient characteristics, such that response to
treatment is effectively a random process. However, if response is not independent of patient
characteristics, the implication is that responders/non-responders to TNF-α inhibitors may be systematically
different from each other. This has implications for the appropriateness of current assumptions being
applied to non-responders at 12/24 weeks and subsequent responders who later withdraw.
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FIGURE 2 Illustration of the scenario of rebound equal to gain.
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FIGURE 3 Illustration of the scenario of rebound to CC.
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For example, all other things being equal, if patients with more severe disease (high BASDAI/high BASFI)
were more likely not to respond, then assuming that the non-responders at 12/24 weeks follow the same
trajectory as the ‘average’ CC/placebo patient is likely to be optimistic towards the anti-TNFs (and vice
versa for if less severe patients are more likely to respond). Hence, rather than following the trajectory of
an ‘average’ placebo/CC patient, a non-responder may actually follow a different trajectory, that is that of
an equivalent more/less severe CC patient. Inevitably, the impact of different patient characteristics is likely
to be more complex than the simplistic scenarios presented above.
As previously noted, all models use changes in BASDAI and/or BASFI to quantitatively model the short- and
longer-term costs and quality-of-life implications (using QALYs) of the use of anti-TNFs versus CC. The
justification for using these measures appears largely driven by the existence of external sources of costs
and health utility estimates which can be directly linked to these measures and not to others (e.g. BASMI,
ASDAS, mSASSS, etc.). Hence current models appear more of a function of the data which are available to
link to costs and utilities rather than being based on a clear underlying biological or clinical process. This
raises more general conceptual concerns regarding existing models and also regarding the generalisability
of findings in an AS population to the separate nr-AxSpA population.
The use of BASDAI/BASFI per se is perhaps not the most significant issue, as in the absence of alternative
mapping functions to costs and/or utilities it is unclear how to estimate longer-term costs and QALYs
without ultimately linking to these measures. However, it is concerning that the majority of existing studies
do not appear to link the data and assumptions applied to these measures to any coherent clinical
underpinning regarding differences between population characteristics and the effect of anti-TNFs.
Consequently, ‘progression’ over time is currently modelled entirely via changes in BASFI, as BASDAI is
assumed to remain constant. However, no attempt is made to justify why BASFI increases, the rate at
which it increases and how this rate might differ across different groups as well as the impact that
anti-TNFs might have (i.e. any effect on BASFI which may be independent of the effect on BASDAI).
Modelling ‘progression’ implicitly (i.e. employing natural history estimates of the rate of change of BASFI
from external studies) rather than explicitly (i.e. attempting to explain how BASFI evolves over time in
relation to inflammatory and other processes and how these may differ within populations and across the
AS and nr-AxSpA groups) has led to a series of implicit/evidence-free assumptions. These include:
l No change in BASFI while receiving anti-TNFs (i.e. assuming implicitly that these act as disease modifiers
and that while patients respond and continue to receive them, further deterioration in functional
progression is completely prevented).
l Lower BASFI changes while receiving anti-TNFs (i.e. assuming that anti-TNFs do not completely halt
further deterioration in functional progression but that the rate of progression is reduced relative
to progression on CC).
l Similar natural history rates of change in BASFI across different subgroups and populations
(i.e. assuming that rate of change in BASFI is independent of time and/or patient characteristics).
Similar conceptual concerns were also highlighted by the NICE DSU in their work to support TA143, noting
that in inflammatory arthritis a clearer conceptual relationship is assumed between disease activity, radiographic
progression and physical functioning, such that changes in physical functioning can be more clearly related to
different processes and evidence for the anti-TNFs on each separate process. In highlighting these issues, the
DSU cited emerging longer-term data reported for anti-TNFs based on measures of radiographic progression
(mSASSS) in AS. Although this evidence was not formally included in their analyses, the evidence was cited to
indicate that an assumption of no further progression while on anti-TNFs for AS was potentially optimistic
based on emerging longer-term radiographic progression data.
Importantly, the only UK study published since the NICE DSU review did subsequently use a less favourable
assumption concerning the impact of anti-TNFs on functional progression (BASFI). The assumption used by
the manufacturer for golimumab37 assumed that the longer-term rate of change in BASFI for responders
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who continued on treatment would be 50% of that assumed for CC/non-responders. Although this
assumption is a significant departure from the base-case assumptions applied within previous industry-funded
studies, no justification appeared to be identified to support this by Armstrong et al.163 in the review of the
manufacturer’s submission.
In summary, there appear to be significant differences between the cost-effectiveness results reported in
existing UK published studies. Many of these differences appear largely because of differences in data
sources (i.e. double-blind period vs. open-label extensions), subsequent assumptions and estimates related
to the magnitude and duration of the differences in BASDAI and BASFI measurements between responders
and non-responders in the short to medium term (i.e. the ‘levelling off’ period) and then longer term
in relation to assumptions concerning BASFI progression, and issues around ‘placebo’ effect and the
withdrawal of anti-TNFs. Some of the main differences between existing studies have been highlighted in
a separate review by the NICE DSU. However, while this review is helpful in identifying the impact of
parameter and structural assumptions, it does not provide a basis for informing which assumptions appear
most justified based on existing data and clinical understanding of the progression of AS and the impact of
anti-TNFs. It is also concerning that many of the existing studies are based on CiC data and hence lack
transparency regarding specific inputs and assumptions.
To date, only two UK studies have attempted to assess the cost-effectiveness of the alternative anti-TNFs.
One of these studies, McLeod et al.,38 assumed that the alternative treatments were identical in terms
of clinical effectiveness and hence only considered differences in the acquisition, administration and
monitoring costs. The justification provided by the authors was based on the lack of statistically significant
differences across key outcome measures based on indirect comparisons. The other study, Armstrong
et al.,163 assumed differences in the clinical effectiveness of the alternative anti-TNFs based on a separate
MTC. However, differences between the anti-TNFs appeared sensitive to the studies included and the
specific outcomes considered. Hence different conclusions could be drawn concerning the most ‘efficient’
intervention depending on the analysis considered. However, the magnitude of differences in clinical effect
and QALYs remained small and the clinical and economic value of this might appear questionable.
There are conceptual concerns surrounding all existing models relating to the subsequent projection of
BASDAI and BASFI over a longer time horizon which are required in order to generate more appropriate
lifetime estimates of costs and QALYs required for cost-effectiveness assessments. The speculative nature
of these projections was highlighted as a significant concern by the previous independent assessment
group (LRiG) and hence their longer-term results were presented as exploratory scenarios. However, it
appears that all existing models are largely based on implicit approaches and assumptions, and lack a
clearer conceptual basis which might help to more appropriately inform parameter estimates and structural
assumptions, and facilitate a more evidence-based assessment of the potential longer-term impact
of anti-TNFs.
The following sections present a summary of the de novo submissions provided by the manufacturers34–37
for the separate AS and nr-AxSpA indications. Brief overviews of the manufacturers’ submissions for AS
and nr-AxSpA are provided alongside a summary of the base-case cost-effectiveness results. This is
followed by a more in-depth comparison of key parameter and structural assumptions across the
manufacturers and the separate indications. The issues and concerns regarding existing published studies
are used as the basis for a more critical assessment of these submissions and the extent to which these
concerns have been adequately addressed and key uncertainties which still remain have been highlighted
is investigated.
It should be noted that although fully incremental results were routinely presented by each manufacturer,
there were differences between manufacturers in terms of how the results were presented and also
whether or not the correct calculations based on dominance and extended dominance were included.
Consequently, the fully incremental ICER tables reported are based on our own calculations to ensure
accuracy and consistency between the various manufacturer results tables.
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Summary of manufacturers’ de novo submissions
Manufacturers submitted de novo analyses for both AS (AbbVie,34 UCB,35 Pfizer36 and Merck Sharp &
Dohme37) and nr-AxSpA (AbbVie,34 UCB35 and Pfizer36) populations.
Overview of AbbVie (adalimumab) model
The economic model presented by AbbVie34 compared the cost-effectiveness of adalimumab versus
conventional therapy and other licensed anti-TNFs for nr-AxSpA and AS. Separate state-transition models
were developed for the two indications separately based on the ASAS guidelines for the use of anti-TNFs.
All patients were assumed to take conventional therapy/background therapy (e.g. NSAIDs) during the
modelled horizon and also receive one of the licensed anti-TNFs or placebo (conventional therapy only).
Specifically, patients were assumed to stay on therapy as long as they had an adequate therapeutic
response (i.e. ASAS 40 for nr-AxSpA and ASAS 20 for AS) and patients were assumed to discontinue
therapy when insufficient response occurred. Discontinuations due to AEs or reasons other than
therapeutic failures were also included.
The model consists of a short-term component (first 12 weeks) and a longer-term component to estimate
lifetime cost-effectiveness (40 years). In common with previously published models, the model was based on
the estimation of BASDAI and BASFI scores over time. The model used the available long-term open-label
extension data of trials of adalimumab (up to 156 weeks in ABILITY-158 for nr-AxSpA and 260 weeks in
ATLAS61 for AS, Figures 4 and 5) as well as including assumptions beyond these study durations to inform
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FIGURE 4 Observed mean BASDAI and BASFI scores for adalimumab ASAS 20 responders in the licensed population
from ATLAS61 (AS).
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FIGURE 5 Observed mean BASDAI and BASFI scores for adalimumab ASAS 40 responders in the licensed population
from ABILITY-158 (nr-AxSpA).
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the life-time cost-effectiveness results. To avoid extrapolating life-time improvement by applying a functional
form to the BASDAI/BASFI data, the manufacturer applied the mean observed BASDAI and BASFI scores until
the last available data point and carried forward the last observed values to the end of horizon.
Response rates and other select treatment efficacy end points were based on a separate systematic review
and network meta-analysis. In the base case, ASAS 40 for nr-AxSpA and ASAS 20 for AS were used to
define clinical response at week 12, based on the primary outcome measures from the clinical trials of
adalimumab. In the base-case analysis, placebo responders at week 12 were assumed to lose response and
return to baseline disease severity. Patients who subsequently withdrew from TNF-α treatment at any time
point were also assumed to return to baseline disease severity (rebound equal to gain). Longer-term
discontinuation was assumed to be time-dependent and was based on a log-normal parametric
distribution from the separate open-label RCTs adjusting for subsequent loss of response.
In the base-case model, the BASFI score for all patients not on TNF-α inhibitor treatment increases in a
linear fashion by 0.084 (scale 0–10) per year in patients with nr-AxSpA, in line with the evidence from
the ABILITY-1 trial,58 in which each additional year of baseline symptom duration was reported to be
associated with a significant (+0.084; p= 0.0005) increase in baseline BASFI score, adjusting for the age of
onset (age at first reported axial SpA symptom) to control for the age effect on functional damage. An
estimate of +0.056 was applied to patients with AS based on applying a similar approach to the ATLAS
trial,61 adjusting for age at disease diagnosis. Hence, a higher BASFI progression was applied to patients
not on anti-TNFs in the nr-AxSpA population compared with the AS population.
The BASDAI and BASFI scores were used jointly to estimate quality of life associated with AS, using the
relationship observed between the utility scores (measured in HUI-3) and the BASDAI and BASFI scores in
the ATLAS trial.61 Observed EQ-5D scores were mapped to BASDAI and BASFI for the relationship in the
base case for nr-AxSpA from ABILITY-1.58
The relationship between BASDAI and costs, derived from a reanalysis of the OASIS data, was applied in
the base case. Costs of drug, administration, initiation and monitoring, and AEs were also included.
Discounting was applied at 3.5% for both costs and outcomes. SMRs of 1 and 1.5 were assumed for
nr-AxSpA and AS, respectively. Uncertainty surrounding results was addressed using probabilistic sensitivity
analyses (PSAs).
Base-case results from AbbVie (adalimumab) model
The main base-case ICER results from the manufacturer are summarised in Table 36 for the AS population.
From a NHS perspective, the base-case cost per QALY gained versus CC ranged from £16,391 per QALY
(adalimumab) and £44,448 per QALY (infliximab).
TABLE 36 Tumour necrosis factor-α inhibitors compared with CC for AS: AbbVie34 (base case)
Technology Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£)
CC 112,762 8.62 – – –
Adalimumab 139,860 10.28 27,098 1.65 16,391
Certolizumab 133,273 9.82 20,511 1.20 17,067
Etanercept 139,574 10.21 26,812 1.59 16,897
Golimumab 138,385 10.17 25,624 1.55 16,535
Infliximab 197,100 10.52 84,339 1.90 44,448
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Table 37 reports the results based on the fully incremental analysis. In the manufacturer base-case analysis,
certolizumab and etanercept were ruled out by extended dominance. The ICER of adalimumab was
£16,391 per QALY compared with CC. The ICER of the next more costly (and non-dominated) TNF-α
inhibitor was £238,500 per QALY for the comparison between infliximab and adalimumab.
The main base-case ICER results from the manufacturer and fully incremental analysis are summarised in
Tables 38 and 39 for the nr-AxSpA population. The ICERs versus CC ranged from £12,866 (certolizumab)
to £13,288 per QALY (adalimumab). In the fully incremental comparison, adalimumab was extendedly
dominated and hence the ICER for certolizumab versus CC is the only ICER reported (£12,866).
The manufacturer reported more favourable ICERs versus CC in the nr-AxSpA population compared with
the AS population. This appears largely driven by two inputs: (1) the lower BASDAI/BASFI scores assumed
for responders based on ABILITY-158 (compared with ATLAS61) and (2) the higher annual BASFI progression
rate assumed for non-responders/CC in the nr-AxSpA population (0.084 vs. 0.056).
TABLE 37 Fully incremental comparison of anti-TNFs for AS: assessment group analysis based on AbbVie34
(base case)
Technology Total costs (£) Total QALYs
Incremental
costs (£) Incremental QALYs ICER (£)
CC 112,762 8.62 – – –
Certolizumab 133,273 9.82 – – Extendedly dominated
Golimumab 138,385 10.17 – – Extendedly dominated
Etanercept 139,574 10.21 – – Extendedly dominated
Adalimumab 139,860 10.28 27,098 1.66 16,391
Infliximab 197,100 10.52 57,240 0.24 238,500
TABLE 38 Anti-TNFs compared with CC for nr-AxSpA: AbbVie34 (base case)
Technology Total costs (£) Total QALYs
Incremental
costs (£) Incremental QALYs ICER (£)
CC 126,075 8.88 – – –
Adalimumab 142,218 10.10 16,143 1.22 13,228
Certolizumab 142,608 10.16 16,532 1.28 12,866
Etanercept Not assessed Not assessed Not assessed Not assessed Not assessed
TABLE 39 Fully incremental comparison of anti-TNFs for nr-AxSpA: assessment group analysis based on AbbVie34
(base case)
Technology Total costs (£) Total QALYs
Incremental
costs (£) Incremental QALYs ICER (£)
CC 126,075 8.88 – – –
Adalimumab 142,218 10.10 – – Extendedly dominated
Certolizumab 142,608 10.16 390 0.06 12,866
Etanercept Not assessed Not assessed Not assessed Not assessed Not assessed
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Overview of UCB (certolizumab) model
The economic model presented by UCB34 compared the cost-effectiveness of certolizumab with conventional
therapy and other licensed anti-TNFs for nr-AxSpA and AS. Separate Markov cohort models were developed
for the two indications separately based on the subpopulations of the RAPID-axSpA trial.64 Separate analyses
were argued to be necessary given that the comparators differed for each subpopulation. Analyses performed
for the AS subpopulation consisted of all patients with AS from the RAPID-axSpA study,64 including those
who were anti-TNF therapy experienced or therapy naive. The nr-AxSpA subpopulation consisted of anti-TNF
therapy-naive patients only, as there were no anti-TNF therapy-experienced patients in this subpopulation.
The analyses used a lifetime time horizon in the base case. An alternative time horizon of 20 years was
tested in a scenario analysis. A NHS and PSS perspective was used and an annual discount rate of 3.5%
was applied to costs and outcomes. All costs are reported at 2013 values.
The model consists of a short-term component and a longer-term component to estimate lifetime
cost-effectiveness. The duration of the short-term component varied between the models used for the AS
and the nr-AxSpA subpopulations based on the response end point assumed. Response was assessed at
24 weeks in the AS subpopulation which was argued by the manufacturer to be in accordance with
clinical practice as indicated key British opinion leaders. For the nr-AxSpA subpopulation, response
assessment was assumed at 12 weeks, as comparator data were available only at that time point. In their
base case, the manufacturer used ASAS 20 to determine response in line with the primary outcome
measure in the RAPID-axSpA.64 However, it should be noted that ASAS 20 response at week 12 was the
primary outcome in the RAPID-axSpA trial. Hence, although the measure of response used is in accordance
with the primary outcome of the RAPID-axSpA trial, the differential timing of this applied across the
separate populations clearly deviates from this. This has potential issues because at week 16 patients were
allowed an ‘early escape’ from placebo and hence results at week 24 used for the AS subpopulation are
no longer based on the original randomised population.
Assessment in Ankylosing Spondylitis 20 response rates for certolizumab and relative treatment effects
for the other anti-TNFs were derived based on a separate systematic review and MTC. The base-case
model inputs applied in the manufacturer’s submission34 are replicated (and associated footnotes) in
Tables 40 and 41.
TABLE 40 Base-case model inputs: ASAS 20 response at week 24 (AS subpopulation, certolizumab pegol-pooled dosing)34
Treatment
ASAS 20
response (%)a SE Relative riskb CI Source
Certolizumab pegol CiC information
has been removed
CiC information
has been removed
– – MTC
Adalimumabb – – AiC information
has been removed
AiC information
has been removed
MTC
Etanerceptb – – AiC information
has been removed
AiC information
has been removed
MTC
Golimumabb – – AiC information
has been removed
AiC information
has been removed
MTC
Infliximabb – – AiC information
has been removed
AiC information
has been removed
MTC
AiC, academic in confidence.
a Proportion responding.
b Certolizumab pegol vs. comparator.
All footnotes supplied by the manufacturers are reported in their entirety for further clarification, although supporting references
have been removed here. Based on pooled certolizumab pegol 200mg Q2W and 400mg Q4W arms from RAPID-axSpA.64
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The MTC was also used to determine change in baseline BASFI and BASDAI scores. The base-case inputs
for change from baseline in BASFI and BASDAI at week 24 for the AS subpopulation reported by the
manufacturer are replicated in Tables 42 and 43. The manufacturer noted that the mean change from
baseline reported in the tables is that observed per trial arm, which includes both the ASAS 20 responders
and non-responders in each arm. In order to determine the change in BASFI and BASDAI for responders
alone, the manufacturer used the equation:
Mean change in BASFI score = (change in BASFI among ASAS 20 responders × proportion ASAS 20
responders) + (change in BASFI among ASAS 20 non‐responders × proportion ASAS 20 non‐responders):
(1)
TABLE 41 Base-case model inputs: ASAS 20 response at week 12 (nr-AxSpA subpopulation, certolizumab
pegol-pooled dosing)34
Treatmenta
ASAS 20
response (%)b SE Relative riska CI Source
Certolizumab pegol AiC information
has been removed
AiC information
has been removed
– – MTC
Adalimumaba – – AiC information
has been removed
AiC information
has been removed
MTC
Etanercepta – – AiC information
has been removed
AiC information
has been removed
MTC
AiC, academic in confidence.
a Certolizumab pegol vs. comparator.
b Proportion responding.
All footnotes supplied by the manufacturers are reported in their entirety for further clarification, although supporting references
have been removed here. Based on pooled certolizumab pegol 200mg Q2W and 400mg Q4W arms from RAPID-axSpA.64
TABLE 42 Base-case model inputs: change from baseline in BASFI score at week 24 (AS subpopulation,
certolizumab pegol-pooled dosing)34
Treatment
Change from baseline in BASFI score at Week 24: initial response
assessment period
SourceMean SD
Certolizumab pegol AiC information has been removed AiC information has been removed MTC
Adalimumab AiC information has been removed AiC information has been removed MTC
Etanercept AiC information has been removed AiC information has been removed MTC
Golimumaba AiC information has been removed AiC information has been removed MTCa
Infliximab AiC information has been removed AiC information has been removed MTC
CCb AiC information has been removed AiC information has been removed Assumed zero
in base caseb
AiC, academic in confidence.
a Golimumab assumed same values as adalimumab, given that specific input values for BASFI at 24 weeks were not
available from MTC.
b CC assumed to produce no change in BASFI score initially in the base case. As noted in main text, it is reasonable to
assume patients receiving CC do not achieve a change from baseline (worsening or improvement) in BASDAI or BASFI as
evidence from RAPID-axSpA,64 ATLAS61 and ABILITY-158 demonstrate that in the placebo arms of these studies where
patients were essentially maintained on CC, patients did not achieve MCID for BASDAI or BASFI.58,61,64 Furthermore,
Dougados et al.43 describe CC regimens as ‘palliative at best, providing no alteration of the disease process’. This
assumption is consistent with previous manufacturers’ submissions to NICE in AS. However, a mean change in BASFI of
(AiC information has been removed) estimated from the MTC was used in the sensitivity analysis.
All footnotes supplied by the manufacturers are reported in their entirety for further clarification, although supporting references
have been removed here. Based on pooled certolizumab pegol 200mg Q2W and 400mg Q4W arms from RAPID-axSpA.64
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This approach assumed that the change in BASFI (and BASDAI) score among ASAS 20 non-responders
is equal to that of the CC arm. Thus, the equation is used to algebraically solve for change in BASFI
(and BASDAI) score among ASAS 20 responders. The manufacturer stated that:
As an example for the AS subpopulation base case, the change in BASFI among ASAS 20 responders
for CZP [certolizumab pegol] is: [academic-in-confidence (AiC) information removed]. Thus, in this
example, the actual change from baseline in AS responders to CZP is [AiC information removed]. The
same approach was used for change from baseline for BASDAI. This approach, where the change
from baseline for BASDAI and BASFI is calculated among responders only, is consistent with previous
evaluations pharmacoeconomic evaluations conducted for AS
Manufacturer’s submission, pp. 69–7034
The manufacturer base-case inputs for change from baseline in BASFI and BASDAI at week 12 for the
nr-AxSpA subpopulation are replicated in Tables 44 and 45.
The manufacturer’s submission34 assumed no change in BASDAI and BASFI for CC during the response
period. The manufacturer justified this assumption with reference to evidence from RAPID-axSpA,64
ATLAS61 and ABILITY-158 studies, although no specific data were reported to support this.
These change scores are assumed to be maintained for BASDAI as long as a patient continues to receive
an anti-TNF. For AS patients on CC, an additional annual increase of 0.07 points (scale 0–10) in BASFI is
assumed and justified by the manufacturer according to the assumptions deemed reasonable by a previous
NICE committee. Hence, while the change scores are assumed constant, the absolute difference between
patients receiving anti-TNFs and CC is increasing over time given the underlying progression assumed for
BASFI for patients receiving CC. The assumption of no progression in BASFI for patients receiving anti-TNFs
is not explicitly discussed within the manufacturer’s submission, neither are separate results provided for
alternative assumptions.
TABLE 43 Base-case model inputs: change from baseline in BASDAI score at week 24 (AS subpopulation,
certolizumab pegol-pooled dosing)34
Treatment
Change from baseline in BASDAI Score at week 24: initial response
assessment period
SourceMean SD
Certolizumab pegol AiC information has been removed AiC information has been removed MTC
Adalimumab AiC information has been removed AiC information has been removed MTC
Etanercept AiC information has been removed AiC information has been removed MTC
Golimumab AiC information has been removed AiC information has been removed MTC
Infliximab AiC information has been removed AiC information has been removed MTC
CCa AiC information has been removed AiC information has been removed Assumed zero
in base casea
AiC, academic in confidence; MTC, mixed-treatment comparison.
a CC assumed to produce no change in BASDAI score initially in the base case. As noted in main text, it is reasonable to
assume patients receiving CC do not achieve a change from baseline (worsening or improvement) in BASDAI or BASFI as
evidence from RAPID-axSpA,64 ATLAS61 and ABILITY-158 demonstrate that in the placebo arms of these studies where
patients were essentially maintained on CC, patients did not achieve MCID for BASDAI or BASFI. Furthermore, Dougados
et al.43 describe CC regimens as ‘palliative at best, providing no alteration of the disease process’. This assumption is
consistent with previous manufacturers’ submissions to NICE in AS.33 However, a mean change in BASDAI of (AiC
information has been removed) estimated from the MTC was used in the sensitivity analysis.
All footnotes supplied by the manufacturers are reported in their entirety for further clarification, although supporting
references have been removed here. Based on pooled certolizumab pegol 200mg Q2W and 400mg Q4W arms from
RAPID-axSpA.64
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TABLE 45 Base-case model inputs: change from baseline in BASDAI score at week 12 (nr-AxSpA subpopulation,
certolizumab pegol-pooled dosing)34
Treatment
Change from baseline in BASDAI score at week 12: initial response
assessment period
SourceMean SD
Certolizumab AiC information has been removed AiC information has been removed MTC
Adalimumab AiC information has been removed AiC information has been removed MTC
Etanercept AiC information has been removed AiC information has been removed MTC
CCa AiC information has been removed AiC information has been removed Assumed zero
in base caseb
a CC assumed to produce no change in BASDAI score initially in the base case. As noted in main text, it is reasonable to
assume patients receiving CC do not achieve a change from baseline (worsening or improvement) in BASDAI or BASFI as
evidence from RAPID-axSpA,64 ATLAS61 and ABILITY-158 demonstrate that in the placebo arms of these studies where
patients were essentially maintained on CC, patients did not achieve MCID for BASDAI or BASFI. Furthermore, Dougados
et al.43 describe CC regimens as ‘palliative at best, providing no alteration of the disease process’. This assumption is
consistent with previous manufacturers’ submissions to NICE in AS. However, a mean change in BASDAI of (AiC
information has been removed) estimated from the MTC was used in the sensitivity analysis.
All footnotes supplied by the manufacturers are reported in their entirety for further clarification, although supporting
references have been removed here. Based on pooled certolizumab pegol 200mg Q2W and 400mg Q4W arms from
RAPID-axSpA.64
TABLE 44 Base-case model inputs: change from baseline in BASFI score at week 12 (nr-AxSpA subpopulation,
certolizumab pegol-pooled dosing)34
Treatment
Change from baseline in BASFI score at week 12: initial response
assessment period
SourceMean SD
Certolizumab pegol AiC information has been removed AiC information has been removed MTC
Adalimumab AiC information has been removed AiC information has been removed MTC
Etanercept AiC information has been removed AiC information has been removed MTC
CCa AiC information has been removed AiC information has been removed Assumed zero
in base casea
a CC assumed to produce no change in BASFI score initially in the base case. As noted in main text, it is reasonable to
assume patients receiving CC do not achieve a change from baseline (worsening or improvement) in BASDAI or BASFI as
evidence from RAPID-axSpA,64 ATLAS61 and ABILITY-158 demonstrate that in the placebo arms of these studies in which
patients were essentially maintained on CC, patients did not achieve MCID for BASDAI or BASFI. Furthermore, Dougados
et al.43 describe CC regimens as ‘palliative at best, providing no alteration of the disease process’. This assumption is
consistent with previous manufacturers’ submissions to NICE in AS. However, a mean change in BASFI of (AiC
information has been removed) estimated from the MTC was used in the sensitivity analysis.
All footnotes supplied by the manufacturers are reported in their entirety for further clarification, although supporting
references have been removed here. Based on pooled certolizumab pegol 200mg Q2W and 400mg Q4W arms from
RAPID-axSpA.64
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The same annual rate (0.07) in BASFI progression for CC is also applied to the nr-AxSpA subpopulation.
In addition, it is assumed that some nr-AxSpA patients may progress to AS during their course of
treatment. The manufacturer’s model adopts an estimate for disease progression for the nr-AxSpA
subpopulation based on a German cohort of axSpA patients, GESPIC. In this cohort, the rates and
predictors of radiographic spinal progression over 2 years were estimated based on mSASSS. In total, 7.4%
of the 95 nr-AxSpA patients were reported to show spinal radiographic progression, which was defined as
a worsening of mSASSS by ≥ 2 units over 2 years. As this 7.4% progression represents a proportion, it was
converted to a rate for use in the economic model, assuming an exponential distribution through the
following formula:
1− 0:074 = exp(−rate × 2 years); rate = 0:0384 or 3:84 per 100 patient‐year: (2)
The manufacturer’s submission34 is not explicit about how this additional aspect of progression
subsequently alters the BASDAI/BASFI trajectories within the nr-AxSpA model. However, examination of
the electronic model submitted by the manufacturer reveals that once patients are assumed to show spinal
radiographic progression, they effectively become AS patients by picking up the same absolute values of
BASDAI and BASFI (on and off treatment) applied in their AS subpopulation model. The justification for
this approach and the values subsequently assigned are not formally discussed by the manufacturer and
the validity of the approach appears questionable (i.e. given other differences, e.g. disease duration,
severity of radiographic disease etc., that may differ between the two populations even after radiographic
progression has occurred in the nr-AxSpA subpopulation).
Patients who subsequently withdrew from TNF-α treatment at any time point were assumed to revert back
to the same trajectory as CC over a 6-month period (i.e. rebound back to CC/natural history). A constant
annual rate of discontinuation of 7% was assumed for all anti-TNFs over the longer-term period in both
the AS and nr-AxSpA populations. The estimate of 7% applied to the AS subpopulation was justified by
citing the rate apparently assumed by the NICE committee for TA143 and the lack of long-term evidence
more generally. This estimate was referred to earlier in the review section of our report when the
additional analyses undertaken by the NICE DSU were considered (see Data extraction). Identical
assumptions for discontinuation rates were assumed for the nr-AxSpA subpopulations, although no
justification was provided by the manufacturer.
The BASDAI and BASFI scores were used jointly to estimate quality of life in both subpopulations based on
EQ-5D data collected in the RAPID-axSpA64 study. Data from patients having EQ-5D, BASDAI and BASFI
scores available at baseline and at weeks 12 and 24 were used to estimate a relationship between utility
and the BASDAI and BASFI scores. Utilities were subsequently converted using a logistic transformation
with the justification based on possible floor and ceiling effects, as they are bounded by 0 and 1. Without
access to the original data, it is not possible to determine the impact of this transformation, although it
should be noted that EQ-5D is not bounded by 0 (i.e. negative values are possible). The manufacturer used
a repeated-measures logistic regression to model the relationship between utility and the BASDAI and
BASFI scores.
The relationship between BASFI and costs, derived from the OASIS study and used by the previous
independent assessment group in TA143,17 was applied in the base case. Costs of drug, administration,
initiation and monitoring were included. The costs and HRQoL of AEs were not included. Discounting was
applied at 3.5% for both costs and outcomes. Uncertainty surrounding outcomes was addressed
using PSA.
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Base-case results from UCB (certolizumab) model
The main base-case ICER results from the manufacturer35 are summarised in Table 46 for the AS
population, together with a fully incremental comparison of ICERs in Table 47. The ICERs versus CC
ranged from £16,647 per QALY (certolizumab) and £42,671 per QALY (infliximab). In the fully incremental
analysis, certolizumab dominated (i.e. less costly and more expensive) all other TNF-α treatments apart
from infliximab. However, it should be noted that the costs of certolizumab are based on a patient access
scheme (PAS) which has been proposed but is not yet formally agreed with the Department of Health and
NICE. Results without the PAS were not reported by the manufacturer. UCB will make certolizumab pegol
(Cimzia,® USB Pharma) available free of charge to all NHS patients for the first 3 months of therapy,
at which point clinical response should be clear. Only after this 3-month stage will the NHS be charged
for continuing to use this therapy.
The ICER of certolizumab was £16,647 per QALY versus CC and the ICER for infliximab was £113,871
(vs. certolizumab).
TABLE 47 Fully incremental comparison of anti-TNFs for AS: assessment group analysis based on UCB (base case)35
Technology Total costs (£) Total QALYs
Incremental
costs (£)
Incremental
QALYs ICER (£)
CC AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
–
Certolizumab AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
16,647
Golimumab AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
Dominated
Adalimumab AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
Dominated
Etanercept AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
Dominated
Infliximab AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
113,871
TABLE 46 Tumour necrosis factor-α inhibitors compared with CC for AS: UCB (base case)35
Technology Total costs (£) Total QALYs
Incremental
costs (£)
Incremental
QALYs ICER (£)
CC AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
–
Adalimumab AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
19,932
Certolizumab AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
16,647
Etanercept AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
19,272
Golimumab AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
19,049
Infliximab AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
42,671
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The main base-case ICER results from the manufacturer35 are summarised in Table 48 for the nr-AxSpA
population, together with a fully-incremental comparison of ICERs in Table 49. In contrast to the results for
AS, there was a more marked difference between the ICERs of the alternative anti-TNFs and CC. The ICERs
versus CC ranged from £15,615 (certolizumab) to £50,692 per QALY (etanercept). The higher differential
ICERs appears to be largely a result of the more heterogeneous trials included in the MTC for the
nr-AxSpA populations and a higher differential effect assumed for certolizumab vis-à-vis the other alternative
anti-TNFs compared with the AS population. Importantly, other manufacturers (Pfizer) argue that the results
for certolizumab in this population may be confounded by population characteristics which could invalidate
the indirect comparison of certolizumab versus the other comparator treatments in the current nr-AxSpA
MTC. In the fully incremental analysis, certolizumab dominated adalimumab and etanercept.
Overview of Pfizer (etanercept) model
The economic model submitted by Pfizer36 compared the cost-effectiveness of etanercept versus
conventional therapy and other licensed anti-TNFs for AS, nr-AxSpA and a combined population (axSpA).
The results for the combined population are not summarised in this review but are reported separately in
the manufacturer’s submission. The model is based on a lifetime time horizon and costs and benefits are
discounted at an annual rate of 3.5%. The reference year for costs was reported to be 2014.
The model was based on a patient-level simulation model based on a discrete event simulation (DES). The
analysis was conducted from a NHS/PSS perspective. Data to populate the model were derived from key
clinical trials for etanercept, the results of a clinical systematic review, MTC and, in a separate analysis
presented for the nr-AxSpA population, a match-adjusted indirect comparison (MAIC). The model structure
was reported to be developed in accordance with current OMERACT (Outcome Measures in Rheumatology)
guidance and was constructed around the BASDAI and the BASFI in line with other published studies.
TABLE 48 Tumour necrosis factor-α inhibitors compared with CC for nr-AxSpA: UCB (base case)35
Technology Total costs (£) Total QALYs
Incremental
costs (£)
Incremental
QALYs ICER (£)
CC AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
–
Adalimumab AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
30,370
Certolizumab AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
15,615
Etanercept AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
50,692
TABLE 49 Fully incremental comparison of anti-TNFs for nr-AxSpA: assessment group analysis based on UCB (base case)35
Technology Total costs (£) Total QALYs
Incremental
costs (£)
Incremental
QALYs ICER (£)
CC AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
–
Certolizumab AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
15,615
Etanercept AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
Dominated
Adalimumab AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
Dominated
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The AS population was defined based on current NICE guidance in TA14317 and TA233.33 The nr-AxSpA
population was defined based on the scope issued by NICE and was defined by the manufacturer as
people with severe axSpA without radiographic evidence of AS but with objective signs of inflammation,
whose disease has responded inadequately to, or who are intolerant to, NSAIDs.
An important aspect of the submission for the nr-AxSpA population was an attempt to adjust analyses
for differences in the baseline patient characteristics between the trials included. The manufacturer
reported that:
The clinical systematic review identified that the baseline characteristics of nr-AxSpA patients within the
randomised controlled trials of certolizumab pegol and adalimumab were heterogeneous, and
potentially differed in characteristics that could act as treatment effect modifiers. Furthermore, the
populations of these trials also included sizable proportions of AS patients who were originally classified
as nr-AxSpA on the basis of a difference between centralised and localised readings of X-rays.
To address the differences in the proportions of AS patents in the trials due to reclassification upon
central assessment, analyses were conducted using match adjusted indirect comparison (MAIC) and
simulated treatment comparison (STC) techniques that incorporated AS patients from the etanercept
314-EU trial. These analyses are referred to collectively as ‘analyses adjusting for differences in study
baseline characteristics’. A comparison of the results from the MAIC and STC approaches show that
while the results of the two analyses are similar, when considering comparisons between etanercept
and both adalimumab and certolizumab, the MAIC analysis provides a lower overall comparative
estimate of the benefit of etanercept, and is therefore considered overall to be the more conservative
of the two approaches. To maintain consistency in the analysis utilised in the economic section, the
MAIC was used throughout as the adjusted comparative efficacy measure between etanercept versus
adalimumab and etanercept versus certolizumab. For the analysis comparing etanercept against
certolizumab pegol, it was possible to address the issue of patient reclassification and differences in
baseline characteristics by utilising the RAPID-axSpA trial results that were also available at the level of
AxSpA patients, an approach not possible in the comparison of etanercept versus adalimumab. We
note that although not explicitly detailed within the scope, the AxSpA population encompasses both
nr-AxSpA and AS patients, thus making it a relevant comparison to the decision problem outlined in
the scope.
Manufacturer’s submission, pp. 226–736
The manufacturer argued that the use of DES conferred potential advantages in relation to modelling
non-linearity because of heterogeneous patient characteristics and in relation to modelling time
dependency. The latter was also argued as an advantage to considering the impact of sequential therapy
which was argued to be complex within a more conventional Markov type structure. Pfizer’s model was
the only model which explicitly explored issues of treatment sequences. However, in the base case the use
of second-line TNF-α inhibitor treatment was restricted to those patients who withdrew because of AEs
and was assumed equal efficacy to first line usage. The schematic of the model provided by the
manufacturer is replicated in Figure 6.
Etanercept RCT data were used to predict an initial 12-week response (in terms of reduction in BASDAI
and BASFI) for etanercept for both nr-AxSpA and AS populations. Separate multivariate regressions were
used to account for correlation between BASDAI and BASFI. A range of variables were initially included in
the regression models based on potential predictors of response identified from their review of economic
studies. The statistical significance and direction of effect were evaluated before final models were specified.
The 12-week models of BASDAI and BASFI for the nr-AxSpA had R2 values of (AiC information has been
removed) respectively. For the AS population, the equivalent R2 values were (AiC information has been
removed). The regressions were used to estimate mean change in BASDAI and BASFI which through the
patient level simulation were used to assign patients into BASDAI 50 responder/non-responder categories
and to assess the associated magnitude of change at 12 weeks for these categories.
DOI: 10.3310/hta20090 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 9
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
93
Remain on treatment
Initial response:
estimate ∆BASDAI
and ∆BASFI at 
12 weeks
Meet
response
criteria
Inadequate
response
Simulate
EQ-5D
from BASFI
and
BASFAI
Estimate
costs
based on
BASDAI/
BASFI and
therapy
Stop treatment
and move to next
line of therapy
Cause of discontinuation
Anti-TNF: simulate from probability of discontinuation owing to
intolerance, used to select next anti-TNF agent (if relevant)
Move to next line of therapy
Rebound effect
Assume BASDAI and BASFI revert to baseline
Death
SMR applied to life tables for England and
Wales, simulated as time to death
Weeks 12 – 48
Anti-TNF: continued
improvement in
BASDAI and BASFI
between weeks 12
and 48. Improvement
based on initial
response and baseline
characteristics
CC: revert to baseline
BASDAI and BASFI at
week 12
> Week 48
 
BASDAI
No change
BASFI
Anti-TNF: no progression
CC: 0.7/year, simulated as 
average time to change 
in BASFI of 7 units
Treatment cessation
Anti-TNF: apply relative effects from NMA to
baseline discontinuation for etanercept,
estimated through parametric survival analysis,
simulated as time to treatment cessation
CC: no treatment cessation as last line
FIGURE 6 Pfizer DES model schematic. NMA, network meta-analysis.36
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Relative effects from the MTC (or MAIC in the analyses adjusting for differences in study baseline
characteristics), in terms of mean differences in BASDAI and BASFI, were applied in order to predict
equivalent response and change scores for the other anti-TNF agents and CC at 12 weeks.
From week 12, the BASFI scores for CC were assumed to increase at a rate of 0.7 units per annum
(0–100 scale). The modelling of change in BASDAI and BASFI at week 48 for responders to etanercept was
conducted using the same approach used for the week 12 treatment response. However, change in
BASDAI and BASFI from baseline at week 12 were included as additional covariates within the resulting
models in order to ensure that an individual’s response at week 48 was dependent on their response at
week 12. The 48-week models of BASDAI and BASFI for the nr-AxSpA had R2 values of (AiC information
has been removed), respectively. For the AS population, the equivalent R2 values were (AiC information has
been removed). In the absence of relative effect estimates at week 48 for other therapies, it was assumed
that patients who remained on TNF-α inhibitor treatment beyond week 12 (i.e. responders) would
converge at the BASDAI and BASFI levels predicted for etanercept by week 48. Constant BASDAI and
BASFI scores for TNF-α inhibitor responders were assumed at the level observed at week 48 for
subsequent periods.
Treatment discontinuation was modelled by fitting separate parametric survival curves to long-term
open-label study data from etanercept for the AS and nr-AxSpA populations. In order to predict treatment
cessation in the population that was likely to continue treatment after 12 weeks, parametric curves were
fitted only to subjects who achieved a BASDAI 50 response at week 12. Only patients who were
randomised to etanercept at baseline were retained within these survival analyses and patients who began
etanercept during open-label phases of studies were excluded. The distributions that provided the best fit
were exponential (AiC information has been removed) and log-normal (AiC information has been
removed), based on the minimisation of the Akaike information criterion and the Bayesian information
criterion. The exponential model was chosen based, in part, on the goodness of fit but also because the
use of hazard ratios, which were applied to estimate the effect of other anti-TNFs on the rate of
discontinuation, required the use of a proportional hazard survival model [to avoid making further
assumptions when applying the hazard ratio to the log-normal (accelerated failure time) model].
The same risk of discontinuation was applied to all individuals in the model. The models of discontinuation
translate into annual probabilities of discontinuation for etanercept, for patients who achieve a BASDAI 50
response, of 5% and 11% for nr-AxSpA and AS populations, respectively. Based on data from the
DANBIO registry, it was assumed that other anti-TNFs have an increased risk of discontinuation compared
with etanercept: a hazard ratio of 1.3 is applied for infliximab and 1.12 for adalimumab. In the absence
of evidence for golimumab and certolizumab, it was assumed that the relative effect is the same
as for adalimumab on the basis that these have common molecular structure and belong to
monoclonal antibodies.
After discontinuation of the first treatment, an alternative TNF-α inhibitor was modelled as second-line
treatment for patients who discontinued due to AEs [(CiC information has been removed)% for AS and
(CiC information has been removed)% for nr-AxSpA]. The same efficacy as applied for first-line treatments
was assumed for second-line treatments for patients switching because of AEs. For patients who
discontinued because of loss of efficacy, no further TNF-α treatment was modelled. These assumptions
were considered by the manufacturer to be consistent with current NICE guidance. For the base-case
model, it was assumed that following discontinuation from anti-TNFs, patients would rebound back to
their baseline BASDAI and BASFI scores and that the rebound takes 6 months based on the approach used
within the TA23333 submission to NICE.
In the absence of previously published studies reporting the relationship between BASDAI/BASFI and EQ-5D
utility scores in the nr-AxSpA population, a de novo relationship was estimated from the 1031 study;166
variables included age, sex, baseline BASDAI and BASFI. Ordinary least squares regression models were
used, with SEs clustered around each subject to account for repeated observations. For consistency, a
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similar relationship was estimated for the AS population using the 314-EU study.167 Alternative linear and
non-linear relationships were evaluated and final model selection based on Akaike information criterion
statistics. In the nr-AxSpA population, the final model included squared terms for BASDAI and BASFI and
an interaction between BASDAI and BASFI, while in the AS population, the covariates for the interaction
term, age and male were not included. Scenario analyses considered using alternative model specifications
for mapping. The manufacturer reported that according to visual inspection, the estimated models were
very similar between populations and reported a high degree of similarity between the results of the
de novo estimated models and those published previously.
Figures 7 and 8 replicate the relationships reported by the manufacturer between EQ-5D, BASDAI and
BASFI in the nr-AxSpA and AS populations, respectively. Additional figures were also presented by the
manufacturer for predicted versus observed EQ-5D in each of the populations. The manufacturer
concluded that the models overpredicted EQ-5D at low observed EQ-5D and underpredicted at higher
observed EQ-5D values. The manufacturer argued that this was a common feature of mapping algorithms
and argued that the approach would be conservative towards the use of anti-TNFs.
The manufacturer included the acquisition, administration and pre-treatment monitoring costs of TNF-α
inhibitors. Subsequent monitoring costs were not included in order to avoid potential double counting of
the costs which were estimated as a function of BASDAI and BASFI. In the base-case analysis the
manufacturer used data from Rafia et al.168 based on BASDAI scores only. A categorical approach was
applied to BASDAI scores based on the following annual costs: BASDAI score of < 40= £151.96; 40
≤ BASDAI score < 60= £311.08; and BASDAI score of ≥ 60= £1039.16. The manufacturer justified the use
of this source as it provides the most recent UK specific data reported and permitted separation of
particular cost items. The costs and HRQoL of AEs (serious infections only) were included in the base-case
analysis (none observed in the nr-AxSpA trial 1031 study;166 however, serious infections were observed in
the AS trial 314-EU study167). A separate sensitivity analysis included the costs of serious infections.
A SMR of 1 for the nr-AxSpA population and 1.5 for the AS population were applied to general
population life-tables.
Results of Pfizer (etanercept) model
The main base-case ICER results from the manufacturer36 are summarised in Table 50 for the AS
population, together with a fully incremental comparison of ICERs in Table 51. The ICERs versus CC
ranged from £19,586 per QALY (certolizumab) and £37,741 per QALY (infliximab). In common with the
FIGURE 8 AiC information has been removed.36
FIGURE 7 AiC information has been removed.36
TABLE 50 Tumour necrosis factor-α inhibitors compared with CC for AS: Pfizer (base case)36
Technology Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£)
CC 18,122 7.318 – – –
Adalimumab 57,535 9.203 39,413 1.885 20,909
Certolizumab 51,843 9.040 33,721 1.722 19,586
Etanercept 60,338 9.334 42,216 2.016 20,938
Golimumab 62,698 9.412 44,576 2.094 21,288
Infliximab 98,340 9.443 80,218 2.125 37,741
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UCB model, it should be noted that the costs of certolizumab assumed within Pfizer’s model were also
based on the PAS for certolizumab which has been proposed but is not yet formally agreed with the
Department of Health and NICE. Hence the ICER for certolizumab versus CC without the PAS will be
higher than the estimates reported here.
In the fully incremental analysis, adalimumab was extendedly dominated. Of the remaining non-dominated
treatments, the ICERs of the next most costly interventions compared with the previous non-dominated
alternative were £19,586 (certolizumab vs. CC), £28,834 (etanercept vs. certolizumab), £30,376
(golimumab vs. etanercept) and £1,131,181 (infliximab vs. golimumab).
The main base-case ICER results from the manufacturer36 are summarised in Table 52 for the nr-AxSpA
population together with a fully incremental comparison of ICERs (Table 53). The ICERs versus CC ranged
from £23,195 (etanercept) and £23,575 (certolizumab). In contrast to the UCB analysis, the ICERs for the
nr-AxSpA population were marginally less favourable than the results for the AS population. There was
also less of a marked difference between the ICERs for each of the anti-TNFs and CC compared with the
UCB results, although a large difference was evident relating to the magnitude of the incremental QALY
estimates for certolizumab vis-à-vis the other anti-TNFs. Table 54 reports the results of the fully incremental
analysis. None of the anti-TNFs was ruled out via dominance or extended dominance, and the ICER of each
comparison remained below £30,000 per QALY for each successively more expensive and effective treatment.
TABLE 51 Fully incremental comparison of anti-TNFs for AS: assessment group analysis based on Pfizer (base case)36
Technology Total costs (£) Total QALYs
Incremental
costs (£) Incremental QALYs ICER (£)
CC 18,122 7.318 – – –
Certolizumab 51,843 9.040 33,721 1.722 19,586
Adalimumab 57,535 9.203 – – Extendedly dominated
Etanercept 60,338 9.334 8495 0.294 28,834
Golimumab 62,698 9.412 2360 0.078 30,376
Infliximab 98,340 9.443 35,642 0.031 1,131,181
TABLE 52 Anti-TNFs compared with CC for nr-AxSpA: Pfizer (base case)36
Technology Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£)
CC 20,609 10.221 – – –
Adalimumab 62,667 12.030 42,058 1.809 23,242
Certolizumab 74,282 12.497 53,673 2.276 23,575
Etanercept 59,635 11.903 39,026 1.682 23,195
TABLE 53 Fully incremental comparison of nr-AxSpA: assessment group analysis based on Pfizer (base case)36
Technology Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£)
CC 20,609 10.221 – – –
Etanercept 59,635 11.903 39,026 1.683 23,195
Adalimumab 62,667 12.030 3033 0.127 23,871
Certolizumab 74,282 12.497 11,615 0.467 24,864
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To address the concerns noted by Pfizer relating to the heterogeneity across the different trials in the
nr-AxSpA population, a separate matched indirect comparison was presented for etanercept versus
adalimumab. A separate comparison was also presented versus certolizumab for the combined axSpA
population in the manufacturer’s submission. Using the MAIC approach, the ICER for etanercept versus
adalimumab was £23,195 per QALY. Total cost and QALYs estimates were reversed in the MAIC approach
compared with the base-case analysis (adalimumab generated greater QALYs at increased cost),
demonstrating the potential impact of trying to minimise observable sources of possible confounding.
Overview of Merck Sharp & Dohme (golimumab, infliximab) model
The economic models submitted by Merck Sharp & Dohme37 compared the cost-effectiveness of
golimumab and infliximab with conventional therapy and other licensed anti-TNFs for AS. Although the
manufacturer made separate submissions for golimumab and infliximab, the model structures and data
sources used to inform the economic models are identical across the submissions. Hence this review
focuses on the specific submission for golimumab but also considers key data sources and assumptions
specific to infliximab. The model base case is based on a lifetime time horizon (approximately 60 years),
and costs and benefits are discounted at an annual rate of 3.5%. A NHS and PSS perspective is used for
costs. The reference year for costs was reported to be 2012/13.
The economic model submitted by the manufacturer for golimumab37 is based on the same model
structure submitted as part of NICE TA23333 and summarised previously in Data extraction (Armstrong
et al. 2013)163 Hence, a description of the structure of the model is not repeated in this section. In summary,
the manufacturer’s cost-effectiveness model was based on a short-term decision tree (based on an
assessment of BASDAI 50 response at 12 weeks in the base case) and a longer-term Markov model.
The proportion of patients achieving BASDAI 50 at week 12 (± 2 weeks) for each TNF-α inhibitor was
obtained from a systematic review and MTC undertaken by the manufacturer. The results are summarised
in Table 55.
TABLE 54 Incremental results of etanercept vs. adalimumab in nr-AxSpA (using MAIC data): Pfizer36
Technology Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£)
Adalimumab 48,494 11.473 – – –
Etanercept 60,404 11.928 11,910 0.455 26,176
TABLE 55 Odds ratios and probability of BASDAI 50 score response to anti-TNFs and conventional therapy
(Merck Sharp & Dohme)37
Treatment
BASDAI 50
OR (95% CrI) Probability
Golimumab 5.54 (2.12 to 12.13) 0.49
Infliximab 22.44 (2.78 to 89.05) 0.79
Adalimumab 5.20 (2.14 to 10.62) 0.47
Etanercept 5.46 (2.03 to 11.74) 0.60
Certolizumab pegol 6.62 (1.66 to 17.59) 0.53
Conventional therapy – 0.15
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Data from the GO-RAISE90 trial and the open-label extension period (up to week 108) were used to
develop predictive equations of mean change from baseline in BASDAI and BASFI scores over time.
Two separate equations were developed based on the 24-week data (0–24 weeks) for all patients and
post-24-week (week 24–108) data from GO-RAISE90 for patients who remained on treatment. The
variables applied in each equation are summarised in Tables 56 and 57.
The treatment coefficient (and interaction term) in the short-term regression equation is used to estimate
separate BASDAI/BASFI scores for anti-TNFs and CC. Hence, up to week 24, the same estimate of BASDAI/
BASFI appears to be applied to all TNFs (i.e. regardless of the differential response rates assumed). Beyond
week 24, the same BASDAI/BASFI score is applied to a responder to any of the TNFs, although a different
response rate for each TNF-α inhibitor is assumed based on the MTC. The BASDAI/BASFI regressions are
applied to responders who continue on TNF-α inhibitor therapy up to week 108 for BASDAI and up to
week 108 for BASFI.
The BASDAI and BASFI scores beyond week 108 for responders who continue to receive anti-TNFs beyond
this period in the model are assumed to remain constant (at the week 108 value). The BASFI scores
beyond week 256 for responders who continue to receive anti-TNFs beyond this period in the model are
assumed to remain constant (at the week 108 value) but are also subject to an annual progression rate of
BASFI at this point which is set to half the rate of CC in the baseline (0.035 units per annum, 0–10 scale).
The justification for this is not explicitly made by the manufacturer. For the base-case model, BASFI scores
for CC patients on conventional therapy are assumed to progress at a rate of 0.07 units per year after
week 24.
An annual discontinuation rate of 6.1% is applied for the entire time horizon after week 12 in the base-case
analysis. This estimate is derived from data reported between weeks 24 and 256 in the 50mg arm of
golimumab from the GO-RAISE90 extension period. The manufacturer does not formally state whether or
TABLE 56 Short-term regression equations used by Merck Sharp & Dohme37 for BASDAI/BASFI score (0–24 weeks):
all patients
Variable Parameter SE
BASFI
Intercept 0.1008 0.557
Age –0.0284 0.009874
Baseline BASFI 0.1780 0.05429
Treatment 1.8096 0.2551
Male 0.04156 0.2767
Week–2 5.226 0.2767
Treatment ×week–2 –14.6396 2.2699
BASDAI
Intercept 0.4685 0.8126
Age –0.03399 0.0105
Baseline BASDAI 0.2212 0.08436
Treatment 2.0620 0.2742
Male 0.2652 0.2953
Week–2 –3.4664 2.1365
Treatment ×week–2 –7.1029 2.6887
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not this is specific to those patients who were identified to be responders at 12 weeks. However, it
appears to be based on all patients who continued to receive golimumab beyond 24 weeks regardless
of their response status. The same discontinuation rate is applied to all TNF-α inhibitors. Following
discontinuation from anti-TNFs, the BASFI and BASDAI scores are assumed to deteriorate/rebound over a
24-week period back to their baseline BASFI and BASDAI scores (i.e. rebound equal to gain). Therefore, in
common with other models which apply this rebound assumption, patients are assumed to achieve a
lifetime benefit from treatment with anti-TNFs for BASFI.
Utilities were derived from a NICE TA (TA14317) and incorporated age, sex, BASFI score and BASDAI score.
Costs included in the model comprised drug acquisition, short-term (12-week) costs, longer-term disease costs
and AEs. Longer-term disease costs were based on BASFI scores from the GO-RAISE90 trial using the same
regression equation used for NICE TA143.17
The proportion of males and females recruited in the GO-RAISE90 trial is used to estimate a weighted
average mortality risk by sex. The sex-specific SMR for AS from a study by Bakland et al.16 is applied to
the mortality rates from the general population to calculate adjusted mortality rates for AS patients in the
model. The study by Bakland reported a SMR of 1.63 (95% CI 1.29 to 1.97) for males and 1.38 (95% CI
0.48 to 2.28) for females.
Results of the Merck Sharp & Dohme (golimumab, infliximab) model
The main base-case ICER results from the manufacturer37 are summarised in Table 58 for the AS
population, together with a fully incremental comparison of ICERs in Table 59. The ICERs versus CC
ranged from £19,070 (golimumab) to £42,532 (infliximab). In the fully incremental analysis, golimumab
and certolizumab were the non-dominated anti-TNFs. The ICER for golimumab versus CC was £19,070 and
for certolizumab versus golimumab was £21,441 per QALY.
Summary and critique of de novo cost-effectiveness submissions
In general, the manufacturer models34–37 appeared to be constructed to a high standard and it is evident
that significant work had been undertaken by each to identify and use previously published studies and to
exploit existing individual patient data from their own RCTs and open-label extension periods to generate
estimates that were appropriate for the requirements of the model.
TABLE 57 Long-term regression equations used by Merck Sharp & Dohme37 for BASDAI/BASFI score (24–108 weeks):
responders only
Variable Parameter SE
BASFI
Intercept 0.4933 0.7364
Age –0.03915 0.01321
Baseline BASFI 0.5706 0.07292
Male 0.6523 0.4001
Log (week) 0.09524 0.04938
BASDAI
Intercept 0.6277 1.0303
Age –0.03531 0.01367
Baseline BASDAI 0.5762 0.1055
Male 0.2196 0.4094
Log (week) 0.2196 0.06908
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Despite the different model structures and assumptions applied across the various manufacturer’s
submissions,34–37 the ICERs reported for the anti-TNFs versus CC were remarkably consistent in the AS
population. Table 60 presents a summary of the ICER reported by each manufacturer for each of the
anti-TNFs versus CC. It is perhaps expected that the majority of manufacturer’s reported the lowest ICER
versus CC for their own products. The only exception to this is the Pfizer model, which estimated the
lowest ICER versus CC for certolizumab in this population (etanercept was the next lowest), although it
should be noted that Pfizer included the proposed PAS costs for certolizumab which was not universally
applied across the different manufacturer’s submissions. Hence, although differences between the ICER
versus CC were quite similar, the variation in approaches used by each manufacturer appears partially
driven by maximising any potential comparative advantage considered vis-à-vis other manufacturer
TABLE 58 Anti-TNFs compared with CC for AS: Merck Sharp & Dohme (base case)37
Technology Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£)
CC 160,837 10.5529 – – –
Adalimumab 181,589 11.6296 20,752 1.0766 19,275
Certolizumab 183,017 11.6962 22,180 1.1432 19,401
Etanercept 183,540 11.5862 22,703 1.0332 21,972
Golimumab 181,427 11.6326 20,590 1.0797 19,070
Infliximab 208,856 11.6819 48,019 1.1290 42,532
TABLE 59 Fully incremental comparison of anti-TNFs for AS: assessment group analysis based on Merck Sharp &
Dohme (base case)
Technology Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£)
CC 160,837 10.5529 – – –
Golimumab 181,427 11.6326 20,590 1.0797 19,070
Adalimumab 181,589 11.6296 – – Dominated
Certolizumab 183,017 11.6962 1590 0.0636 21,441
Etanercept 183,540 11.5862 – – Dominated
Infliximab 208,856 11.6819 – – Dominated
TABLE 60 Comparison of manufacturer ICER estimates vs. CC (AS population)
Technology
AbbVie34
(adalimumab),
ICER (£)
UCB35
(certolizumab),
ICER (£)
Pfizer36
(etanercept),
ICER (£)
Merck Sharp & Dohme37
(golimumab, infliximab),
ICER (£)
CC – – – –
Adalimumab 16,391 19,932 20,909 19,275
Certolizumab 17,067 16,647 19,586 19,401
Etanercept 16,897 19,272 20,938 21,972
Golimumab 16,535 19,049 21,288 19,070
Infliximab 44,448 42,671 37,741 42,532
The figures reported in bold indicate which specific TNF-α inhibitor has the lowest ICER vs. CC in each of the
manufacturer’s submissions.
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products (i.e. in terms of assumptions made about similarities and differences for response rates,
magnitude of changes in BASDAI and BASFI and withdrawal rates). However, it should be noted that no
manufacturer makes a strong claim regarding differential efficacy between the alternative anti-TNFs which
is borne out in the relatively small differentials reported between the different products in each of
the submissions.
Table 61 presents a summary of the ICERs reported by each manufacturer for each of the anti-TNFs versus
CC for the nr-AxSpA population. There appears to be much more heterogeneity across the manufacturer’s
submissions34–36 compared with the AS population. There appears an almost twofold difference in the
ICERs reported across the submissions for each of the anti-TNFs. Importantly, there also appears variation
across the populations with more favourable ICERs reported than CC for the nr-AxSpA population vis-à-vis
the estimates by AbbVie (both adalimumab and certolizumab) and UCB (certolizumab only). Hence, the
differences in structural and parameter assumptions appear more evident in the results for the nr-AxSpA
population compared with results for the AS population.
To assist in identifying possible reasons for the differences between populations, summaries of the key
structural assumptions used by each manufacturer are provided in Tables 62 and 63. A more micro-level
analysis of comparison of specific parameter estimates is reported separately in Appendix 11.
In general, it is difficult to identify the specific factors which can easily explain differences within and
between the two populations across the manufacturer’s submissions. In general, similar model structures
were applied by each manufacturer across the separate populations. However, it is evident that there are
important differences based on a number of key structural issues: (1) the response criteria and timings
applied; (2) the magnitude of change scores and particularly the assumption concerning the time at which
these were assumed to ‘level off’ (generally longer in the AS populations because of the longer open-label
extension periods); (3) the underlying rate of progression of BASFI with CC and the impact of anti-TNFs on
this rate; and (4) the rebound assumption and timing of this.
TABLE 61 Comparison of manufacturer ICER estimates vs. CC (nr-AxSpA population)
Technology AbbVie34 (adalimumab), ICER (£) UCB35 (certolizumab), ICER (£) Pfizer36 (etanercept), ICER (£)
CC – – –
Adalimumab 13,228 30,370 23,242
Certolizumab 12,866 15,615 23,575
Etanercept Not assessed 50,692 23,195
The figures reported in bold indicate which specific TNF-α inhibitor has the lowest ICER vs. CC in each of the
manufacturer’s submissions.
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TABLE 62 Model structure and key structural assumptions: AS population
Parameter
Merck Sharp & Dohme
economic model37
(infliximab, golimumab)
AbbVie34 economic model
(adalimumab)
UCB35 economic model
(certolizumab)
Pfizer36 economic model
(etanercept)
Model type Decision tree followed by Markov
model
Markov model Markov model Patient-level simulation model (DES)
Time horizon Lifetime 40 years Lifetime Lifetime
Response criterion BASDAI 50 response at week 12 ASAS 20 response at week 12 ASAS 20 response at week 24 BASDAI 50 response at week 12
Response criterion justification Efficacy outcome in GO-RAISE90
study; recommended by the ASAS
Working Group (Keat 2005)169
Primary end point of ATLAS61
study
ASAS 20 is the primary end
point of RAPID-axSpA64 study
Based on the current NICE definition
of treatment response (TA14317)
Progression assumption BASDAI
Anti-TNFs responders Constant after week 108 Constant after week 260 Constant after week 24 Constant after week 48
Anti-TNFs non-responders Constant Constant Constant Constant
CC Constant after week 24 Constant Constant Constant after week 12
Progression assumption BASFI
Anti-TNFs responders Constant after week 108; 0.035
after week 256
Constant after week 260 Constant after week 24 Constant after week 48
Anti-TNFs non-responders 0.07 0.056 0.07 0.07
CC 0.07 after week 24 0.056 0.07 0.07 after week 12
Rebound assumption Rebound to baseline Rebound to baseline Rebound to conventional
therapy
Rebound to baseline
Rebound assumption duration Over a 6-month period Immediately Over a 6-month period Over a 6-month period
Placebo response 14.5% at week 12; loss or
maintenance of placebo response
not reported
BASDAI and BASFI scores
return to baseline at week 12
No placebo response BASDAI and BASFI scores return to
baseline at 12 weeks
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Given the complex inter-relationship between these structural assumptions and subsequent parameter
estimates, it is difficult to identify single specific reasons for differences. However, the structural differences
clearly lead to marked differences in the BASDAI and BASFI scores estimated over time by each manufacturer
for each population. Figures 9–11 provide a graphical summary of the cohort BASDAI and BASFI scores, for
the AS population, from three of the manufacturers. These highlight the significant differences in subsequent
parameter estimates applied at a cohort level. Equivalent estimates are not presented for the Pfizer model
because of the complexities of generating this data from the DES model. The BASDAI and BASFI scores are
presented here only for the case made by each manufacturer for their own product.
Tables 64 and 65 summarise the mean difference in BASDAI and BASFI scores applied to responders to
anti-TNFs and those applied to CC at various time points in each model. The tables clearly highlight the
range of different values applied across the separate manufacturers. This further emphasises the variation
in approaches, sources and assumptions.
The equivalent figures and tables are reported for the nr-AxSpA population (Figures 12 and 13 and
Tables 66 and 67).
TABLE 63 Model structure and key structural assumptions: nr-AxSpA population
Parameter
AbbVie34 economic
model (adalimumab)
UCB35 economic
model (certolizumab)
Pfizer36 economic model
(etanercept)
Model type Markov model Markov model Patient-level simulation
model (DES)
Time horizon 40 years Lifetime Lifetime
Response criterion ASAS 40 response at
week 12
ASAS 20 response at
week 12
BASDAI 50 response at
week 12
Response criterion justification Primary end point of
ABILITY-158 study
Primary end point of
RAPID-axSpA64 study
Based on the current NICE
definition of treatment
response (TA14317)
Progression assumption BASDAI
Anti-TNFs responders Constant after week 140 Constant after week 12 Constant after week 48
Anti-TNFs non-responders Constant Constant Constant
CC Constant Constant Constant after week 12
Progression assumption BASFI
Anti-TNFs responders Constant after week 140 Constant after week 12 Constant after week 48
Anti-TNFs non-responders 0.084 0.07 Constant/0.07
CC 0.084 0.07 0.07 after week 12
Rebound assumption Rebound to baseline Rebound to
conventional therapy
Rebound to baseline
Rebound assumption duration Immediately Over a 6-month period Over a 6-month period
Placebo response BASDAI and BASFI scores
return to baseline at
week 12
No placebo response BASDAI and BASFI scores
return to baseline at
12 weeks
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TABLE 65 The BASFI score difference for responders vs. CC: AS population
Time Adalimumab vs. CC Certolizumab vs. CC Infliximab/golimumab vs. CC
12 weeks –2.03 AiC information has been removed –1.68
24 weeks –3.28 AiC information has been removed –1.74
1 year –3.71 AiC information has been removed –2.49
3 years –4.25 AiC information has been removed –2.59
5 years –4.25 AiC information has been removed –2.66
10 years –4.53 AiC information has been removed –2.85
20 years –5.09 AiC information has been removed –3.18
40 years –6.21 AiC information has been removed –3.75
TABLE 64 The BASDAI score difference for treatment responders vs. CC: AS population
Time Adalimumab vs. CC Certolizumab vs. CC Infliximab/golimumab vs. CC
12 weeks –2.98 AiC information has been removed –2.01
24 weeks –4.42 AiC information has been removed –2.05
1 year –4.9 AiC information has been removed –2.77
3 years –5.23 AiC information has been removed –2.83
5 years –5.31 AiC information has been removed –2.83
10 years –5.31 AiC information has been removed –2.83
20 years –5.31 AiC information has been removed –2.83
40 years –5.31 CiC information has been removed –2.83
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FIGURE 12 Comparison of cohort BASDAI/BASFI scores for nr-AxSpA population from AbbVie
model (adalimumab).34
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FIGURE 13 Comparison of cohort BASDAI/BASFI scores for nr-AxSpA population from UCB model (certolizumab).35
TABLE 66 The BASDAI score difference for responders vs. CC: nr-AxSpA population
Time Adalimumab vs. CC Certolizumaba vs. CC
12 weeks –3.89 AiC information has been removed
24 weeks –5.54 AiC information has been removed
1 year –5.42 AiC information has been removed
3 years –5.99 AiC information has been removed
5 years –5.99 AiC information has been removed
10 years –5.99 AiC information has been removed
20 years –5.99 AiC information has been removed
40 years –5.99 AiC information has been removed
a Certolizumab patients who remain nr-AxSpA and do not transition to AS.
TABLE 67 The BASFI score difference for responders vs. CC: nr-AxSpA population
Time Adalimumab vs. CC Certolizumaba vs. CC
12 weeks –2.95 AiC information has been removed
24 weeks –4.11 AiC information has been removed
1 year –4.12 AiC information has been removed
3 years –4.55 AiC information has been removed
5 years –4.72 AiC information has been removed
10 years –5.14 AiC information has been removed
20 years –5.98 AiC information has been removed
40 years –7.66 AiC information has been removed
a Certolizumab patients who remain nr-AxSpA and do not transition to AS.
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The differences across manufacturers and between the populations are further illustrated by the summary
of key parameter inputs reported in Appendix 11. As well as reporting the main parameter inputs,
Appendix 11 also explores differences in approaches at a parameter level for key inputs (e.g. withdrawal,
costs, etc.).
It is evident from these comparisons that there are significant differences across the manufacturers in
terms of key structural and parameter estimates. While it might appear reassuring that these differences
do not appear to lead to significant differences across the ICER estimates reported for the AS population,
the greater heterogeneity reported in the ICER estimates for the nr-AxSpA is clearly an issue. However,
even within the AS population, any reassurance that one might have regarding the robustness and
appropriateness that these estimates have for informing NHS practice needs to be carefully considered in
relation to the key conceptual issues and concerns highlighted in Summary and critique of published
cost-effectiveness studies for previously published cost-effectiveness studies. Despite significant work
undertaken by each manufacturer in support of existing and new indications for their products, it is
particularly concerning that many of the key conceptual issues and concerns appear to have not been
fully addressed. Indeed, many of these issues seem to have not been addressed at all, such that many
models still seem reliant on the use of open-label extension data (and even more so with the extended
follow-up reported in the AS population) without any formal consideration of the potential issues with
selection that the use of these studies inevitably are subject to. Consequently, the benefits of anti-TNFs
are being projected over significant periods of time without any evidence on the counterfactual (i.e. what
happens to patients who do not enter into the open-label extension periods? What happens to patients
who subsequently withdraw from anti-TNFs? And what would have happened to patients over a
longer-time horizon who did not receive anti-TNFs?).
It appears that much of the case being made concerning the cost-effectiveness of the anti-TNFs rests on
comparison of single-arm studies (the subject of open-label data) and retrospective comparisons against
historical cohorts (as the counterfactual, for patients not on treatment, is unknown). While such a
comparison may be necessitated by the short-term nature of the double-blind periods, the lack of a more
detailed consideration of the appropriateness of the comparisons being made in relation to sources of
natural history data (and subsequent assumptions made concerning the BASDAI/BASFI trajectories
of the different patient categories) is concerning and, hence, current ICER estimates reported by the
manufacturers must be considered to be both speculative and highly uncertain.
Many of these problems can be associated with whether or not BASDAI and BASFI scores provide an
appropriate conceptual basis for modelling the chronic and progressive nature of AS and nr-AxSpA. Hence
current models appear largely driven by data availability (i.e. the extensive evidence which has been
generated and continues to be generated investigating the relationship between BASDAI/BASFI and
costs/utilities) rather than trying to develop a clearer underlying biological or clinical process which may
better characterise the disease and subsequent progression across the separate populations.
Until such time that sufficient data-linking costs and utilities to other measures are reported, it seems
inevitable that models will continue to be driven largely by BASDAI and BASFI scores over time together
with assumptions concerning the longer-term effect of anti-TNFs. However, given the nature of existing
models and the reliance on uncontrolled longer-term follow-up of anti-TNFs, and comparison with
historical ‘controls’ (particularly in relation to BASFI progression over time and the assumptions being made
concerning the potential disease modification properties of anti-TNFs in both AS and nr-AxSpA populations),
it is surprising that greater efforts have not been made by the manufacturers to try to more formally link to the
increasing evidence base being generated in relation to radiographic progression in the AS population.
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It is also surprising that more thought has also not been given to characterising the potential difference in
BASFI progression across the separate populations and how generalisable assumptions may be between
these. The result is that many of the key assumptions concerning whether the anti-TNFs are primarily
symptom control treatments or whether they are also potential disease modifiers remains implicitly dealt
with within existing submissions. The result is that several manufacturers use identical assumptions across
populations with respect to BASFI progression and the effect of the anti-TNFs. Interestingly, only one
manufacturer appears to use differential rates of BASFI progression across the populations (AbbVie),
although the same structural assumption concerning the effect of anti-TNFs is still made. Interestingly,
this manufacturer applies a higher rate of change in BASFI for patients receiving CC in the nr-AxSpA
population vis-à-vis the AS population. However, while such a difference is interesting, the basis of and
implication for this differential is not fully explained or justified by the manufacturer.
The issue of intermittent and sequential use of anti-TNFs remain important clinical questions but the
existing models do not provide a robust basis for informing these decisions. The cost-effectiveness of
intermittent therapy versus continuous therapy was not formally considered in any model identified.
However, it could be argued that such a comparison might be deemed outside the scope of a NICE
appraisal. Although one manufacturer (Pfizer36) explored the potential cost-effectiveness of sequential
therapy, much of this has been done via assumptions (e.g. assuming equal efficacy second line in patients
who discontinue first line as a result of an AE) or via adjustments applied to first-line efficacy estimates
based on ‘real-world’ evidence reported from large-scale registries (which typically show anti-TNFs to be
clinically effective but with lower response rates than reported in naive patients). Consequently, existing
attempts to model sequential therapy are largely based on applying adjustments to first-line efficacy data
using observational evidence which are clearly subject to potential confounding. In large part, the
limitations of existing cost-effectiveness models for informing these clinical questions appears less a
function of the models themselves but rather that robust clinical data to date has not been generated to
inform unbiased estimates of relative efficacy of alternative strategies for using the anti-TNFs.
The following sections report the development of a de novo model to address some of the key issues and
uncertainties which have been identified in this review. Chapter 5 reports the results of an extended
synthesis which has been developed to provide a more generalisable framework for synthesising clinical
efficacy data ensuring that appropriate estimates are generated for the model which make use of all
relevant and available evidence. This is followed in Chapter 6 by a description of the de novo model (York
model) which attempts to link this framework to a more coherent conceptual model of the chronic and
progressive nature of AS and nr-AxSpA.
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Chapter 5 Independent economic assessment:
extended synthesis
Existing evidence on the short-term clinical effectiveness of anti-TNF drugs has been presented anddiscussed in Chapter 3. The methods of evidence synthesis are extended in this section to more directly
address the decision problem and the parameter inputs required for the economic model. There were two
specific aims to these analyses. Firstly, we aimed to more formally explore the differences between
individual anti-TNF treatments to inform the most appropriate assumption for the economic model (i.e.
equivalence or drug-specific differences). Within Chapter 3 of this report, the assumption of independent
treatment effects was evaluated alongside the assumption of a common (equal) treatment effect across
anti-TNFs, for every outcome of interest. While there is no evidence that supports differences in the
effectiveness of these drugs, assuming equal effectiveness means that the trials are pooled as if the same
drug had been trialled; this leads to an arguably overly precise estimate of effect for the class of drugs.
For this reason, we explore an additional scenario in which treatments are assumed to have a similar,
but not equal, effectiveness, that is there are differences between the effectiveness of treatments that we
may not be able to explain but that we should consider.
The second aim was to generate appropriate effect-size estimates and their associated uncertainty to
inform the main input parameters of the economic model by synthesising together evidence on BASDAI
and BASFI outcomes jointly. Initially, we considered the two related BASDAI outcomes relevant to the
decision model reported in the effectiveness evidence available: changes in BASDAI scores over a certain
period of time and a probability of response to BASDAI 50 (that is, a 50% change in the BASDAI score in
relation to baseline). The BASDAI 50 is important, as patients are expected to discontinue anti-TNFs if, at
12 weeks, they have not been able to achieve response to this criterion (according to NICE guidance).17,33
Changes in BASDAI scores observed at this same time point determine the magnitude of initial response to
treatment and have often been used in economic modelling as the basis for extrapolating treatment
effects. Given that these outcomes are both central to informing effect parameters in the decision model,
a synthesis model that considers the relation between these two outcomes provides a more consistent and
coherent basis for informing these parameters.
We developed a synthesis model that pools evidence on the change in BASDAI score by considering both
those studies that report this measure directly and also those that report the proportion of patients
achieving a BASDAI 50 response. We expressed BASDAI 50 as a function of the absolute change in
BASDAI and we use this relationship in the extended synthesis. We also aim to simultaneously synthesise
information on BASFI score, a measure that is used together with BASDAI score to determine the
long-term QALY and cost burden of the disease in the economic model. Treatments improving AS symptoms
are expected to affect both disease activity and function, and thus we expect a reduction in both BASDAI
and BASFI scores, this means that we expect the changes to these two measures to be correlated.
Extending the synthesis modelling to consider BASFI scores not only allows all relevant evidence to
contribute to the synthesis but also ensures that all measures are synthesised together to reflect the
expected correlations between the two outcomes. Uncertainty is also more appropriately quantified than
synthesising each outcome separately.
In the decision model, prognosis, costs and QALYs are determined by absolute BASDAI and BASFI scores.
Given that treatment continuation is determined by response to BASDAI 50 at 12 weeks, it is important for
the economic model to estimate the absolute change in BASDAI and BASFI separately for responders and
non-responders, that is the conditional scores. However, the published clinical effectiveness evidence does
not report the conditional scores. Consequently, we requested the conditional data from the pivotal trials
in both the AS and nr-AxSpA indications from each manufacturer. These data were subsequently provided
by the manufacturers for their four pivotal trials. However, this information was not available for the other
trials in the evidence-base (there were 15 trials in the evidence base and conditional scores were only
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available for four). In view of the limited data available on the conditional scores, another important
extension of the synthesis approach was the evaluation of these. We used the results from the extended
synthesis model to evaluate the conditional scores by simulating BASDAI and BASFI scores for two
equivalent cohorts of patients the only difference being that one cohort was treated and the other
was not.
This section provides only a summary of these analyses; full details are in Appendices 5, 12 and 13.
We will describe first the approach for the synthesis of evidence on the AS population, followed by
the approaches and results for the nr-AxSpA population.
Ankylosing spondylitis population
Brief description of the data
Based on study population and follow-up (i.e. around 12 weeks in duration), 16 of the RCTs are
considered directly relevant to the decision problem for the AS population (studies 1–16 in Table 68).
One of these studies did not report BASDAI or BASFI outcomes (study 357) and thus could not be included
in the analyses. The 15 remaining studies reported at least one outcome measure of BASDAI 50 score
and/or change from baseline on BASDAI and BASFI scores.
TABLE 68 Evidence on BASDAI- and BASFI-related outcomes for the AS population
Study
number Trial name Treatments
Number in
treatment
group
Number in
placebo
group
BASDAI
50 score
Change
BASDAI
score
Change
BASFI
score
1 Hu (2012)55 1 26 20 ✗ ✗
2 Huang (2014)56 1 229 115 ✗ ✗ ✗
3 Lambert (2007)57 1 38 44
4 ATLAS (2006)61 1 208 107 ✗ ✗
5 RAPID-axSpA (2014)64 2 121 57 ✗ ✗ ✗
6 Barkham (2010)71 3 20 20 ✗ ✗a ✗a
7 Davis (2003)72 3 138 139 ✗ ✗
8 Dougados (2011)74 3 39 43 ✗ ✗ ✗
9 Gorman (2002)79 3 20 20 ✗
10 Calin (2004)83 3 45 39 ✗ ✗
11 van der Heijde (2006)86 3 305 51 ✗
12 GO-RAISE (2008)90 4 138 78 ✗ ✗
13 Bao (2012)96 4 108 105 ✗ ✗
14 Braun (2002)98 5 34 35 ✗ ✗a ✗a
15 Marzo-Ortega (2005)100 5 28 14 ✗ ✗a
16 Van den Bosch (2002)101 5 9 12 ✗a ✗a
a Do not report any measure of dispersion (such as SDs).
Treatment: 1, adalimumab; 2, certolizumab (certolizumab 200mg and/or certolizumab 400mg); 3, etanercept (etanercept
25mg and/or etanercept 50mg); 4, golimumab 50mg; 5, infliximab. Note that some studies only report one of the BASDAI
measures. For example, the golimumab trials (studies 1290 and 1396) only report BASDAI 50 score and not the absolute
change in this score.
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General aspects of implementation and software
The synthesis was conducted from a Bayesian perspective, using WinBUGS [a Markov chain Monte Carlo
(MCMC) simulation-based software for Bayesian inference]. For burn-in, we ran 100,000 simulations and
another 100,000 were used in inferences. Convergence was assessed by running two chains and
convergence was assumed if the Gelman–Rubin statistic was equal to 1. Goodness of fit was assessed
using the DIC, a criterion developed by Spiegelhalter et al.170 based on the trade-off between the fit of the
data to the model and the complexity of the model. Fit is measured using the deviance, and complexity is
included using a measure of the ‘effective number of parameters’ (i.e. posterior mean deviance minus
deviance evaluated at the posterior mean of the parameters). Models with smaller DIC are better
supported by the data: that is, the lower the DIC, the better the data fit the model. In the presence of
autocorrelation, the MCMC simulation for inference was increased to 200,000 and a thin of 20 was
applied (yielding a sample for inference of 10,000 for each chain).
The main synthesis models (approaches B and C described next) pooled differences between treatment
and control in change in scores from baseline (BASDAI and BASFI). The treatment associated with the
lowest (most negative) mean change score is expected to be best. However, it is important to quantify the
uncertainty around the estimates and for this reason SDs were reported alongside expected values.
When averaged ORs were presented median values instead of means were used, as ORs tend to follow a
skewed distribution.
Relative effectiveness estimates for models assuming exchangeability across treatments are based on the
predictive distribution, representing the distribution of the data averaged over all possible parameter
values. This summary statistic best reflects the impact of uncertainty in the parameters of the model and is
here judged as a more appropriate basis to be used in the decision model.171
When possible, meta-regression analyses were conducted to evaluate potential treatment effect modifiers.
Meta-regression is a tool aimed at examining the impact of variables on effect size using regression-based
techniques. In these explorations, the following baseline characteristics were considered: BASDAI score,
BASFI score, age, sex, duration of symptoms (years) and CRP level.
Exploring assumptions for the relative effectiveness of individual anti-tumour
necrosis factor treatments (modelling approach A)
In AS, pivotal trials for the licensed anti-TNFs do not perform head-to-head comparisons with other agents
but instead compare the effect of treatments against standard care. These trials show anti-TNFs to be
effective in relation to standard care. In view of the available evidence, previous NICE guidance (TA14317
and TA23333) concluded that there was no compelling evidence on which it could reliably distinguish
between the anti-TNFs on the basis of clinical effectiveness when making recommendations.
Our analysis, based on the most up-to-date evidence base, aimed to evaluate anti-TNF drugs using indirect
comparisons across trials. Within this subsection, alternative assumptions of equivalence in the
effectiveness of anti-TNF treatments will be more formally assessed. Note that at this stage each outcome
was synthesised independently.
Brief description of synthesis methods
In brief, the synthesis model directly aggregates relative treatment effects, that is log OR for BASDAI 50
response and the difference between treatment and placebo in change in BASDAI from baseline (the data
set analysed is shown in Appendix 12). In common with the approach implemented in Chapter 3, all
outcomes are here assumed normally distributed. We implemented alternative models that differ in the
way treatment effects are considered; a summary of each is presented below.
Model A1 (treatments: independent; studies: fixed effect): This model considers treatments to be
independent: that is, it assumes the effects to differ between treatments. This is a fixed-effect model in
that multiple studies evaluating the same treatment are considered to measure the same treatment effect.
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Model A2 (treatments: independent; studies: random effects): This model differs from model A1 in that a
random effect is assumed to describe the findings of multiple studies evaluating the same treatment.
Model A3 (treatments: equal; studies: fixed effect): This model differs from model A1 in that treatments
are not assumed to differ. The model thus evaluates a common relative effectiveness for all anti-TNFs.
Model A4 (treatments: equal; studies: random effects): This model differs from model A3 in that a random
effect is assumed to describe the findings of multiple studies evaluating the same treatment.
Model A5 (treatments: exchangeable; studies: fixed effect): This model differs from model A1 in that a
random effect is used to describe any differences between treatments (exchangeability is assumed). This
model thus assumes the treatments to have a similar, but not equal, effectiveness: there are differences
between the effectiveness of treatments that we may not be able to explain but that we should consider.
There is some evidence that health outcomes may depend on patients’ characteristics such as age, BASFI
score, enthesitis, therapy, CRP level and HLA-B27 genotype.172 There is, however, no evidence on which
factors may modify the effects of treatment with anti-TNFs (note that Lord et al. 2010173 studied predictors
of BASDAI 50 response in patients receiving anti-TNFs, but by not including a placebo arm this study was
not able to evaluate treatment effect modifiers). To our knowledge, previous meta-analyses of studies in
AS have not explored how the effect of treatment may depend on characteristics of the patients or of their
disease. Within this modelling approach we explored potential heterogeneity in treatment effects using
meta-regression (i.e. potential treatment effect modifiers). We did so by extending the modelling approach
in A1 to include treatment effect interactions with baseline characteristics (centred on their means where
relevant). We have explored the inclusion of alternative covariates by evaluating the DIC associated with
alternative models.
Results of modelling approach A
All models implemented synthesise results on each of the outcomes separately. The results of each
modelling approach are shown in Table 69.
Models A1 and A2 consider that anti-TNF have distinct relative effects. Applying the assumptions of model
A1, adalimumab is expected to be the least effective of the set of treatments analysed in terms of BASDAI
50 (the expected OR is 4.71), but in terms of the differences in change scores it is certolizumab that is
expected to be the least effective, with differences of –1.45 and –1.10 in BASDAI and BASFI scores,
respectively. It should be noted that studies on golimumab (studies 1290 and 1396 in Table 68) do not
report absolute changes in BASDAI scores, and thus using this modelling approach we were unable to
estimate a treatment effect for this outcome measure. Model A2 reports similar results to model A1, but
the SE of the estimates is slightly higher, reflecting increased uncertainty because of the use of the random
effects to characterise between study results. The DIC is lower in model A1 (52 vs. 57), indicating that
model A1 is preferable to model A2.
Outcome 1 is OR for BASDAI 50; outcome 2 is the difference between treatment and placebo on change
in BASDAI from baseline; and outcome 3 is the difference between treatment and placebo on change in
BASFI from baseline.
Models A3 and A4 consider the treatments as equal in terms of their effectiveness in each of the three
outcomes. This means drugs are assumed equally effective and results from trials are pooled together as if
these trials evaluated the same drug, which will return more precise estimates (i.e. less uncertainty) and
interpretations of this evidence may thus be overly confident. The DIC of these models is substantially
lower than that of models A1 and A2, indicating that the data supports the assumption of equivalence,
rather than one of independence. As with models A1 and A2, the random-effect assumption was also not
deemed worthwhile.
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Model A5 assumes the treatments to have a similar, but not equal, effectiveness; this model introduces
more flexibility than assuming treatment effects to be equal (model A3), but does not fully assume
treatments to differ as in model A1. It does imply that there are differences between the effectiveness
of treatments that we may not be able to explain but that we should consider. These may be a result of
differences between the treatments themselves or because of differences in the design of the trials used
to evaluate each treatment. Ignoring such difference could lead to misrepresenting uncertainty, with
overprecise results. Model A5 shows a slightly higher DIC than model A3 but this difference is not
significant (i.e. lower than 5 units), which means that both models represent equally well the existing data.
Given the underlying assumptions, results differ to those of model A3 particularly in relation to the
measures of uncertainty. As expected, results from model A3 are more precise than the results of model A5.
The results from model A5 in Table 69 relate to the predictive distribution which reflects uncertainty in all
model parameters; in this case, such uncertainty explicitly accounts for the observed differences in the
effects treatments.
TABLE 69 Assumptions over the relative effectiveness of anti-TNF treatments: results
A1. Treatment:
independent;
studies: fixed
effect
A2. Treatment:
independent;
studies: random
effects
A3. Treatment:
common; studies:
fixed effect
A4. Treatment:
common; studies:
random effects
A5. Treatment:
exchangeable;
studies: fixed
effect
Outcome 1: OR
on BASDAI 50 Median (SD) Median (SD) Median (SD) Median (SD) Median (SD)
Adalimumab 4.71 (1.00) 4.69 (6.11) 5.21 (0.72) 5.30 (0.98) 5.34 (9.79)
Certolizumab 6.02 (3.33) 6.04 (22.87)
Etanercept 4.73 (1.43) 4.72 (3.32)
Golimumab 5.86 (1.81) 6.10 (7.45)
Infliximab 11.9 (11.94) 12.10 (44.00)
Outcome 2:
change in
BASDAI Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Adalimumab –1.56 (0.16) –1.57 (0.27) –1.66 (0.11) –1.67 (0.15) –1.70 (0.87)
Certolizumab –1.45 ( 0.37) –1.46 (0.51)
Etanercept –1.76 (0.20) –1.73 (0.28)
Golimumab N/A N/A
Infliximab –2.28 (0.46) –2.27 (–2.28)
Outcome 3:
change in
BASFI Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Adalimumab –1.22 (0.18) –1.18 (0.29) –1.38 (0.11) –1.39 (0.13) –1.41 (0.49)
Certolizumab –1.10 (0.37) –1.11 (0.47)
Etanercept –1.48 (0.19) –1.50 (0.24)
Golimumab –1.45 (0.20) –1.44 (0.29)
Infliximab –2.16 (0.53) –2.17 (0.56)
DIC 52.4 57.0 39.1 44.3 43.6
N/A, not applicable.
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Despite our preferred summary from model A5 in this evaluation being the common effect for the ‘class of
drugs’ (see Table 69), the assumption of treatment effects being drug specific may still retain some plausibility.
From model A5, drug-specific estimates can be retrieved (Table 70). Within this model drug-specific inferences
will borrow strength from the common-class effect and estimates are thus shrunken towards the mean of
this class effect (that is estimates are closer to the value reported for the class in Table 2).
Explorations of heterogeneity suggested only sex to potentially modify the effect of anti-TNF treatment,
specifically for change in BASDAI as outcome; however, when sex is used together with all covariates,
such evidence on effect modification disappears.
Interpretation/discussion
The models implemented above show that there is no significant heterogeneity across trials evaluating
each treatment, that is the DIC of model A2 is higher than that of model A1, indicating the use of a
random effect across studies to be unnecessary.
The statistical analysis has also shown the effectiveness of the different treatments to be similar. This is in
line with the published evidence, in AS, that does not demonstrate one anti-TNF treatment to be
significantly more effective than another. Specifically, we implemented a model considering a common
effect for all anti-TNFs when compared with placebo (model A3). This model shows a better fit than the
one estimating a different effect for each anti-TNF (model A1). However, unless we believe this assumption
to hold AND the trials to be homogeneous in design and in the populations included, we believe adopting
model A3 would misrepresent uncertainty in the estimates.
For this reason, we evaluated an alternative model (model A5) that assumes treatments to have a similar
(but not equal) effect. In this model, the treatment effects for the anti-TNFs are assumed to come from
a ‘common’ distribution, assumed Normal with a common mean, that is a ‘class effect’. This is an
assumption of exchangeability across treatments within the class, which we also refer to as a random-effect
distribution. The DIC for this model is not significantly different from that of model A3, and it allows a more
appropriate description of the uncertainty over the effects of anti-TNFs. However, it should be noted that
this model is not explicit about the source of the differences in the effects of treatments.
The evidence available does not appear to suggest obvious treatment effect modifiers. However, because
only aggregate data were available, the results may be prone to ecological fallacy in which statistical
associations between variables present or absent at the group level may not be reflective of associations at
the individual level.174
TABLE 70 Shrunken estimates of treatment effect from model A5
Treatment
Model A5
Outcome 1: OR on
BASDAI 50 (median, SD)
Outcome 2: change in
BASDAI (mean, SD)
Outcome 3: change in
BASFI (mean, SD)
Adalimumab 5.05 (0.87) –1.60 (0.15) –1.31 (0.16)
Certolizumab 5.42 (1.71) –1.59 (0.26) –1.31 (0.23)
Etanercept 5.13 (1.08) –1.72 (0.17) –1.43 (0.15)
Golimumab 5.47 (1.25) –1.69 (0.84) –1.42 (0.16)
Infliximab 5.70 (3.30) –1.88 (0.34) –1.55 (0.33)
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Extending the modelling approach to jointly relate outcomes
(modelling approach B)
In the previous chapter the two outcomes based on BASDAI scores were synthesised separately; however,
BASDAI 50 is the probability of having a reduction in BASDAI score of 50%, and thus it should be possible to
relate the proportion of BASDAI 50 responders to the change in absolute BASDAI scores from baseline
observed in each study. Such structural constraints should be incorporated into the synthesis, when possible,
by expressing it algebraically.174 Within this chapter, we use this structural relation within the synthesis,
allowing change scores from baseline to be informed not only from direct data on this quantity but also from
data on BASDAI 50 (Joint synthesis of Bath Ankylosing Spondylitis Disease Activity Index outcomes). We then
extend the modelling framework further to consider BASFI outcomes [(Extending the modelling framework to
synthesise change in Bath Ankylosing Spondylitis Functional Index scores (modelling approach C)].
Joint synthesis of Bath Ankylosing Spondylitis Disease Activity
Index outcomes
The model implemented here pools the change in BASDAI score from baseline to evaluate the difference
between treatment and placebo, using evidence reported in trials directly on the change scores for each
arm and also data on BASDAI 50.
The following description briefly explains the approach used to model these data.
Brief description of synthesis methods
Data on the mean change in BASDAI score from baseline, alongside the SE for this measure, were assumed
normally distributed (likelihood). The mean of this distribution was the treatment effect, defined as the sum
of the change score for the placebo arm plus the difference in change score for the treatments. Some studies
also reported the number of responders to BASDAI 50 (a 50% reduction in BASDAI score), out of the total
individuals in the study. The likelihood for the BASDAI 50 data was expressed as a binomial distribution.
The probability parameter of this distribution was then related to the change score as follows. The BASDAI
score at baseline and the change score were assumed correlated using a bivariate normal distribution. To
define the bivariate distribution a number of quantities were needed. First, the mean score at baseline was
reported in the data and was thus assumed known. Second, the variability on BASDAI score at baseline was
assumed equal to that of the change score. This was also reported in the data and was thus assumed known.
Finally, the unknown correlation between baseline and change score was estimated within the model by
assuming this quantity was independent of study. The correlation parameter was estimated separately for
placebo and anti-TNF treatment. Under these assumptions, the probability parameter from BASDAI 50 data
was expressed algebraically as a function of the change score. For treatment effects, our preferred approach
was to assume a common class effect (i.e. exchangeable effects across treatments, analogous assumption to
model A5). See Appendix 12 for a fuller description of the methods used in analyses.
Results of modelling approach B
The summary results regarding relative treatment effects from this modelling approach are reported in
Table 71 for model B. The treatment effect reported here represents difference between treatment and
placebo on BASDAI score changes from baseline.
TABLE 71 Modelling approach B: results
Treatment
Estimated Assumeda Predicted
Difference in
change score from
baseline, mean (SD)
Probability of having
a BASDAI 50 response,
placebo, mean (SD)
Probability of having
a BASDAI 50 response,
anti-TNF, mean (SD)
OR for BASDAI 50
response, anti-TNF vs.
placebo, median (SD)
Anti-TNFs –1.91 (0.48) 0.10 (–) 0.40 (0.08) 5.94 (4.06)
a This figure is based on a BASDAI baseline score of 6.11 (SD 1.56) and a placebo change score of –0.61 (SD 1.44), which
represent the average across trials (weighted by number of patients)
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With model B, we were now able to consider the evidence from trials only reporting information on
BASDAI 50 to estimate the change in BASDAI score, an example being evidence on golimumab. The class
effect of anti-TNFs is evaluated to be slightly higher –1.91 (SD 0.48) in comparison to model A5 [reporting
a class effect on the change score of –1.70 (SD 0.87)], reflecting the inclusion of BASDAI 50 evidence. By
using the indirect evidence on BASDAI 50, model B returns more precise estimates of the pooled change
score than model A5 (SE of 0.48 in model B compared with 0.87 in model A5). This modelling approach,
despite pooling absolute change scores, can be used to evaluate BASDAI 50 response for a specific
baseline BASDAI score and change score in the placebo arm. We assumed a baseline BASDAI score of 6.11
(SD 1.56) and a change score for placebo of 0.61 (SD 1.44), which represent the average across trials
(weighted by number of patients). According to these, the assumed probability of having a BASDAI 50
response to placebo is evaluated at 0.10. Based on the change score evaluated in the synthesis model, the
probability of having a BASDAI 50 response when on anti-TNFs is evaluated at 0.40 (SD 0.08), which
results in an OR for BASDAI 50 response of 5.94 (SD 4.06).
Drug-specific (shrunken) estimates from model B are shown in Table 72.
Interpretation/discussion
The current modelling approach, by synthesising together evidence on both BASDAI outcomes, is a
theoretically coherent approach to the synthesis. Moreover, it allows using the whole of the evidence on
this outcome. In addition, given these outcomes are to be both used in the decision model, the combined
synthesis model will generate consistent estimates by considering their structural relation explicitly.
The results of modelling approach B show that using information on BASDAI 50 alongside direct evidence
on change scores from baseline results in slightly higher estimates of effectiveness compared with
approach A. There are two possible explanations for this. One is that higher treatment effects are observed
in the trials only reporting BASDAI 50 compared with the remaining studies. The few studies that only
report BASDAI 50 are studies 11,86 1290 and 13;96 these report ORs for BASDAI of, respectively, 5.9, 4.4
and 10.42. The second possible explanation relates to the assumptions used when defining the relation
between the outcomes in the model. While we expected the model to use the BASDAI 50 evidence in
such a way that would exactly predict the value of change score observed in the sample, we cannot
guarantee this is the case as our analysis is based on assumptions over the distribution of BASDAI scores
across patients. Given we did not have access to individual patient data when developing this relationship,
and thus the validity of the assumptions of analysis cannot be established. The differences observed are,
however, not significant and any misspecification of the model can be thus deemed irrelevant.
Extending the modelling framework to synthesise change in Bath
Ankylosing Spondylitis Functional Index scores (modelling approach C)
The models implemented here extend those in Joint synthesis of Bath Ankylosing Spondylitis Disease
Activity Index outcomes by adding the syntheses of changes in BASFI score. This is of particular relevance
to the economic modelling because BASFI scores are used together with BASDAI scores. Given we expect
that, within each trial, changes to BASDAI scores to be related to changes in BASFI scores, this section will
model the trial evidence to reflect this correlation. Figure 14 plots the BASDAI change scores against the
BASFI change scores observed in the trials, showing support for the existence of correlation.
TABLE 72 Shrunken estimates of treatment effect from model B
Treatment Change in BASDAI, mean (SD)
Adalimumab –1.77 (0.25)
Certolizumab –2.01 (0.37)
Etanercept –1.88 (0.18)
Golimumab –1.92 (0.30)
Infliximab –2.02 (0.32)
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Brief description of synthesis methods
The data on mean change in BASFI score reported in some of the studies was assumed normally
distributed. The mean of this distribution was the treatment effect, defined as the sum of the change score
for the placebo arm plus the difference in change score for the treatments (analogous to BASDAI).
Treatment effects on BASFI were considered correlated to those on BASDAI across trials. The variation
in treatment effects for both BASDAI and BASFI, and the correlation parameter between these were
estimated from the data. As in Joint synthesis of Bath Ankylosing Spondylitis Disease Activity Index
outcomes, we assumed again exchangeability across the effects of the different treatments (analogous to
models ‘5’ in modelling approach A).
Results of modelling approach C
The results on differences between treatment and placebo on change score form baseline are reported in
Table 73, for both BASDAI and BASFI scores.
Based on the change score evaluated in the synthesis model, the probability of having a BASDAI 50
response when on anti-TNFs is evaluated at 0.41 (SD 0.05), which returns an OR for BASDAI 50 response
of 6.3 (SD 1.56). Note that estimates on BASDAI treatment effects are more precise than in modelling
approach B, reflecting the support to inferences from the data on BASFI; the correlation between
outcomes observed in the data and allowed in the synthesis model allows inferences in BASDAI to borrow
strength from those on BASFI. Drug-specific (shrunken) estimates from model C are shown in Table 74.
TABLE 73 Modelling approach C: results
Outcome
Estimated Assumeda Predicted
Difference in change
score from baseline,
mean (SD)
Probability of having
a BASDAI 50 response,
placebo, mean (SD)
Probability of having
a BASDAI 50 response,
anti-TNF, mean (SD)
OR for BASDAI 50
response, anti-TNF vs.
placebo, median (SD)
Effect of anti-TNFs
on BASDAI
–1.95 (0.30) 0.10 (–) 0.41 (0.05) 6.30 (1.56)
Effect of anti-TNFs
on BASFI
–1.40 (0.28) – – –
a Based on a BASDAI baseline score of 6.11 (SD 1.56) and a placebo change score of –0.61 (SD .44), which represent the
average across trials (weighted by number of patients).
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FIGURE 14 Scatterplot of BASDAI and BASFI change scores observed in the trials (AS).
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Interpretation/discussion
We hypothesised that treatments improving AS symptoms are expected to affect both disease activity and
function, and therefore we expected changes to these two measures to be correlated. We have thus
extended the synthesis model to consider BASFI scores. This not only allows all relevant evidence to
contribute to the synthesis but also ensures that all measures are synthesised together to reflect the
expected correlations between the two outcomes.
The results obtained with this modelling approach for BASDAI outcomes are similar to those of modelling
approach B, the difference being that estimates are now more precise because of the borrowing of
strength between outcomes.
Non-radiographic axial spondyloarthritis population
This section examines the evidence on the effectiveness of anti-TNFs on the nr-AxSpA population.
Brief description of the data
On the nr-AxSpA population, five RCTs were considered directly relevant to the decision problem
(studies 17–2150,51,58,64,76 in Table 75). All studies reported BASDAI and BASFI outcomes and one study did
not report BASDAI 50 (study 2150).
TABLE 74 Shrunken estimates of treatment effect from model C
Treatment Change in BASDAI, mean (SD) Change in BASFI, mean (SD)
Adalimumab –1.89 (0.22) –1.34 (0.17)
Certolizumab –2.02 (0.28) –1.36 (0.21)
Etanercept –1.94 (0.18) –1.43 (0.16)
Golimumab –1.98 (0.25) –1.42 (0.17)
Infliximab –2.03 (0.27) –1.49 (0.25)
TABLE 75 Evidence on BASDAI and BASFI-related outcomes for the nr-AxSpA population
Study
number Trial name Treatments
Number in
treatment
group
Number in
placebo
group
BASDAI
50 score
Change
BASDAI
score
Change
BASFI
score
17 Haibel 200852 Adalimumab 22 24 ✗ ✗ ✗
18 ABILITY-1 201358 Adalimumab 69 73 ✗ ✗ ✗
19 RAPID-axSpA
201464
Certolizumab
pegol
46+ 51 50 ✗ ✗ ✗
20 Dougados 201476 Etanercept
50
106 109 ✗ ✗ ✗
21 Barkham 200950 Infliximab 20 20 ✗ ✗
✗ denotes whether or not each outcome is measured in each of the studies.
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Description of approaches to the synthesis
To synthesise these data we used the same implementation and software specifications as described in
Chapter 5, Ankylosing spondylitis population. Analyses explored two different scenarios to consider these data:
l scenario 1 – data from nr-AxSpA trials were considered in isolation
l scenario 2 – data from AS population were also used, no difference between the populations
was assumed.
All models implemented here jointly synthesise BASDAI and BASFI outcomes [for our preferred modelling
approach, C, see description in Extending the modelling framework to synthesise change in Bath
Ankylosing Spondylitis Functional Index scores (modelling approach C)].
Results of the synthesis
In what concerns scenario 1, in which only data from the nr-AxSpA trials has been considered, we
implemented two models: one assuming an equal effect across treatments and another assuming
exchangeable treatment effects. Both models represented the data equally well (DIC of 87.6 vs. 88.7),
and thus we only present results in Table 76 for the latter model [the preferred model; see Exploring
assumptions for the relative effectiveness of individual anti-tumour necrosis factor treatments (modelling
approach A)]. Results are qualitatively similar to those in AS but slightly lower estimates for both change
scores: BASDAI –1.95 in AS and –1.86 in the nr-AxSpA population; and BASFI –1.40 in AS and –1.30 in
the nr-AxSpA population. The uncertainty over these estimates is higher in the nr-AxSpA population,
which was expected as the number of trials (and overall number of patients in the set of trials) is
substantially lower.
When the data from the nr-AxSpA trials were considered together with data on AS (scenario 2), inferences
were more precise. As treatment effects in AS trials are not significantly different from those observed in the
nr-AxSpA population, pooled treatment effect estimates do not differ significantly from those reported in AS.
TABLE 76 Nr-axSpA population: results
Estimated Assumeda Predicted
Difference in
change score
from baseline,
mean (SD)
Probability of
having a
BASDAI 50
response,
placebo, mean
(SD)
Probability of
having a BASDAI
50 response,
anti-TNF, mean
(SD)
OR for BASDAI
50 response,
anti-TNF versus
placebo, median
(SD)
Scenario 1: data from nr-AxSpA trials
Effect of anti-TNFs on BASDAI –1.86 (0.79) 0.20 (–) 0.53 (0.13) 4.39 (6.59)
Effect of anti-TNFs on BASFI –1.30 (0.84) – – –
Scenario 2: data from AS and nr-AxSpA trials, no difference between the populations
Effect of anti-TNFs on BASDAI –1.97 (0.32) 0.20 (–) 0.55 (0.06) 4.94 (1.48)
Effect of anti-TNFs on BASFI –1.37 (0.3) – – –
a Based on a BASDAI baseline score of (AiC information has been removed) and a placebo change score of (AiC
information has been removed), which represent the results seen in the certolizumab trial (RAPID-axSpA64).
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Interpretation/discussion
The evidence base of the effect of anti-TNFs in the nr-AxSpA population consists of five trials that observed
four treatments and CC in a total of 590 patients. The effect measures pooled across the five trials were
not significantly different from the outcomes expected in the AS population. Thus, it may be reasonable to
consider the evidence in nr-AxSpA and AS together for inferences over treatment effects.
Bath Ankylosing Spondylitis Disease Activity Index and Bath
Ankylosing Spondylitis Functional Index scores conditional on
Bath Ankylosing Spondylitis Disease Activity Index response
We previously highlighted that NICE guidance determines that BASDAI 50 at 12 weeks defines treatment
continuation with anti-TNFs in clinical practice. Given much of the evidence on prognosis, costs and utility
scores links to the absolute values of BASDAI and BASFI scores, it is important to consider absolute
changes in BASDAI and BASFI separately for responders and non-responders, that is the conditional scores.
However, the published clinical effectiveness evidence does not report the conditional scores. In this
section we use the results from the extended synthesis model to evaluate the conditional scores by
simulating BASDAI and BASFI scores for two equivalent cohorts of patients, one treated with an anti-TNF
and the other with conventional therapy.
Brief description of methods
From the inferences obtained using the synthesis model above, it is possible to derive the conditional
change score in responders and non-responders using simulation. While the synthesis focuses on the
pooling of mean estimates of change scores and proportion of responders to BASDAI 50, to derive
conditional mean scores there is the need to consider the distributions at the individual patient level.
Hence, conditional scores could not directly be derived from the synthesis, but through a simulation
procedure based on the assumptions and results of the synthesis model. The simulation procedure is
described in detail in Appendix 5. Briefly, we used a simulation sample size of 10,000 patients. Given
results depend on the baseline distributions of BASDAI and BASFI scores and on the change scores from
baseline for placebo, we used the averages across trials (weighted by the number of patients in each trial)
in AS. Baseline BASDAI scores were thus assumed normally distributed with mean 6.11 and SD 1.56; the
change from baseline for placebo was simulated from a normal distribution with mean –0.61 and SD 1.44.
For BASFI, the baseline was assumed to have a mean of 5.27 and a SD 1.79 and the change from baseline
for placebo a mean of –0.19 and a SD 0.22. The correlation between baseline BASFI and BASDAI scores
was valued at (AiC information has been removed). This value was based on the sample correlation on
BASDAI and BASFI at baseline from etanercept studies [the individual patient data were available in
the Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA) file for the etanercept submission]; the
Spearman’s rank correlation coefficient was (AiC information has been removed) in 314-EU study167 in AS
and (AiC information has been removed) in 1031 study166 in nr-AxSpA.
Results for ankylosing spondylitis
The conditional change scores derived from the synthesis model (and underlying assumptions) are reported
in Table 77. While it is natural to consider that conditional change in BASDAI scores differ between
respondents and non-respondents, differences in the baseline of respondents and non-respondents may
be less intuitive. These are, however, natural. If we consider two patients that obtained the same change
score in BASDAI from anti-TNF treatment, for example –2 units, but one started with a baseline of 4 and
another with a baseline of 5, the first would be considered a responder and the second would not. For this
reason, respondents are expected to have a lower BASDAI than non-responders. Results of the prediction
of conditional scores using the synthesis model are presented in Table 77.
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Results show, as expected, that the change in BASDAI score for respondents is more negative than the
mean change score (–3.86 for the 42% predicted anti-TNF responders vs. –2.63 for all anti-TNF users; in
the control arm, responders were predicted to have a change score of –2.70 vs. –0.66 for all participants).
Non-respondents were still expected to have a negative change score in both arms revealing some level of
symptom control but this was lower than the mean (–1.73 vs. –2.63 for anti-TNF users and –0.45 vs. –0.66
in control arm). The baseline BASDAI and BASFI were predicted to be lower for respondents than
non-respondents (e.g. the BASDAI baseline for responders to treatment was 4.76 in respondents when the
group baseline was 6.08).
We requested the conditional data from the pivotal trials in AS from each manufacturer. These data were
subsequently provided by all manufacturers for their pivotal trials. Conditional scores observed in the trials
are summarised in Table 78. The results show that there are some differences between the conditional
results predicted using the synthesis and the ones observed in trials. Differences are especially relevant for
the conditional baseline scores; although the synthesis model predicts, for example, that treated patients
that respond have a baseline BASDAI score of 4.76 and those that do not respond have a baseline score
of 7.03, the trials show much smaller differences. Despite incorporating all evidence available at the
aggregate level, the predictive ability of the conditional baseline score from the synthesis could only be
improved if we had access to the individual patient data, as this methodology is strongly dependent on
assumptions over the distribution of scores across patients.
TABLE 77 Conditional scores predicted for the AS population using the synthesis model
BASDAI BASFI
Control Treatment Control Treatment
Base case
% responders to BASDAI 50 0.09 0.42
Change in score
Responders –2.89 –3.86 –1.72 –3.08
Non-responders –0.36 –1.64 –0.04 –0.44
All –0.59 –2.57 –0.19 –1.55
Baseline
Responders 4.01 4.80 3.52 4.20
Non-responders 6.33 7.08 5.46 6.07
All 6.12 6.12 5.28 5.28
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TABLE 78 Conditional scores observed in trials in AS
BASDAI BASFI
Control Treatment Control Treatment
ATLAS61 trial (adalimumab, studies = 4)
% responders to BASDAI 50 0.16 0.46
Change in score
Conditional on response –4.5 –4.64 –2.74 –2.92
Conditional on non-response –0.2 –0.82 –0.17 –0.72
Total –0.90 –2.58 –0.59 –1.73
Baseline
Conditional on response 6.31 6.14 4.50 4.53
Conditional on non-response 6.37 6.35 5.91 5.78
Total 6.36 6.25 5.68 5.21
GO-RAISE90 (golimumab, studies = 12)
% responders to BASDAI 50 0.15 0.46
Change in score
Conditional on response –4.25 –4.74 –1.80 –3.03
Conditional on non-response –0.18 –1.22 0.38 –0.53
Total –0.81 –2.84 0.05 –1.68
Baseline
Conditional on response 6.52 6.25 3.56 4.45
Conditional on non-response 6.63 6.69 5.39 5.48
Total 6.61 6.49 5.11 5.01
RAPID-axSpA64 (certolizumab, studies = 5)
% responders to BASDAI 50 CiC information
has been removed
CiC information
has been removed
Change in score
Conditional on response CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Conditional on non-response CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Total CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Baseline
Conditional on response CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Conditional on non-response CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Total CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
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Results for non-radiographic axial spondyloarthritis
The conditional results were also predicted for the nr-AxSpA population using both scenarios implemented
of the synthesis model.
For this population, conditional data were provided by only two manufacturers (Pfizer and AbbVie).
Conditional scores observed are summarised in Tables 79 and 80.
Prediction results are consistent with those in AS, and the differences between the conditional results
predicted using the synthesis and the ones observed in trials are also present in this analysis.
Interpretation/discussion
Conditional scores predicted using synthesis model C differ from those seen in the trials. Differences are
probably because of distributional assumptions over the baseline and change scores. Only with access to
the individual patient data could such predictions be improved. Note that the synthesis model itself does
not rely as heavily on such assumptions, and thus any concerns should not be transposed to the results
obtained in Ankylosing spondylitis population and Non-radiographic axial spondyloarthritis population.
TABLE 78 Conditional scores observed in trials in AS (continued )
BASDAI BASFI
Control Treatment Control Treatment
314-EU study167 (etanercept, studies = 11)a
% responders to BASDAI 50 CiC information
has been removed
CiC information
has been removed
Change in score
Conditional on response CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Conditional on non-response CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Total CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Baseline
Conditional on response CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Conditional on non-response CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Total CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
a Pooled results for etanercept arms (etanercept 25mg twice weekly and etanercept 50mg once weekly).
For the trials of adalimumab and etanercept were week 12 responders, for golimumab they were week 14 responders
(week-12 data for week-14 responders is available but not reported in the table).
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TABLE 79 Conditional scores predicted for the nr-AxSpA population using results and assumptions of the
synthesis modela
BASDAI BASFI
Control Treatment Control Treatment
Scenario 1
% responders to BASDAI 50 AiC information
has been removed
AiC information
has been removed
Change in score AiC information
has been removed
AiC information
has been removed
Responders AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
Non-responders AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
All AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
Baseline AiC information
has been removed
AiC information
has been removed
Responders AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
Non-responders AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
All AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
Scenario 2
% responders to BASDAI 50 AiC information
has been removed
AiC information
has been removed
Change in score AiC information
has been removed
AiC information
has been removed
Responders AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
Non-responders AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
All AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
Baseline AiC information
has been removed
AiC information
has been removed
Responders AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
Non-responders AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
All AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
AiC information
has been removed
a Based on a BASDAI baseline score of (AiC information has been removed) a placebo change in BASDAI score of (AiC
information has been removed), a BASFI baseline score of (AiC information has been removed) and a placebo change in
BASFI score of (AiC information has been removed), which represent the results seen in the certolizumab trial
(RAPID-axSpA64).
INDEPENDENT ECONOMIC ASSESSMENT: EXTENDED SYNTHESIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
126
TABLE 80 Conditional scores observed in trials in nr-AxSpA
BASDAI BASFI
Control Treatment Control Treatment
ABILITY-158 trial (adalimumab, studies = 18)
% responders to BASDAI 50 0.14 0.40
Change in score
Conditional on response –3.9 –4.79 –2.78 –2.75
Conditional on non-response –0.69 –0.55 –0.40 –0.32
Total –1.16 –2.23 –0.75 –1.29
Baseline
Conditional on response 5.64 6.21 4.37 3.60
Conditional on non-response 6.46 6.53 4.91 4.97
Total 6.34 6.40 4.83 4.43
RAPID-axSpA64 (certolizumab, study = 19)
% responders to BASDAI 50 CiC information
has been removed
CiC information
has been removed
Change in score
Conditional on response CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Conditional on non-response CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Total CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Baseline
Conditional on response CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Conditional on non-response CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Total CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
EU-1031166 (etanercept, studies = 20)
% responders to BASDAI 50 CiC information
has been removed
CiC information
has been removed
Change in score
Conditional on response CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Conditional on non-response CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Total CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
continued
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Discussion/conclusion
The analyses developed in this section focused on extending the synthesis evidence on the short-term
clinical effectiveness of anti-TNF drugs in Chapter 3 that considered individually multiple outcomes of
interest reported in the trials, namely the mean change in BASDAI scores at 12 weeks, the proportion
of BASDAI 50 responders (i.e. those who had, at 12 weeks, a change in the baseline BASDAI score of
50% or more) and the mean change in BASFI scores at 12 weeks.
Initially, within such a univariate framework, we further explored assumptions over the relative
effectiveness of anti-TNFs. We evaluated the possibility of the evidence suggesting treatment effects to
be independent, equal or similar effects (treatment effects were assumed to come from a ‘common’
distribution, i.e. a ‘class effect’). Independence was ruled out through statistical checks of goodness of fit;
this is in line with the published evidence, in AS, that does not demonstrate one anti-TNF treatment to be
significantly more effective than another. The data were as well represented by the other two models.
However, unless we believe the equality assumption to hold AND the trials to be homogeneous in design
and in the populations included, assuming equality in treatment effects will provide overprecise estimates.
For this reason, our preferred assumption was that of similarity; however, it should be noted that this
model is not explicit about the source of the differences in the effects of treatments. Whereas
heterogeneity may be a plausible explanation, further research needs to examine data at the individual
patient level to avoid the potential for ecological bias.
We also extended the synthesis in a way that allowed multiple outcomes to be jointly modelled. We did so
by (1) structurally relating the BASDAI-based outcomes, allowing for trials reporting BASDAI 50 to inform
BASDAI change scores, and (2) by concomitantly synthesising BASFI outcomes, allowing correlation
between outcomes and the borrowing of strength between results to BASDAI and BASFI. For these
reasons, the synthesis model developed here more directly addresses the decision problem. It also
generates appropriate effect-size estimates and their associated uncertainty to inform the main input
parameters of the economic model.
In the decision model, treatment continuation is determined by response to BASDAI 50 at 12 weeks.
Given that prognosis, costs and QALYs are determined by absolute BASDAI and BASFI scores, it is
important to evaluate the absolute change in BASDAI and BASFI separately for responders and
non-responders: that is, the conditional scores. We used the results from the extended synthesis model
to develop a simulation model that allowed prediction of the conditional scores. The results obtained
differ from those seen in three pivotal trials (data provided by the manufacturers on request), probably
because of distributional assumptions over the baseline and change scores. Only with access to the
individual-patient data such predictions could be improved.
TABLE 80 Conditional scores observed in trials in nr-AxSpA (continued )
BASDAI BASFI
Control Treatment Control Treatment
Baseline
Conditional on response CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Conditional on non-response CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Total CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Etanercept and adalimumab studies included week-12 responders. Pfizer reported results only for etanercept 50mg.
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Chapter 6 Independent economic assessment:
York model
Overview
Chapter 4 indicates that there are significant conceptual concerns and uncertainties arising from previously
published studies and the submissions made by manufacturers. For this reason, it has been necessary to
develop a de novo model (hereafter referred to as the ‘York model’). Although it shares some of the
assumptions and parameter estimates from the manufacturer models, it has a different conceptual
structure and applies a more generalised framework for the synthesis of data from the double-blind
periods of existing RCTs, combined with a more explicit approach to modelling the progressive nature of
AS and nr-AxSpA and the potential impact of the anti-TNFs.
The aim of the York model is to assess the cost-effectiveness of adalimumab, certolizumab, etanercept,
golimumab and infliximab, in accordance with their respective licences, for the treatment of AS and
nr-AxSpA. The model uses short-term trial data, based on the extended evidence synthesis, to model the
response of patients to TNF-α inhibitor therapy at 12 weeks based on BASDAI 50 measured in the trials.
In contrast to the models submitted by the manufacturers, the York model is based on an assumption of
similar (but not identical) effects for the alternative biologics based on the results of the extended synthesis
reported in Chapter 5.
In common with all existing cost-effectiveness studies, measures of disease activity (BASDAI) and
functioning (BASFI) are used to characterise the chronic, progressive nature of AS and nr-AxSpA and the
effect of anti-TNFs. However, the York model uses an alternative conceptual model applied to estimate
longer-term BASFI scores. The effect of response to TNF-α therapy is modelled in terms of the short- and
longer-term impact on BASDAI and BASFI scores.
The NHS and PSS costs are based on the cost of the TNF-α therapies (acquisition, administration and
monitoring) and disease costs linked to BASFI scores. HRQoL, in terms of utility, is based on both BASDAI
and BASFI scores. Health effects are subsequently expressed in terms of QALYs. Both costs and QALYs are
discounted at 3.5% per annum. Costs are presented based on current prices.
The model is developed in accordance with the NICE reference case. The model has a lifetime horizon
(60 years) and considers costs from the perspective of the NHS and PSS.
Contribution of the York model
Although the York model shares some of the assumptions and parameters from existing studies and
manufacturer’s submissions, it also provides a number of significant developments to existing cost-effectiveness
analyses. First, the short-term clinical effectiveness inputs are based on an evidence-synthesis approach which
is based on all available trial data for each biological therapy and which jointly synthesises ‘related’
parameters ensuring uncertainty is more appropriately characterised. Second, the evidence-synthesis
approach is more explicitly linked to the decision problem and the requirements of the economic model,
that is the model requires estimates of response and the impact on BASDAI/BASFI conditional upon this.
As the conditional response scores are not conventionally reported in existing publications, existing models
have largely been based on selective approaches (i.e. using conditional scores from single studies or
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assumptions) or appear to have ignored the conditional scores entirely and instead use estimates from
longer-term follow-up and/or open-label sources (i.e. implicitly assuming that patients who continue to
participate in longer-term follow-up and open-label sources are more likely to be responders than patients
who do not). Neither approach appears satisfactory in terms of meeting the requirements of the economic
model and ensuring that all relevant evidence is considered. The evidence synthesis approach which
underpins the York model is based on a joint synthesis of related parameters which makes fuller use of
existing evidence and which can more appropriately estimate the input parameters which are required to
populate existing models and better characterise the uncertainty surrounding these.
Another important development of the York model is the approach to modelling longer-term BASFI
changes over time to characterise the progressive nature of AS and nr-AxSpA. In previous sections we
highlighted our concerns over how this has been previously modelled and the implicit assumptions
underlying the effect of anti-TNFs (i.e. potential disease modification properties resulting in halting further
‘progression’, or reducing the rate of progression, while patients respond and continue to receive
anti-TNFs). Within the York model, we attempt to model the impact of different processes on BASFI over
time, relating the changes more explicitly to the existing clinical effectiveness data for anti-TNFs on these
different processes. Specifically, we consider the independent effects on BASFI because of disease activity
(BASDAI) and the extent and progression of radiographic disease (as measured by the mSASSS) for AS.
For the nr-AxSpA population, we assume a similar underlying clinical process relating to BASFI.
This approach confers several advantages over current approaches by linking changes in BASFI to a more
explicit clinical/biological process and facilitating a more formal consideration of the potential impact of
anti-TNFs on BASFI, via the specific effects these drugs have on the different processes which
independently relate to this parameter. This approach allows consideration of the impact on BASFI that
might be achieved via symptomatic improvements (i.e. in terms of reductions in disease activity) and those
which might be conferred by disease modification properties (i.e. the effect on the likelihood and/or rate of
further radiographic progression). The latter aspect is particularly important given the increasing amount
of published evidence reported on the potential impact of anti-TNFs on radiographic progression which has
not been formally considered or incorporated within existing cost-effectiveness studies.
Comparators
Table 81 summarises the comparators included in each of the populations, in line with the relevant existing
(or likely to be granted by the time of the NICE appraisal) marketing authorisations for each manufacturer.
TABLE 81 Comparators evaluated in the different indications
Comparator Manufacturer AS nr-AxSpA
CC – Yes Yes
Adalimumab AbbVie Yes Yes
Certolizumab UCB Yes Yes
Etanercept Pfizer Yes Yes
Golimumab Merck Sharp & Dohme Yes No
Infliximab Merck Sharp & Dohme Yes No
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Model structure
The York model is a cohort model and takes the form of a modified decision tree for AS and nr-AxSpA.
A simplified version of the structure is shown in Figure 15. A similar structure has been previously been
used to evaluate the cost-effectiveness of anti-TNFs in psoriatic arthritis.175
For the alternative TNF-α inihibitors, initial response is determined on the basis of a short-term BASDAI
50 response (12 weeks). For those who respond, there is then an ongoing risk of withdrawal of treatment
at any time point in the model. Initial or later treatment failures are assumed to move on to CC. The use of
BASDAI 50 is consistent with existing BSR guidelines and previous NICE appraisals for AS.17,33,169 Ensuring
consistency in the response measure between the various appraisals provides a more comparable basis for
exploring any subsequent differences in results. In addition, using BASDAI 50 as a response measure
for the economic model maximises the evidence base used to inform the various clinical-effectiveness
parameters required and, as outlined in Chapter 5, uses the same clinical constructs to inform response
and subsequent BASDAI score changes.
Those patients who receive anti-TNFs will experience an initial improvement which is based on results of
the evidence synthesis (average of mean change in BASDAI and BASFI scores estimated for responders and
non-responders). From week 12, patients who continue to receive anti-TNFs are assigned the conditional
mean change in BASDAI and BASFI scores estimated from the evidence synthesis which is assumed to
remain constant for the treatment duration period. In addition to this initial improvement in BASDAI and
BASFI, patients continuing on anti-TNFs treatment are also assumed to experience a slower progression
rate in BASFI as long as they are responding (see Longer-term discontinuation).
Anti-TNF therapy
CC
No treatment failure
CC
CC
CC
CC
Treatment failure (t3)
Treatment failure (t2)
Treatment failure (t1)
No treatment response at 12 weeks
Treatment response
at 12 weeks
FIGURE 15 A simplified schematic of the York model structure.
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Patients who fail on TNF-α inhibitor therapy after the initial (12-week) period will experience some form of
rebound in terms of BASDAI/BASFI score, but the trial data are too short term to be able to characterise
this accurately. The model, therefore, considers two rebound scenarios:
1. Rebound equal to gain (BASDAI and BASFI). When patients fail therapy (after initially responding), their
BASDAI and BASFI deteriorates by the same amount by which it improves when they responded
to therapy.
2. Rebound back to natural history/CC (BASFI only). When patients fail therapy (after initially responding),
their BASFI deteriorates to the level and subsequent trajectory it would have been had they not initially
responded to therapy. As BASDAI is not assumed to progress over time on CC, the same assumptions
are applied to BASDAI in both scenarios.
Given the absence of evidence on rebound, both scenarios (rebound equal to gain and rebound back to
natural history) are presented as the ‘best-case’ and ‘worst-case’ scenarios possible. In other words, the
reality regarding rebound is likely to be somewhere between these two scenarios which should, therefore,
be seen as the limits.
Importantly, the York model explores the impact of assuming different baseline BASDAI and BASFI scores
for responders and non-responders. Hence, in contrast to existing models, the York model assumes that
response is unlikely to be independent of baseline patient characteristics and hence the baseline
characteristics of responders/non-responders to anti-TNFs may be systematically different from each other.
Importantly, the results from the extended synthesis model estimated higher baseline BASDAI and BASFI
scores for non-responders vis-à-vis responders and a similar relationship was also reported by those
manufacturers who provided conditional response data requested by the assessment group. Consequently,
assuming that non-responders revert back to the ‘average’ of the baseline BASDAI/BASFI score of all
patients randomised to receive TNF-α inhibitor treatment, or the ‘average’ of patients receiving CC, is likely
to be overly optimistic towards the subsequent cost-effectiveness of anti-TNFs. The model thus use
different baselines for responders and non-responders (at 12 weeks) and at the point of discontinutation
patients are assumed to revert to their respective baseline BASDAI and BASFI scores (i.e. at 12 weeks
non-responders revert back to the non-responder baseline and after 12 weeks patients who subsequently
discontinue from their TNF-α therapy revert back to their responder baseline). The impact of using these
data is explored as part of the sensitivity analysis.
Patients are at risk of all-cause mortality at every time point in the model but no differential mortality
risk between the therapies being evaluated. Aside from the cost of the TNF-α therapies themselves
(i.e. acquisition, administration, monitoring and AEs), all other costs of AS and nr-AxSpA are assumed to
vary according to BASFI score. Costs are presented based on current prices. HRQoL (in terms of utility) is
implemented as a function of BASDAI and BASFI scores.
Model input parameters
The parameter estimates used in the York model, together with their sources, are detailed in Tables 82
and 83.
Baseline patient characteristics
Baseline characteristics applied to the AS and nr-AxSpA populations are summarised in Tables 82 and
83, respectively.
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TABLE 82 List of parameter estimates used in the York model: AS population
Parameter Mean value SE Distribution Source
Annual discount
rate costs/QALYs
3.5% – Fixed –
Time horizon (years) 60 – Fixed –
Cycle length (years) 0.25 – Fixed –
Baseline patient characteristics
Average age (years) 40 – Fixed Assumption
Proportion male 0.7 – Fixed Assumption
Average weight (kg) 73 – Fixed Assumption
Average baseline
BASDAI
6.12 N/A Derived from responder
and non-responder
baseline
Evidence synthesis
(see Chapter 5)
Average baseline
BASFI
5.28 N/A
Baseline BASDAI CC
responders
4.01 N/A From evidence synthesis Evidence synthesis
(see Chapter 5)
Baseline BASDAI CC
non-responders
6.33 N/A From evidence synthesis
Baseline BASFI CC
responders
3.52 N/A From evidence synthesis
Baseline BASFI CC
non-responders
5.46 N/A From evidence synthesis
Baseline BASDAI
anti-TNF responders
4.80 N/A From evidence synthesis
Baseline BASDAI
anti-TNF non-
responders
7.08 N/A From evidence synthesis
Baseline BASFI
anti-TNF responders
4.20 N/A From evidence synthesis
Baseline BASFI anti-
TNF non-responders
6.07 N/A From evidence synthesis
Response (12-week BASDAI 50)
Anti-TNF 42.0% N/A From evidence synthesis Evidence synthesis
(see Chapter 5)
Conventional
therapy
9.1% N/A From evidence synthesis
Treatment effect
Initial BASDAI
Change| Tx
response: anti-TNF
–3.86 N/A From evidence synthesis Evidence synthesis
(see Chapter 5)
Initial BASDAI
Change| Tx
response: CC
–2.89 N/A From evidence synthesis
Initial BASDAI
Change| Tx no
response: anti-TNF
–1.64 N/A From evidence synthesis
Initial BASDAI
Change| Tx no
response: CC
–0.36 N/A From evidence synthesis
continued
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TABLE 82 List of parameter estimates used in the York model: AS population (continued )
Parameter Mean value SE Distribution Source
Initial BASFI Change|
Tx response: anti-
TNF
–3.08 N/A From evidence synthesis
Initial BASFI Change|
Tx response: CC
–1.72 N/A From evidence synthesis
Initial BASFI Change|
Tx no response:
anti-TNF
–0.44 N/A From evidence synthesis
Initial BASFI Change|
Tx no response: CC
–0.04 N/A From evidence synthesis
Long-term annual BASFI progression
BASFI annual
progression anti-TNF
0.034 – Derived from probabilistic
inputs (the following four
rows)
–
BASFI annual
progression CC
0.082 – –
Annual rate of
mSASSS change for
mSASSS ≥ 10
1.44 0.133 Normal Ramiro et al. (2013)148
BASFI change with
1 unit change in
mSASSS
0.057 0.0049 Normal Landewe et al. (2009)10
Treatment effect
on progression
(relative risk)
0.42 0.122 Normal Haroon et al. (2013)121
Time to treatment
effect (years)
4 – – Haroon et al. (2013),121
Baraliakos et al.
(2014)122
Long-term annual BASDAI progression
BASDAI annual
progression anti-TNF
0 N/A
BASDAI annual
progression CC
0 N/A
Annual withdrawal probability
Constant rate of
annual withdrawal
0.11 AiC information has
been removed
Log-normal; from
exponential model
[coefficient (AiC
information has been
removed); SE (AiC
information has been
removed)]
Pfizer submission34
Mortality
SMR women 1.38 0.163 Normal Bakland (2011)16
SMR men 1.63 0.163 Normal Bakland (2011)16
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TABLE 82 List of parameter estimates used in the York model: AS population (continued )
Parameter Mean value SE Distribution Source
Quality of life
Intercept (AiC information
has been removed)
Uncertainty from
reported
variance–covariance
matrix
Multivariate normal Pfizer submission34
BASDAI coefficient (AiC information
has been removed)
Multivariate normal
BASFI coefficient (AiC information
has been removed)
Multivariate normal
BASDAI2 coefficient (AiC information
has been removed)
Multivariate normal
BASFI2 coefficient (AiC information
has been removed)
Multivariate normal
Initial 12-week period costs (drug + initiation + administration)
Adalimumab 2422 – Fixed As discussed in
Resource use and
costsCertolizumab pegol 3884 – Fixed
Etanercept 2454 – Fixed
Golimumab 2415 – Fixed
Infliximab 6878 – Fixed
Certolizumab pegol
PAS
309 – Fixed
Subsequent 12-week costs (drug +monitoring + administration)
Adalimumab 2171 – Fixed As discussed in
Resource use and
costsCertolizumab pegol 2203 – Fixed
Etanercept 2203 – Fixed
Golimumab 2164 – Fixed
Infliximab 3435 – Fixed
Certolizumab pegol
PAS
2203 – Fixed
Disease-related costs: annual
Intercept 1284 0.165 Log-normal OASIS data,118 AbbVie
submission34
BASFI coefficient 0.213 0.038 Normal
AE costs (£ per patient)
Year 1 18.2 – Fixed Excess rates for anti-
TNFs from Cochrane
review,137 costs from
NHS Reference
Costs 2012/13176
Subsequent years 0 – Fixed
N/A, not applicable; Tx, treatment.
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TABLE 83 List of parameter estimates used in the York model: nr-AxSpA population
Parameter Mean value SE Distribution Source
Annual discount rate
costs/QALYs
3.5% – Fixed –
Time horizon (years) 60 – Fixed –
Cycle length (years) 0.25 – Fixed –
Baseline patient characteristics
Average age (years) 40 – Fixed Assumption
Proportion male 0.5 – Fixed Assumption
Average weight (kg) 73 – Fixed Assumption
Average baseline
BASDAI
6.42 N/A Derived from responder
and non-responder
baseline
Evidence synthesis
(see Chapter 5)
Average baseline
BASFI
4.92 N/A
Baseline BASDAI CC
responders
4.54 N/A From evidence synthesis Evidence synthesis
(see Chapter 5)
Baseline BASDAI CC
non-responders
6.86 N/A From evidence synthesis
Baseline BASFI CC
responders
2.95 N/A From evidence synthesis
Baseline BASFI CC
non-responders
5.38 N/A From evidence synthesis
Baseline BASDAI
anti-TNF responders
5.45 N/A From evidence synthesis
Baseline BASDAI
anti-TNF
non-responders
7.51 N/A From evidence synthesis
Baseline BASFI
anti-TNF responders
3.92 N/A From evidence synthesis
Baseline BASFI anti-
TNF non-responders
6.04 N/A From evidence synthesis
Response (12-week BASDAI 50)
Anti-TNF 52.9% N/A From evidence synthesis Evidence synthesis
(see Chapter 5)
Conventional therapy 18.9% N/A From evidence synthesis
Treatment effect
Initial BASDAI
Change| Tx response:
anti-TNF
–4.31 N/A From evidence synthesis Evidence synthesis
(see Chapter 5)
Initial BASDAI
Change| Tx response:
CC
–3.34 N/A From evidence synthesis
Initial BASDAI
Change| Tx no
response: anti-TNF
–2.28 N/A From evidence synthesis
Initial BASDAI
Change| Tx no
response: CC
–1.06 N/A From evidence synthesis
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TABLE 83 List of parameter estimates used in the York model: nr-AxSpA population (continued )
Parameter Mean value SE Distribution Source
Initial BASFI Change|
Tx response: anti-TNF
–3.24 N/A From evidence synthesis
Initial BASFI Change|
Tx response: CC
–1.88 N/A From evidence synthesis
Initial BASFI Change|
Tx no response:
anti-TNF
0.08 N/A From evidence synthesis
Initial BASFI Change|
Tx no response: CC
–0.05 N/A From evidence synthesis
Long-term annual BASFI progression
BASFI annual
progression anti-TNF
0.017 Derived from probabilistic
inputs (the following
four rows)
–
BASFI annual
progression CC
0.039 –
Annual rate of
mSASSS change for
mSASSS < 10
0.69 0.031 Normal Ramiro et al. (2013)148
BASFI change with
1 unit change in
mSASSS
0.057 0.0049 Normal Landewe et al. (2009)10
Treatment effect on
progression (relative
risk)
0.42 0.122 Normal Haroon et al. (2013)121
Time to treatment
effect (years)
4 – – Haroon et al. (2013),121
Baraliakos et al. (2014)122
Long-term annual BASDAI progression
BASDAI annual
progression anti-TNF
0 N/A – –
BASDAI annual
progression CC
0 N/A – –
Annual withdrawal probability
Constant rate of
annual withdrawal
0.06 (AiC information
has been removed)
Log-normal; from
exponential model
[coefficient (AiC
information has been
removed); SE (AiC
information has been
removed)]
Pfizer submission36
Mortality
SMR women 1.38 0.163 Normal Bakland (2011)16
SMR men 1.63 0.163 Normal Bakland (2011)16
continued
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TABLE 83 List of parameter estimates used in the York model: nr-AxSpA population (continued )
Parameter Mean value SE Distribution Source
Quality of life
Intercept AiC information
has been removed
Uncertainty from
reported
variance–covariance
matrix
Multivariate normal Pfizer submission36
BASDAI coefficient AiC information
has been removed
Multivariate normal
BASFI coefficient AiC information
has been removed
Multivariate normal
Male coefficient AiC information
has been removed
Multivariate normal
Age coefficient AiC information
has been removed
Multivariate normal
BASDAI2 coefficient AiC information
has been removed
Multivariate normal
BASFI2 coefficient AiC information
has been removed
Multivariate normal
BASFI × BASDAI
coefficient
AiC information
has been removed
Multivariate normal
Initial 12-week period costs (drug + initiation + administration)
Adalimumab 2573 – Fixed As discussed in
Resource use and costs
Certolizumab pegol 4035 – Fixed
Etanercept 2606 – Fixed
Golimumab 2566 – Fixed
Infliximab 7213 – Fixed
Certolizumab pegol
PAS
460 – Fixed
Subsequent 12-week costs (drug +monitoring + administration)
Adalimumab 2177 – Fixed As discussed in
Resource use and costs
Certolizumab pegol 2210 – Fixed
Etanercept 2210 – Fixed
Golimumab 2170 – Fixed
Infliximab 3441 – Fixed
Certolizumab pegol
PAS
2210 – Fixed
Disease-related costs: annual
Intercept 1284 0.165 Log-normal OASIS data,118 AbbVie
submission34
BASFI coefficient 0.213 0.038 Normal
AE costs (£ per patient)
Year 1 18.2 – Fixed Excess rates for anti-
TNFs from Cochrane
review,137 costs from
NHS Reference Costs
2012/13176
Subsequent years 0 – Fixed
N/A, not applicable; Tx, treatment.
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Response, change in Bath Ankylosing Spondylitis Disease Activity Index/Bath
Ankylosing Spondylitis Functional Index and conditional baselines
The BASDAI 50 response, the conditional change scores for BASDAI and BASFI at 12 weeks and the
separate conditional baselines estimated for BASDAI and BASFI (responders vs. non-responders) were
derived directly from the results of the extended synthesis model reported in Chapter 5. In the base case,
it was assumed that the percentage of BASDAI 50 responders, change in BASDAI/BASFI and conditional
baselines were the same for all anti-TNFs. The outputs [CODA (Convergence Diagnostic and Output
Analysis) file format] from the simulations were incorporated directly into the model to maintain correlation
and to avoid any additional distributional assumptions.
Longer-term Bath Ankylosing Spondylitis Functional Index progression
As previously highlighted in the overview section, the York model attempts to address some of the
conceptual concerns outlined in Chapter 4 surrounding the assumptions applied within existing models in
relation to modelling BASFI progression over time. Specifically, we assume that BASFI is a function of
separate processes which are independently related to disease severity/activity (BASDAI) and to the extent
and subsequent progression of radiographic disease (mSASSS). The rationale for this is that the association
between BASDAI and BASFI is already accounted for in the separate mean change scores applied to both
BASDAI and BASFI for responders versus non-responders/CC patients. Differences in BASDAI are assumed
to remain constant over the longer-term horizon (an assumption which is common across all models).
Hence any additional changes which might affect BASFI need to be more explicitly related to a separate
clinical process (or processes). Based on the studies included in the reviews reported in Chapter 3 for
natural history (see Review of natural history of ankylosing spondylitis and non-radiographic axial
spondyloarthritis) and the effect on anti-TNFs on radiographic progression (see Effect of anti-tumour
necrosis factors on radiographic progression), we modelled longer-term changes in BASFI (for CC and
anti-TNFs) as a function of mSASSS scores.
The approach applied in the AS population is based on the following studies and assumptions:
1. The multivariate relationship reported in Landewe et al.,10 based on longitudinal assessments of BASFI,
BASDAI and mSASSS, was used to estimate the independent effect of a 1-unit change in mSASSS on
BASFI scores (mean 0.057 units, SE 0.0049 units).
2. Data from a 12-year prospective follow-up of the OASIS study was used to estimate the annual rate of
change in mSASSS. Although at the individual level progression of mSASSS is highly variable, the study
by Ramiro et al.124 demonstrated that at a group level (i.e. akin to the cohort approach applied in the
York model) changes in mSASSS were stable, progressing at an annual rate of 0.98 mSASSS units per
year.125 Combining the estimates reported across the studies implies a change in BASFI of 0.056 units
per annum (0–10 scale). However, as the population included in the study by Ramiro et al.124 included
patients who would not be eligible to receive anti-TNFs, we used data in the subgroup of patients with
baseline mSASSS ≥ 10 units. The annual rate of mSASSS progression in this subgroup was 1.44 units
(95% CI 1.18 to 1.70 units) per year with an implied annual BASFI score change of 0.082 units per
year. This compares with an annual change of BASFI score of between 0.056 and 0.07 units assumed
across the manufacturer’s submissions. The specific subgroup (mSASSS ≥ 10 units) was chosen to
reflect that AS patients eligible to receive anti-TNFs are likely to be more similar to this subgroup than
the entire cohort reported by Ramiro et al.124 This also provided a basis for differentiating between the
AS and nr-AxSpA populations which is discussed in the following section.
Given the uncertainties noted in Chapter 3 (see Effect of anti-tumour necrosis factors on radiographic
progression), surrounding the effect of anti-TNFs on radiographic progression, we explored alternative
scenarios in the decision model. In the base case, we assumed that the effect was related to the
duration of therapy which has been reported in recent studies by Haroon et al.121 and Baraliakos
et al.122 Both studies consistently reported evidence that the difference in mSASSS between patients
who received anti-TNFs and historical controls became different only in patients who had received
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treatment for approximately 4 years or more. In the absence of any relative-effect measure reported
by Baraliakos et al.,122 we used results reported by Haroon et al.121 applying a zero-inflated binomial
model with a relative rate of mSASSS change of 0.42 units (95% CI 0.18 to 0.98 units). Hence, in the
model, no effect on mSASSS was assumed until year 4 of the model and then only applied to patients
who continued to receive therapy beyond this period.
3. Given the inherent uncertainties regarding the effect of anti-TNFs on radiographic progression we
explored alternative scenarios based on (1) an assumption of no impact on radiographic progression;
and (2) an immediate effect, applying the estimate of 0.42 from the outset.
For the nr-AxSpA population, we assume a similar underlying clinical process relating to BASFI but model
separate BASFI processes for patients depending upon the probability of developing radiographic disease
over time and thereafter modelling the extent and progression of radiographic disease via mSASSS
changes. Hence, our intention in the nr-AxSpA model was to employ a constant BASFI score (on and
off treatment) until a patient develops radiographic progression. At the time point of ‘progression’ an
increasing BASFI would be assumed using a similar approach applied to the AS population. However,
programming the additional transition to allow separate BASFI progression estimates based on the time of
progression (and time since progression for patients who had previously progressed) proved more complex
than anticipated. Consequently, a more simplified assumption was made such that all patients were
assumed to incur progression in BASFI albeit at a lower rate relative to the AS population.
The approach we intended to apply in the nr-AxSpA population was based on the following studies
and assumptions:
1. Poddubnyy et al.155 is used to estimate the probability of nr-AxSpA patients progressing to radiographic
disease based on the outcome ‘% progressed by ≥ 2 mSASSS over 2 years’ (7.4%) reported. These
estimates are converted into a rate to estimate the cycle-specific probability.
Following progression, the mSASSS scores of patients are subsequently assumed to increase at a rate of
0.69 units (95% CI 0.63 to 0.75 units) per year, based on the subgroup of patients with baseline
mSASSS < 10 reported by Ramiro et al.148 BASFI is assumed to remain constant for patients who do not
progress in each cycle of the model.
The same results reported by Haroon et al.,121 applying a zero-inflated binomial model with a relative
rate of mSASSS change of 0.42 units (95% CI 0.18 to 0.98 units), were applied to the mSASSS scores
for patients who progressed to estimate the treatment effect of anti-TNFs. Hence, in common with the
AS model, no effect on mSASSS was assumed until year 4 and then it was only applied to patients who
continued to receive therapy beyond this period.
2. Given the inherent uncertainties regarding the effect of anti-TNFs on radiographic progression we
explored alternative scenarios based on (1) an assumption of no impact on radiographic progression
and (2) an immediate effect – applying the estimate of 0.42 from the outset. We also considered an
exploratory scenario where we assumed no radiographic progression for nr-AxSpA for patients receiving
anti-TNFs, to investigate the untested hypothesis that early intervention in patients, prior to established
radiographic disease, might halt subsequent progression.
Given the additional programming challenges that could not be overcome within the remaining time and
funding constraints, the mSASSS scores of all nr-AxSpA patients were assumed to increase at the rate of
0.69 units per year. Hence the subsequent results reported for the nr-AxSpA population are potentially
optimistic, as not all patients will develop radiographic progression. However, the use of mSASSS in this
context inevitably represents an uncertain proxy process for BASFI changes. Further, it should also be noted
that the BASFI trajectory of nr-AxSpA patients has been reported in publications to be similar to early AS
patients.177 Consequently, applying the change in mSASSS reported in the subgroup of patients with
baseline mSASSS < 10 reported by Ramiro et al.148 may not be an unreasonable proxy for the purposes of
predicting future changes in BASFI over longer periods.
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Longer-term discontinuation
Patients who achieve a response at 12 weeks are subsequently assumed to remain on that treatment until
the treatment is discontinued (i.e. because of loss of efficacy or AEs) and hence the evidence required to
inform the decision model is the post-12 week withdrawal data for responders. The rationales for this are
(1) that discontinuation for lack of efficacy is higher during the first 3 months, and this has already been
accounted for in the model using the probability of no BASDAI 50 response during the initial treatment
period; and (2) that discontinuation rates in responders may differ from withdrawal rates in studies which
potentially include both responders and non-responders. Although Chapter 3, Drug survival and
anti-tumour necrosis factor switching identified 12 studies reporting on longer-term drug survival from
registries, none of these appears to directly inform the model requirements (i.e. either including the initial
3-month period and/or not being specific to responders).
The most relevant estimates appeared to be those presented in previous and current submissions by the
manufacturers. Three alternative approaches and sources were identified which appeared to meet
the requirements of the economic model. These included:
1. A constant annual probability of 15% applied in the study by Kobelt et al.,160 based on data from
infliximab responders (BASDAI 50) reported as part of the 2nd year of the open-label extension period
of the Braun trial (n= 18).
2. Separate time-dependent estimates of the probability for AS and nr-AxSpA reported in the AbbVie
submission.34 These estimates were based on a parametric function (log-normal distribution) estimated
from responders (ASAS 20 for AS and ASAS 40 for nr-AxSpA at week 12) from the open-label
extensions of ATLAS61 (up to 260 weeks; n= not stated) and ABILITY-158 (up to 156 weeks; n= 28).
3. A constant annual estimate (approximately 5% for nr-AxSpA and 11% for AS) reported in the Pfizer
submission.36 These estimates were based on a parametric function (exponential distribution) estimated
from responders (BASDAI 50 at week 12) from the open-label extensions of studies 311-EU,83–85
312-EU146 and 907-EU147 (up to approximately 250 weeks for 311-EU; n= not stated) for the AS
population and 1031 study166 (up to approximately 110 weeks; n= 46) for the nr-AxSpA population.
Figure 16 provides a comparison of the different estimates in terms of the subsequent drug survival over a
longer-time horizon for AS.
Figure 17 provides a comparison of the different estimates in terms of the subsequent drug survival over
a longer-time horizon for nr-AxSpA.
The base case of the York model is based on the estimates reported in the submission by Pfizer for both
populations. The justification for this is that (1) the estimates relate to the response end point used in the York
model (BASDAI 50); (2) full details were reported by Pfizer concerning the alternative parametric models
and associated goodness-of-fit statistics and the exponential model appeared the most appropriate function;
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FIGURE 16 Comparison of withdrawal rates: AS population.
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and (3) the continued use of a time-dependent function with long tails such as the log-normal distribution
results in a significant proportion of patients who would still be assumed to be on TNF-α therapy even after
40 years. Although it is not possible to completely rule out this possibility, the approach by Pfizer was deemed
to be a more appropriate basis for informing the York model based on a series of considerations.
Health-related quality of life
The current manufacturer’s submissions are based on alternative mapping algorithms to link BASDAI and
BASFI scores to a generic utility measure. The approach used by AbbVie in their base case was based on
separate mapping algorithms for the AS and nr-AxSpA populations using data from the ATLAS61 and
ABILITY-158 trials, respectively. For the nr-AxSpA population, BASDAI and BASFI were mapped to EQ-5D,
whereas the algorithm for the AS population mapped to HUI-3; reflecting the use of different generic
utility measures used in the two trials. The approach employed by Pfizer in their base case was similarly
based on separate algorithms for each population estimated using data from the 1031 study166 (nr-AxSpA)
and the 314-EU study167 (AS) both mapped to EQ-5D. Both regressions were based on the relationships
between BASDAI, BASFI and EQ-5D. The approach employed by UCB in their base case was based on the
same single-mapping algorithm from the RAPID-axSpA64 trial that included both patient populations.
Merck Sharp & Dohme adopted the algorithm reported in McLeod et al.38
We undertook a separate search for other published utility algorithms and identified only the algorithm
reported in Ara et al.,161 which was based on the cost-effectiveness analysis submitted by Pfizer to NICE for
TA143.17 Full details of the search and an associated review of utility studies are reported in Appendices 1 and
14, respectively. A summary of the alternative algorithms based on EQ-5D is provided in Tables 84 and 85.
Figures 18–21 provide a comparison of the utility predictions for each algorithm in each population. For each
population, two separate figures are presented. Each figure is based on the impact of holding either BASDAI
or BASFI constant (at the mean value) and allowing the other measure to vary across the entire range.
The baseline characteristics (BASDAI, BASFI and age) were derived from a weighted average of the baseline
characteristics of the clinical trials for the AS population used in the manufacturer’s economic models.
For nr-AxSpA, baseline characteristics (BASDAI, BASFI and age) of the nr-AxSpA subpopulation from the
RAPID-axSpA64 study were used. Sex was assumed to be 65% male in AS and 35% male in nr-AxSpA.
It is evident that there is significant variation in the utility predictions arising from each separate algorithm.
In particular, the non-linear function estimated by Pfizer results in important differences across several of
the figures at the extremes of the BASDAI/BASFI ranges. However, limited details were provided in relation
to goodness of fit and/or predictive performance for the majority of algorithms and hence a formal
assessment of the validity of the different approaches is problematic. Only the submission by Pfizer36
reported additional detail on these aspects and hence was subsequently used in the York model base case
(separate algorithms for the different populations). The non-linear function for utilities was also considered
to be more consistent with the non-linear approach applied to costs.
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FIGURE 17 Comparison of withdrawal rates: nr-AxSpA population.
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TABLE 84 Comparison of alternative EQ-5D utility regression models (AS)
AS Ara 2007161 Merck Sharp & Dohme UCB Pfizer
BASDAI/BASFI scale 0–10 0–10 0–10 0–100
Regression model Linear Linear Logistic Non-linear
Intercept 0.92300000 0.877213 AiC information
has been removed
AiC information
has been removed
BASFI –0.04318800 –0.032252 AiC information
has been removed
AiC information
has been removed
BASDAI –0.04019000 –0.038409 AiC information
has been removed
AiC information
has been removed
Male 0.00000000 –0.027891 AiC information
has been removed
AiC information
has been removed
Age 0.00000000 0.001681 AiC information
has been removed
AiC information
has been removed
BASFI2 0.00000000 0.000000 AiC information
has been removed
AiC information
has been removed
BASDAI2 0.00000000 0.000000 AiC information
has been removed
AiC information
has been removed
BASFI × BASDAI 0.00000000 0.000000 AiC information
has been removed
AiC information
has been removed
TABLE 85 Comparison of alternative EQ-5D utility regression models (nr-AxSpA)
Nr-axSpA UCB AbbVie Pfizer
BASDAI/BASFI scale 0–10 0–10 0–100
Regression model Logistic Linear Non-linear
Intercept AiC information has been removed 0.9220000 AiC information has been removed
BASFI AiC information has been removed –0.0411700 AiC information has been removed
BASDAI AiC information has been removed –0.0392400 AiC information has been removed
Male AiC information has been removed 0.0000000 AiC information has been removed
Age AiC information has been removed 0.0000000 AiC information has been removed
BASFI2 AiC information has been removed 0.0000000 AiC information has been removed
BASDAI2 AiC information has been removed 0.0000000 AiC information has been removed
BASFI × BASDAI AiC information has been removed 0.0000000 AiC information has been removed
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FIGURE 18 Illustration of predicted EQ-5D values using different mapping algorithms: constant BASDAI and varying
BASFI (AS). MSD, Merck Sharp & Dohme.
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FIGURE 19 Illustration of predicted EQ-5D values using different mapping algorithms: constant BASFI and varying
BASDAI (AS). MSD, Merck Sharp & Dohme.
FIGURE 20 AiC information has been removed.
FIGURE 21 AiC information has been removed.
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A potential limitation of all the manufacturer analyses is that their algorithms are based on trial data.
These data may represent a more limited range of BASDAI and BASFI values and hence there may be
issues associated with their subsequent predictive performance in the context of the longer-term economic
model, although, from the data reported by Pfizer36 at least, it appeared as if the full range of BASDAI and
BASFI scores were represented in the sample used. However, a separate sensitivity analysis was also
undertaken based on the algorithm used by Merck Sharp & Dohme. This algorithm is based on a reanalysis
of the Kobelt et al.152 data from patients (n= 1144) who had BASDAI and BASFI scores across the whole
0–10 scale and was previously used by McLeod et al.38 for the previous multiple TA. Hence this scenario also
provides a more consistent basis for comparing the results from our new analysis.
Resource use and costs
Drug acquisition costs
The unit costs of anti-TNFs were sourced from the British National Formulary. Doses were calculated in
accordance with their respective licences. Tables 86 and 87 summarise the drug acquisition costs and the
licensed dosage for AS and nr-AxSpA patients.
TABLE 87 Anti-TNFs licensed dosage in AS and nr-AxSpA
Drug Licensed dosage in AS and nr-AxSpA
Infliximab (Remicade®,
Merck Sharp & Dohme)
Dose of 5mg/kg given as an intravenous infusion followed by additional 5-mg/kg infusion doses at
2 and 6 weeks after the first infusion, then every 6 to 8 weeks. If a patient does not respond by
6 weeks (i.e. after two doses), no additional treatment with infliximab should be given
Golimumab (Simponi®,
Merck Sharp & Dohme)
Dose of 50mg given once a month, on the same date each month. For patients with a body
weight of more than 100 kg who do not achieve an adequate clinical response after three or
four doses, increasing the dose of golimumab to 100mg once a month may be considered
Adalimumab (Humira®,
AbbVie)
Recommended dose for patients with AS and axSpA without radiographic evidence of AS is 40mg
of adalimumab administered every other week as a single dose via subcutaneous injection
Certolizumab (Cimzia®,
UCB)
The recommended starting dose of Cimzia for adult patients is 400mg (given as 2
subcutaneous injections of 200mg each) at weeks 0, 2 and 4. After the starting dose, the
recommended maintenance dose of Cimzia for adult patients with AS is 200mg every 2 weeks
or 400mg every 4 weeks
Etanercept (Enbrel®,
Pfizer)
The recommended dose is 25mg of Enbrel administered twice weekly, or 50mg administered
once weekly
TABLE 86 Drug acquisition costs
Drug Dose Cost (£) Source
Infliximab (Remicade®, Merck Sharp &
Dohme)
i.v. infusion: 100-mg vial 419.62 BNF,178 November 2014
Golimumab (Simponi®, Merck Sharp &
Dohme)
Injection: 50-mg prefilled pen or
prefilled syringe
762.97 BNF,178 November 2014
Injection: 100-mg prefilled pen 1525.94
Adalimumab (Humira®, AbbVie) Injection: 40-mg prefilled pen/prefilled
syringe or 40-mg/0.8-ml vial
352.14 BNF,178 November 2014
Certolizumab (Cimzia®, UCB) Injection: 200-mg prefilled syringe 357.5 BNF,178 November 2014
Etanercept (Enbrel®, Pfizer) Injection: powder for reconstitution,
25-mg vial or 25-mg prefilled syringe
89.38 BNF,178 November 2014
Injection: 50-mg prefilled pen or
prefilled syringe
178.75 BNF,178 November 2014
BNF, British National Formulary; i.v. intravenous.
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Patient access scheme details
Certolizumab with PAS: UCB will make Cimzia available free of charge to all NHS patients for the first
3 months of therapy, at which point clinical response should be clear. Only after this 3-month stage will
the NHS be charged for continuing to use this therapy. However, it should be noted that the proposed
PAS is not yet formally agreed with the Department of Health and NICE.
Golimumab PAS: the manufacturer provides the 100-mg dose of golimumab at the same cost as the
50-mg dose, agreed as part of the PAS.
Drug administration costs
Administration costs for intravenous therapies were based on a regular chemotherapy cost [Healthcare
Resource Group (HRG) code SB15Z, Deliver subsequent elements of a chemotherapy cycle], similar to
NICE TA143 (Table 88).17 Therapies administered subcutaneously were assumed to be self-administered
following instruction. The cost of instruction in the model was based on 1 hour of nurse time [Personal
Social Services Research Unit (PSSRU) 2013].179 Drug administration did not differ between the AS and
nr-AxSpA indications.
Initiation and monitoring costs
The initiation and monitoring costs for anti-TNF therapies were restricted to the additional costs incurred
compared with patients receiving CC alone, as these drugs are used in addition to current practice. The
resource use assumptions for laboratory testing for anti-TNF initiation and monitoring have been sourced
from the York model for psoriatic arthritis (TA199175) and conform to guidelines from the BSR169 for the use
of biologics.
Specifically, during the initial 12-week period AS patients on anti-TNF therapy are assumed to undertake a
series of tests at treatment initiation and at week 12 when assessing treatment response (i.e. a full blood
count, ESR, liver function test, and urea and electrolytes). Additional testing is conducted once during the
initial period (i.e. chest radiography, tuberculosis Heaf test, antinuclear antibody and a double-stranded
deoxyribonucleic acid test). AS patients on anti-TNF therapy are also assumed to visit a specialist twice
during the initial 12-week period (at treatment initiation and when assessing 12-week response) and two
times per year thereafter for monitoring. For quarterly monitoring, AS patients are assumed to receive a
series of laboratory tests once every 3 months (i.e. a full blood count, ESR, liver function test, and urea
and electrolytes).
Non-radiographic axial spondyloarthritis patients, in addition to the initiation and monitoring resource use
assumed for AS patients on anti-TNF therapy, are also assumed to get a MRI test and a CRP test at
treatment initiation, as well as a radiograph once per year after the initial period for monitoring, in order
to assess radiographic progression.
Cost estimates for laboratory testing have been sourced from the York model for psoriatic arthritis
(TA199175) and have been inflated to 2012/13 prices, using the Hospital and Community Health Services
Pay and Prices Index.175,179 The CRP test cost is derived from Henriksson 2010.180 Specialist visits are costed
at £100 (outpatient rheumatology follow-up attendance), using the NHS Reference Costs 2012/13.176
TABLE 88 Drug administration costs
Type of therapy Cost (£) Source
Subcutaneous therapies 49 Cost of nurse training for self-administration (PSSRU 2013)179
Intravenous therapies 291 HRG code SB15Z – Deliver Subsequent Elements of a
Chemotherapy Cycle (NHS Reference Costs 2012/13)176
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A summary of the initiation and monitoring resource use assumptions for anti-TNF therapies and the
subsequent costs for the AS and nr-AxSpA populations is reported in Tables 89 and 90.
Summary of drug acquisition, administration and monitoring costs
Tables 91 and 92 summarise the drug acquisition, administration and monitoring costs applied in the
economic model, for the initial 12-week period and on an annual basis thereafter.
TABLE 90 Initiation and monitoring resource use and costs: nr-AxSpA population
Item
Resource use Cost
Initiation period
(12 weeks)
Quarterly
monitoring
Initiation period
(12 weeks) (£)
Quarterly
monitoring (£)
Full blood count 2 1 5.97 2.98
ESR 2 1 5.90 2.95
Liver function test 2 1 1.50 0.75
Urea and electrolytes 2 1 2.77 1.38
Chest radiography 1 0.25 26.19 6.55
Tuberculosis Heaf test 1 0 8.72 0.00
Antinuclear antibody 1 0 4.65 0.00
Double-stranded DNA test 1 0 4.65 0.00
Specialist visit 2 0.5 200.00 50.00
MRI 1 0 144.45 0.00
CRP level 1 0 6.62 0.00
Total – – 411 65
DNA, deoxyribonucleic acid.
TABLE 89 Initiation and monitoring resource use and costs: AS population
Item
Resource use Cost
Initiation period
(12 weeks)
Quarterly
monitoring
Initiation period
(12 weeks) (£)
Quarterly
monitoring (£)
Full blood count 2 1 5.97 2.98
ESR 2 1 5.90 2.95
Liver function test 2 1 1.50 0.75
Urea and electrolytes 2 1 2.77 1.38
Chest radiography 1 0 26.19 0.00
Tuberculosis Heaf test 1 0 8.72 0.00
Antinuclear antibody 1 0 4.65 0.00
Double-stranded DNA test 1 0 4.65 0.00
Specialist visit 2 0.5 200.00 50.00
CRP level 0 0 0.00 0.00
Total – – 260 58
DNA, deoxyribonucleic acid.
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TABLE 91 Summary of drug acquisition, administration and monitoring costs used in economic model: AS population
Treatment (dosage)
Initial period (3 months) Annual cost (after initial 3 months) Total costs
Acquisition
cost (£)
Administration
cost (£)
Monitoring
costs (£)
Acquisition
cost (£)
Administration
cost (£)
Monitoring
costs (£)
Initial period
(3 months) (£)
Subsequent
annual costs (£)
Adalimumab, 40mg eow 2112.8 49.0 260.4 8451.4 0.0 232.3 2422.2 8683.6
Certolizumab, 200mg/2 weeks 3575.0 49.0 260.4 8580.0 0.0 232.3 3884.4 8812.3
Certolizumab, 200mg/2 weeks, with PAS 0.0 49.0 260.4 8580.0 0.0 232.3 309.4 8812.3
Etanercept, 25mg twice/week 2145.1 49.0 260.4 8580.5 0.0 232.3 2454.5 8812.8
Etanercept, 50mg once/week 2145.0 49.0 260.4 8580.0 0.0 232.3 2454.4 8812.3
Golimumab, 50mg once monthly, with PAS 2105.6 49.0 260.4 8422.4 0.0 232.3 2415.0 8654.7
Infliximab, 5mg/kg every 7 weeks, four vials 5639.7 978.8 260.4 11,509.6 1997.5 232.3 6878.8 13,739.3
eow, every other week.
TABLE 92 Summary of drug acquisition, administration and monitoring costs used in economic model: nr-AxSpA population
Treatment (dosage)
Initial period (3 months) Annual cost (after initial 3 months) Total costs
Acquisition
drug cost
(£)
Administration
cost (£)
Monitoring
costs (£)
Acquisition
drug cost
(£)
Administration
cost (£)
Monitoring
costs (£)
Initial period
(3 months) (£)
Subsequent
annual costs (£)
Adalimumab, 40mg eow 2112.8 49.0 411.4 8451.4 0.0 258.5 2573.3 8709.8
Certolizumab, 200mg/2 weeks 3575.0 49.0 411.4 8580.0 0.0 258.5 4035.4 8838.5
Certolizumab, 200mg/2 weeks, with PAS 0.0 49.0 411.4 8580.0 0.0 258.5 460.4 8838.5
Etanercept, 25mg twice/week 2145.1 49.0 411.4 8580.5 0.0 258.5 2605.5 8838.9
Etanercept, 50mg once/week 2145.0 49.0 411.4 8580.0 0.0 258.5 2605.4 8838.5
Golimumab, 50mg once monthly, with PAS 2105.6 49.0 411.4 8422.4 0.0 258.5 2566.0 8680.9
Infliximab, 5mg/kg every 7 weeks, four vials 5796.08 1005.9 411.4 11,509.6 1997.5 258.5 7213.4 13,765.5
eow, every other week.
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Long-term disease management costs
Patients who remain on anti-TNF treatment incur disease management costs. Previously published
economic evaluations employed observational cohort studies to estimate disease management costs and
modelled these according to BASDAI and/or BASFI (e.g. NICE TA14317). In addition, as discussed in
Chapter 4, the majority of the manufacturer’s submissions within this appraisal (and the LRiG model in
TA14317) have analysed health-care resource use data from the OASIS118 to estimate disease management
costs. The submission by Pfizer36 estimated disease-related costs using data from Rafia et al.168 arguing that
it is a more recent study and provides a UK-specific cost estimate. However, the comparative analysis of
the different long-term cost models in Appendix 11 showed that the Rafia model provided considerably
lower cost estimates; the reasons for this discrepancy are not clear.
In NICE TA14317 the committee judged that the OASIS data were the most reliable source, being a 2-year
prospective study of 208 AS patients from four centres in France, Belgium and the Netherlands, and
collecting clinical assessments and economic data including BASDAI and BASFI every 2 or 6 months. The
NICE committee also decided that only BASFI should be employed as the major predictor of costs as it
reflects long-term disease progression, while BASDAI appears to fluctuate but not increase over time.
The base case of the York model uses the exponential BASFI regression model from the AbbVie
submission, which is a reanalysis of the OASIS resource utilisation data using up-to-date published tariffs
(NHS Reference Costs 2012/13176 and PSSRU 2013179) (Table 93).
Adverse events
Only serious infections and tuberculosis reactivation were included in the economic model. Anti-TNF excess
rates versus CC for serious infections and tuberculosis reactivation for were sourced from the Cochrane review
of AEs137 which has been discussed in Chapter 3, Cost-effectiveness results: adverse events. The cost of a serious
infection was sourced from the Pfizer submission36 and was assumed to be £1457 based on a weighted
average of relevant HRG costs from NHS Reference Costs 2012/13176 (Table 94). The cost of tuberculosis was
estimated to be £3204.50 per episode and was based on a weighted average of the relevant HRG codes with
different levels of severity (codes DZ14C, DZ14D and DZ14E) from NHS Reference Costs 2012/13.
TABLE 94 Costs of serious infection (from Pfizer submission36)
HRG code HRG description Activity
National average
unit cost (£)
WA03C Septicaemia, with CC score 0–1 44,956 1792
DZ23G Bronchopneumonia with CC score 0–4 5231 1252
LA04M Kidney or urinary tract infections, with interventions, with CC score 0–2 2587 2289
PA16B Major infections with CC score 0 7859 1573
DZ22J Unspecified acute lower respiratory infection with CC score 0–1 21,109 657
DZ21U Chronic obstructive pulmonary disease or bronchitis, without NIV,
without intubation, with CC Score 0–3
52,421 1453
Weighted average cost (£) 1457
CC, complications; NIV, non-invasive ventilation.
Activity refers to how many times each HRG has been used.
Source: NHS Reference Costs schedule 2012/13.176
TABLE 93 Disease-related costs
Cost (£) Source
£1284.186 × exp(0.213 × BASFI) AbbVie submission;34 reanalysis of OASIS118 data
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Mortality
Sex-specific SMRs are applied to the mortality rates from the general population to calculate separate
adjusted mortality rates for AS and nr-AxSpA populations in the model.16
Analytic methods
The expected costs and QALYs of the alternative anti-TNFs are estimated and cost-effectiveness assessed
based on the incremental cost per additional QALY gained. As an assumption is made concerning the
similarity in terms of clinical effect between the alternative anti-TNFs, the differences between each of the
treatments are driven entirely by their respective acquisition, administration and monitoring costs. Under
this assumption, inevitably the lowest cost TNF-α inhibitor would clearly dominate (i.e. lower cost and
equal effect) in a fully incremental comparison of cost-effectiveness. Consequently, each TNF-α inhibitor is
compared separately versus CC alone. This provides a more consistent basis for assessing the impact that
the different drug costs have across each separate scenario.
Probabilistic sensitivity analysis is used to assess the implications of parameter uncertainty (the imprecision
with which input parameters are estimated). The mean costs and QALY reported in the tables are derived
from the PSA and the probabilities that each TNF-α inhibitor is more cost-effective than CC alone are
reported at thresholds of £20,000 and £30,000 per QALY.
Sensitivity analyses
A number of separate scenarios are presented to assess the implications of key parameter assumptions and
sources of structural uncertainty in the model. These include the following.
Scenario 1: no response to conventional care assumed at 12 weeks
The base-case model incorporates the probability of response to CC at 12 weeks and assigns separate
baselines to responders and non-responders. Although the changes in BASDAI/BASFI estimated at
12 weeks for CC are assumed to disappear in the following 12-week cycle, the separate baselines
estimated for responders and non-responders are retained for the remainder of the model horizon. Given
uncertainties surrounding the nature of the ‘placebo’ response assumed to apply to CC and whether or
not this would be evident in actual clinical practice, a separate scenario was modelled which assumed that
no patients receiving CC would achieve a BASDAI 50 response. This scenario was based on a separate
simulation using the extended synthesis model where the magnitude of ‘placebo’ effect was assumed to
be 0. Hence, employing this scenario, the impact of the ‘placebo’ effect is effectively netted out of the
model for both CC and the anti-TNFs. Hence, although the difference in response rates and BASDAI/BASFI
scores for responders to anti-TNFs remains similar to the base-case model, the absolute response rate for
anti-TNFs and the absolute BASDAI/BASFI scores are lower when the adjustment is applied. In addition, as
no response is assumed for CC, a single baseline BASDAI and BASFI score is applied to CC patients.
Scenario 2: different baselines assumed for responders and non-responders
In the base-case analysis, the extended synthesis model is used to estimate both changes in BASDAI and
BASFI conditional upon BASDAI 50 response as well as different baseline BASDAI/BASFI scores for
responder and non-responders. It was noted in Chapter 5 that there appeared a disparity in the magnitude
of the difference in the conditional baseline scores estimated from the extended synthesis model compared
with the differences reported by those manufacturers who provided additional data on request.
Specifically, the difference between responders and non-responders appeared higher in our extended
synthesis compared with the direct data reported by manufacturers. To explore the potential impact of this
difference on the cost-effectiveness results, a separate scenario was undertaken wherein the difference in
the conditional baselines was based on a pooled estimate of the differences across the trials provided by
manufacturers rather than those estimated by the extended synthesis model.
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In addition to exploring the impact of assuming different baselines, this scenario also included a pooled
estimate of the change in BASDAI/BASFI scores for responders and non-responders reported by
manufacturers. Hence, in this scenario, the extended synthesis model is used only to predict the response
to BASDAI 50, the differences in the conditional baselines and change scores being derived from pooled
estimates from the data reported by manufacturers.
Scenario 3: no effect of anti-tumour necrosis factors on Bath Ankylosing
Spondylitis Functional Index progression
In the base-case model, a treatment effect is applied from year 4 of the model on the rate of further BASFI
progression for patients who continue to receive TNF-α inhibitors beyond this time point. Given the
uncertainty reported in Chapter 3 surrounding existing evidence for anti-TNFs in relation to disease
modification, a separate scenario was explored which assumed that the rate of BASFI progression would
be the same for patients receiving anti-TNFs and CC alone.
Scenario 4: treatment effect of anti-tumour necrosis factors applied from
start of model (Bath Ankylosing Spondylitis Functional Index progression)
A separate scenario was also undertaken assuming that the treatment effect on further BASFI progression
would be incurred from the start of the model, as opposed to year 4. This scenario assumes that any disease
modification would be achieved immediately compared with the delayed effect assumed in the base case.
Scenario 5: utilities – linear Bath Ankylosing Spondylitis Disease Activity
Index/Bath Ankylosing Spondylitis Functional Index model
The base-case analysis in both the AS and nr-AxSpA populations are based on the non-linear mapping
algorithms reported in the submission by Pfizer. A separate scenario was run in both populations using an
alternative linear model which has been applied in previous NICE appraisals (referred to as the ‘Merck
Sharp & Dohme’ algorithm in Health-related quality of life). This scenario was incorporated to explore the
impact of using a linear model and to provide results which are more consistent with the utility approach
applied in previous NICE appraisals (TA14317 and TA23333).
Scenario 6 (non-radiographic axial spondyloarthritis only): trials in
non-radiographic axial spondyloarthritis and ankylosing spondylitis
populations combined
The base-case analysis for the nr-AxSpA population is based on the extended synthesis model using only
the trials reporting in this population. A separate scenario was undertaken based on the results from the
extended synthesis model which combined the AS and nr-AxSpA trials.
Following the consultation process to the NICE appraisal, additional analyses were undertaken to address
comments received on Chapters 5 and 6. These focused on the conditional baseline BASDAI scores used in
Chapter 5 and on the existence of a biosimilar product for infliximab with a lower list price. Further details
on these analyses and their results are shown in Appendix 15.
Model validation
The conceptualisation of the model and related structural assumptions were informed by the review of
existing models and discussions with two clinical advisors. The face validity of the model structure, data
sources and key assumptions were addressed using inputs based on systematic reviews, targeted searching
and clinical input. Verification of the model and the associated inputs was undertaken using a staged
process. One researcher developed the initial model structure and the preliminary coding. This was then
checked and extended for the final model by a second researcher. Both researchers were subsequently
involved in the subsequent quality-assurance process entailing detailed cross-checks of input data against
their sources and undertook extensive logical checks and scenarios to assess the performance of the
model. Two other researchers were involved in further checks of key aspects including the integration of
the results from the extended synthesis within the Excel model. A fifth researcher was involved in all stages
with preparing and checking parameter inputs for the model. Cross-validation was assessed by comparing
the results with existing models and identifying differences and their causes.
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Results of the independent economic assessment
Base-case results: ankylosing spondylitis population
The base-case results for the AS population, for the alternative rebound assumptions, are reported in
Tables 95 and 96.
In the rebound equal to gain scenario, the ICER of the alternative anti-TNFs varied between £19,240
(certolizumab with the proposed PAS) to £40,576 per additional QALY (infliximab). Infliximab had the
highest ICER (£40,576 per QALY) and the lowest probability of being cost-effective at a £20,000 and
£30,000 per QALY threshold (0.001 and 0.089, respectively). Excluding infliximab, the ICERs of the other
anti-TNFs were similar, ranging from £19,240 (certolizumab with the proposed PAS) to £23,133
(certolizumab without the proposed PAS).
TABLE 95 Base-case cost-effectiveness results: AS (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£)
ICER
(£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.245 – 110,821 – – – –
Certolizumab
with PAS
8.163 0.918 128,485 17,665 19,240 0.550 0.895
Golimumab 8.163 0.918 130,173 19,352 21,079 0.427 0.841
Adalimumab 8.163 0.918 130,257 19,436 21,170 0.423 0.839
Etanercept 8.163 0.918 130,630 19,810 21,577 0.402 0.826
Certolizumab 8.163 0.918 132,059 21,238 23,133 0.299 0.761
Infliximab 8.163 0.918 148,073 37,252 40,576 0.001 0.089
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 96 Base-case cost-effectiveness results: AS (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£)
ICER
(£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.265 – 109,933 – – – –
Certolizumab
with PAS
7.867 0.603 130,277 20,344 33,762 0.035 0.399
Golimumab 7.867 0.603 131,960 22,027 36,554 0.019 0.299
Adalimumab 7.867 0.603 132,045 22,111 36,695 0.017 0.293
Etanercept 7.867 0.603 132,423 22,489 37,322 0.017 0.275
Certolizumab 7.867 0.603 133,851 23,918 39,693 0.011 0.203
Infliximab 7.867 0.603 150,022 40,088 66,529 0.000 0.001
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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As previously highlighted, the difference in the ICERs between the individual anti-TNFs is driven entirely by
the different acquisition and administration costs associated with each. Excluding infliximab, the probability
that each TNF-α inhibitor was more cost-effective than CC alone ranged between 0.299 and 0.550 at a
£20,000 per QALY threshold and between 0.761 and 0.895 at a £30,000 threshold. There was less
variation in these probabilities when the proposed PAS for certolizumab was included, ranging from 0.402
to 0.550 at a £20,000 per QALY threshold and from 0.826 to 0.895 at a £30,000 threshold.
In the rebound to CC scenario, the ICER of the alternative anti-TNFs varied between £33,762 (certolizumab
with the proposed PAS) to £66,529 per additional QALY (infliximab). Infliximab had the highest ICER
(£66,529 per QALY) and the lowest probability of being cost-effective at a £20,000 and £30,000 per QALY
threshold (0.000 and 0.001, respectively). Excluding infliximab, the ICERs of the other anti-TNFs varied
between £33,762 (certolizumab with the proposed PAS) to £39,693 (certolizumab without the proposed
PAS) and the probability that each TNF-α inhibitor was more cost-effective than CC alone ranged between
0.011 and 0.035 at a £20,000 per QALY threshold and between 0.203 and 0.399 at a £30,000 threshold.
There was less variation in these probabilities when the proposed PAS for certolizumab was included,
ranging from 0.017 to 0.035 at a £20,000 per QALY threshold and from 0.275 to 0.399 at a
£30,000 threshold.
Base-case results: non-radiographic axial spondyloarthritis population
The base-case results for the nr-AxSpA population, for the alternative rebound assumptions, are reported
in Tables 97 and 98.
TABLE 98 Base-case cost-effectiveness results: nr-AxSpA (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£)
ICER
(£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.963 – 90,219 – – – –
Certolizumab
with PAS
11.200 1.237 131,714 41,495 33,555 0.057 0.396
Adalimumab 11.200 1.237 133,109 42,890 34,684 0.038 0.343
Etanercept 11.200 1.237 133,859 43,640 35,290 0.035 0.318
Certolizumab 11.200 1.237 135,286 45,067 36,444 0.029 0.284
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 97 Base-case cost-effectiveness results: nr-AxSpA (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£)
ICER
(£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.956 – 89,493 – – – –
Certolizumab
with PAS
11.351 1.395 128,911 39,418 28,247 0.139 0.591
Adalimumab 11.351 1.395 130,316 40,823 29,253 0.106 0.545
Etanercept 11.351 1.395 131,057 41,563 29,784 0.093 0.529
Certolizumab 11.351 1.395 132,484 42,991 30,807 0.066 0.482
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
DOI: 10.3310/hta20090 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 9
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
153
In the rebound equal to gain scenario, the ICER of the alternative anti-TNFs varied between £28,247
(certolizumab with the proposed PAS) and £30,807 per additional QALY (certolizumab without the
proposed PAS). The probability that each TNF-α inhibitor was more cost-effective than CC alone ranged
between 0.066 and 0.139 at a £20,000 per QALY threshold and between 0.482 and 0.591 at a £30,000
threshold. Again, there was less variation in these probabilities when only the proposed PAS for
certolizumab was considered, ranging from 0.093 to 0.139 at a £20,000 per QALY threshold and from
0.529 to 0.591 at a £30,000 threshold.
In the rebound to CC scenario, the ICER of the alternative anti-TNFs varied between £32,528 (certolizumab
with the proposed PAS) and £35,365 per additional QALY (certolizumab without the proposed PAS). The
probability that each TNF-α inhibitor was more cost-effective than CC alone varied between 0.030 and
0.062 at a £20,000 per QALY threshold and between 0.312 and 0.429 at a £30,000 threshold. Again,
there was less variation in these probabilities when only the proposed PAS for certolizumab was included,
ranging from 0.039 to 0.062 at a £20,000 per QALY threshold and from 0.369 to 0.429 at a
£30,000 threshold.
Sensitivity analyses results: ankylosing spondylitis population
Table 99 summarises the scenarios undertaken for the AS population.
Each of these scenarios was undertaken for the two alternative rebound assumptions. Tables 100 and 101
summarise the ICER estimates for each scenario. Full ICER tables for each scenario are reported in Appendix 16.
TABLE 99 Summary of cost-effectiveness scenarios: AS population
Number Parameter/structural Approach in scenario Approach in base case
1 CC (‘placebo’) response No response to CC assumed at 12 weeks Response to CC included at
12 weeks
2 Different baselines assumed for
responders and non-responders
and change in BASDAI/BASFI
scores
Separate baselines based on pooled
estimates provided by manufacturers.
Changes in BASDAI/BASFI conditioned
on response also based on pooled
estimates provided by manufacturers
Separate baselines and changes
in BASDAI/BASFI conditioned
on responses estimated via
extended synthesis model
3 BASFI progression No effect of anti-TNFs on BASFI
progression
Treatment effect applied from
year 4 onwards
4 BASFI progression Treatment effect of anti-TNFs applied
from start of model
Treatment effect applied from
year 4 onwards
5 Utilities Linear BASDAI/BASFI model (based on
Kobelt et al.152)
Non-linear BASDAI/BASFI
model (Pfizer submission36)
TABLE 100 Summary of ICERs across scenarios (rebound equal to gain): AS population
Strategy Base case (£)
Scenario (£)
1 2 3 4 5
Conventional therapy – – – – – –
Certolizumab (with PAS) 19,240 20,319 11,527 20,655 18,466 23,290
Golimumab 21,079 22,920 12,785 22,581 20,213 25,469
Adalimumab 21,170 23,013 12,851 22,677 20,301 25,579
Etanercept 21,577 23,425 13,143 23,106 20,695 26,073
Certolizumab 23,133 25,495 14,220 24,739 22,180 27,926
Infliximab 40,576 43,510 26,699 43,125 39,037 49,021
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The ICER estimates appeared to remain relatively stable across the majority of scenarios compared with the
base-case ICER estimates. The exception to this appeared to be scenario 2 which used data submitted on
request by several manufacturers which was used to inform the differences in the conditional baselines
and the change scores assumed for responders versus non-responders. In summary, when the
manufacturer’s data were used, the ICER estimates became more favourable towards the anti-TNFs. The
more favourable results are driven by smaller differences between responders and non-responders in terms
of their conditional baselines and marginally higher differences in the conditional change scores. Both
differences result in improvements in the ICER estimates compared with the base-case results derived from
the extended synthesis model.
Sensitivity analyses results: non-radiographic axial spondyloarthritis population
Table 102 summarises the scenarios undertaken for the nr-AxSpA population.
Each of these scenarios was undertaken for the two alternative rebound assumptions. Tables 103 and 104
summarise the ICER estimates for each scenario. Full ICER tables for each scenario are reported in
Appendix 16.
TABLE 101 Summary of ICERs across scenarios (rebound to CC): AS population
Strategy Base case (£)
Scenario (£)
1 2 3 4 5
Conventional therapy – – – – – –
Certolizumab (with PAS) 33,762 34,229 25,530 36,518 32,222 29,414
Golimumab 36,554 38,068 27,986 39,483 34,910 31,827
Adalimumab 36,695 38,207 28,107 39,634 35,045 31,950
Etanercept 37,322 38,824 28,652 40,306 35,647 32,499
Certolizumab 39,693 41,885 30,731 42,828 37,928 34,554
Infliximab 66,529 68,815 54,045 71,565 63,684 58,022
TABLE 102 Summary of cost-effectiveness scenarios: nr-AxSpA population
Number Parameter/structural Approach in scenario Approach in base case
1 CC (‘placebo’) response No response to CC assumed at
12 weeks
Response to CC included at
12 weeks
2 Different baselines assumed for
responders and non-responders
and change in BASDAI/BASFI
scores
Separate baselines based on pooled
estimates provided by manufacturers.
Changes in BASDAI/BASFI conditioned
on response also based on pooled
estimates provided by manufacturers
Separate baselines and changes
in BASDAI/BASFI conditioned
on responses estimated via
extended synthesis model
3 BASFI progression No effect of anti-TNFs on BASFI
progression
Treatment effect applied from
year 4 onwards
4 BASFI progression Treatment effect of anti-TNFs applied
from start of model
Treatment effect applied from
year 4 onwards
5 Utilities Linear BASDAI/BASFI model (based on
Kobelt et al.152)
Non-linear BASDAI/BASFI
model (Pfizer submission36)
6 Treatment effect of anti-TNFs Trials in nr-AxSpA and AS populations
combined
Only trials in nr-AxSpA included
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In common with the AS scenarios, the ICER estimates appeared to remain relatively stable across the
majority of scenarios compared with the base-case ICER estimates. However, the impact of applying
adjustments to the conditional baseline estimates and BASDAI/BASFI scores provided by the manufacturers
(scenario 2) had less of an impact in the nr-AxSpA population. The scenario which showed the largest
variation compared with the base-case analysis was scenario 1. This scenario was based on results from the
extended synthesis which excluded any placebo effect and resulted in a single baseline applied to all CC
patients. The differences in the ICERs appear largely as a result of the impact of ignoring the non-linear
relationship between baseline BASDAI/BASFI scores because of variation in the baseline of responders
versus non-responders in scenario 1. Interestingly, the impact of this approach appears more marked in the
nr-AxSpA population, compared with the AS population, which is likely to be driven by several inter-related
factors including the magnitude of difference assumed between the conditional baseline scores and the
absolute BASDAI and BASFI scores which differ across the populations.
Discussion and comparison with manufacturer models
Based on an underlying assumption of similarity in the clinical effectiveness of each of the anti-TNFs, the
York model demonstrates that the cost-effectiveness results are dependent on several factors, including
(1) the different acquisition and administration costs; (2) the rebound assumption applied to patients who
discontinue therapy; (3) the magnitude of the change in BASDAI/BASFI scores assumed for responders
versus non-responders; (4) the different baseline BASDAI/BASFI scores assumed for responders versus
non-responders; and (5) the impact of anti-TNFs on the rate of longer-term BASFI progression.
Interestingly, the importance of specific factors also appears to vary across the separate indications. For
example, the impact of the alternative rebound assumptions appears more marked in the AS population
compared with the nr-AxSpA population. This appears largely driven by the smaller rate of BASFI
progression applied in the York model to the nr-AxSpA population, such that the impact of alternative
TABLE 103 Summary of ICERs across scenarios (rebound equal to gain): nr-AxSpA population
Strategy Base case (£)
Scenario (£)
1 2 3 4 5 6
Conventional therapy – – – – – – –
Certolizumab (with PAS) 28,247 34,841 25,482 28,643 27,471 25,324 28,282
Adalimumab 29,988 37,884 27,302 29,670 28,466 29,228 29,512
Etanercept 29,253 38,507 27,821 30,208 28,988 29,753 30,041
Certolizumab 30,807 40,949 29,378 31,250 29,996 30,732 31,034
TABLE 104 Summary of ICERs across scenarios (rebound to CC): nr-AxSpA population
Strategy Base case (£)
Scenario (£)
1 2 3 4 5 6
Conventional therapy – – – – – – –
Certolizumab (with PAS) 32,528 40,928 29,884 34,416 31,841 26,900 33,184
Adalimumab 33,639 44,365 31,942 35,615 32,940 27,850 34,270
Etanercept 34,232 45,078 32,528 36,241 33,523 28,343 34,866
Certolizumab 35,365 47,842 34,288 37,456 34,642 29,303 35,985
INDEPENDENT ECONOMIC ASSESSMENT: YORK MODEL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
156
assumptions regarding possible rebound effects has a less significant impact within this population.
This difference also has an important bearing on the subsequent interpretation of the base-case ICERs
estimated by the York model in the separate populations. Our findings suggest that the ICER estimates
for anti-TNFs appear more favourable for the AS population, relative to those estimated for the
nr-AxSpA population, based on the rebound equal to gain scenario. The more favourable results in the
AS population based on the rebound equal to gain scenario appear to be driven by two main factors:
(1) the smaller conditional change in BASDAI/BASFI scores estimated for the nr-AxSpA population and
(2) the lower rate of BASFI progression assumed for the nr-AxSpA population. However, this finding
appears reversed in the rebound to CC scenario. Interestingly, within this scenario, the lower conditional
change in BASDAI/BASFI scores appears offset by the less significant influence of BASFI progression in the
nr-AxSpA model, that is the impact on the ICERs of the two rebound assumptions is closely related to
the underlying rate of BASFI progression assumed and the contribution that this makes to the ICER
estimates under the separate scenarios. However, it should also be noted that, although the ICERs for
the nr-AxSpA population appear more favourable in this scenario compared with those estimated for the
AS population, all of the ICER estimates exceeded £30,000 per QALY in the York base case across
both populations.
Tables 105 and 106 compare the results of the York model with the base-case results reported by each
manufacturer for the alternative populations. In contrast to the manufacturer models which reported a
single base case based on an assumption of either rebound equal to gain (AbbVie, Pfizer, Merck Sharp &
Dohme) or rebound to CC (UCB), the York model presents both rebound scenarios in order to represent
the potential limits to the ICER; recognising that the reality lies somewhere between these scenarios.
TABLE 106 Comparison of cost-effectiveness results from York model vs. manufacturers (nr-AxSpA population)
Strategy
AbbVie
(adalimumab),
ICER (£)
UCB (certolizumab),
ICER (£)
Pfizer (etanercept),
ICER (£)
York (rebound
equal to gain),
ICER (£)
York (rebound
to CC), ICER (£)
CC – – – – –
Adalimumab 13,228 30,370 23,242 29,988 33,639
Certolizumab 12,866 15,615a 23,575a 28,247a 32,528a
Etanercept Not assessed 50,692 23,195 29,253 34,232
a PAS costs assumed for certolizumab.
TABLE 105 Comparison of cost-effectiveness results from York model vs. manufacturers (AS population)
Strategy
AbbVie,
ICER (£)
UCB,
ICER (£)
Pfizer,
ICER (£)
Merck Sharp &
Dohme, ICER (£)
York (rebound
equal to gain),
ICER (£)
York (rebound
to CC), ICER (£)
CC – – – – – –
Adalimumab 16,391 19,932 20,909 19,275 21,170 36,695
Certolizumab 17,067 16,647a 19,586a 19,401a 19,240a 33,762a
Etanercept 16,897 19,272 20,938 21,972 21,577 37,322
Golimumab 16,535 19,049 21,288 19,070 21,079 36,554
Infliximab 44,448 42,671 37,741 42,532 40,576 66,529
a PAS costs assumed for certolizumab.
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Although there are a number of important differences in approaches both among the different
manufacturer models and compared with the York model, the comparison of ICERs based on the York
rebound equal to gain scenario appear broadly consistent in the AS population. This might appear
surprising given that the York model is based on two key assumptions that appear less favourable than
those used by manufacturers, specifically: (1) incorporating separate baseline BASDAI/BASFI scores for
responders and non-responders which assume that responders are likely to be less severe in terms of their
baseline BASDAI and BASFI scores than non-responders; and (2) only incorporating an effect of anti-TNFs
on disease progression for patients remaining on therapy for at least 4-years. However, these appear
counterbalanced by the higher rate of BASFI progression applied to AS patients [0.082 (0–10 scale) units
per annum compared with estimates between 0.056 and 0.07 assumed by the manufacturers]. As we
highlighted at the start of this section, it is our view that the York model has a more coherent basis for
modelling longer-term BASFI progression.
Another important counterbalancing effect is the use of the conditional scores for responders and
non-responders obtained via the extended synthesis within the York model. This contrasts with the
selective approaches (i.e. using conditional scores from single studies or assumptions) or use of longer-term
follow-up and/or open-label sources (i.e. implicitly assuming that patients who continue to participate in
longer-term follow-up and open label sources are more likely to be responders than patients who do not).
Consequently, the change scores assumed in the York model for BASDAI 50 responders appear higher
than those assumed by several of the manufacturers. The approach applied within the York model is based
on a more generalised framework for synthesis and hence utilises more evidence than considered by the
manufacturers. This approach directly informs the conditional change scores which are fundamental to an
appropriate assessment of the cost-effectiveness when a response-based assessment is incorporated to
determine eligibility for continued treatment.
In Chapter 4 it was noted that there appeared more variation in the ICER estimates reported across
the manufacturer’s submissions in the nr-AxSpA population compared with those reported in the AS
population. Again, the ICER estimates reported by the York model in the nr-AxSpA population do not
appear inconsistent with the range of ICERs reported across the separate manufacturers. However,
any attempt to formally cross-validate the results from the York model with those reported by the
manufacturers is difficult given the contrasting approaches and assumptions employed. As the York model
uses several of the key parameter inputs reported in the submission by Pfizer,36 a comparison may be more
usefully made by comparing the results of the York model and those reported by Pfizer. In general, the
ICER estimates appear less favourable in the York model compared with those reported by Pfizer. One
possible explanation for these differences is that the York model uses a lower rate of BASFI progression
and only assumes that anti-TNFs affect this rate after at least 4 years of treatment. However, our results
have also shown that the impact of progression appears less of a driver of cost-effectiveness in the
nr-AxSpA model. Another possible explanation is the use of different baselines assumed for responders and
non-responders assumed in the York model, that is the York model assumes that responders and typically
less severe in terms of baseline BASDAI/BASFI scores compared with non-responders. Consequently, an
additional scenario was undertaken using the York model to further assist in cross-validation. For this
scenario, an assumption was made that the responders and non-responders did not differ in terms of
baseline BASDAI/BASFI scores.
The results of the additional validation scenario are reported in Table 107. The ICERs in this scenario
appeared closer to those reported by Pfizer.36 Hence this additional validation scenario is important in
helping to identify potential drivers of difference between the results of the York model and those
reported by the manufacturers. The scenario also demonstrates that the assumption made concerning
potential differences (and the magnitude of any difference) between the baseline BASDAI/BASFI scores of
responders and non-responders has an important impact on the cost-effectiveness results. Hence, studies
which are based on similar baselines are likely to be potentially overly optimistic in the subsequent ICER
estimates reported for anti-TNFs. Equally, it might be argued that the results from the York base-case
model may be conservative towards the anti-TNFs because the magnitude of differences in the baseline
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scores estimated from the extended synthesis model appeared higher than those obtained on request from
manufacturers (although the direction of the difference was consistent). Hence, in a similar manner to
which the different rebound assumptions represent the potential limits on the ICER given uncertainties
surrounding rebound, the differences in the ICERs based on assuming no difference in baselines and the
magnitude of differences employed in the York base case may also represent the limits of the ICER based
on uncertainty surrounding the magnitude of this difference. Given the potential importance of this
assumption, Appendix 16 reports the full ICER results for each population (and under each rebound
assumption) assuming identical baselines for responders and non-responders.
Although the York model provides a number of significant developments to existing cost-effectiveness
analyses, there are still several potential limitations. First, in common with all existing models, subsequent
linkages to costs and QALYs are related to BASDAI and BASFI, largely because of the existence of data.
Second, the cost-effectiveness estimates are based on uncertain projections of BASDAI and BASFI over a
longer time horizon in order to generate more appropriate lifetime estimates of costs and QALYs required
for cost-effectiveness assessments. Although extensive efforts have been made to identify a more
appropriate basis for informing these longer-term estimates (particularly for BASFI), inevitably, significant
uncertainty remains. Third, it should be noted that there are potential benefits which have not been
formally captured and quantified within the current model, specifically any potential impact on productivity
costs and any additional benefits that anti-TNFs may confer for other comorbidities (e.g. inflammatory
bowel disease, psoriasis, etc.). A final limitation is that it was not possible to include the biosimilar version
of infliximab (CT-P13) within the analysis as a formal list price was not available at the time of
the assessment.
In addition, the York model has not specifically addressed important clinical questions concerning the issue
of intermittent and sequential use of anti-TNFs. However, in the absence of robust clinical evidence from
RCTs, existing evidence is clearly subject to potential confounding. Consequently, existing attempts to
model sequential therapy within the current manufacturer’s submissions (Pfizer36 only) are largely based on
applying simple adjustments to first-line efficacy but which are unlikely to provide a robust basis for
informing these decisions. Clearly, until such time that more robust data are available, a rough rule of
thumb could similarly be applied to the results presented from the York model, such that the ICERs of a
second-line TNF-α inhibitor in a patient who had previously responded but subsequently lost response,
might be in the order of one-third higher than the results presented here.
TABLE 107 Non-radiographic axial spondyloarthritis: additional validation scenario (rebound equal to gain and
responders/non-responders do not differ in terms of baseline BASDAI/BASFI scores)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.977 – 88,692 – – – –
Certolizumab
(with PAS)
11.551 1.574 125,205 36,513 23,199 0.390 0.759
Adalimumab 11.551 1.574 126,606 37,914 24,089 0.341 0.733
Etanercept 11.551 1.574 127,350 38,658 24,562 0.319 0.720
Certolizumab 11.551 1.574 128,777 40,085 25,469 0.272 0.702
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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Finally, it is important to appreciate that the assessments of cost-effectiveness reported in the York model
are based on a normative approach, that is they are based on the assumption that 12-week continuation
rules (and ongoing monitoring of response) would be fully adhered to in clinical practice. Hence, they do
not necessarily reflect the cost-effectiveness of how anti-TNFs are currently used in the management of AS
within the NHS or how they might be used, in the event of positive guidance from the NICE in nr-AxSpA.
The findings of West Midland Rheumatology Audit from 2010 give some grounds for potential concern.181
This regional audit was undertaken to assess compliance with the NICE guidelines (TA14317) in 17
rheumatology centres across the East and West Midlands. The findings from this audit revealed that (1) the
proportion of patients being assessed at 12 weeks after treatment initiation was suboptimal; (2) fewer
than 20% of patients with an inadequate response at 12 weeks had their treatment discontinued; and
(3) fewer than half of the patients received regular 12-weekly assessments. During the course of our
assessment we contacted the British Society for Rheumatology Biologics Register (BSRBR) Ankylosing
Spondylitis Register to assess the feasibility of obtaining access to data which has been collected since the
register was set up in 2012. Although our request was positively received, it was clear during ongoing
discussions that the data and analyses requested could not be undertaken within the time frame of
our assessment.
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Chapter 7 Assessment of factors relevant to the
NHS and other parties
The results of this technology assessment have some implications for clinical practice. Existing NICEguidance recommends adalimumab, certolizumab, etanercept and golimumab for the treatment of AS
and therefore the use of these drugs is already widespread in the NHS. However, in the light of the
additional evidence presented here, the use of these agents in AS may increase further.
Furthermore, the available clinical evidence indicates that adalimumab, certolizumab and etanercept are
effective in patients with nr-AxSpA, although there is some uncertainty regarding the definition of the
nr-AxSpA patient population who would benefit most from these anti-TNFs. The effectiveness
demonstrated in the nr-AxSpA population suggests that early treatment of AS/nr-AxSpA patients is
warranted. A key study on flares in AS suggested that the 12-week period required to confirm sustained
active spinal disease in AS patients commencing an anti-TNF may be too long. The findings suggest that
shorter time periods may therefore be considered in future guidance, which would minimise the delay in
starting treatment and the discomfort experienced by patients.
The potential extra cost to the NHS of providing anti-TNFs for patients with nr-AxSpA in addition to AS
patients is unclear because the prevalence of nr-AxSpA in the UK is somewhat uncertain. The potentially
large volume of new patients to be assessed for eligibility for anti-TNF treatment could add a large burden
to existing services. NICE guidance recommending the use of adalimumab, certolizumab and etanercept in
nr-AxSpA would further increase the impact of these agents on the NHS budget.
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Chapter 8 Discussion
Statement of principal findings
The systematic review of clinical efficacy identified a substantial and, generally, high-quality evidence base
on the efficacy and safety of anti-TNFs in patients with AS, either as individual treatments or as a common
class; there was limited evidence to suggest meaningful differences between the therapies in terms
of efficacy, other than infliximab providing more rapid improvements during the first few months of
treatment. The results of our meta-analyses demonstrated that anti-TNFs (when compared with placebo)
produce statistically significant and clinically important benefits in patients with AS in terms of improving
function and reducing disease activity over a 3- to 6-month period (none of the trials maintained
randomised treatment allocations across groups beyond 6 months). Of the limited number of trials which
reported quality-of-life outcomes, significant improvements were found following anti-TNF therapy but very
few data were available on efficacy relating to any peripheral symptoms (other than enthesitis) or other
possible symptoms such as uveitis, inflammatory bowel disease and psoriasis.
Although far fewer trials have been performed in the nr-AxSpA population, similar, although slightly
smaller, benefits were achieved. The smaller benefit was most noticeable for the function (BASFI) and
disease-activity (BASDAI 50) outcomes. However, in the nr-AxSpA trials, both clinical and statistical
heterogeneity were evident, bringing into question both the reliability of the nr-AxSpA meta-analysis
results and their true relevance to patients seen in clinical practice. This heterogeneity may have been
compounded by the inclusion criteria applied in previous nr-AxSpA trials. For example, ABILITY-158
recruited patients who fulfilled the ASAS classification criteria and relied on the expertise of the local
clinicians and/or radiologists to read sacroiliac joint radiographs and MRI images, as happens in real clinical
practice. RAPID-axSpA64 selected its population carefully by requiring objective evidence of disease activity
at study entry by either a positive MRI showing signs of sacroiliac joint inflammation according to the
ASAS/OMERACT definition or an elevated than normal CRP level. The difficulty of identifying which
nr-AxSpA patients should receive anti-TNFs remains.
Results from open-label trial extension studies suggested that across all the anti-TNFs around half of
patients still achieve a good level of response after around 2 years of treatment. The data also suggest that
at 5 years around 60% of golimumab patients, 50% of etanercept patients and 30% of adalimumab
patients still achieve a good treatment response. However, these longer-term studies were not as
well-reported as the RCTs, and their results were derived from less reliable data; it is therefore unknown
if these are true treatment differences or if they are a result of differences in the follow-up protocols
(e.g. stopping rules) and/or methods used to impute missing data.
Evidence for an effect of anti-TNFs on radiographic disease progression was limited; the relatively
short-term follow-up available to date and the insensitivity of radiography as an imaging tool precluded
the drawing of firm conclusions regarding the role of anti-TNFs in preventing or delaying the progression
of AS. There are some data to suggest an identifiable benefit from around 4 years but results from
ongoing long-term studies should help to clarify this issue.
The results from studies based on registry data demonstrated that sequential treatment with anti-TNFs can
be worthwhile in patients with AS. However, the drug survival, response rates and benefits were reduced
with second and third anti-TNFs, with the proportion of BASDAI 50 responders falling approximately
10% with each subsequent anti-TNF and the median BASDAIs and BASFIs achieved increasing (worsening).
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Data from large systematic reviews, which included patients with a wide range of diseases, suggest that,
in the short-term, anti-TNFs as a group are associated with significantly higher rates of serious infections,
tuberculosis reactivation, non-melanoma skin cancer, total AEs and withdrawals because of AEs than
control treatments. Specifically, infliximab is associated with significantly higher rates of total AEs and
withdrawals because of AEs, and certolizumab pegol is associated with significantly higher rates of serious
infections and SAEs. Evaluations of longer-term data are more scarce and are limited by small sample sizes
and uncontrolled designs. They suggest similar safety profiles across anti-TNFs, other than a higher
incidence of injection site reactions following treatment with etanercept.
The systematic review of cost-effectiveness studies revealed significant conceptual issues and uncertainties
arising from previously published studies and the submissions made by manufacturers. For this reason, a
de novo model (‘York model’) was developed. Although it shared some of the assumptions and parameter
estimates from the manufacturer models, it was based on a different conceptual structure and applies a
more generalised framework for the synthesis of data from the double-blind periods of existing RCTs,
combined with a more explicit approach to modelling the progressive nature of AS and nr-AxSpA and the
potential impact of the TNF-α inhibitors.
Based on an underlying assumption of similarity in the clinical effectiveness of each of the TNF-α inhibitors,
the York model demonstrates that the cost-effectiveness results are dependent on several factors, including
(1) the different acquisition and administration costs; (2) the rebound assumption applied to patients who
discontinue therapy; (3) the magnitude of the change in BASDAI/BASFI scores assumed for responders
versus non-responders; (4) the different baseline BASDAI/BASFI scores assumed for responders versus
non-responders; and (5) the impact of TNF-α inhibitors on the rate of longer-term BASFI progression.
Although there are a number of important differences in approaches both among the different
manufacturer models and compared with the York model, the comparison of ICERs based on the York
rebound equal to gain scenario appear broadly consistent with those reported by the manufacturers in
both populations.
Strengths and limitations of the assessment
Strengths
Through our comprehensive searches we sought to identify all relevant published and unpublished trials,
which minimised the possibility of publication or language biases affecting the review results. A full
evaluation of the risk of bias in each RCT was performed, which incorporated an additional assessment of
key baseline characteristics to allow firmer judgements to be made on the risk of selection bias. The use
of multiple-treatment meta-analyses allowed for greater precision in random-effect models, and the
calculation of relative risks was based on the population risk across all the trials. A key further strength of
our review lies in the extensive breadth of other types of study we included, such as non-randomised trial
extension studies, registry studies of patients taking anti-TNFs, systematic reviews and other large studies
of adverse effects of anti-TNFs and a review of the natural history of AS and nr-AxSpA. Our review of
AEs incorporated a wealth of data from RCTs in patients on anti-TNFs with diseases other than AS and
nr-AxSpA, although the results only relate to short-term use. Our review was performed according to
Centre for Reviews and Dissemination guidance, so the potential for reviewer errors and biases was
minimised. Our review was reported according to the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) statement.
The York model confers several advantages over current cost-effectiveness studies by linking changes in
BASFI to a more explicit clinical/biological process and facilitating a more formal consideration of the
potential impact of TNF-α inhibitors on BASFI, via the specific effects these drugs have on the different
processes which independently relate to this parameter. This approach allows consideration of the impact
on BASFI that might be achieved via symptomatic improvements (i.e. in terms of reductions in disease
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activity) and those which might be conferred by disease modification properties (i.e. the effect on the
likelihood and/or rate of further radiographic progression). The latter aspect is particularly important
given the increasing amount of published evidence reported on the potential impact of TNF-α inhibitors
on radiographic progression that has not been formally considered or incorporated within existing
cost-effectiveness studies. In addition, the evidence synthesis approach which underpins the York model is
based on a joint synthesis of related parameters which makes fuller use of existing evidence and which can
more appropriately estimate the input parameters and better characterise the uncertainty surrounding these.
Limitations
A key limitation of the systematic review was the variation in the reporting of outcomes across trials. ASAS
20 was the most commonly reported responder outcome, but its value in determining efficacy was
somewhat limited by the relatively high rates of ‘placebo’ response associated with the 20% threshold.
Results for 40%, 50% and 70% improvements (i.e. ASAS 40, ASAS 50 and ASAS 70) were reported less
frequently, despite the fact that trial investigators would have had the data available to do so. Many trials
did not report HRQoL outcomes and most trials were also limited in their assessment (or reporting) of
improvement in any peripheral symptoms or symptoms of extra-articular manifestations. Although largely
free of important biases, most RCTs had quite short durations (generally around 3 months) and several
were limited by their small sample sizes (increasing the possibility of chance results for some outcomes).
Although we sought data beyond those available from RCTs, much of the data reported in studies
using other designs may have been affected by biases or confounding; furthermore, key method details
(e.g. imputation methods, or anti-TNF stopping rules) were often absent from publications. Much less
reliability and certainty could therefore be ascribed to the results obtained from these other studies.
The York model did not directly address important clinical questions concerning the issue of intermittent
and sequential use of anti-TNFs because of the lack of robust clinical evidence from RCTs.
Uncertainties
l The magnitude of treatment effect of anti-TNFs in patients with nr-AxSpA remains uncertain because
of the heterogeneous nature of the trials performed to date.
l The limited design and reporting of the studies looking at the long-term use of anti-TNFs means there
is uncertainty whether or not there are differences in efficacy between the different anti-TNFs in the
long term.
l The evidence on the long-term risk of AEs is uncertain because of small study sample sizes and the
study designs used.
l The long-term impact of anti-TNFs on other important outcomes in AS and nr-AxSpA remain uncertain,
such as AS-related causes of death (cardiac valvular disease, amyloidosis and fractures), and
extra-articular symptoms such as uveitis, inflammatory bowel disease and psoriasis. Studies based on
ongoing anti-TNF registries (e.g. BSRBR) that record such data should inform this.
l With the patents of some anti-TNFs studied in this assessment due to expire shortly, biosimilars are
likely to become available in the next few years (CT-P13 became available early in 2015). As they are
difficult to produce, the number of biosimilars which will become available, and their price, is uncertain.
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Chapter 9 Conclusions
Meta-analysis results derived from a substantial and, generally, high-quality evidence base on theefficacy of anti-TNFs in patients with AS (considered either as individual treatments or as a common
class) show statistically significant and clinically important benefits in terms of improved function and
reduced disease activity following around 3 months of treatment with an anti-TNF. Smaller benefits were
seen across outcomes in patients with nr-AxSpA, being most noticeably smaller for the function and
disease-activity outcomes. However, in the light of the clinical and statistical heterogeneity seen across the
nr-AxSpA trials, both the reliability of the nr-AxSpA-pooled estimates and their true relevance to patients
seen in clinical practice are questionable. Data from (less robust) observational studies suggest that good
levels of treatment response are maintain in around 50% of patients after around 2 years of treatment.
Evidence for an effect of anti-TNFs on radiographic disease progression is limited, although results from
ongoing studies should clarify whether or not progression rates are reduced in the longer term. The results
from studies based on registry data demonstrated that sequential treatment with anti-TNFs can be
worthwhile in patients with AS, although drug survival, response rates and benefits were reduced with
second and third anti-TNFs. Data from large systematic reviews, which included patients with a wide range
of diseases, suggested that, in the short term, anti-TNFs as a group were associated with significantly
higher rates of serious infections, tuberculosis reactivation, non-melanoma skin cancer, total AEs and
withdrawals because of AEs than control treatments. Longer-term data on AEs were limited.
Implications for service provision
l From our review of natural history a key study on flares suggested that the 12-week period required
to confirm sustained active spinal disease in AS patients commencing an anti-TNF may be too long.
The findings suggest that shorter time periods might therefore be considered in future guidance,
which would minimise the delay in starting treatment and the discomfort experienced by patients.
Suggested research priorities
l Randomised trials are needed to identify the nr-AxSpA population that will benefit the most from
TNF-inhibitors; trials using stratified randomisation and pre-planned analyses by stratified group should
inform this issue. Groups could be stratified according to their imaging status (i.e. MRI positive or not)
and their CRP level; both the cut-off points to be used for CRP level elevation, and the eligibility criteria
used for CRP level elevation, should be given careful consideration, given the variation evident in
previous trials. These studies should help to inform clearer guidance as to what ASAS and the anti-TNF
licences mean when referring to ‘elevated CRP level’ in patients with nr-AxSpA. There is also a clear
need for more accurate biomarkers, or other measures of disease activity, to be developed. In the
previous nr-AxSpA trials the placebo-controlled phases typically lasted around 3 months; a
placebo-controlled follow-up period of at least 6 months in future trials would therefore be useful for
studying persistence of response.
l Long-term longitudinal studies are needed on the natural history of nr-AxSpA to help clarify the
characteristics of patients who do (or do not) eventually develop AS. Similar to the RCT recommendations,
these studies should include analyses stratified by how patients were diagnosed; a comparison of patients
with imaging (MRI) evidence of nr-AxSpA versus patients who are diagnosed with only clinical criteria
evidence, would be particularly useful, albeit difficult to perform.
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l Large, long-term longitudinal, cohort studies are needed to clarify the effect of anti-TNFs on the
progression of structural damage in AS. In the absence of a gold standard imaging tool across the
spectrum from nr-AxSpA to AS, sequential MRI and radiography assessment should be used at
pre-defined end points to ascertain the true sensitivity and specificity of these tools in the diagnosis
and assessment of neo-formation, and ankyloses characteristic of structural progression in the spine
and sacroiliac joints of these patients.
Studies are also needed to better inform the efficacy estimates relating to sequential use of anti-TNFs.
An ongoing study is looking at comparing the effect of intermittent versus standard use of anti-TNFs in
patients with stable (low-active) disease.182
CONCLUSIONS
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Appendix 1 Search strategies for clinical and
economic reviews
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (Ovid)
Date range searched: 1946 to present.
Searched: 5 June 2014 via OVID interface.
Search strategy
1. spondylarthritis/ or spondylitis, ankylosing/ (12,386)
2. ((ankyl$ or axial) adj2 spondyl$).ti,ab. (10,322)
3. (ankyl$ adj2 (spine$ or spinal or vertebra$)).ti,ab. (402)
4. ((Bechtere$ or Bekhtere$ or “Marie Strumpell$” or “Marie Struempell$”) adj2 (disease or
syndrome)).ti,ab. (451)
5. 1 or 2 or 3 or 4 (14,886)
6. (adalimumab or humira or 331731-18-1).af. (3751)
7. (certolizumab or CDP870 or cimzia or 428863-50-7).af. (497)
8. (etanercept or enbrel or altebrel or 185243-69-0).af. (5540)
9. (golimumab or CNTO 148 or simponi or 476181-74-5).af. (328)
10. (infliximab or remicade or 170277-31-3 or inflectra or remsima or CT-P13).af. (9166)
11. 6 or 7 or 8 or 9 or 10 (13,950)
12. randomized controlled trial.pt. (375,396)
13. controlled clinical trial.pt. (88,473)
14. randomized.ab. (295,232)
15. placebo.ab. (154,473)
16. drug therapy.fs. (1,704,080)
17. randomly.ab. (213,686)
18. trial.ab. (306,623)
19. groups.ab. (1,359,351)
20. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 (3,348,700)
21. animals/ not (animals/ and humans/) (3,855,883)
22. 20 not 21 (2,872,482)
23. 5 and 11 and 22 (1008)
EMBASE
Date range searched: 1974 to week 22, 2014.
Searched: 5 June 2014 via OVID interface.
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Search strategy
1. exp spondylarthritis/ or exp ankylosing spondylitis/ (20,531)
2. ((ankyl$ or axial) adj2 spondyl$).ti,ab. (14,760)
3. (ankyl$ adj2 (spine$ or spinal or vertebra$)).ti,ab. (542)
4. ((Bechtere$ or Bekhtere$ or “Marie Strumpell$” or “Marie Struempell$”) adj2 (disease or
syndrome)).ti,ab. (551)
5. 1 or 2 or 3 or 4 (22,426)
6. (adalimumab or humira or 331731-18-1).af. (15,439)
7. (certolizumab or CDP870 or cimzia or 428863-50-7).af. (3097)
8. (etanercept or enbrel or altebrel or 185243-69-0).af. (19,368)
9. (golimumab or CNTO 148 or simponi or 476181-74-5).af. (2124)
10. (infliximab or remicade or 170277-31-3 or inflectra or remsima or CT-P13).af. (29,667)
11. 6 or 7 or 8 or 9 or 10 (41,065)
12. (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind) or
(singl$ adj blind$) or assign$ or allocat$ or volunteer$).ti,ab,kw. (1,351,644)
13. crossover-procedure/ or double-blind procedure/ or randomized controlled trial/ or single-blind
procedure/ (390984)
14. 12 or 13 (1,428,385)
15. 5 and 11 and 14 (603)
16. limit 15 to embase (581)
17. animals/ not (animals/ and humans/) (1,188,711)
18. 16 not 17 (581)
Cumulative Index to Nursing and Allied Health Literature Plus
Date range searched: inception to 5 June 2014.
Searched: 5 June 2014 via EBSCOhost interface.
Search strategy
S19 S6 AND S12 AND S18 (87)
S18 S13 OR S14 OR S15 OR S16 OR S17 (148,267)
S17 singl* N blind* or doubl* N blind* or singl* N mask* or doubl* N mask (285)
S16 (ZT “randomized controlled trial”) (38,240)
S15 (allocate* or assign* or divid*) N5 (condition* or experiment* or treatment* or control* or
group*) (26,737)
S14 crossover or “cross over” or “latin square” or placebo* (41,898)
S13 randomi* or random N allocate* or random N assign* or random N divid* or random N trial* or
random N study or random N studies (108,710)
S12 S7 OR S8 OR S9 OR S10 OR S11 (3091)
S11 TX (infliximab or remicade or 170277-31-3 or inflectra or remsima or CT-P13) (1792)
S10 TX (golimumab or CNTO 148 or simponi or 476181-74-5) (119)
S9 TX (etanercept or enbrel or altebrel or 185243-69-0) (1298)
S8 TX (certolizumab or CDP870 or cimzia or 428863-50-7 (91)
S7 TX (adalimumab or humira or 331731-18-1) (647)
S6 S1 OR S2 OR S3 OR S4 OR S5 (2566)
S5 TX ((Bechtere* or Bekhtere* or “Marie Strumpell*” or “Marie Struempell*”) N2 (disease or
syndrome)) (3)
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S4 TX (ankyl* N2 (spine* or spinal or vertebra*)) (91)
S3 TX ((ankyl* or axial) N2 spondyl*) (2277)
S2 MH spondylitis, ankylosing (1803)
S1 MH spondylarthritis (500)
Science Citation Index
Date range searched: 1900 to 2014.
Searched: 16 June 2014 via Web of Science.
Indexes=SCI-EXPANDED Timespan=1900-2014.
Search strategy
#13 #12 AND #11 AND #5 (1001)
#12 TS= clinical trial* OR TS=research design OR TS=comparative stud* OR TS=evaluation stud* OR
TS=controlled trial* OR TS=follow-up stud* OR TS=prospective stud* OR TS=random* OR TS=placebo*
OR TS=(single blind*) OR TS=(double blind*) (2,435,907)
#11 #10 OR #9 OR #8 OR #7 OR #6 (20,446)
#10 TOPIC: ((infliximab or remicade or 170277-31-3 or inflectra or remsima or CT-P13)) (13,285)
#9 TOPIC: ((golimumab or CNTO 148 or simponi or 476181-74-5)) (494)
#8 TOPIC: ((etanercept or enbrel or altebrel or 185243-69-0)) (7138)
#7 TOPIC: ((certolizumab or CDP870 or cimzia or 428863-50-7)) (916)
#6 TOPIC: ((adalimumab or humira or 331731-18-1)) (4754)
#5 #4 OR #3 OR #2 OR #1 (14,918)
#4 TOPIC: (((Bechtere* or Bekhtere* or “Marie Strumpell*” or “Marie Struempell*”) NEAR/2 (disease or
syndrome))) (191)
#3 TOPIC: ((ankyl* NEAR/2 (spine* or spinal or vertebra*))) (644)
#2 TOPIC: (((ankyl* or axial) NEAR/2 spondyl*)) (13,854)
#1 TOPIC: (spondylarthritis OR spondyloarthritis) (2394)
National Institutes of Health ClinicalTrials.gov register
Searched: 23 July 2014 online at http://clinicaltrials.gov/ct2/search.
Search strategy
((spondylarthritis OR spondyloarthritis OR spondylitis) AND (infliximab OR remicade OR inflectra OR
remsima OR golimumab OR simponi OR etanercept OR enbrel OR altebrel OR certolizumab OR cimzia OR
adalimumab OR humira))
160 results.
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Cochrane Library (includes Cochrane Database of Systematic
Reviews, Database of Abstracts of Reviews of Effects, Health
Technology Assessment Database, Cochrane Central Register of
Controlled Trials and NHS Economic Evaluation Database)
Searched: 5 June 2014 online at http://onlinelibrary.wiley.com/o/cochrane/cochrane_search_fs.html.
Search strategy
#1 MeSH descriptor: [Spondylitis, Ankylosing] explode all trees
#2 MeSH descriptor: [Spondylarthritis] explode all trees
#3 ((ankyl* or axial) near/2 spondyl*):ti,ab,kw (Word variations have been searched)
#4 (ankyl* near/2 (spine* or spinal or vertebra*)):ti,ab,kw (Word variations have been searched)
#5 ((Bechtere* or Bekhtere* or “Marie Strumpell*” or “Marie Struempell*”) near/2 (disease or
syndrome)):ti,ab,kw
#6 #1 or #2 or #3 or #4 or #5
#7 (adalimumab or humira or 331731-18-1):ti,ab,kw
#8 (certolizumab or CDP870 or cimzia or 428863-50-7):ti,ab,kw
#9 (etanercept or enbrel or altebrel or 185243-69-0):ti,ab,kw
#10 (golimumab or CNTO 148 or simponi or 476181-74-5):ti,ab,kw
#11 (infliximab or remicade or 170277-31-3 or inflectra or remsima or CT-P13):ti,ab,kw
#12 #7 or #8 or #9 or #10 or #11
#13 #6 and #12
284 total results comprised two Cochrane Database of Systematic Reviews, five Database of Abstracts of
Reviews of Effects, 21 HTA, 233 Cochrane Central Register of Controlled Trials and 14 NHS Economic
Evaluation Database.
Conference Proceedings Citation Index – Science
Searched: 2 September 2014 via Wiley Web of Science interface.
Indexes=CPCI-S Timespan=1900-2014.
Search strategy
#12 #11 AND #5 (341)
#11 #10 OR #9 OR #8 OR #7 OR #6 (4745)
#10 TOPIC: ((infliximab or remicade or 170277-31-3 or inflectra or remsima or CT-P13)) (2537)
#9 TOPIC: ((golimumab or CNTO 148 or simponi or 476181-74-5)) (141)
#8 TOPIC: ((etanercept or enbrel or altebrel or 185243-69-0)) (1221)
#7 TOPIC: ((certolizumab or CDP870 or cimzia or 428863-50-7)) (291)
#6 TOPIC: ((adalimumab or humira or 331731-18-1)) (1140)
#5 #4 OR #3 OR #2 OR #1 (2117)
#4 TOPIC: (((Bechtere* or Bekhtere* or “Marie Strumpell*” or “Marie Struempell*”) NEAR/2 (disease or
syndrome))) (4)
#3 TOPIC: ((ankyl* NEAR/2 (spine* or spinal or vertebra*))) (55)
#2 TOPIC: (((ankyl* or axial) NEAR/2 spondyl*)) (1906)
#1 TS=(spondylarthritis OR spondyloarthritis) (393)
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International Prospective Register of Systematic
Reviews (PROSPERO)
Searched: 7 October 2014 online at www.crd.york.ac.uk/prospero/search.asp.
Search strategy
spondylitis [In All Fields]
OR
spondylarthritis [In All Fields]
OR
spondyloarthritis [In All Fields]
6 results.
National Guideline Clearinghouse
Searched: 7 October 2014 online at www.guideline.gov.
Search strategy
spondylitis OR spondylarthritis OR spondyloarthritis
15 results.
NHS Evidence
Searched 27 October 2014 online at www.evidence.nhs.uk.
Search strategy
((((ankyl* or axial) near/2 spondyl*) OR (ankyl* near/2 (spine* or spinal or vertebra*)) AND (adalimumab or
humira or certolizumab or CDP870 or cimzia or etanercept or enbrel or altebrel or golimumab or CNTO
148 or simponi or infliximab or remicade or inflectra or remsima or CT-P13))
350 results.
NHS Clinical Knowledge Summaries
Searched: 27 October 2014 online at http://cks.nice.org.uk/#?char=A.
1 result for ankylosing spondylitis.
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Searches for economic review
NHS Economic Evaluation Database
Searched: 5 June 2014 online at http://onlinelibrary.wiley.com/o/cochrane/cochrane_search_fs.html.
Search strategy
#1 MeSH descriptor: [Spondylitis, Ankylosing] explode all trees
#2 MeSH descriptor: [Spondylarthritis] explode all trees
#3 ((ankyl* or axial) near/2 spondyl*):ti,ab,kw (Word variations have been searched)
#4 (ankyl* near/2 (spine* or spinal or vertebra*)):ti,ab,kw (Word variations have been searched)
#5 ((Bechtere* or Bekhtere* or “Marie Strumpell*” or “Marie Struempell*”) near/2 (disease or
syndrome)):ti,ab,kw
#6 #1 or #2 or #3 or #4 or #5
#7 (adalimumab or humira or 331731-18-1):ti,ab,kw
#8 (certolizumab or CDP870 or cimzia or 428863-50-7):ti,ab,kw
#9 (etanercept or enbrel or altebrel or 185243-69-0):ti,ab,kw
#10 (golimumab or CNTO 148 or simponi or 476181-74-5):ti,ab,kw
#11 (infliximab or remicade or 170277-31-3 or inflectra or remsima or CT-P13):ti,ab,kw
#12 #7 or #8 or #9 or #10 or #11
#13 #6 and #12
14 results.
Searches for European Quality of Life-5 Dimensions
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (Ovid)
Date range searched: 1946 to present.
Searched: 16 June 2014 via OVID interface.
Search strategy
1. spondylarthritis/ or spondylitis, ankylosing/ (12,394)
2. ((ankyl$ or axial) adj2 spondyl$).ti,ab. (10,334)
3. (ankyl$ adj2 (spine$ or spinal or vertebra$)).ti,ab. (402)
4. ((Bechtere$ or Bekhtere$ or “Marie Strumpell$” or “Marie Struempell$”) adj2 (disease or syndrome)).ti,
ab. (451)
5. 1 or 2 or 3 or 4 (14,899)
6. (5d or 5-d or 5 dimension or eq-5d or eq5d or eq 5d).ti,ab. (13,976)
7. 5 and 6 (27)
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EMBASE (June 2014)
Searched: 16 June 2014 via OVID interface.
Search strategy
1. exp spondylarthritis/ or exp ankylosing spondylitis/ (20,653)
2. ((ankyl$ or axial) adj2 spondyl$).ti,ab. (14,855)
3. (ankyl$ adj2 (spine$ or spinal or vertebra$)).ti,ab. (545)
4. ((Bechtere$ or Bekhtere$ or “Marie Strumpell$” or “Marie Struempell$”) adj2 (disease or syndrome)).ti,
ab. (552)
5. 1 or 2 or 3 or 4 (22,550)
6. (5d or 5-d or 5 dimension or eq-5d or eq5d or eq 5d).ti,ab. (17,019)
7. 5 and 6 (60)
8. limit 7 to embase (55)
Searches for economic models
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (Ovid)
Date range searched: 1946 to present.
Searched: 25 July 2014 via OVID interface.
Search strategy
1. spondylarthritis/ or spondylitis, ankylosing/ (12,505)
2. ((ankyl$ or axial) adj2 spondyl$).ti,ab. (10,436)
3. (ankyl$ adj2 (spine$ or spinal or vertebra$)).ti,ab. (407)
4. ((Bechtere$ or Bekhtere$ or “Marie Strumpell$” or “Marie Struempell$”) adj2 (disease or syndrome)).ti,
ab. (455)
5. 1 or 2 or 3 or 4 (15,038)
6. exp models, economic/ (10,268)
7. ((economic$ or cost$ or pric$ or value or statistic$) and model$).ti,ab. (245,686)
8. 6 or 7 (250,668)
9. 5 and 8 (107)
EMBASE
Date range searched: 1974 to 24 July 2014.
Searched: 25 July 2014 via OVID interface.
Search strategy
1. exp spondylarthritis/ or exp ankylosing spondylitis/ (20,858)
2. ((ankyl$ or axial) adj2 spondyl$).ti,ab. (14,996)
3. (ankyl$ adj2 (spine$ or spinal or vertebra$)).ti,ab. (553)
4. ((Bechtere$ or Bekhtere$ or “Marie Strumpell$” or “Marie Struempell$”) adj2 (disease or
syndrome)).ti,ab. (553)
5. 1 or 2 or 3 or 4 (22,760)
6. statistical model/ (102,203)
7. ((economic$ or cost$ or pric$ or value or statistic$) adj2 model$).ti,ab. (24,642)
8. 6 or 7 (119,366)
9. 5 and 8 (63)
10. limit 9 to embase (55)
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Appendix 2 Synthesis methods for clinical
efficacy network meta-analyses
Estimating standard deviations from interquartile ranges
Where Q1 is the lower quartile, Q3 is the upper quartile and σ is the SD, then the SD was estimated as:
σ =
(Q3 + Q1)
2 × 0:67
. (3)
Calculating change from baseline outcomes and
standard deviations
Given baseline and final values and their SDs, the change from baseline values and SDs can be calculated if
the within-study correlation between baseline and final values is known. Similarly, the final values can
be computed.
The within-study correlation ρ between baseline and final values can be calculated as follows, as stated in
the Cochrane Handbook,183 where
ρ =
SD2baseline + SD
2
f inal−SD
2
change
2 × SDf inal × SDbaseline
. (4)
The SD of the change from baseline can be found by rearranging the above equation. The SD of the final
value can be found by rearranging the above equation which produces a quadratic. As a range of
correlation estimates were obtained from the studies available, we tested 0.3 and 0.7 correlation estimates
in our analyses. In calculating the SD of final values, this sometimes resulted in complex roots. In these
cases, the lowest correlation estimate that allowed a real root was used in the calculation.
Prior distribution for the between-study standard deviation for
the placebo absolute risk
In running fixed-effect and random-effect models to estimate the placebo absolute risk, the random-effect
models had better fit. For ASAS 70 response, there were insufficient trials to run a random-effects model,
so a prior distribution for the between-study SD was specified. This was derived from the between-study
SD from the ASAS 40 analysis. The prior distribution was specified as a log-normal distribution, and the
log-normal distribution parameters µ and σ2 were derived from the following equations:
Mean = e µ+ σ
2=
2. (5)
Median = eµ. (6)
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I2
As noted in Higgins et al.,184 I2 was calculated as
I2 =
τ2
τ2 + s2
, (7)
where τ2 is the between-study variance estimated in the multiple-treatment meta-analysis,
s2 =
Σw i(k−1)
(Σw i)
2−Σw2i
, (8)
which was calculated in Excel, and wi is the precision of study i.
Correlation
Table 108 presents the results for BASDAI change from baseline assuming a class effect and independent
treatment effects, and assuming 0.3 and 0.7 within-study correlation. It is clear that the different
correlation assumptions make no difference in this case. This is perhaps because the studies affected by
the correlation assumption were small studies.
TABLE 108 The class and independent BASDAI change from baseline of the anti-TNFs vs. placebo assuming
0.3 and 0.7 within-study correlation
Intervention
0.3 correlation 0.7 correlation
Mean 95% CrI Mean 95% CrI
Class –1.66 –1.89 to –1.43 –1.66 –1.88 to –1.43
Adalimumab –1.55 –1.88 to –1.23 –1.56 –1.88 to –1.24
Centrolizumab –1.46 –2.16 to –0.74 –1.46 –2.16 to –0.74
Etanercept –1.76 –2.15 to –1.37 –1.76 –2.15 to –1.37
Infliximab –2.28 –3.18 to –1.38 –2.28 –3.18 to –1.38
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Appendix 3 Risk-of-bias data
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TABLE 109 Full risk-of-bias results
Trial
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of
participants and
researchers
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting
Exclude in
sensitivity
analysis?
Haibel 200852 Unclear Unclear Unclear Low Low Low Low No
– – Imbalance for
HLA-B27 positive and
MRI positive
– – Number of
withdrawals and
dropouts: 0
All main
relevant
outcomes
reported
Imputation used
for continuous
outcomes: N/A
Hu 201255 Unclear Unclear Low Unclear Low Unclear Unclear Yes
There is no
description of the
randomisation
procedure and no
explanation for the
imbalance in number
of patients in
treatment arms,
26 vs. 20
No details reported Main prognostic
indicators were
similar across trial
arms at baseline
No details reported – Number of
withdrawals and
dropouts: NR
No reporting
of AEs
Imputation used
for continuous
outcomes: NR
Huang 201456 Low Low Low Low Low Low Low No
Centralised
computer-based
system
Centralised
computer-based
system
Groups comparable
for all important
factors
Matching placebo
and all study
personnel and
patients stated to be
blinded
– Number of
withdrawals and
dropouts: 12
All main
outcomes
reported
Imputation used
for continuous
outcomes: LOCF
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Trial
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of
participants and
researchers
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting
Exclude in
sensitivity
analysis?
Lambert 200757 Unclear Unclear Low Unclear Low Low Low No
– – No imbalances in
possible prognostic
factors
Stated to be double
blind
– Number of
withdrawals and
dropouts: 0 at
week 12; two
from placebo arm
at week 52
BASDAI
score not
reported at
follow-up
Imputation used
for continuous
outcomes: no
imputation for
missing SPARCC
enthesitis index
score
ABILITY-1
201358
Low Low Low Low Low Low Low No
Centralised
randomisation with
interactive voice
response system
– – Matching placebo – Number of
withdrawals and
dropouts: n= 6
–
Imputation used
for continuous
outcomes: LOCF
imputed values
continued
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TABLE 109 Full risk-of-bias results (continued )
Trial
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of
participants and
researchers
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting
Exclude in
sensitivity
analysis?
ATLAS 200661 Unclear Unclear Low Low Low Low Low No
– – Balanced across
treatment arms
Matching placebo – Number of
withdrawals and
dropouts: by week
12, n= 4 placebo
and n= 4 active;
by week 24, n= 6
placebo and
n= 13 active
(Note: week 24
was still RCT
although no
responders
permitted early
escape after
week 12).
Imputation used
for continuous
outcomes: LOCF
Primary and
all main
outcomes
reported
RAPID-axSpA
(Landewe
2014)64
Low Low Low Unclear Low Low Low No
Central
randomisation
Central
randomisation
Small difference in
baseline CRP level
and HLA-B27
positive, making the
placebo group have
slightly increased risk
(but unclear possible
impact)
Administration of
treatment was by
unblinded trained
personnel; their role
in assessment is
unclear and so the
impact of their
unblinded status is
unclear
– Number of
withdrawals and
dropouts: unclear
at 12 weeks but
at 24 weeks,
n= 10 placebo,
n= 6 200mg and
n= 9 400mg
Hierarchical
analysis plan
adhered to
Imputation used
for continuous
outcomes: LOCF
A
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Trial
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of
participants and
researchers
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting
Exclude in
sensitivity
analysis?
Barkham
201071
Unclear Unclear Unclear Low Low Unclear Low Yes
– – – – – Number of
withdrawals and
dropouts: unclear,
although it
appears to be
n= 9 for
etanercept and
n= 8 for placebo
(the number for
which ASAS
40 data were
available)
–
Imputation used
for continuous
outcomes: ITT
LOCF
Davis 200372 Unclear Unclear Low Low Low Low Low No
– – – – – Number of
withdrawals and
dropouts: at
12 weeks, n= 6
etanercept and
n= 5 placebo; at
24 weeks, n= 12
etanercept, n= 19
placebo
–
Imputation used
for continuous
outcomes: LOCF
using etanercept
n= 138, and using
placebo n= 139
continued
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TABLE 109 Full risk-of-bias results (continued )
Trial
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of
participants and
researchers
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting
Exclude in
sensitivity
analysis?
Dougados
201174
Unclear Unclear Low Low Low Low Low No
– – – – – Number of
withdrawals and
dropouts: n= 1
etanercept and
n= 4 placebo.
Imputation used
for continuous
outcomes: mITT
(at least one dose)
with LOCF
–
Dougados
201476
Low Low Low Low Low Low Low No
– – – – – Number of
withdrawals and
dropouts: n= 6
etanercept and
n= 3 placebo. In
addition to this,
five patients in
each group were
excluded from
analyses because
of misdiagnosis
–
Imputation used
for continuous
outcomes:
LOCF in mITT
population,
n= 106
etanercept and
n= 109 placebo
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TABLE 109 Full risk-of-bias results (continued )
Trial
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of
participants and
researchers
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting
Exclude in
sensitivity
analysis?
van der Heijde
200686
Unclear Unclear Unclear Low Low Low Low No
– – No data for HLA-B27 – – Number of
withdrawals and
dropouts: n= 14
in 50-mg group,
n= 14 in 25-mg
group and n= 7 in
placebo group. In
addition to this,
five patients did
not receive one
dose of treatment
(no further details)
–
Imputation used
for continuous
outcomes: mITT
population
analysed (had at
least one dose)
using the n= 155,
n= 150, n= 51
group sizes and
LOCF was used to
impute missing
data
Giardina
201088
High High Low High High Low Low Yes
– – – – – Number of
withdrawals and
dropouts: n= 0
–
Imputation used
for continuous
outcomes: none
needed
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Trial
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of
participants and
researchers
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting
Exclude in
sensitivity
analysis?
GO-RAISE
200890
Low Low Low Low Low Low Low No
Random assignment
using voice response
system
Random assignment
using voice response
system
No important
imbalance in key
prognostic variables
Matching placebo
used
– Number of
withdrawals and
dropouts: n= 17
to week 24 (n= 2
placebo, n= 9
50mg and n= 6
100mg). Not clear
how many at
week 14 (primary
time point)
Primary end
point and all
other main
outcomes
(BASDAI,
BASFI,
BASMI and
SF-36)
reported
Imputation used
for continuous
outcomes: LOCF
(ITT population)
Bao 201296 Unclear Unclear Unclear Low Low Unclear Low No
– – No HLA-B27 data – – Number of
withdrawals and
dropouts: not
reported for
week 14
Primary
outcome and
other main
outcomes
reported
Imputation used
for continuous
outcomes: NR
Tam 201497 Unclear Unclear Unclear Unclear Low Unclear Unclear No
Abstract only, very
small study (Chinese)
Abstract only, very
small study (Chinese)
Abstract only, very
small study (Chinese)
Abstract only, very
small study (Chinese)
– Number of
withdrawals and
dropouts: NR
Abstract
only, very
small study
(Chinese)
Imputation used
for continuous
outcomes: NR
continued
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TABLE 109 Full risk-of-bias results (continued )
Trial
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of
participants and
researchers
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting
Exclude in
sensitivity
analysis?
Barkham
200950
Unclear Unclear High Low Low Low Low Yes
– – Median CRP level
11.5 placebo vs.
5 infliximab; likely a
result of chance, as
there was higher CRP
level in placebo group
(and higher CRP level
was associated with
better responses)
– – Number of
withdrawals and
dropouts: n= 1 in
the placebo group
(at 12 weeks)
–
Imputation used
for continuous
outcomes: NR but
ITT population
analysed
Braun 200298 Low Low Low Low Low Low Low No
– – – – – Number of
withdrawals and
dropouts: n= 0
–
Imputation used
for continuous
outcomes: none
required
Marzo-Ortega
2005100
Low Low Unclear Low Low Unclear Low No
– – The only issue is with
age, and the
difference of 2 years
could be caused by
rounding
– – Number of
withdrawals and
dropouts: n= 5
out of 14 for
placebo and n= 2
out of 28 for
infliximab
–
Imputation used
for continuous
outcomes: ITT
with LOCF
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Trial
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of
participants and
researchers
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting
Exclude in
sensitivity
analysis?
Van den Borsch
2002101
Unclear Unclear High; Low Low Low Low Yes
– – BASFI > 1 point – – Number of
withdrawals and
dropouts: n= 0
–
Imputation used
for continuous
outcomes: N/A
ASSERT 2005102 Unclear Unclear Low Low Low Low Low No
– – – – – Number of
withdrawals and
dropouts: n= 8
(n= 4 in each
group)
–
Imputation used
for continuous
outcomes: not
reported, but ITT
population
analysed. LOCF
was used for
ASAS 20
PLANETAS
2013110
Low Low Unclear Low Low Low Low No
– – HLA-B27 was not
reported
– – Number of
withdrawals and
dropouts: n= 21
(n= 12 CT-P13 vs.
n= 9 infliximab)
–
Imputation used
for continuous
outcomes: NR,
although ITT
population was
analysed
N/A, not applicable; NR, not reported; SPARCC, Spondyloarthritis Research Consortium of Canada.
High, low and unclear relate to the trial’s risk-of-bias judgement based on the Cochrane risk-of-bias tool. See Chapter 4, Summary and critique of published cost-effectiveness studies.
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TABLE 110 Prognostic indicators of important baseline imbalance used in risk-of-bias assessment
Possible
prognostic
indicator
Results of association
Implications for baseline imbalance across
groups within a trial (and variation in
efficacy across trials)
Glintborg 2010 (DANBIO
registry)112 (n= 842);
6-month time point;
adalimumab, etanercept,
infliximab
Vastesaeger 2011172 (ASSERT102
and GO-RAISE90 trial data)a
(n= 635); 3-month time point;
infliximab, golimumab
Lord 2009 (BSRBR)173 (n= 261);
6-month time point; adalimumab,
etanercept, infliximab
HLA-B27
status
No data Moderate association No data HLA-B27 positive patients have a better
outcome. Use 20% group difference as an
important imbalance?
CRP level ≤ 14mg/l vs. > 14mg/l
(OR 0.45, p< 0.001)
≤ 6mg/l vs. > 6mg/l to 20mg/l:
moderate; ≤ 6mg/l vs. > 20mg/l:
moderate to strong
‘Raised inflammatory markers’ an important
predictor, but result only available for CRP level
or ESR (not CRP level alone)
Higher CRP levels are associated with a better
outcome. Use Glintborg and Vastesaeger
cut-offs (providing there’s at least a 2mg/l
difference between groups)
Age OR 0.98 per year; p= 0.03 < 40 years vs. > 40 years: weak to
moderate
No significant association Younger age associated with a better
outcome. Use Vastesaeger cut-off point
providing at least a 2-year difference between
groups
BASFI score OR 0.87 per cm increase;
p= 0.008
< 6.5 vs. > 6.5 moderate to strong Per unit increase, OR 0.78 (95% CI 0.64 to
0.99)
Lower BASFI scores associated with a better
outcome. Use a 1-point difference as an
indication of important imbalance? Use
< 6.5 vs. > 6.5 providing there’s at least a
0.5-point difference between groups
BASDAI Not analysed No significant association Per unit increase, OR 1.30 (95% CI 1.04 to
1.62)
Higher BASDAI scores associated with a better
outcome. Use a 1-point difference as an
indication of important imbalance?
Disease
duration
No significant association No significant association No significant association Do not assess
Sex No significant association No significant association No significant association Do not assess
a OR results categorised association using weak, moderate, strong or very strong terminology (based on size of OR).
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TABLE 111 Continuous outcomes: final values results
Trial Population Treatment arm Dose
Time point
(weeks) Patients
Mean final values
BASDAI BASFI BASMI MASES SF-36 PCS SF-36 MCS
Haibel 200852 Nr-axSpA Adalimumab 40mg every
2 weeks
12 22 3.8 (SD 2.5) 3 (SD 2.4) 1.3 (SD 1.4) 2.5 (SD 3.5) 38.8 (SD 11.8) 44.6 (SD 12.7)
Nr-axSpA Placebo – 12 24 5 (SD 2.4) 4.1 (SD 2.6) 1.7 (SD 1.5) 2.8 (SD 3.4) 34.9 (SD 9.6) 43.9 (SD 11.8)
Hu 201255 AS Adalimumab 40mg every
2 weeks
12 NR 2.3 (SD 1.8) 1.8 (SD 1.6) – – – –
AS Placebo – 12 NR 4.2 (SD 2.6) 2.9 (SD 1.9) – – – –
Huang 201456 AS Adalimumab 40mg every
2 weeks
12 229 – – – – – –
AS Placebo – 12 115 – – – – – –
Lambert 200757 AS Adalimumab 40mg every
2 weeks
12 38 – – – – – –
AS Placebo – 12 44 – – – – – –
aABILITY-1 201358 Nr-axSpA Adalimumab 40mg every
2 weeks
12 69 – – – – – –
Nr-axSpA Placebo – 12 73 – – – – – –
ATLAS 200661 AS Adalimumab 40mg every
2 weeks
12 208 – 1.414 – – – –
AS Placebo – 12 107 – – – – – –
RAPID-axSpA 201464 AS Certolizumab pegol 200mg every
2 weeks
12 65 – – – – – –
AS Certolizumab pegol 400mg every
4 weeks
12 56 – – – – – –
AS Placebo – 12 57 – – – – – –
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Trial Population Treatment arm Dose
Time point
(weeks) Patients
Mean final values
BASDAI BASFI BASMI MASES SF-36 PCS SF-36 MCS
RAPID-axSpA 201464 Nr-axSpA Certolizumab pegol 200mg every
2 weeks
12 46 – – – – – –
Nr-axSpA Certolizumab pegol 400mg every
4 weeks
12 51 – – – – – –
Nr-axSpA Placebo – 12 50 – – – – – –
Barkham 201071 AS Etanercept 25mg twice
weekly
12 20 – – – – – –
AS Placebo – 12 20 – – – – – –
Davis 200372 AS Etanercept 25mg twice
weekly
12 138 – – – – – –
AS Placebo – 12 139 – – – – – –
AS Etanercept 25mg twice
weekly
24 138 3.45
(SE 0.21)
3.6
(SE 0.22)
– – – –
AS Placebo – 24 139 5.51
(SE 0.2)
5.47
(SE 0.22)
– – – –
Dougados 201174 AS Etanercept 50mg weekly 12 39 3.7 (SD 2.6) 4.1 (SD 2.9) 5.1 (SD 1.7) – – –
AS Placebo – 12 43 4.5 (SD 1.9) 4.8 (SD 2.1) 5.6 (SD 1.3) – – –
Dougados 201476 AS Etanercept 50mg weekly 12 106 – – – – 43.7 (SD 8.9) –
AS Placebo – 12 109 – – – – 41 (SD 7.8) –
Nr-axSpA Etanercept 50mg weekly 12 94 – – – – – –
Nr-axSpA Placebo – 12 95 – – – – – –
Gorman 200279 AS Etanercept 25mg twice
a week
16 20 – 2.2 (SD 2.1) – – – –
AS Placebo – 16 20 – 3.1 (SD 3) – – – –
Calin 200483 AS Etanercept 25mg twice
weekly
12 45 3.38 3.96 – – – –
AS Placebo – 12 39 5.01 5.39 – – – –
continued
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TABLE 111 Continuous outcomes: final values results (continued )
Trial Population Treatment arm Dose
Time point
(weeks) Patients
Mean final values
BASDAI BASFI BASMI MASES SF-36 PCS SF-36 MCS
van der Heijde
200686
AS Etanercept 25mg twice
weekly
12 150 – – – – – –
AS Etanercept 50mg weekly 12 155 – – – – – –
AS Placebo – 12 51 – – – – – –
Giardina 201088 AS Etanercept 50mg weekly 12 25 – 5 – – – –
AS Infliximab 5mg/kg at 0,
2 and
≥ 6 weeks
12 25 – 3.5 – – – –
GO-RAISE 200890 AS Golimumab 50mg
(two every
4 weeks)
14 138 – – – – – –
AS Golimumab 100mg
(two every
4 weeks)
14 140 – – – – – –
AS Placebo – 14 78 – – – – – –
Bao 201296 AS Golimumab 50mg every
4 weeks
14 – – – – – – –
AS Placebo – 14 – – – – – – –
Tam 201497 AS Golimumab 50mg
monthly
26 NR – – – – – –
AS Placebo – 26 NR – – – – – –
Barkham 200950 Nr-axSpA Infliximab 5mg/kg
(0, 2 and
≥ 6 weeks)
16 20 – – – – – –
Nr-axSpA Placebo – 16 20 – – – – – –
Braun 200298 AS Infliximab 5mg/kg (0, 2
and 6 weeks)
12 34 3.3 – – – – –
AS Placebo – 12 35 5.7 – – – – –
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Trial Population Treatment arm Dose
Time point
(weeks) Patients
Mean final values
BASDAI BASFI BASMI MASES SF-36 PCS SF-36 MCS
Marzo-Ortega
2005100
AS Infliximab+
methotrexate
5mg/kgb 10 28 3.34
(SD 2.56)
4.96 – – – –
AS Placebo+
methotrexate
–
c 10 14 5.19
(SD 2.52)
6.1 – – – –
AS Infliximab+
methotrexate
5mg/kgb 30 28 4.6
(SD 2.85)
5.04 – – – –
AS Placebo+
methotrexate
–
c 30 14 5.74
(SD 2.34)
5.68 – – – –
Van den Bosch
2002101
AS Infliximab 5mg/kg (0, 2
and 6 weeks)
12 9 2.66 2.74 4 – – –
AS Placebo – 12 12 5.01 7.19 4 – – –
ASSERT 2005102 AS Infliximab 5mg/kg
(0, 2 and
≥ 6 weeks)
24 201 – – – – – –
AS Placebo – 24 78 – – – – – –
PLANETAS 2013110 AS CT-P13 5mg/kg 14 125 – – – – – –
AS Infliximab 5mg/kg 14 125 – – – – – –
AS CT-P13 5mg/kg 30 125 – – – – – –
AS Infliximab 5mg/kg 30 125 – – – – – –
AS CT-P13 5mg/kg 54 125 – – – – – –
AS Infliximab 5mg/kg 54 125 – – – – – –
NR, not reported.
a Licensed population.
b Infliximab 5mg/kg (infusion at weeks 0, 2, 6, 14 and 22)+methotrexate oral 7.5mg with folic acid (5mg twice a week which increased to 10mg a week).
c Methotrexate oral 7.5mg with folic acid (5mg twice a week which increased to 10mg a week).
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TABLE 112 Continuous outcomes: change from baseline results
Trial Population Treatment arm Dose
Time point
(weeks) Patients
Mean change from baseline
BASDAI BASFI BASMI MASES SF-36 PCS SF-36 MCS
Haibel 200852 Nr-axSpA Adalimumab 40mg every
2 weeks
12 22 – – – – – –
Nr-axSpA Placebo – 12 24 – – – – – –
Hu 201255 AS Adalimumab 40mg every
2 weeks
12 NR – – – – – –
AS Placebo – 12 NR – – – – – –
Huang 201456 AS Adalimumab 40mg every
2 weeks
12 229 –2.8
(SD 1.9)
–1.75
(SD 2.02)
–0.5
(SD 0.6)
–1.2
(SD 2.1)
6.6 (SD 6.4) 5.1 (SD 9.9)
AS Placebo – 12 115 –1.4
(SD 1.9)
–0.47
(SD 1.64)
–0.2
(SD 0.7)
–0.8
(SD 1.7)
4 (SD 6.3) 2.8 (SD 9.4)
Lambert 200757 AS Adalimumab 40mg every
2 weeks
12 38 – – – – – –
AS Placebo – 12 44 – – – – – –
aABILITY-1 201358 Nr-axSpA Adalimumab 40mg every
2 weeks
12 69 –2.2
(SD 2.5)
–1.28
(SD 2.02)
–0.2
(SD 0.73)
–0.7
(SD 2.78)
6.9 (SD 9.32) 1.4 (SD 8.63)
Nr-axSpA Placebo – 12 73 –1.1
(SD 1.96)
–0.63
(SD 1.79)
–0.2
(SD 0.64)
–1
(SD 2.71)
2.3 (SD 6.81) 0.7 (SD 11.38)
ATLAS 200661 AS Adalimumab 40mg every
2 weeks
12 208 –2.6
(SE 0.2)
– –0.5
(SE 0.1)
–2.7
(SE 0.4)
6.9 (SE 0.6) 2.7 (SE 0.7)
AS Placebo – 12 107 –0.8
(SE 0.2)
– 0.1 (SE 0.1) –1.3
(SE 0.5)
1.6 (SE 0.8) 2.4 (SE 1)
RAPID-axSpA 201464 AS Certolizumab 200mg every
2 weeks
12 65 –2.5
(SE 0.3)
–1.7
(SE 0.3)
–0.6
(SE 0.1)
– 8.73 (SD 7.63) 2.42 (SD 9.08)
AS Certolizumab 400mg every
4 weeks
12 56 –2.4
(SE 0.3)
–1.7
(SE 0.3)
–0.3
(SE 0.2)
– 7.6 (SD 7.65) 2.22 (SD 10.44)
AS Placebo – 12 57 –1 (SE 0.3) –0.6
(SE 0.3)
–0.2
(SE 0.1)
– 2.56 (SD 5.67) 1.07 (SD 10.92)
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Trial Population Treatment arm Dose
Time point
(weeks) Patients
Mean change from baseline
BASDAI BASFI BASMI MASES SF-36 PCS SF-36 MCS
RAPID-axSpA 201464 Nr-axSpA Certolizumab 200mg 12 46 –3.3
(SE 0.4)
–2.3
(SE 0.4)
–0.6
(SE 0.2)
– 9.56 (SD 9.46) 4.59 (SD 9.7)
Nr-axSpA Certolizumab 400mg 12 51 –3.4
(SE 0.4)
–2.3
(SE 0.4)
–0.5
(SE 0.2)
– 8.72 (SD 8.84) 6.12 (SD 10.94)
Nr-axSpA Placebo – 12 50 –1.5
(SE 0.4)
–0.4
(SE 0.4)
0 (SE 0.1) – 2.13 (SD 7.47) 1.39 (SD 10.24)
Barkham 201071 AS Etanercept 25mg twice
weekly
12 20 –1.97 –1.35 – – – –
AS Placebo – 12 20 –0.1 0.21 – – – –
Davis 200372 AS Etanercept 25mg twice
weekly
12 138 –2.36
(SE 0.19)
–1.67
(SE 0.2)
– – – –
AS Placebo – 12 139 –0.45
(SE 0.18)
–0.33
(SE 0.21)
– – – –
AS Etanercept 25mg twice
weekly
24 138 – – – – – –
AS Placebo – 24 139 – – – – – –
Dougados 201174 AS Etanercept 50mg weekly 12 39 –2.6 (SD 2) –2.2
(SD 1.8)
–0.57
(SD 0.65)
– – –
AS Placebo – 12 43 –1.4 (SD 2) –1 (SD 1.8) –0.2
(SD 0.65)
– – –
Dougados 201476 AS Etanercept 50mg weekly 12 106 –2 (SE 0.3) –1.4
(SE 0.2)
–0.3
(SE 0.2)
– – –
AS Placebo – 12 109 –1.3
(SE 0.3)
–0.8
(SE 0.2)
–0.3
(SE 0.1)
– – –
Nr-axSpA Etanercept 50mg weekly 12 94 – – – – – –
Nr-axSpA Placebo – 12 95 – – – – – –
continued
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TABLE 112 Continuous outcomes: change from baseline results (continued )
Trial Population Treatment arm Dose
Time point
(weeks) Patients
Mean change from baseline
BASDAI BASFI BASMI MASES SF-36 PCS SF-36 MCS
Gorman 200279 AS Etanercept 25mg twice
a week
16 20 – – – – – –
AS Placebo – 16 20 – – – – – –
Calin 200483 AS Etanercept 25mg twice
weekly
12 45 –2.72
(SE 0.34)
–2.06
(SE 0.33)
– – – –
AS Placebo – 12 39 –0.85
(SE 0.35)
–0.33
(SE 0.31)
– – – –
van der Heijde
200686
AS Etanercept 25mg twice
weekly
12 150 – – – – – –
AS Etanercept 50mg weekly 12 155 – – – – – –
AS Placebo – 12 51 – – – – – –
Giardina 201088 AS Etanercept 50mg weekly 12 25 – – – – – –
AS Infliximab 5mg/kg
(0, 2 and
≥ 6 weeks)
12 25 – – – – – –
GO-RAISE 200890 AS Golimumab 50mg
(two every
4 weeks)
14 138 – –1.4
(IQR –3.1
to –0.1)
0
(IQR –1 to 0)
–0.5
(SD 2.6)
7.3 (IQR 1.5
to 15.3)
1.5 (IQR –2.2
to 7.8)
AS Golimumab 100mg
(two every
4 weeks)
14 140 – –1.5
(IQR –3.0
to –0.1)
0
(IQR –1 to 0)
–1.3
(SD 3.11)
8.4 (IQR 2.3
to 14.1)
3.7 (IQR –3.2
to 12.1)
AS Placebo – 14 78 – 0.1 (IQR
–1.1 to 1.1)
0 (SD –1 to 0) –0.2
(SD 2.99)
2.4 (IQR –1.4
to 7.8)
0.1 (IQR –4.3
to 5.3)
Bao 201296 AS Golimumab 50mg every
4 weeks
14 – –1.26
(SD 2.57)
–0.42
(SD 0.91)
– 6.25 (SD 7.95) 3.86 (SD 8.92)
AS Placebo – 14 – 0.11
(SD 2.1)
–0.19
(SD 0.72)
– 1.59 (SD 6.12) 0.82 (SD 9.44)
A
P
P
E
N
D
IX
4
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
2
2
0
Trial Population Treatment arm Dose
Time point
(weeks) Patients
Mean change from baseline
BASDAI BASFI BASMI MASES SF-36 PCS SF-36 MCS
Tam 201497 AS Golimumab 50mg
monthly
26 NR –1.82
(SD 1.64)
–0.13
(SD 0.25)b
–1 (IQR –2
to 0)
– – –
AS Placebo – 26 NR –0.66
(SD 1.24)
0.17
(SD 0.72)b
0 (IQR –1
to 0)
– – –
Barkham 200950 Nr-axSpA Infliximab 5mg/kg
(0, 2 and
≥ 6 weeks)
16 20 –3.41
(SD 2.53)
–2.7
(SD 2.36)
– – – –
Nr-axSpA Placebo – 16 20 –0.75
(SD 2.42)
–0.47
(SD 2.25)
– – – –
Braun 200298 AS Infliximab 5mg/kg
(0, 2 and
≥ 6 weeks)
12 34 –3.2 –2.1 – – – –
AS Placebo – 12 35 –0.6 –0.1 – – – –
Marzo-Ortega
2005100
AS Infliximab+
methotrexate
5mg/kgc 10 28 –3.11
(SD 2.23)
– – – – –
AS Placebo+
methotrexate
–
d 10 14 –1.38
(SD 2.11)
– – – – –
AS Infliximab+
methotrexate
5mg/kgc 30 28 –1.85
(SD 2.84)
– – – – –
AS Placebo+
methotrexate
–
d 30 14 –0.84
(SD 1.8)
– – – – –
Van den Bosch
2002101
AS Infliximab 5mg/kg (0, 2
and 6 weeks)
12 9 – – – – – –
AS Placebo – 12 12 – – – – – –
ASSERT 2005102 AS Infliximab 5mg/kg
(0, 2 and
≥ 6weeks)
24 201 –2.9
(IQR –4.9
to –0.9)
–1.7
(IQR –3.6
to –0.6)
–1 (IQR –1
to 0)
– 10.2 (IQR 3.9
to 17.1)
2.7 (IQR –2.9
to 8.8)
AS Placebo – 24 78 –0.4 (IQR
–1.4 to 0.7)
0 (IQR –1
to 1)
0 (IQR –1
to 0)
– 0.8 (IQR –1.9
to 6)
2 (IQR –2.6
to 7.5)
continued
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TABLE 112 Continuous outcomes: change from baseline results (continued )
Trial Population Treatment arm Dose
Time point
(weeks) Patients
Mean change from baseline
BASDAI BASFI BASMI MASES SF-36 PCS SF-36 MCS
PLANETAS 2013110 AS CT-P13 5mg/kg 14 125 –2.91
(SD 2.17)
–2.51
(SD 2.14)
–0.7
(SD 1.2)
– – –
AS Infliximab 5mg/kg 14 125 –2.77
(SD 2.08)
–2.47
(SD 2.18)
–0.7
(SD 1.4)
– – –
AS CT-P13 5mg/kg 30 125 –3.04
(SD 2.23)
–2.6
(SD 2.19)
–1 (SD 1.4) – 7.6 6.5
AS Infliximab 5mg/kg 30 125 –2.71
(SD 2.24)
–2.54
(SD 2.17)
–0.9
(SD 1.4)
– 8.5 5.2
AS CT-P13 5mg/kg 54 125 – – – – – –
AS Infliximab 5mg/kg 54 125 – – – – – –
IQR, interquartile range; NR, not reported.
a Licensed population.
b These values are uncertain because of poor reporting.
c Infliximab 5mg/kg (infusion at weeks 0, 2, 6, 14 and 22 weeks)+methotrexate oral 7.5mg with folic acid (5mg twice a week which increased to 10mg a week).
d Methotrexate oral 7.5mg with folic acid (5mg twice a week which increased to 10mg a week).
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TABLE 113 Binary response outcomes results
Trial Population Treatment arm Dose
Time point
(weeks) Patients
Number of responders (%)
ASAS 20 ASAS 40 ASAS 50 ASAS 70 BASDAI 50
Haibel 200852 Nr-axSpA Adalimumab 40mg every 2 weeks 12 22 15 (68) 12 (55) – – 11 (50)
Nr-axSpA placebo – 12 24 6 (25) 3 (13) – – 5 (21)
Hu 201255 AS Adalimumab 40mg every 2 weeks 12 26 – – – – –
AS Placebo – 12 20 – – – – –
Huang 201456 AS Adalimumab 40mg every 2 weeks 12 229 154 (67) 102 (45) – – 114 (50)
AS Placebo – 12 115 35 (30) 11 (10) – – 19 (17)
Lambert 200757 AS Adalimumab 40mg every 2 weeks 12 38 18 (47) – 12 (32) – –
AS Placebo – 12 44 12 (27) – 5 (11) – –
aABILITY-1 201358 Nr-axSpA Adalimumab 40mg every 2 weeks 12 69 41 (59) 28 (41) 24 (35) 13 (19) 27 (39)
Nr-axSpA Placebo – 12 73 23 (32) 10 (14) 6 (8) 3 (4) 10 (14)
ATLAS 200661 AS Adalimumab 40mg every 2 weeks 12 208 121 (58) 83 (40) – – 94 (45)
AS Placebo – 12 107 22 (21) 14 (13) – – 17 (16)
RAPID-axSpA 201464 AS Certolizumab pegol 200mg every 2 weeks 12 65 37 (57) 26 (40) – – 27 (42)
AS Certolizumab pegol 400mg every 4 weeks 12 56 36 (64) 28 (50) – – 23 (41)
AS Placebo – 12 57 21 (37) 11 (19) – – 6 (11)
Nr-axSpA Certolizumab pegol 200mg 12 46 27 (59) 22 (48) – – 23 (50)
Nr-axSpA Certolizumab pegol 400mg 12 51 32 (63) 24 (47) – – 24 (47)
Nr-axSpA Placebo – 12 50 20 (40) 8 (16) – – 8 (16)
Barkham 201071 AS Etanercept 25mg twice weekly 12 20 – 4 (20) – – 7 (35)
AS Placebo – 12 20 – 0 (0) – – 1 (5)
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
2
0
0
9
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
6
V
O
L
.
2
0
N
O
.
9
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
6
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
C
o
rb
e
tt
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
2
2
3
TABLE 113 Binary response outcomes results (continued )
Trial Population Treatment arm Dose
Time point
(weeks) Patients
Number of responders (%)
ASAS 20 ASAS 40 ASAS 50 ASAS 70 BASDAI 50
Davis 200372 AS Etanercept 25mg twice weekly 12 138 82 (59) – 62 (45) 40 (29) –
AS Placebo – 12 139 39 (28) – 18 (13) 10 (7) –
AS Etanercept 25mg twice weekly 24 138 78 (57) – 58 (42) – –
AS Placebo – 24 139 31 (22) – 14 (10) – –
Dougados 201174 AS Etanercept 50mg weekly 12 39 25 (64) 17 (44) 15 (38) 10 (26) 18 (46)
AS Placebo – 12 43 14 (33) 10 (23) 6 (14) 4 (9) 10 (23)
Dougados 201476 AS Etanercept 50mg weekly 12 106 55 (52) 34 (32) – – 46 (43)
AS Placebo – 12 109 39 (36) 17 (16) – – 26 (24)
Nr-axSpA Etanercept 50mg weekly 12 94 – 33 (35) – – –
Nr-axSpA Placebo – 12 95 – 16 (17) – – –
Gorman 200279 AS Etanercept 25mg twice a week 16 20 16 (80) – – – –
AS Placebo – 16 20 6 (30) – – – –
Calin 200483 AS Etanercept 25mg twice weekly 12 45 26 (58) – – – –
AS Placebo – 12 39 9 (23) – – – –
van der Heijde 200686 AS Etanercept 25mg twice weekly 12 150 107 (71) 80 (53) – – 87 (58)
AS Etanercept 50mg weekly 12 155 115 (74) 90 (58) – – 93 (60)
AS Placebo – 12 51 19 (37) 11 (22) – – 10 (20)
Giardina 201088 AS Etanercept 50mg weekly 12 25 15 (60) 11 (44) – – –
AS Infliximab 5mg/kg (0, 2 and
≥ 6 weeks)
12 25 19 (76) 14 (56) – – –
A
P
P
E
N
D
IX
4
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
2
2
4
Trial Population Treatment arm Dose
Time point
(weeks) Patients
Number of responders (%)
ASAS 20 ASAS 40 ASAS 50 ASAS 70 BASDAI 50
GO-RAISE 200890 AS Golimumab 50mg (two every
4 weeks)
14 138 82 (59) 62 (45) – – 61 (44)
AS Golimumab 100mg (two every
4 weeks)
14 140 84 (60) 69 (49) – – 56 (40)
AS Placebo – 14 78 17 (22) 12 (15) – – 12 (15)
Bao 201296 AS Golimumab 50mg every 4 weeks 14 108 53 (49) 38 (35) – – 37 (34)
AS Placebo – 14 105 26 (25) 10 (10) – – 5 (5)
Tam 201497 AS Golimumab 50mg monthly 26 20 11 (55) – – – –
AS Placebo – 26 21 3 (14) – – – –
Barkham 200950 Nr-axSpA Infliximab 5mg/kg (0, 2 and
≥ 6 weeks)
16 20 – 11 (55) – – –
Nr-axSpA Placebo – 16 20 – 3 (15) – – –
Braun 200298 AS Infliximab 5mg/kg (0, 2 and
6 weeks)
12 34 23 (68) – 16 (47) – 18 (53)
AS Placebo – 12 35 10 (29) – 2 (6) – 3 (9)
Marzo-Ortega 2005100 AS Infliximab+
methotrexate
5mg/kgb 10 28 20 (71) – – – –
AS Placebo+
methotrexate
–
c 10 14 4 (29) – – – –
AS Infliximab+
methotrexate
5mg/kgb 30 28 14 (50) – – – –
AS Placebo+
methotrexate
–
c 30 14 3 (21) – – – –
continued
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TABLE 113 Binary response outcomes results (continued )
Trial Population Treatment arm Dose
Time point
(weeks) Patients
Number of responders (%)
ASAS 20 ASAS 40 ASAS 50 ASAS 70 BASDAI 50
Van den Bosch 2002101 AS Infliximab 5mg/kg (0, 2 and
6 weeks)
12 9 – – – – –
AS Placebo – 12 12 – – – – –
ASSERT 2005102 AS Infliximab 5mg/kg (0, 2 and
≥ 6 weeks)
24 201 123 (61) 93 (46) – – –
AS Placebo – 24 78 15 (19) 9 (12) – – –
PLANETAS 2013110 AS CT-P13 5mg/kg 14 125 72 (58) 48 (38) – – –
AS Infliximab 5mg/kg 14 125 79 (63) 56 (45) – – –
AS CT-P13 5mg/kg 30 125 79 (63) 58 (46) – – –
AS Infliximab 5mg/kg 30 125 84 (67) 55 (44) – – –
AS CT-P13 5mg/kg 54 125 71 (57) 51 (41) – – –
AS Infliximab 5mg/kg 54 125 75 (60) 46 (37) – – –
NR, not reported.
a Licensed population.
b Infliximab 5mg/kg (infusion at 0, 2, 6, 14 and 22 weeks)+methotrexate oral 7.5mg with folic acid (5mg twice a week which increased to 10mg a week).
c Methotrexate oral 7.5mg with folic acid (5mg twice a week which increased to 10mg a week).
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Appendix 5 Bath Ankylosing Spondylitis Disease
Activity Index and Bath Ankylosing Spondylitis
Functional Index scores conditional on Bath
Ankylosing Spondylitis Disease Activity
Index response
In this appendix we use the results from the extended synthesis model (Appendices 12 and 13) toevaluate the conditional scores by simulating BASDAI and BASFI scores for two equivalent cohorts of
patients one treated with an anti-TNF and the other with conventional therapy.
Description of methods
From the inferences obtained using the synthesis model in Appendix 13 it is possible to derive the
conditional change score in responders and non-responders using simulation. Whereas the synthesis
focuses on the pooling of mean estimates of change scores and proportion of responders to BASDAI 50,
to derive conditional mean scores there is the need to consider the distributions at the individual patient
level. Hence, conditional scores could not directly be derived from the synthesis but instead were derived
through a simulation procedure based on the assumptions and results of the synthesis model.
The steps undertaken within the simulation procedure were:
1. Simulate baseline BASDAI scores, xBASDAI*, from beliefs over its distribution, X∼N(ν, σ)
2. Simulate y∗k=1 from beliefs over the mean (µ) of this quantity considering correlation with x
BASDAI*:
Y k=1jX=x∼N(µ + ρ (x−µÞ, (1−ρ 2pla )σ2). (9)
3. Simulate y∗k=2 (where k= 2 represents treatment with anti-TNF) by considering:
Y k≠1jX=x∼N (µ + d + ρ (x−µ), (1−ρ 2anti−TNF )σ
2). (10)
4. Calculate final score for placebo and treatment separately, by summing xBASDAI∗f inal = y
BASDAI∗
k + x
BASDAI∗
5. Compute response variables for both groups as yBASDAIk + x
∗=2 < 0
Repeat steps 1 to 4 until the desired sample size is achieved, and calculate conditional scores based on
response variable and change in scores.
To evaluate BASFI conditional on BASDAI scores one needs to firstly consider we have available
information on the BASFI scores at baseline: XBASFI∼N(νBASFI, (seBASFI)2), and also on correlation with BASDAI
scores, φ (at individual level). By considering xBASDAI*, one can:
6. Simulate from the distribution of the baseline BASFI score conditional on the baseline BASDAI score
being x*:
xBASFI jxBASDAI=x∼N(ν
BASFI
+
σBASFI
σBASDAI
φ(xBASDAI−νBASDAI), (1−φ2)σ2BASFI). (11)
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Note the correlation parameter, φ which represents the individual-level correlation between baseline BASFI
and BASDAI scores.
7. Simulate the change from baseline on BASFI for placebo yBASFIk=1 from belief over this quantity, consider
this to be correlated with the y∗k=1 simulated for BASDAI (use correlation parameter estimated within
the synthesis):
yBASFIk=1 jyBASDAIk=1 =µ∗∼N (µ
BASFI
+
σBASFI
σBASDAI
ρm(µ
BASDAI∗−µBASDAI), (1−ρ 2m )σ
2
BASFI). (12)
8. Simulate the change from baseline for anti-TNF treatment:
θBASFI jyBASDAI=µ∗∼N(µBASFI + d +
σBASFI
σBASDAI
ρm(x
BASDAI∗
f inal −mean.x
BASDAI∗
f inal ), (1−ρ
2
m )σ
2
BASFI). (13)
Note that d represents the mean of the predictive distribution from the synthesis model.
We used a simulation sample size of 10,000 patients. Given results depend on the baseline distributions of
BASDAI and BASFI and on the change scores from baseline for placebo, we used the averages across trials
(weighted by the number of patients in each trial) in AS. Baseline BASDAI scores were thus assumed
normally distributed with mean 6.11 and SD of 1.56; change from baseline for placebo was simulated
from a normal distribution with mean –0.61 and SD of 1.44. For BASFI, the baseline was assumed to have
a mean of 5.27 and a SD of 1.79 and change from baseline for placebo a mean of –0.19 and a SD of
0.22. The correlation between baseline BASFI and BASDAI scores was valued at 0.7 (φ). Average scores
from the RAPID-axSpA64 trial for certolizumab were used for the nr-AxSpA analysis.
Results
Results of the prediction of conditional scores using the synthesis model in the AS population are
presented in Table 114 and for the nr-AxSpA population in Table 115.
TABLE 114 Conditional scores predicted for the AS population using the synthesis model
BASDAI BASFI
Control Treat Control Treat
Scenario 1
% responders to BASDAI 50 0.10 0.42 – –
Change in score
Responders –2.70 –3.86 –1.41 –3.02
Non-responders –0.45 –1.73 –0.17 –0.63
All –0.66 –2.63 –0.29 –1.64
Baseline
Responders 3.83 4.76 3.42 4.17
Non-responders 6.31 7.03 5.43 6.02
All 6.08 6.08 5.24 5.24
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TABLE 115 Conditional scores predicted for the nr-AxSpA population using results and assumptions of the
synthesis model
BASDAI BASFI
Control Treat Control Treat
Scenario 1
% responders to
BASDAI 50
AiC information has
been removed
AiC information has
been removed
– –
Change in score
AiC information has
been removeda
AiC information has
been removeda – –
Responders AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
Non-responders AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
All AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
Baseline
AiC information has
been removeda
AiC information has
been removeda – –
Responders AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
Non-responders AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
All AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
Scenario 2
% responders to
BASDAI 50
AiC information has
been removed
AiC information has
been removed
– –
Change in score
AiC information has
been removeda
AiC information has
been removeda – –
Responders AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
Non-responders AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
All AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
Baseline
AiC information has
been removeda
AiC information has
been removeda – –
Responders AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
Non-responders AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
All AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
a Based on a BASDAI baseline score (AiC information has been removed) and a placebo change in BASDAI score of
(AiC information has been removed) and a BASFI baseline score of (AiC information has been removed) and a placebo
change in BASFI score of (AiC information has been removed) which represent the results seen in the certolizumab trial
(RAPID-axSpA64).
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Appendix 6 Bath Ankylosing Spondylitis Disease
Activity Index and Bath Ankylosing Spondylitis
Functional Index scores conditional on response data
TABLE 116 Baseline BASDAI score according to conditional on response at week 12 (or nearest time point)
Anti-TNF
Population
(trial)
Response
criterion Treatment Response n Mean SD
Adalimumab AS
(ATLAS61)
ASAS 20 Adalimumab
40mg
Non-responder 83 6.23 1.929
Responder 121 6.27 1.542
Placebo Non-responder 82 6.29 1.712
Responder 22 6.64 1.468
ASAS 40 Adalimumab
40mg
Non-responder 119 6.21 1.802
Responder 85 6.32 1.568
Placebo Non-responder 89 6.37 1.714
Responder 15 6.34 1.362
BASDAI 50 Adalimumab
40mg
Non-responder 119 6.21 1.802
Responder 85 6.32 1.568
Placebo Non-responder 89 6.37 1.714
Responder 15 6.34 1.362
Golimumab AS
(GO-RAISE90)
ASAS 20 Golimumab
50mg
Non-responder 56 6.51 1.687
Responder 82 6.49 1.494
Placebo Non-responder 61 6.65 1.622
Responder 17 6.46 1.120
ASAS 40 Golimumab
50 mg
Non-responder 76 6.54 1.680
Responder 62 6.45 1.433
Placebo Non-responder 66 6.65 1.579
Responder 12 6.41 1.194
BASDAI 50 Golimumab
50 mg
Non-responder 72 6.69 1.523
Responder 61 6.25 1.638
Placebo Non-responder 66 6.63 1.581
Responder 12 6.51 1.194
continued
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TABLE 116 Baseline BASDAI score according to conditional on response at week 12 (or nearest time point) (continued)
Anti-TNF
Population
(trial)
Response
criterion Treatment Response n Mean SD
Etanercept AS
(314-EU167
study)
ASAS 20 Etanercept
25mg twice
weekly
Non-responder 43 CiC information
has been removed
CiC information
has been removed
Responder 107 CiC information
has been removed
CiC information
has been removed
Etanercept
50mg once
weekly
Non-responder 40 CiC information
has been removed
CiC information
has been removed
Responder 115 CiC information
has been removed
CiC information
has been removed
Placebo Non-responder 32 CiC information
has been removed
CiC information
has been removed
Responder 19 CiC information
has been removed
CiC information
has been removed
ASAS 40 Etanercept
25mg twice
weekly
Non-responder 70 CiC information
has been removed
CiC information
has been removed
Responder 80 CiC information
has been removed
CiC information
has been removed
Etanercept
50mg once
weekly
Non-responder 65 CiC information
has been removed
CiC information
has been removed
Responder 90 CiC information
has been removed
CiC information
has been removed
Placebo Non-responder 40 CiC information
has been removed
CiC information
has been removed
Responder 11 CiC information
has been removed
CiC information
has been removed
BASDAI 50 Etanercept
25mg twice
weekly
Non-responder 63 CiC information
has been removed
CiC information
has been removed
Responder 87 CiC information
has been removed
CiC information
has been removed
Etanercept
50mg once
weekly
Non-responder 62 CiC information
has been removed
CiC information
has been removed
Responder 93 CiC information
has been removed
CiC information
has been removed
Placebo Non-responder 41 CiC information
has been removed
CiC information
has been removed
Responder 10 CiC information
has been removed
CiC information
has been removed
Adalimumab
ABILITY-158
(nr-AxSpA
sub-population
with a positive
MRI and/or
elevated CRP
level)
ASAS 20 Adalimumab
40mg
Non-responder 27 6.31 1.66
Responder 41 6.46 1.49
Placebo Non-responder 46 6.49 1.37
Responder 23 6.05 1.77
ASAS 40 Adalimumab
40mg
Non-responder 40 6.60 1.63
Responder 28 6.13 1.41
Placebo Non-responder 59 6.41 1.55
Responder 10 5.93 1.27
BASDAI 50 Adalimumab
40mg
Non-responder 41 6.53 1.69
Responder 27 6.21 1.31
Placebo Non-responder 59 6.46 1.52
Responder 10 5.64 1.34
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TABLE 116 Baseline BASDAI score according to conditional on response at week 12 (or nearest time point) (continued)
Anti-TNF
Population
(trial)
Response
criterion Treatment Response n Mean SD
Etanercept
(1031 study,166
nr-AxSpA)
ASAS 20 Etanercept
50mg
Non-responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Placebo Non-responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
ASAS 40 Etanercept
50mg
Non-responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Placebo Non-responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
BASDAI 50 Etanercept
50mg
Non-responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Placebo Non-responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
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TABLE 117 Baseline BASFI according to conditional on response at week 12 (or nearest time point)
Anti-TNF
(trial)
Response
criterion Treatment Response n Mean SD
Adalimumab
AS (ATLAS61)
ASAS 20 Adalimumab
40mg
Non-responder 83 53.03 23.881
Responder 121 51.38 20.843
Placebo Non-responder 82 57.96 23.089
Responder 22 52.27 16.661
ASAS 40 Adalimumab
40mg
Non-responder 119 53.05 22.864
Responder 85 50.65 21.005
Placebo Non-responder 89 57.05 22.954
Responder 15 54.98 14.996
BASDAI 50 Adalimumab
40mg
Non-responder 110 57.79 21.015
Responder 94 45.34 21.514
Placebo Non-responder 87 59.06 21.989
Responder 17 44.98 17.979
Golimumab AS
(GO-RAISE90)
ASAS 20 Golimumab
50mg
Non-responder 56 5.35 2.530
Responder 82 4.76 2.249
Placebo Non-responder 59 5.38 2.260
Responder 17 4.13 1.985
ASAS 40 Golimumab
50mg
Non-responder 76 5.33 2.488
Responder 62 4.60 2.184
Placebo Non-responder 64 5.33 2.247
Responder 12 3.88 1.932
BASDAI 50 Golimumab
50mg
Non-responder 72 5.48 2.412
Responder 61 4.45 2.288
Placebo Non-responder 64 5.39 2.179
Responder 12 3.56 2.070
Etanercept AS
(314-EU167)
ASAS 20 Etanercept
25mg twice
weekly
Non-responder 43 CiC information
has been removed
CiC information
has been removed
Responder 107 CiC information
has been removed
CiC information
has been removed
Etanercept
50mg once
weekly
Non-responder 40 CiC information
has been removed
CiC information
has been removed
Responder 115 CiC information
has been removed
CiC information
has been removed
Placebo Non-responder 32 CiC information
has been removed
CiC information
has been removed
Responder 19 CiC information
has been removed
CiC information
has been removed
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TABLE 117 Baseline BASFI according to conditional on response at week 12 (or nearest time point) (continued )
Anti-TNF
(trial)
Response
criterion Treatment Response n Mean SD
ASAS 40 Etanercept
25mg twice
weekly
Non-responder 70 CiC information
has been removed
CiC information
has been removed
Responder 80 CiC information
has been removed
CiC information
has been removed
Etanercept
50mg once
weekly
Non-responder 65 CiC information
has been removed
CiC information
has been removed
Responder 90 CiC information
has been removed
CiC information
has been removed
Placebo Non-responder 40 CiC information
has been removed
CiC information
has been removed
Responder 11 CiC information
has been removed
CiC information
has been removed
BASDAI 50 Etanercept
25mg twice
weekly
Non-responder 63 CiC information
has been removed
CiC information
has been removed
Responder 87 CiC information
has been removed
CiC information
has been removed
Etanercept
50mg once
weekly
Non-responder 62 CiC information
has been removed
CiC information
has been removed
Responder 93 CiC information
has been removed
CiC information
has been removed
Placebo Non-responder 41 CiC information
has been removed
CiC information
has been removed
Responder 10 CiC information
has been removed
CiC information
has been removed
Adalimumab
nr-AxSpA,
ABILITY-158
(subpopulation
with a positive
MRI and/or
elevated CRP
level)
ASAS 20 Adalimumab
40mg
Non-responder 27 45.17 22.07
Responder 40 43.05 19.31
Placebo Non-responder 47 48.07 22.99
Responder 23 47.91 23.75
ASAS 40 Adalimumab
40mg
Non-responder 40 47.61 22.60
Responder 27 39.09 15.41
Placebo Non-responder 60 48.26 23.46
Responder 10 46.54 21.67
BASDAI 50 Adalimumab
40mg
Non-responder 40 49.71 20.05
Responder 27 35.97 18.12
Placebo Non-responder 59 49.06 23.25
Responder 10 43.66 23.07
continued
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TABLE 117 Baseline BASFI according to conditional on response at week 12 (or nearest time point) (continued )
Anti-TNF
(trial)
Response
criterion Treatment Response n Mean SD
Etanercept
(1031 study166
nr-AxSpA)
ASAS 20 Etanercept
50mg
Non-responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Placebo Non-responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
ASAS 40 Etanercept
50mg
Non-responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Placebo Non-responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
BASDAI 50 Etanercept
50mg
Non-responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Placebo Non-responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Responder CiC information
has been removed
CiC information
has been removed
CiC information
has been removed
Summary
The mean baseline BASDAI and BASFI are presented by treatment response at week 12 (or 14 for
golimumab) for three of the five anti-TNFs. This reveals that in patients with AS and patients with nr-AxSpA,
on average baseline BASDAI score does not differ greatly between responders and non-responders either
to placebo or to active anti-TNF therapy. In patients with AS or nr-AxSpA from the trials of adalimumab
(ATLAS61 and ABILITY-158) and golimumab (GO-RAISE90) on average baseline BASFI score was higher in
non-responders compared with responders. However, this was not seen in the etanercept trials.
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Appendix 7 Relative effects of anti-tumour
necrosis factors
Ankylosing spondylitis population
In the following tables, the intervention is stated in the top row and the comparator is in the left-hand
column, which is reverse to normal.
TABLE 118 Relative effects relative risk BASDAI 50 AS
Anti-TNF
ADA CER ETA GOL INF
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 1.15 0.61 to
1.86
1.01 0.65 to
1.50
1.13 0.75 to
1.66
1.55 0.74 to
2.50
CER 0.87 0.54 to
1.63
– – 0.88 0.50 to
1.70
0.99 0.58 to
1.89
1.34 0.61 to
2.74
ETA 0.99 0.67 to
1.53
1.14 0.59 to
1.98
– – 1.12 0.71 to
1.78
1.53 0.72 to
2.66
GOL 0.88 0.60 to
1.33
1.01 0.53 to
1.74
0.89 0.56 to
1.40
– – 1.37 0.65 to
2.30
INF 0.65 0.40 to
1.35
0.74 0.37 to
1.65
0.65 0.38 to
1.38
0.73 0.43 to
1.54
– –
ADA, adalimumab; CER, certolizumab; ETA, etanercept; GOL, golimumab; INF, infliximab.
TABLE 119 Relative effects OR BASDAI 50 AS
Anti-TNF
ADA CER ETA GOL INF
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 1.28 0.47 to
3.48
1.01 0.51 to
2.02
1.25 0.62 to
2.48
2.58 0.62 to
10.60
CER 0.78 0.29 to
2.14
– – 0.79 0.27 to
2.32
0.98 0.33 to
2.89
2.02 0.39 to
10.33
ETA 0.99 0.50 to
1.97
1.26 0.43 to
3.71
– – 1.23 0.56 to
2.73
2.55 0.58 to
11.01
GOL 0.80 0.40 to
1.61
1.02 0.35 to
3.03
0.81 0.37 to
1.80
– – 2.06 0.47 to
8.91
INF 0.39 0.09 to
1.62
0.50 0.10 to
2.56
0.39 0.09 to
1.72
0.49 0.11 to
2.12
– –
ADA, adalimumab; CER, certolizumab; ETA, etanercept; GOL, golimumab; INF, infliximab.
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TABLE 120 Relative effects relative risk ASAS 20 AS
Anti-TNF
ADA CER ETA GOL INF
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 0.79 0.53 to
1.07
0.98 0.82 to
1.17
0.94 0.75 to
1.15
1.07 0.75 to
1.38
CER 1.27 0.93 to
1.88
– – 1.24 0.91 to
1.83
1.19 0.85 to
1.77
1.35 0.88 to
2.09
ETA 1.03 0.86 to
1.22
0.81 0.55 to
1.10
– – 0.96 0.76 to
1.18
1.10 0.77 to
1.41
GOL 1.07 0.87 to
1.34
0.84 0.56 to
1.18
1.04 0.85 to
1.31
– – 1.14 0.79 to
1.53
INF 0.93 0.73 to
1.34
0.74 0.48 to
1.14
0.91 0.71 to
1.31
0.87 0.66 to
1.27
– –
ADA, adalimumab; CER, certolizumab; ETA, etanercept; GOL, golimumab; INF, infliximab.
TABLE 121 Relative effects OR ASAS 20 AS
Anti-TNF
ADA CER ETA GOL INF
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 0.57 0.28 to
1.20
0.94 0.58 to
1.50
0.85 0.49 to
1.46
1.23 0.50 to
3.01
CER 1.74 0.84 to
3.57
– – 1.62 0.78 to
3.35
1.47 0.67 to
3.16
2.13 0.74 to
6.13
ETA 1.07 0.67 to
1.71
0.62 0.30 to
1.28
– – 0.90 0.52 to
1.55
1.31 0.54 to
3.20
GOL 1.18 0.69 to
2.05
0.68 0.32 to
1.49
1.11 0.65 to
1.91
– – 1.46 0.57 to
3.70
INF 0.82 0.33 to
1.99
0.47 0.16 to
1.36
0.76 0.31 to
1.86
0.69 0.27 to
1.75
– –
ADA, adalimumab; CER, certolizumab; ETA, etanercept; GOL, golimumab; INF, infliximab.
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TABLE 122 Relative effects relative risk ASAS 40 AS
Anti-TNF
ADA CER ETA GOL
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 0.74 0.41 to
1.22
0.80 0.51 to
1.20
0.91 0.61 to
1.32
CER 1.35 0.82 to
2.45
– – 1.09 0.61 to
2.04
1.23 0.72 to
2.26
ETA 1.24 0.83 to
1.95
0.92 0.49 to
1.63
– – 1.13 0.72 to
1.81
GOL 1.10 0.76 to
1.64
0.81 0.44 to
1.38
0.88 0.55 to
1.38
– –
ADA, adalimumab; CER, certolizumab; ETA, etanercept; GOL, golimumab.
TABLE 123 Relative effects OR ASAS 40 AS
Anti-TNF
ADA CER ETA GOL
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 0.59 0.25 to
1.45
0.68 0.33 to
1.40
0.84 0.42 to
1.67
CER 1.68 0.69 to
4.04
– – 1.14 0.45 to
2.90
1.42 0.57 to
3.50
ETA 1.47 0.71 to
3.02
0.87 0.35 to
2.24
– – 1.23 0.58 to
2.63
GOL 1.19 0.60 to
2.38
0.71 0.29 to
1.75
0.81 0.38 to
1.72
– –
ADA, adalimumab; CER, certolizumab; ETA, etanercept; GOL, golimumab.
TABLE 124 Relative effects relative risk ASAS 50 AS
Anti-TNF
ADA ETA INF
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 1.24 0.60 to 3.31 2.00 0.73 to 5.87
ETA 0.81 0.30 to 1.66 – – 1.63 0.68 to 2.95
INF 0.50 0.17 to 1.36 0.61 0.34 to 1.46 – –
ADA, adalimumab; ETA, etanercept; INF, infliximab.
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TABLE 125 Relative effects OR ASAS 50 AS
Anti-TNF
ADA ETA INF
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 1.40 0.40 to 5.05 4.11 0.59 to 29.29
ETA 0.71 0.20 to 2.49 – – 2.92 0.55 to 15.51
INF 0.24 0.03 to 1.71 0.34 0.06 to 1.81 – –
ADA, adalimumab; ETA, etanercept; INF, infliximab.
TABLE 126 Relative effects mean difference BASDAI change from baseline AS
Anti-TNF
ADA CER ETA INF
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 0.10 –0.68 to
0.88
–0.20 –0.71 to
0.30
–0.73 –1.69 to
0.24
CER –0.10 –0.88 to
0.68
– – –0.30 –1.12 to
0.52
–0.82 –1.98 to
0.33
ETA 0.20 –0.30 to
0.71
0.30 –0.52 to
1.12
– – –0.53 –1.50 to
0.47
INF 0.73 –0.24 to
1.69
0.82 –0.33 to
1.98
0.53 –0.47 to
1.50
– –
ADA, adalimumab; CER, certolizumab; ETA, etanercept; INF, infliximab.
TABLE 127 Relative effects mean difference BASFI change from baseline AS
Anti-
TNF
ADA CER ETA GOL INF
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 0.15 –0.67 to
0.97
–0.18 –0.73 to
0.36
–0.20 –0.75 to
0.35
–0.91 –2.00 to
0.20
CER –0.15 –0.97 to
0.67
– – –0.33 –1.16 to
0.49
–0.35 –1.17 to
0.47
–1.05 –2.31 to
0.22
ETA 0.18 –0.36 to
0.73
0.33 –0.49 to
1.16
– – –0.02 –0.57 to
0.55
–0.72 –1.83 to
0.39
GOL 0.20 –0.35 to
0.75
0.35 –0.47 to
1.17
0.02 –0.55 to
0.57
– – –0.71 –1.82 to
0.42
INF 0.91 –0.20 to
2.00
1.05 –0.22 to
2.31
0.72 –0.39 to
1.83
0.71 –0.42 to
1.82
– –
ADA, adalimumab; CER, certolizumab; ETA, etanercept; GOL, golimumab; INF, infliximab.
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TABLE 128 Relative effects mean difference BASMI change from baseline AS
Anti-TNF
ADA CER ETA GOL
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 0.11 –0.21 to
0.42
0.00 –0.32 to
0.31
0.26 0.06 to
0.46
CER –0.11 –0.42 to
0.21
– – –0.11 –0.51 to
0.30
0.15 –0.17 to
0.48
ETA 0.00 –0.31 to
0.32
0.11 –0.30 to
0.51
– – 0.26 –0.06 to
0.58
GOL –0.26 –0.46 to
–0.06
–0.15 –0.48 to
0.17
–0.26 –0.58 to
0.06
– –
ADA, adalimumab; CER, certolizumab; ETA, etanercept; GOL, golimumab.
TABLE 129 Relative effects mean difference SF-36 PCS change from baseline AS
Anti-TNF
ADA CER GOL
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 2.11 –0.20 to 4.44 1.52 –0.24 to 3.30
CER –2.11 –4.44 to 0.20 – – –0.59 –2.99 to 1.85
GOL –1.52 –3.30 to 0.24 0.59 –1.85 to 3.00 – –
ADA, adalimumab; CER, certolizumab; GOL, golimumab.
TABLE 130 Relative effects mean difference MASES change from baseline AS
Anti-TNF
GOL
Mean difference 95% CrI
ADA –0.20 –1.12 to 0.70
ADA, adalimumab; GOL, golimumab.
TABLE 131 Relative effects mean difference SF-36 MCS change from baseline AS
Anti-TNF
ADA CER GOL
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – –0.15 –3.83 to 3.54 1.33 –0.97 to 3.63
CER 0.15 –3.53 to 3.83 – – 1.51 –2.24 to 5.21
GOL –1.33 –3.63 to 0.98 –1.51 –5.20 to 2.24 – –
ADA, adalimumab; CER, certolizumab; GOL, golimumab.
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Relative effects of anti-tumour necrosis factors:
non-radiographic axial spondyloarthritis population
In the following tables, the intervention is stated in the top row and the comparator is in the left-hand
column, which is reverse to normal.
TABLE 132 Relative effects relative risk BASDAI 50 nr-AxSpA
Anti-TNF
ADA CER ETA
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 1.11 0.62 to 1.96 0.76 0.44 to 1.30
CER 0.90 0.51 to 1.61 – – 0.69 0.38 to 1.22
ETA 1.31 0.77 to 2.28 1.46 0.82 to 2.62 – –
ADA, adalimumab; CER, certolizumab; ETA, etanercept.
TABLE 133 Relative effects OR BASDAI 50 nr-AxSpA
Anti-TNF
ADA CER ETA
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 1.24 0.42 to 3.75 0.62 0.25 to 1.55
CER 0.81 0.27 to 2.40 – – 0.50 0.18 to 1.40
ETA 1.62 0.65 to 3.99 2.01 0.72 to 5.68 – –
ADA, adalimumab; CER, certolizumab; ETA, etanercept.
TABLE 134 Relative effects relative risk ASAS 20 nr-AxSpA
Anti-TNF
ADA CER ETA
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 0.83 0.54 to 1.20 0.77 0.52 to 1.08
CER 1.20 0.84 to 1.87 – – 0.92 0.60 to 1.44
ETA 1.31 0.93 to 1.94 1.09 0.70 to 1.67 – –
ADA, adalimumab; CER, certolizumab; ETA, etanercept.
TABLE 135 Relative effects OR ASAS 20 nr-AxSpA
Anti-TNF
ADA CER ETA
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 0.62 0.25 to 1.59 0.52 0.23 to 1.19
CER 1.60 0.63 to 3.98 – – 0.83 0.34 to 2.01
ETA 1.92 0.84 to 4.33 1.20 0.50 to 2.92 – –
ADA, adalimumab; CER, certolizumab; ETA, etanercept.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
242
TABLE 136 Relative effects relative risk ASAS 40 nr-AxSpA
Anti-TNF
ADA CER ETA INF
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 0.97 0.51 to 1.78 0.66 0.35 to 1.21 1.16 0.42 to 2.29
CER 1.04 0.56 to 1.98 – – 0.68 0.35 to 1.35 1.20 0.43 to 2.55
ETA 1.51 0.83 to 2.82 1.46 0.74 to 2.85 – – 1.74 0.63 to 3.70
INF 0.86 0.44 to 2.37 0.84 0.39 to 2.33 0.57 0.27 to 1.58 – –
ADA, adalimumab; CER, certolizumab; ETA, etanercept; INF, infliximab.
TABLE 137 Relative effects OR ASAS 40 nr-AxSpA
Anti-TNF
ADA CER ETA INF
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 0.94 0.31 to 2.90 0.51 0.19 to 1.35 1.36 0.26 to 7.22
CER 1.07 0.34 to 3.25 – – 0.54 0.18 to 1.58 1.45 0.25 to 8.10
ETA 1.98 0.74 to 5.23 1.86 0.63 to 5.51 – – 2.68 0.52 to 13.91
INF 0.73 0.14 to 3.91 0.69 0.12 to 3.93 0.37 0.07 to 1.91 – –
ADA, adalimumab; CER, certolizumab; ETA, etanercept; INF, infliximab.
TABLE 138 Relative effects mean difference BASDAI change from baseline nr-AxSpA
Anti-TNF
ADA CER ETA INF
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – –0.63 –1.77 to 0.52 0.53 –0.51 to 1.56 –1.43 –3.08 to 0.22
CER 0.63 –0.52 to 1.77 – – 1.15 –0.12 to 2.42 –0.81 –2.62 to 1.00
ETA –0.53 –1.56 to 0.51 –1.15 –2.42 to 0.12 – – –1.97 –3.70 to –0.21
INF 1.43 –0.21 to 3.08 0.81 –1.00 to 2.62 1.97 0.21 to 3.70 – –
ADA, adalimumab; CER, certolizumab; ETA, etanercept; INF, infliximab.
TABLE 139 Relative effects mean difference BASFI change from baseline nr-AxSpA
Anti-TNF
ADA CER ETA INF
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – –1.00 –2.10 to 0.10 0.30 –0.48 to 1.08 –1.33 –2.86 to 0.19
CER 1.00 –0.10 to 2.10 – – 1.30 0.19 to 2.41 –0.33 –2.05 to 1.38
ETA –0.30 –1.08 to 0.48 –1.30 –2.41 to –0.19 – – –1.63 –3.15 to –0.09
INF 1.33 –0.19 to 2.86 0.33 –1.38 to 2.05 1.63 0.09 to 3.15 – –
ADA, adalimumab; CER, certolizumab; ETA, etanercept; INF, infliximab.
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TABLE 140 Relative effects mean difference BASMI change from baseline nr-AxSpA
Anti-TNF
ADA CER ETA
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – –0.53 –0.93 to –0.12 0.02 –0.47 to 0.51
CER 0.53 0.12 to 0.93 – – 0.55 –0.02 to 1.10
INF –0.02 –0.51 to 0.47 –0.55 –1.10 to 0.02 – –
ADA, adalimumab; CER, certolizumab; ETA, etanercept; INF, infliximab.
TABLE 141 Relative effects mean difference SF-36 PCS change from baseline nr-AxSpA
Anti-TNF
ADA CER ETA
Mean
difference 95% CrI
Mean
difference 95% CrI
Mean
difference 95% CrI
ADA – – 2 –1.53 to 5.57 –2.88 –6.11 to 0.31
CER –2.00 –5.57 to 1.53 – – –4.88 –8.52 to –1.29
INF 2.88 –0.31 to 6.11 4.88 1.29 to 8.52 – –
ADA, adalimumab; CER, certolizumab; ETA, etanercept; INF, infliximab.
TABLE 142 Relative effects mean difference SF-36 MCS change from baseline nr-AxSpA
Anti-TNF
ADA CER
Mean difference 95% CrI Mean difference 95% CrI
ADA – – 2.87 –1.78 to 7.49
CER –2.87 –7.49 to 1.78 – –
ADA, adalimumab; CER, certolizumab.
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Appendix 8 Long-term efficacy data
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TABLE 143 Data from open label extensions of included RCTs
Study characteristics
Results
Number of responders (%) Other outcomes
Trial cohort and
references of
open-label studies Population Treatment and dose Time point
Number of
patients
Imputation
methods and
withdrawal
criteria ASAS 20 ASAS 40 BASDAI 50
Other results ASAS 50,
ASAS 70, BASDAI, BASFI,
BASMI, mSASSS, MASES,
SF-36 MCS, SF-36 PCS, EQ-5D
Haibel
200852–54,185–188
Nr-axSpA with
inflammation
Adalimumab, 40mg
every other week.
Non-responders at the
end of the double-
blind trial (week 12)
and after open-label
therapy for at least
12 weeks were eligible
for dose escalation to
40mg/week
52 weeks 46 ITT. Patients who
withdrew from the
study were counted
as non-responders
for categorical data.
LOCF was used for
continuous variables
– 23/46
(50)
24/46
(52)
BASDAI change from baseline
2.8 (95% CI 2.1 to 3.6)
BASFI change from baseline
2 (95% CI 1.4 to 2.6)
BASMI change from baseline
–0.4 (95% CI –0.7 to –0.04)
EQ-5D change from baseline
0.22 (95% CI 0.13 to 0.31)
SF-36 MCS change from
baseline 4.9 (95% CI 1.6 to
8.1)
SF-36 PCS change from
baseline 10.3 (95% CI 6.9 to
13.8)
ASQoL change from baseline
5.3 (95% CI 3.8 to 6.7)
MASES change from baseline
0.9 (95% CI –0.02 to 1.9)
In total, 26 patients with MRIs
at baseline and 52 weeks
showed no change in sclerosis
or in erosions
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Study characteristics
Results
Number of responders (%) Other outcomes
Trial cohort and
references of
open-label studies Population Treatment and dose Time point
Number of
patients
Imputation
methods and
withdrawal
criteria ASAS 20 ASAS 40 BASDAI 50
Other results ASAS 50,
ASAS 70, BASDAI, BASFI,
BASMI, mSASSS, MASES,
SF-36 MCS, SF-36 PCS, EQ-5D
ABILITY-1
201358,189–194
Nr-axSpA with
inflammation
Adalimumab, placebo/
adalimumab
52 weeks 61 – – – – SF-36 PCS change from
baseline 10.0 (SD 9.91)
Adalimumab,
adalimumab/
adalimumab
52 weeks 55 – – – – SF-36 PCS change from
baseline 11.0 (SD 9.93)
Adalimumab, 40mg
every other week
68 weeks 111 (patients
MRI positive or
CRP positive)
Observed (n= 142
at week 12)
77/111
(69)
74/111
(67)
–
Adalimumab, 40mg
every other week
104 weeks 102 – – – – –
Adalimumab, 40mg
every other week
156 weeks 97 (patients
MRI positive or
CRP positive)
Observed (n= 142
at week 12)
83/97
(86)
67/97
(69)
70/97
(72)
ASAS 50 responders: n= 58
ASAS 70 responders: n= 47
ATLAS
200661,140,141,195–201
AS Adalimumab, 40mg
every other week
52 weeks 311 had at
least one dose
Observed 193/276
(70)
138/276
(50)
167/276
(61)
BASDAI change from baseline
–3.5 (SD 2.55), n= 274
BASFI change from baseline
–2.6 (SD 2.04), n= 274
BASMI final value 3.2
(SD 2.2), n= 273
SF-36 MCS change from
baseline 5.6 (SD 10.35), n=265
SF-36 PCS change from
baseline 10.19 (SD 9.5), n=265
ASQoL change from baseline
–4.8 (SD 4.41), n= 274
MASES final value 2.4
(SD 4.6), n= 279
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TABLE 143 Data from open label extensions of included RCTs (continued )
Study characteristics
Results
Number of responders (%) Other outcomes
Trial cohort and
references of
open-label studies Population Treatment and dose Time point
Number of
patients
Imputation
methods and
withdrawal
criteria ASAS 20 ASAS 40 BASDAI 50
Other results ASAS 50,
ASAS 70, BASDAI, BASFI,
BASMI, mSASSS, MASES,
SF-36 MCS, SF-36 PCS, EQ-5D
Adalimumab, 40mg
every other week
76 weeks – Observed – – – BASDAI change from baseline
–3.8 (SD 2.33), n= 270
BASFI change from baseline
–2.8 (SD 2.1), n= 270
SF-36 MCS change from
baseline 5.1 (SD 11.06), n=263
SF-36 PCS change from
baseline 10.8 (SD 9.88), n=263
ASQoL change from baseline
–5 (SD 4.32), n= 270
Adalimumab, 40mg
every other week
104 weeks 173 Observed 135/173
(78)
109/173
(63)
122/173
(71)
BASDAI change from baseline
–3.9 (SD 2.44), n= 262
BASFI change from baseline
–2.9 (SD 2.14), n= 261
BASMI final value 3.1
(SD 2.2), n= 173
SF-36 MCS change from
baseline 5.7 (SD 10.96),
n= 255
SF-36 PCS change from
baseline 11 (SD 9.88), n= 255
ASQoL change from baseline
–5.4 (SD 4.28), n= 263
MASES change from baseline
2.2 (SD 4.4), n= 217
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Study characteristics
Results
Number of responders (%) Other outcomes
Trial cohort and
references of
open-label studies Population Treatment and dose Time point
Number of
patients
Imputation
methods and
withdrawal
criteria ASAS 20 ASAS 40 BASDAI 50
Other results ASAS 50,
ASAS 70, BASDAI, BASFI,
BASMI, mSASSS, MASES,
SF-36 MCS, SF-36 PCS, EQ-5D
Adalimumab, 40mg
every other week
128 weeks – Observed – – – BASDAI change from baseline
–3.9 (SD 2.39), n= 242
BASFI change from baseline
–2.9 (SD 2.17), n= 242
SF-36 MCS change from
baseline 4.1 (SD 10.84),
n= 229
SF-36 PCS change from
baseline 11.3 (SD 9.68),
n= 229
ASQoL change from baseline
–5.3 (SD 4.35), n= 242
Adalimumab, 40mg
every other week
156 weeks – Observed – – – BASDAI change from baseline
–3.9 (SD 3.39), n= 236
BASFI change from baseline
–3 (SD 2.1), n= 236
BASMI final value 3.7
(SD 1.8), n= 233
SF-36 MCS change from
baseline 5.6 (SD 11.59),
n= 227
SF-36 PCS change from
baseline 11.6 (SD 9.65),
n= 227
ASQoL change from baseline
–5.4 (SD 4.36), n= 236
continued
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TABLE 143 Data from open label extensions of included RCTs (continued )
Study characteristics
Results
Number of responders (%) Other outcomes
Trial cohort and
references of
open-label studies Population Treatment and dose Time point
Number of
patients
Imputation
methods and
withdrawal
criteria ASAS 20 ASAS 40 BASDAI 50
Other results ASAS 50,
ASAS 70, BASDAI, BASFI,
BASMI, mSASSS, MASES,
SF-36 MCS, SF-36 PCS, EQ-5D
Adalimumab, 40mg
every other week
5 years 125 (patients
randomised to
adalimumab
and completed
5 years)
Observed 111/125
(89)
88/125
(70)
96/124
(77)
BASDAI score final value 1.8
(SD 1.9), n= 124
BASFI score final value 2.1
(SD 2.1), n= 125
BASMI score final value 3.7
(SD 1.8), n= 124
SF-36 PCS score final value
44.4 (SD 10), n= 165
ASQoL score final value 4.8
(SD 4.8), n= 169
RAPID-axSpA
201464,202–204
AS Certolizumab pegol
200mg every 2 weeks
48 weeks 65 NRI+ LOCF 47/65
(72)
34/65
(52)
– BASDAI score final value 3.3
BASFI score final value 3
Certolizumab pegol
400mg every 4 weeks
48 weeks 56 42/56
(75)
36/56
(64)
– BASDAI score final value 3
BASFI score final value 3.2
Certolizumab pegol, all 48 weeks 121 AiC
information
has been
removed
AiC
information
has been
removed
– –
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Study characteristics
Results
Number of responders (%) Other outcomes
Trial cohort and
references of
open-label studies Population Treatment and dose Time point
Number of
patients
Imputation
methods and
withdrawal
criteria ASAS 20 ASAS 40 BASDAI 50
Other results ASAS 50,
ASAS 70, BASDAI, BASFI,
BASMI, mSASSS, MASES,
SF-36 MCS, SF-36 PCS, EQ-5D
Certolizumab pegol,
200mg every 2 weeks
96 weeks 65 NRI 39 – – –
Certolizumab pegol,
400mg every 4 weeks
96 weeks 56 NRI 39 – – –
Certolizumab pegol, all 96 weeks 121 NRI 78/121
(64)
61/121
(50)
– –
Certolizumab pegol, all 96 weeks 93 Observed case 78/93
(84)
61/93
(66)
– –
Nr-axSpA with
inflammation
Certolizumab pegol,
200mg every 2 weeks
48 weeks 46 NRI was used for
categorical
measures and LOCF
for quantitative
measures (48-week
data)
32/46
(70)
25/46
(54)
– BASDAI score final value 2.9
BASFI score final value 2.1
Certolizumab pegol,
400mg every 4 weeks
48 weeks 51 35/51
(69)
30/51
(59)
– BASDAI score final value 3.3
BASFI score final value 2.8
Certolizumab pegol, all 48 weeks 97 AiC
information
has been
removed
AiC
information
has been
removed
– –
Certolizumab pegol
200mg every 2 weeks
96 weeks 46 NRI 30 – –
Certolizumab pegol
400mg every 4 weeks
96 weeks 51 NRI 29 – –
Certolizumab pegol, all 96 weeks 97 NRI 59/97
(61)
49/97
(51)
– –
Certolizumab pegol, all 96 weeks 74 Observed case 59/74
(80)
49/74
(66)
– –
continued
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TABLE 143 Data from open label extensions of included RCTs (continued )
Study characteristics
Results
Number of responders (%) Other outcomes
Trial cohort and
references of
open-label studies Population Treatment and dose Time point
Number of
patients
Imputation
methods and
withdrawal
criteria ASAS 20 ASAS 40 BASDAI 50
Other results ASAS 50,
ASAS 70, BASDAI, BASFI,
BASMI, mSASSS, MASES,
SF-36 MCS, SF-36 PCS, EQ-5D
Davis
200372,119,144,145,205,206
AS Placebo then
etanercept
72 weeks 105 Observed case – – – BASFI score final value 32.3
(SD 2.5)
Etanercept then
etanercept
96 weeks 95 Observed case 70/95
(74)
– – ASAS 70 responders 44
BASFI score final value 25.4
(SD 2.4)
Combined groups 96 weeks 257 – – – – mSASSS change from baseline
0.91 (SD 2.45)
Placebo then
etanercept
168 weeks 127 LOCF 77/127
(61)
64/127
(50)
– –
Etanercept then
etanercept
192 weeks 124 LOCF 83/124
(67)
61/124
(49)
– –
Dougados 201476,207 Nr-axSpA
mixed
Etanercept then
etanercept, 50mg
weekly
32 weeks 100 NRI – AiC
information
has been
removed
– –
Placebo then
etanercept, 50mg
weekly
32 weeks 105 NRI – AiC
information
has been
removed
– –
Etanercept then
etanercept, 50mg
weekly
40 weeks 100 NRI – AiC
information
has been
removed
– –
Placebo then
etanercept, 50mg
weekly
40 weeks 105 NRI – AiC
information
has been
removed
– –
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Study characteristics
Results
Number of responders (%) Other outcomes
Trial cohort and
references of
open-label studies Population Treatment and dose Time point
Number of
patients
Imputation
methods and
withdrawal
criteria ASAS 20 ASAS 40 BASDAI 50
Other results ASAS 50,
ASAS 70, BASDAI, BASFI,
BASMI, mSASSS, MASES,
SF-36 MCS, SF-36 PCS, EQ-5D
Etanercept plus
placebo groups
together, 50mg
weekly
48 weeks AiC
information
has been
removed
(189 observed)
NRI+ LOCF 147 108 128 AiC information has been
removed
Etanercept then
etanercept, 50mg
weekly
48 weeks 100 – – AiC
information
has been
removed
– –
Placebo then
etanercept, 50mg
weekly
48 weeks 105 – – AiC
information
has been
removed
– –
Gorman
200279,206,208
Etanercept then
etanercept
28 weeks 19 NRI AiC
information
has been
removed
– – AiC information has been
removed
Placebo then
etanercept
28 weeks 19 NRI AiC
information
has been
removed
– – AiC information has been
removed
Etanercept then
etanercept
40 weeks 19 NRI AiC
information
has been
removed
– – AiC information has been
removed
Placebo then
etanercept
40 weeks 19 NRI AiC
information
has been
removed
– – AiC information has been
removed
continued
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TABLE 143 Data from open label extensions of included RCTs (continued )
Study characteristics
Results
Number of responders (%) Other outcomes
Trial cohort and
references of
open-label studies Population Treatment and dose Time point
Number of
patients
Imputation
methods and
withdrawal
criteria ASAS 20 ASAS 40 BASDAI 50
Other results ASAS 50,
ASAS 70, BASDAI, BASFI,
BASMI, mSASSS, MASES,
SF-36 MCS, SF-36 PCS, EQ-5D
Calin 200483,146,147 AS Etanercept then
etanercept
60 weeks 42 LOCF – – – BASDAI score final value 2.1
BASFI score final value 2.9
mSASSS change from baseline
0.36 (95% CI –0.1 to 0.8),
n= 33
Placebo then
etanercept
60 weeks 39 LOCF – – – BASDAI final value 2.7
BASFI final value 3.4
mSASSS change from baseline
–0.15 (95% CI –0.7 to 0.4),
n= 34
Combined group 108 weeks 81 LOCF AiC
information
has been
removed
44/81
(54)
AiC
information
has been
removed
AiC information has been
removed
BASFI final value: 2.9
Etanercept then
etanercept
108 weeks 42 LOCF – – – BASDAI score final value 2.3
BASFI score final value 3
Placebo then
etanercept
108 weeks 39 LOCF – – – BASDAI score final value 2.9
BASFI score final value 3.5
Combined group 264 weeks 59 LOCF 40/59
(68)
39/59
(66)
AiC information has been
removed
BASDAI score final value 2.7
BASFI score final value 3.2
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Study characteristics
Results
Number of responders (%) Other outcomes
Trial cohort and
references of
open-label studies Population Treatment and dose Time point
Number of
patients
Imputation
methods and
withdrawal
criteria ASAS 20 ASAS 40 BASDAI 50
Other results ASAS 50,
ASAS 70, BASDAI, BASFI,
BASMI, mSASSS, MASES,
SF-36 MCS, SF-36 PCS, EQ-5D
Bao 201295,96,209,210 AS Golimumab, 50mg 52 weeks 108 ITT 76/108
(70)
53/108
(49)
62/108
(57)
–
GO-RAISE
200890,120,142,143,211–222
AS Golimumab placebo,
50mg
104 weeks 78 ITT 30/78 (38) 30/78
(38)
– BASDAI score final value
median 6 (IQR 1.36 to 7.79)
BASFI score final value median
4.9 (IQR 0.98 to 7.07)
mSASSS score change from
baseline 1.6 (SD 4.6), n= 66
Golimumab, 50mg 104 weeks 138 ITT 83/138
(60)
77/138
(56)
– BASDAI score final value
median 2.7 (IQR 0.84 to 6.08)
BASFI score final value median
2.2 (IQR 0.52 to 5.80)
mSASSS score change from
baseline 0.9 (SD 2.7), n= 111
Golimumab, 100mg 104 weeks 140 ITT 100/140
(71)
76/140
(54)
– BASDAI score final value
median 2.7 (IQR 1.08 to 5.34)
BASFI score final value median
1.8 (IQR 0.49 to 4.79)
mSASSS score change from
baseline 0.9 (SD 3.9), n= 122
All patients
randomised (all
golimumab from
week 24)
104 weeks 356 NRI+ LOCF 249/356
(70)
213/356
(60)
– –
continued
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TABLE 143 Data from open label extensions of included RCTs (continued )
Study characteristics
Results
Number of responders (%) Other outcomes
Trial cohort and
references of
open-label studies Population Treatment and dose Time point
Number of
patients
Imputation
methods and
withdrawal
criteria ASAS 20 ASAS 40 BASDAI 50
Other results ASAS 50,
ASAS 70, BASDAI, BASFI,
BASMI, mSASSS, MASES,
SF-36 MCS, SF-36 PCS, EQ-5D
All patients
randomised (all
golimumab from
week 24)
160 weeks 356 NRI+ LOCF 246/356
(69)
208/356
(58)
– –
Golimumab placebo,
50mg
208 weeks 78 – – – – mSASSS change from baseline
2.1 (SD 5.2), n= 66
Golimumab, 50mg 208 weeks 138 – – – – mSASSS change from baseline
1.3 (SD 4.1), n= 111
Golimumab, 100mg 208 weeks 140 – – – – mSASSS change from baseline
2 (SD 5.6), n= 122
All patients
randomised (all
golimumab from
week 24)
256 weeks 356 NRI+ LOCF 235/356
(66)
203/356
(57)
199/356
(58)
–
Tam 201497 AS Golimumab, 50mg
monthly
54 weeks 19 UC 18 – – –
Placebo/golimumab 54 weeks 17 UC 14 – – –
Placebo/placebo 54 weeks 3 UC 1 – – –
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Study characteristics
Results
Number of responders (%) Other outcomes
Trial cohort and
references of
open-label studies Population Treatment and dose Time point
Number of
patients
Imputation
methods and
withdrawal
criteria ASAS 20 ASAS 40 BASDAI 50
Other results ASAS 50,
ASAS 70, BASDAI, BASFI,
BASMI, mSASSS, MASES,
SF-36 MCS, SF-36 PCS, EQ-5D
PLANETAS
2013110,223
AS CT-P13 (biosimilar to
infliximab) 5mg/kg
78 weeks 88 ITT 61/88
(69)
50/88
(57)
– –
CT-P13 then infliximab
(switched at week 54)
5mg/kg
78 weeks 86 ITT 64/86
(74)
43/86
(50)
– –
CT-P13 (biosimilar to
infliximab) 5mg/kg
102 weeks 88 ITT 67/88
(76)
53/88
(60)
– –
CT-P13 then infliximab
(switched at week 54)
5mg/kg
102 weeks 86 ITT 60/86
(70)
48/86
(56)
– –
Braun
200298,148,164,224–230
AS Infliximab 5mg/kg
(infusion at 0, 2 and
6 weeks)
54 weeks 34 NRI for binary data.
A completer analysis
was conducted
– – 47% mSASSS reported for two
groups: patients with
worsening of BASFI score of
>1 and those with score of <1
Placebo/infliximab 54 weeks 35 – – 51%
Aggregate 54 weeks 69 – – 33/69
(48)
BASDAI score final value: 2.5
(SD 1.7), n= 52
BASFI score final value: 3.0
(SD 2.2), n= 52
BASMI score final value: 2.4
(SD 2.0), n= 52
SF-36 MCS score final value:
50.9 (SD 8.9), n= 52
SF-36 PCS score final value:
40.6 (SD 10.6), n= 52
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TABLE 143 Data from open label extensions of included RCTs (continued )
Study characteristics
Results
Number of responders (%) Other outcomes
Trial cohort and
references of
open-label studies Population Treatment and dose Time point
Number of
patients
Imputation
methods and
withdrawal
criteria ASAS 20 ASAS 40 BASDAI 50
Other results ASAS 50,
ASAS 70, BASDAI, BASFI,
BASMI, mSASSS, MASES,
SF-36 MCS, SF-36 PCS, EQ-5D
BASDAI score final value: 2.4
(SD 1.6), n= 46
BASFI score final value: 3.1
(SD 2.2), n= 46
BASMI score final value: 2.4
(SD 1.9), n= 46
SF-36 MCS score final value:
51.5 (SD 8.6), n= 46
SF-36 PCS score final value:
40.2 (SD 10.8), n= 46
Aggregate 102 weeks 69 NRI for binary data.
A completer analysis
was conducted
– – 30/69
(43)
BASDAI score final value: 2.6
(SD 2), n= 52
BASFI score final value: 3.0
(SD 2.2), n= 52
BASMI score final value: 2.7
(SD 2.1), n= 52
SF-36 MCS score final value:
50.2 (SD 9.5), n= 52
SF-36 PCS score final value:
40.9 (SD 11.1), n= 52
BASDAI score final value: 2.6
(SD 2), n= 46
BASFI score final value: 3.1
(SD 2.3), n= 46
BASMI score final value: 2.7
(SD 2.1), n= 46
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Study characteristics
Results
Number of responders (%) Other outcomes
Trial cohort and
references of
open-label studies Population Treatment and dose Time point
Number of
patients
Imputation
methods and
withdrawal
criteria ASAS 20 ASAS 40 BASDAI 50
Other results ASAS 50,
ASAS 70, BASDAI, BASFI,
BASMI, mSASSS, MASES,
SF-36 MCS, SF-36 PCS, EQ-5D
SF-36 MCS score final value:
51.4 (SD 8.9), n= 46
SF-36 PCS score final value:
40.5 (SD 11.4), n= 46
Aggregate 156 weeks 46 Completer analysis.
To calculate means,
LOCF was used
– – 28/46
(61)
BASDAI score final value: 2.7
(SD 2), n= 46?
BASFI score final value: 3.1
(SD 2.5)
BASMI score final value: 2.8
(SD 2.2)
SF-36 MCS score final value:
48.8 (SD 10.4)
SF-36 PCS score final value:
41.6 (SD 11.7)
ASSERT
2005102,231–236
AS Infliximab (on placebo
0–24 weeks) 5mg
Week 102 78 (remaining
study patients
may have
taken high
unlicensed
dose of
infliximab)
Completer analysis
and ITT LOCF
– Completer
analysis
28/61 (46)
– BASMI score change from
baseline: –1 (IQR –2.0 to 0.0)
ITT LOCF
33/78 (42)
SF-36 MCS change from
baseline: 2.3 (IQR –3.6 to 11.9)
SF-36 PCS change from
baseline: 8.3 (IQR 2.5 to 17.7)
IQR, interquartile range; NR, not reported; UC, unclear.
One trial which was extended evaluated only spinal and sacroiliac joint inflammation (Lambert et al.57); results not shown.
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Appendix 9 Adverse events
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TABLE 144 Adverse events in RCT placebo phases
Trial name Population Treatment arm Dose
Time
point
(weeks)
Number of
patients
randomised SAEs
Haibel 200852 Nr-axSpA Adalimumab 40mg 12 22 0
Nr-axSpA Placebo 0 12 24 0
Hu 201255 AS Adalimumab 40mg 12 26
AS Placebo 0 12 20
Huang 201456 AS Adalimumab 40mg 12 229 1
AS Placebo 0 12 115 1
Lambert 200757 AS Adalimumab 40mg 12 38
AS Placebo 0 12 44
ABILITY-1 2013
(licensed population)58
Nr-axSpA Adalimumab 40mg 12 95 3
Nr-axSpA Placebo 0 12 97 1
ATLAS 200661 AS Adalimumab 40mg 12 208
AS Placebo 0 12 107
RAPID-axSpA 201464 AS Certolizumab pegol 200mg 12 65 a
AS Certolizumab pegol 400mg 12 56
AS Placebo 0 12 57
Nr-axSpA Certolizumab pegol 200mg 12 46
Nr-axSpA Certolizumab pegol 400mg 12 51
Nr-axSpA Placebo 0 12 50
Barkham 201071 AS Etanercept 25mg
twice
weekly
12 20 0
AS Placebo 0 12 20 0
Davis 200372 AS Etanercept 25mg 12 138
AS Placebo 0 12 139
AS Etanercept 25mg 24 138
AS Placebo 0 24 139
Dougados 201174 AS Etanercept 50mg 12 39
AS Placebo 0 12 43
Dougados 201476 Nr-axSpA
mixed
Etanercept 50mg 12 106 2
Nr-axSpA
mixed
Placebo 0 12 109 1
Nr-axSpA Etanercept 50mg 12 94
Nr-axSpA Placebo 0 12 95
Gorman 200279 AS Etanercept 25mg 16 20 0
AS Placebo 0 16 20 0
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Serious
infections
Tuberculosis
(including
tuberculosis
reactivation)
Injection
site
reactions
Congestive
heart failure Malignancies
Non-melanoma
skin cancer
Withdrawals
because of AEs
0 0 0 0 0
0 0 0 0 0
1 0 0 0 0 4
0 0 0 0 0 0
0 0 0 1
0 0 0 1
a a
0
0
0 0 41 7
1 0 13 1
3 1 1
0 0 0
5 0
1 0
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TABLE 144 Adverse events in RCT placebo phases (continued )
Trial name Population Treatment arm Dose
Time
point
(weeks)
Number of
patients
randomised SAEs
Calin 200483 AS Etanercept 25mg 12 45 1
AS Placebo 0 12 39 0
van der Heijde 200686 AS Etanercept 25mg 12 150
AS Etanercept 50mg 12 155
AS Placebo 0 12 51
Giardina 201088 AS Etanercept 50mg 104 25
AS Infliximab 5mg/kg 104 25
GO-RAISE 200890 AS Golimumab 50mg 16 138 5
AS Golimumab 100mg 16 140 7
AS Placebo 0 16 78 4
Bao 201495 AS Golimumab 50mg 14 108
AS Placebo 0 14 105
Tam 201497 AS Golimumab 50mg 24 20
AS Placebo 0 24 21
Barkham 200950 Nr-axSpA Infliximab 5mg/kg 16 20 0
Nr-axSpA Placebo 0 16 20
Braun 200298 AS Infliximab 5mg/kg 12 34 3
AS Placebo 0 12 35
Marzo-Ortega 2005100 AS Infliximab+
methotrexate
5mg/kg 10 28
AS Placebo+
metotrexate
0 10 14
AS Infliximab+
methotrexate
5mg/kg 30 28 0
AS Placebo+
metotrexate
0 30 14 0
Van den Bosch 2002101 AS Infliximab 5mg/kg 12 9 Unclear
AS Placebo 0 12 12 Unclear
ASSERT 2005102 AS Infliximab 5mg/kg 24 202 7
AS Placebo 0 24 75 2
PLANETAS 2013110 AS CT-P13 5mg/kg 14 125
AS Infliximab 5mg/kg 14 125
AS CT-P13 5mg/kg 30 128 6
AS Infliximab 5mg/kg 30 122 8
AS CT-P13 5mg/kg 54 125
AS Infliximab 5mg/kg 54 125
a Data only for whole group.
Blank fields indicate that data were not reported for that outcome.
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Serious
infections
Tuberculosis
(including
tuberculosis
reactivation)
Injection
site
reactions
Congestive
heart failure Malignancies
Non-melanoma
skin cancer
Withdrawals
because of AEs
0 15 0
0 6 0
1 0 32 0 6
1 0 34 0 8
0 0 6 0 0
1 0 5 0 0 0
2 0 1 0 0 0
0
1
1
1 0 4
0 0 0
1 0
0 0
Unclear
Unclear
2 0 22 0 2
0 0 7 0 1
2 5 8
1 6 5
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Appendix 10 Quality assessment of studies
included in the cost-effectiveness review
TABLE 145 Quality assessment of studies included in the cost-effectiveness reviewa
Question
Ara et al.
2007161
Botteman
et al. 2007162
Kobelt et al.
2007160
McLeod et al.
200738
Armstrong
et al. 2013163
1. Was a well-defined
question posed in answerable
form?
Yes Yes Yes Yes Yes
2. Was a comprehensive
description of the competing
alternatives given (i.e. can you
tell who did what to whom,
where, and how often)?
Yes Yes No Yes Yes
3. Was the effectiveness of
the programme or services
established?
Yes
(short–medium
term)
Yes
(short–medium
term)
Yes
(short term)
Yes
(short–medium
term)
Yes
(short–medium
term)
4. Were all the important
and relevant costs and
consequences for each
alternative identified?
No Yes Yes Yes Yes
(consequences);
cannot tell (costs)
5. Were costs and
consequences measured
accurately in appropriate
physical units (e.g. hours
of nursing time, number
of physician visits, lost
work-days, gained life-years)?
Cannot tell Cannot tell Cannot tell Yes Cannot tell
6. Were the cost and
consequences valued credibly?
Cannot tell Cannot tell Cannot tell Yes Cannot tell
7. Were costs and
consequences adjusted for
differential timing?
Yes Yes Yes Yes Cannot tell
8. Was an incremental analysis
of costs and consequences of
alternatives performed?
Yes Yes Yes Yes Yes
9. Was allowance made for
uncertainty in the estimates of
costs and consequences?
Yes Yes Yes Yes Yes
10. Did the presentation and
discussion of study results
include all issues of concern to
users?
No No No Yes No
a Only stated publications were quality assessed and further materials (e.g. assessment group reports from the NICE
website) were not consulted. The checklist used was Drummond et al.237
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Appendix 11 Comparison of parameter inputs
across manufacturer models
T ables 146 and 147 provide an overview of the main parameter inputs applied in each of themanufacturer models for the AS and nr-AxSpA populations.
TABLE 146 Summary of main model inputs in manufacturer models: AS population
Parameter
Merck Sharp &
Dohme economic
model37 (infliximab,
golimumab)
AbbVie economic
model34 (adalimumab)
UCB economic model35
(certolizumab)
Pfizer economic
model36 (etanercept)
Time horizon Lifetime 40 years Lifetime Lifetime
Discount rate (%) 3.5 3.5 3.5 3.5
Average age (years) 39 42 41 41
Percentage male 72 75 72 74
Average weight (kg) 70 81.1 81.7 76.4
Baseline BASDAI
score
6.5 6.3 6.4 6.1
Baseline BASFI score 5.0 5.3 5.7 5.9
Source of baseline
characteristics
GO-RAISE90 ATLAS61 RAPID-axSpA64 trial 314-EU study167
Mortality (SMR) Male 1.63; female 1.38 1.5 1.5 1.5
Response criterion BASDAI 50 response at
week 12
ASAS 20 response at
week 12
ASAS 20 response at
week 24
BASDAI 50 response
at week 12
Percentage of
responders
l Infliximab 79.3
l Golimumab 48.5
l Adalimumab 47.0
l Certolizumab 53.0
l Etanercept 48.2
l Placebo 14.5
l Infliximab 72.4
l Golimumab 59.3
l Adalimumab 63.2
l Certolizumab 46.2
l Etanercept 60.7
l Placebo 27.2
l Infliximab 65.7
l Golimumab 54.1
l Adalimumab 56.2
l Certolizumab 55.7
l Etanercept 56.4
l Placebo –
l Infliximab 68
l Golimumab 61
l Adalimumab 54
l Certolizumab 47
l Etanercept 54
l Placebo 22
Placebo response Loss or maintenance of
placebo response not
clearly reported
BASDAI and BASFI score
return to baseline at
week 12
No placebo response BASDAI and BASFI
score return to
baseline at 12 weeks
Annual long-term
rate of anti-TNFs
withdrawal
6.1% (GO-RAISE90),
a common rate for all
anti-TNFs
Time-dependent
discontinuation; log-
normal model fitted to
adalimumab week 12
responder data
(ATLAS61). Less than
15% projected to stay
on treatment at year 40,
a common rate for all
anti-TNFs
7% (NICE TA14317), a
common rate for all
anti-TNFs
Exponential model
fitted to etanercept
data; model translates
to 11% annual
discontinuation for
etanercept. Hazard
ratios applied for
other anti-TNFs
(Glintborg 2010)112
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TABLE 146 Summary of main model inputs in manufacturer models: AS population (continued )
Parameter
Merck Sharp &
Dohme economic
model37 (infliximab,
golimumab)
AbbVie economic
model34 (adalimumab)
UCB economic model35
(certolizumab)
Pfizer economic
model36 (etanercept)
Natural history:
annual rate of BASFI
progression
0.07 points
(Kobelt et al. 2004152)
0.056 points (ATLAS61) 0.07 points
(Kobelt et al. 2004152)
0.07 points
(Kobelt et al. 2004152)
AEs included;
annual probability/
rate
Serious AEs and ISRs
included. Convent.
care rates from
GO-RAISE study. ORs
from the NMA applied
for each anti-TNF
Only infectious AEs
included; excess
proportion for
adalimumab 29.7%
annually (ATLAS61 trial).
Same rate applied to all
anti-TNFs
No AEs included Serious infections for
etanercept: 3.8%
annually. Relative
effects from a
published NMA
(Singh 2011137)
applied for other
anti-TNFs
HRQoL algorithm
(EQ-5D)
0.877121 – 0.03841 ×
BASDAI – 0.03225 ×
BASFI – 0.02789 ×
male+ 0.00168 ×
age (NICE TA14317)
0.899 – 0.031 ×
BASDAI-0.041 ×
BASFI (HUI-3, data from
ATLAS61)
2.126 – 0.132 ×
BASFI – 0.245 ×
BASDAI (RAPID-axSpA64
study)
0.887 – 0.006030 ×
BASFI+ 0.001030 ×
BASDAI+ 0.000020 ×
BASFI2 – 0.0000064 ×
BASDAI2
(314-EU study167)
Annual health-care
resource use costs
1902.49 × exp
(0.1832 × BASFI)
(NICE TA14317)
£1124.619 × exp
(0.264 × BASDAI)
(OASIS118)
1909.33 × exp
(0.1832 × BASFI) (NICE
TA14317)
l BASDAI score of
< 4: annual cost:
£151.96
l 4 ≤ BASDAI score
< 6: annual
cost: £311.08
l BASDAI score of
≥ 6: annual cost:
£1039.16
(Rafia et al. 2012168)
ISR, injection/infusion site reaction; NMA, network meta-analysis.
TABLE 147 Summary of main model inputs in manufacturer models: nr-AxSpA population
Parameter
AbbVie economic model34
(adalimumab)
UCB economic model35
(certolizumab)
Pfizer economic model36
(etanercept)
Time horizon 40 years Lifetime Lifetime
Discount rate (%) 3.5 3.5 3.5
Average age (years) 38 37 32
Percentage male 45 48 60
Average weight (kg) NR 82 74
Baseline BASDAI score 6.4 6.5 6.0
Baseline BASFI score 4.6 4.9 4.0
Source of baseline
characteristics
ABILITY-158 RAPID-axSpA64 trial 1031 study166
Mortality (SMR) 1.0 1.5 1.0
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TABLE 147 Summary of main model inputs in manufacturer models: nr-AxSpA population (continued )
Parameter
AbbVie economic model34
(adalimumab)
UCB economic model35
(certolizumab)
Pfizer economic model36
(etanercept)
Response criterion ASAS 40 response at
week 12
ASAS 20 response at
week 12
BASDAI 50 response at
week 12
Percentage of responders l Adalimumab 55.9
l Certolizumab 58.8
l Etanercept NR
l Placebo 22.2
l Adalimumab 56.3
l Certolizumab 59.0
l Etanercept 47.1
l Placebo –
l Adalimumab 44
l Certolizumab 59
l Etanercept 38
l Placebo 27
Placebo response BASDAI and BASFI score
return to baseline at
week 12
No placebo response BASDAI and BASFI score
return to baseline at
12 weeks
Annual long-term rate of
anti-TNFs withdrawal
Time-dependent
discontinuation; Log-normal
model fitted to adalimumab
week 12 responder data
(ABILITY-158). Less than 10%
projected to stay on
treatment at year 40, a
common rate for all
anti-TNFs
7% (NICE TA143), common
rate for all anti-TNFs
Exponential model fitted to
etanercept week 12
responder data; model
translates to 5% annual
discontinuation for
etanercept. Hazard ratios
applied for other anti-TNFs
(Glintborg et al. 2010)112
Progression rate from
nr-AxSpA to AS
– 3.84% per year –
Natural history: annual rate
of BASFI progression
0.084 points (ABILITY-158) 0.07 points (Kobelt et al.
2004152)
0.07 points (Kobelt et al.
2004152)
AEs included; annual
probability/rate
Only tuberculosis AEs and
non-tuberculosis SAEs
included; excess rate for
adalimumab 7.3% for non
tuberculosis SAEs and
0.16% for tuberculosis AEs
annually (ABILITY-158 trial).
Same rate applied to all
anti-TNFs
No AEs included No AEs included
HRQoL algorithm 0.922 – 0.039 ×
BASDAI – 0.041 ×
BASFI (ABILITY-158)
2.1262 – 0.1323 ×
BASFI – 0.2450 ×
BASDAI (RAPID-axSpA64
study)
0.919 – 0.00431 ×
BASFI+ 0.000788 ×
BASDAI+ 0.0000511×
BASFI2 – 0.0000194 ×
BASDAI2 – 0.00102 ×
Age+ 0.0478 ×male –
0.0000754 × BASDAI ×
BASFI (1031 study166)
Annual health-care
resource use costs
£1124.62 × exp
(0.264 × BASDAI) (OASIS118)
1909.33 × exp
(0.1832 × BASFI)
(NICE TA14317)
l BASDAI score of < 4:
annual cost: £151.96
l 4 ≤ BASDAI score < 6:
annual cost: £311.08
l BASDAI score of ≥ 6:
annual cost: £1039.16
(Rafia et al. 2012168)
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Comparison of disease costs assumed for the ankylosing
spondylitis and non-radiographic axial
spondyloarthritis populations
A variety of alternative regressions were applied across the submissions to estimate the annual disease
costs associated with BASDAI and BASFI scores. Merck Sharp & Dohme37 and UCB35 used the same
exponential regression function estimated by LRiG, uprated to current prices, as part of NICE TA14317
based on the OASIS study.118
Regression in NICE TA14317 based on OASIS data and cost element uprated to current prices:
£1902.492 × exp(0.1832 × BASFI).
AbbVie undertook their own reanalysis of the OASIS data set based on current prices. In their base-case
regression an exponential model based on BASDAI was assumed. However, results from separate linear
and exponential models were also presented.
Base-case regression used by AbbVie:34
Exp BASDAI: £1124:619 × exp(0:264×BASDAI). (14)
Alternative regressions presented by AbbVie:
Linear BASFI : £520:32102 + £804:64642 × BASFI (15)
BASDAI : £118:47088 + £943:21394 × BASDAI (16)
Exp BASFI: £1284:186 × exp(0:213 × BASFI). (17)
The submission by Pfizer36 was based on a recent UK study by Rafia et al.168 Rather than employing a
regression approach, the manufacturer used results based on a categorical analysis of the annual costs for
BASDAI: BASDAI score of < 4= £151.96, 4 ≤ BASDAI score < 6= £311.08; and BASDAI score
of ≥ 6= £1039.16.
However, the paper by Rafia et al.170 also specified a separate two-part regression function which was not
included within the Pfizer submission36 but is used in the subsequent comparisons of regressions to provide
a more comparable approach to assessing the alternative costs sources used across the manufacturer’s
submissions and the predictions across a range of different BASDAI and BASFI scores.
Two-part model in Rafia et al.168:
Logistic regression model to derive probability of incurring costs:
2:71795 + 0:16716 × BASFI + 0:37053 × BASDAI−0:02468 × BASFI × BASDAI+ 0:33778
×Male−0:04389 × Age− 0:01373 × Disease Duration (18)
Generalised linear model to obtain 3-month costs:
6:79876+ 0:27548 × BASFI + 0:13265 × BASDAI−0:01602 × BASFI × BASDAI+ 0:46458
×Male− 0:01656 × Age+ 0:00381 × Disease Duration (19)
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Figures 22 and 23 provide a comparison of the predictions from the alternative cost regressions using the
separate sources identified across the manufacturer models. The baseline characteristics (BASDAI, BASFI,
age and disease duration) are derived from a weighted average of the baseline characteristics of the
clinical trials for the AS population from the manufacturer’s submissions.
In Figure 22, BASDAI scores are held constant at the mean value and the impact of varying BASFI across
the range (0–10 scale) are reported. In Figure 23, BASFI scores are held constant at the mean value
and the impact of varying BASDAI across the range (0–10 scale) are reported.
Figures 24 and 25 compare the alternative regression functions reported in the submission by AbbVie
based on their reanalysis of the OASIS study.
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FIGURE 22 Comparison of main manufacturer cost regressions: assuming constant BASDAI score.
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FIGURE 23 Comparison of main manufacturer cost regressions: assuming constant BASFI score.
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FIGURE 25 Comparison of AbbVie cost regressions: assuming constant BASFI score.
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TABLE 148 Cost inputs in manufacturer’s submissions (AS and nr-AxSpA population)
Parameter
Merck Sharp &
Dohme economic
model37 (infliximab
and golimumab)
AbbVie economic
model34
(adalimumab)
UCB economic
model35
(certolizumab)
Pfizer economic
model36 (etanercept)
Administration
costs
Subcutaneous
therapies: no
administration cost
Subcutaneous
therapies: no
administration cost
Subcutaneous
therapies: £49 cost of
nurse training for
self-administration
(PSSRU179)
Subcutaneous
therapies: £49 cost of
nurse training for
self-administration
(PSSRU179)
Intravenous therapies:
cost of £109 per
administration (no
reference provided)
Intravenous therapies:
cost of £99 per
administration (no
reference provided)
Intravenous therapies:
cost of £398 per
administration
(PSSRU179)
Intravenous therapies:
cost of £302 per
administration (NICE
TA14317)
Doses and unit
costs
Costs estimated in line
with licensed doses
Costs estimated in line
with licensed doses
Costs estimated in line
with licensed doses
Costs estimated in line
with licensed doses
PAS included for
certolizumab and
golimumab
PAS included for
golimumab, not
included for
certolizumab
PAS included for
certolizumab and
golimumab
PAS included for
certolizumab and
golimumab
Infliximab dosage:
average weight of
70 kg assumed
(four vials), subsequent
administration every
7 weeks
Infliximab dosage:
average weight of
81.1 kg assumed
(five vials), subsequent
administration every
6 weeks
Infliximab dosage:
average weight of
81.7 kg assumed
(4.88 vials), subsequent
administration every
7 weeks
Infliximab dosage:
average weight of
76.4 kg assumed
(four vials), subsequent
administration every
6 weeks
Monitoring costs Short-term treatment
costs applied in first
cycle only for CC and
anti-TNFs. Costs were
informed by key
opinion leader
interviews. Anti-TNFs:
£873.2. CC: £1459.5
Initiation and quarterly
monitoring costs
included. Common for
all anti-TNFs
comparators (York
Model TA199175).
Initiation: £470.09.
Monitoring: £110.98
per cycle
No monitoring costs
included
No monitoring costs
included in the base
case
Annual health-
care resource
use costs
1902.49 × exp
(0.1832 × BASFI)
(NICE TA14317)
£1124.619 × EXP
(0.264 × BASDAI)
(OASIS118)
1909.33 × exp
(0.1832 × BASFI)
(NICE TA14317)
l BASDAI score of
< 4: annual cost
£151.96
l 4 ≤ BASDAI score
< 6: annual
cost £311.08
l BASDAI score of
≥ 6: annual cost
£1039.16
(Rafia et al. 2012168)
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TABLE 149 Withdrawal inputs in manufacturer’s submissions (AS and nr-AxSpA population)
Parameter
Merck Sharp & Dohme
economic model37
(infliximab, golimumab)
AbbVie economic
model34 (adalimumab)
UCB economic
model35
(certolizumab)
Pfizer economic
model36 (etanercept)
Annual long-term
rate of anti-TNF
withdrawal: AS
population
6.1% (GO-RAISE90 study,
data of patients on
treatment with
golimumab from week 24
to week 256), common
rate for all anti-TNFs
Time-dependent
discontinuation rate;
log-normal model fitted
to adalimumab week-12
responder data up to
week 260 (ATLAS61).
Fewer than 15% of
week-12 responders
were projected to stay
on treatment at year 40
for AS, a common rate
for all anti-TNFs
7% (NICE TA143),
common rate for
all anti-TNFs
Exponential model fitted
to etanercept data;
model translates to 11%
annual discontinuation
for etanercept. Hazard
ratios applied for other
anti-TNFs (Glintborg
2010).112 Annual
discontinuation:
l infliximab: 14.3%
l golimumab: 12.3%
l adalimumab: 12.3%
l certolizumab: 12.3%
Annual long-term
rate of anti-TNF
withdrawal:
nr-AxSpA
population
Not applicable Time-dependent
discontinuation; log-
normal model fitted to
adalimumab week-12
responder data up to
week 156 (ABILITY-158).
Fewer than 10% of
week-12 responders
were projected to stay
on treatment at year 40,
a common rate for all
anti-TNFs
7% (NICE TA143),
common rate for
all anti-TNFs
Exponential model fitted
to etanercept week-12
responder data; model
translates to 5% annual
discontinuation for
etanercept. Hazard ratios
applied for other anti-
TNFs (Glintborg 2010).112
Annual discontinuation:
l infliximab: 6.5%
l golimumab: 5.6%
l adalimumab: 5.6%
l certolizumab: 5.6%
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TABLE 150 Adverse events inputs in manufacturer’s submissions: AS population
Parameter
Merck Sharp & Dohme
economic model37
(infliximab and
golimumab)
AbbVie economic
model34 (adalimumab)
UCB economic
model35
(certolizumab)
Pfizer economic
model36 (etanercept)
AEs included;
annual
probability
SAEs and ISRs included. CC
rates from GO-RAISE90 study
at 24 weeks. OR of SAEs and
ISRs from the NMA applied
for each anti-TNF
Only infectious AEs
included; excess
proportion for
adalimumab was 29.7%
annually (ATLAS61 trial)
No AEs included Only serious infections
included. Annual
probability: 3.8%
(312-EU146)
Annual probability (%) of
SAEs:
l placebo: 7.6
l infliximab: 21.4
l golimumab: 5.4
l adalimumab: 6.8
l certolizumab: 13.4
l etanercept: 20.5
Same rate applied to all
anti-TNFs
Relative effects for
other anti-TNF agents
were applied in the
model, obtained from
a published NMA
(Singh 2011)137
Annual probability (%) of ISRs:
l placebo: 19.7
l infliximab: 24.3
l golimumab: 51.0
l adalimumab: 38.5
l certolizumab: 38.5
l etanercept: 52.6
Annual probability (%):
l infliximab: 4.1
l golimumab: 3.3
l adalimumab: 3.6
l certolizumab: 13.9
l etanercept: 3.8
Unit cost of
AE
Cost per serious AE episode
(weighted average): £214.26
anti-TNFs, £397.32 for CC
(GO-RAISE90). Cost of injection
site reaction £94.18 per
episode
Cost per infectious AE
episode: £45 (one GP
visit assumed per
infectious AE)
– Cost per serious
infection episode:
£1457 (weighted
average) (NHS
Reference Costs
2012/13)176
Disutility of
AE
Only disutility associated with
SAEs applied; utility decrement
of 0.01 applied for one cycle
(NICE TA23333)
No disutility applied – 0.156 for 28 days
NMA, network meta-analysis.
TABLE 151 Adverse events inputs in manufacturer’s submissions: nr-AxSpA population
Parameter
AbbVie economic model34
(adalimumab)
UCB economic model35
(certolizumab)
Pfizer economic
model36 (etanercept)
AEs included; annual
probability
Only tuberculosis AEs and
non-tuberculosis SAEs included; the excess
percentage for adalimumab was 7.3% for
non-tuberculosis SAEs and 0.16% for
tuberculosis AEs annually (ABILITY-158
trial), same rate applied to all anti-TNFs
No AEs included No AEs included
Unit cost of AE Non-tuberculosis SAEs: £4216 per episode
(NHS Reference Costs 2012/13)176
– –
Tuberculosis AEs: £6559.76 per episode
(Botteman 2007)162
Disutility of AE No disutility applied – –
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Appendix 12 Extended synthesis models
In this appendix we describe in more detail the data and modelling approaches implemented in Chapter 5.Note that while this appendix aims to provide a methodological description of methods, a full description
of findings and its interpretations are in Chapter 5.
General aspects of implementation and software
The synthesis was conducted from a Bayesian perspective, using WinBUGS (a MCMC simulation based
software for Bayesian inference). For burn-in, we ran 100,000 simulations and another 100,000 were used
in inferences. Convergence was assessed by running two chains and convergence was assumed if the
Gelman–Rubin statistic was equal to 1. Goodness of fit was assessed using the DIC.170 Models with smaller
DIC are better supported by the data. In the presence of autocorrelation, the MCMC simulation for
inference was increased to 200,000 and a thin of 20 was applied (yielding a sample for inference of
10,000 for each chain).
The main synthesis models will pool differences between treatment and control in change scores from
baseline (BASDAI and BASFI). The treatment associated with the lowest (most negative) mean change
score is expected to be best. However, it is important to quantify the uncertainty around the estimates and
for this reason SDs will be reported alongside expected values. When ORs are presented, median values
instead of means were used to summarise inferences.
When possible, meta-regression analyses were conducted to evaluate potential treatment effect modifiers.
Meta-regression is a tool aimed at examining the impact of variables on effect size using regression-based
techniques. In these explorations, the following baseline characteristics were considered: BASDAI score,
BASFI score, age, sex, duration of symptoms (years) and CRP level.
Relative effectiveness estimates for models assuming exchangeability across treatments (model A5) are
based on the predictive distribution, representing the distribution of the data averaged over all possible
parameter values. This summary statistic best reflects the impact of uncertainty in the parameters of the
model and is here judged as a more appropriate basis to be used in the decision model.171
Modelling approach A
Brief description of the data
Based on study populations and follow-up (i.e. around 12 weeks in duration), 16 of the RCTs are
considered directly relevant to the decision problem for the AS population (studies 1 to 16 in Table 152).
One of these studies did not report BASDAI or BASFI outcomes (study 3) and thus could not be included in
analyses. The 15 remaining studies reported at least one outcome measure: BASDAI 50 score and/or
change from baseline on BASDAI and BASFI scores.
This modelling approach directly evaluates relative treatment effects, that is log OR for BASDAI 50
response and the difference between treatment and placebo in change in BASDAI and BASFI scores from
baseline. The data set analysed is shown in Table 153.
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TABLE 152 Evidence on BASDAI and BASFI score-related outcomes for the AS population
Study
number Trial name Treatment
Number in
treatment
group
Number in
placebo
group
BASDAI
50 score
Change
BASDAI
score
Change
BASFI
score
1 Hu 201255 1 26 20 ✗ ✗
2 Huang 201456 1 229 115 ✗ ✗ ✗
3 Lambert 200757 1 38 44
4 ATLAS 200661 1 208 107 ✗ ✗
5 RAPID-axSpA 201464 2 121 57 ✗ ✗ ✗
6 Barkham 201071 3 20 20 ✗ ✗a ✗a
7 Davis 200372 3 138 139 ✗ ✗
8 Dougados 201174 3 39 43 ✗ ✗ ✗
9 Gorman 200279 3 20 20 ✗
10 Calin 200483 3 45 39 ✗ ✗
11 van der Heijde 200686 3 305 51 ✗
12 GO-RAISE 200890 4 138 78 ✗ ✗
13 Bao 201296 4 108 105 ✗ ✗
14 Braun 200298 5 34 35 ✗ ✗a ✗a
15 Marzo-Ortega 2005100 5 28 14 ✗ ✗a
16 Van den Bosch 2002101 5 9 12 ✗a ✗a
a Do not report any measure of dispersion (such as SDs).
Treatment: 1, adalimumab; 2, certolizumab (certolizumab 200mg and/or certolizumab 400mg); 3, etanercept (etanercept
25mg and/or etanercept 50mg); 4, golimumab 50mg; 5, infliximab.
Note that some studies only report one of the BASDAI measures. For example, the golimumab trials (studies 12 and 13)
only report BASDAI 50 and not the absolute change in this score.
TABLE 153 Modelling approach A: data
Study, j Treatment, t Outcome, o y SE
1 1 1 – –
2 1 1 1.61 0.28
3 1 1 – –
4 1 1 1.47 0.30
5 2 1 1.79 0.42
6 3 1 2.30 1.13
7 3 1 – –
8 3 1 1.04 0.48
9 3 1 – –
10 3 1 – –
11 3 1 1.78 0.37
12 4 1 1.47 0.36
13 4 1 2.34 0.50
14 5 1 2.45 0.69
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TABLE 153 Modelling approach A: data (continued )
Study, j Treatment, t Outcome, o y SE
15 5 1 – –
16 5 1 – –
1 1 2 –1.60 0.67
2 1 2 –1.40 0.22
3 1 2 – –
4 1 2 –1.80 0.28
5 2 2 –1.45 0.36
6 3 2 –1.87 0.90a
7 3 2 –1.91 0.26
8 3 2 –1.20 0.44
9 3 2 – –
10 3 2 –1.87 0.49
11 3 2 – –
12 4 2 – –
13 4 2 – –
14 5 2 –2.60 0.69a
15 5 2 –1.73 0.70
16 5 2 –2.97 1.26a
1 1 3 –0.90 0.68
2 1 3 –1.28 0.20
3 1 3 – –
4 1 3 – –
5 2 3 –1.10 0.37
6 3 3 –1.56 0.93a
7 3 3 –1.34 0.29
8 3 3 –1.20 0.40
9 3 3 –2.20 0.92
10 3 3 –1.73 0.45
11 3 3 – –
12 4 3 –1.50 0.27
13 4 3 –1.37 0.32
14 5 3 –2.00 0.71a
15 5 3 –1.82 1.00a
16 5 3 –3.21 1.28a
a No SD was reported in the original studies, the highest SD from the other trials was used as a conservative estimate.
Outcome: 1, logOR for BASDAI 50; 2, difference between treatment and placebo on change in BASDAI from baseline;
3, difference between treatment and placebo on change in BASFI from baseline.
Treatment: 1, adalimumab; 2, certolizumab; 3, etanercept; 4, golimumab; 5, infliximab.
BASDAI, results from individual studies on difference between treatment and placebo in change from baseline in BASDAI
scores; BASFI, results from individual studies on difference between treatment and placebo in change from baseline in
BASFI scores; SE, SE associated with each outcome.
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Description of synthesis methods for modelling approach A
Consider we have available information on J trials comparing an individual treatment, k (out of the total
number of treatments T) to placebo. Trials report one or more outcomes, o. Information on outcome o
for treatment k in a study j is represented by yjko and is used alongside the SE for this measure, se
2
jko.
In common with the approach implemented in Chapter 3, all outcomes are here assumed normally
distributed, with mean θjko. We implemented alternative models that differ in the way treatment effects are
considered; a summary of each is presented below. Note that at this stage each outcome was
synthesised independently.
Model A1 (treatments; independent, studies; fixed effect): this model considers the j treatments to be
independent, that is it assumes the effects to differ between treatments, d[k,o]. This is a fixed effect model
in that multiple studies evaluating the same treatment are considered to measure the same treatment effect.
The model used was:
Likelihood:
yjko∼dnorm(θjko, se
2
jko). (20)
Model:
θjko=d½k, o. (21)
Priors:
d½k, o∼N(0, 0:001). (22)
Model A2 (treatments; independent, studies; random effects): this model differs from A1 in that a random
effect is assumed to describe the findings of multiple studies evaluating the same treatment.
The model used was:
Likelihood:
yjko∼dnorm(θjko, se
2
jko). (23)
Model:
θjko∼N(d½k, o, σ2o). (24)
Priors:
d½k, o∼N(0,0:001); σ2o∼dunif (0,10). (25)
The random effect is defined using a variance parameter for each outcome but common across
treatments, σ2o.
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Model A3 (treatments; equal, studies; fixed effect): this model differs from model A1 in that treatments are
not assumed to differ. The model thus evaluates a common relative effectiveness for all anti-TNFs, d[o],
for each outcome.
The model used was:
Likelihood:
yjko∼dnorm(θjko, se
2
jko). (26)
Model:
θjko=d½o. (27)
Priors:
d½k, o∼N(0,0:001). (28)
Model A4 (treatments; equal, studies; random effects): this model differs from model A3 in that a random
effect is assumed to describe the findings of multiple studies evaluating the same treatment.
The model used was:
Likelihood:
yjko∼dnorm(θjko, se
2
jko). (29)
Model:
θjko∼N(d½o, σ2o). (30)
Priors:
d½o∼N(0,0:001); σ2o∼dunif (0,10). (31)
Model A5 (treatments; exchangeable, studies; fixed effect): this model differs from model A1 in that a
random effect is used to describe any differences between treatments (exchangeability is assumed). This
model thus assumes the treatments to have a similar, but not equal, effectiveness; there are differences
between the effectiveness of treatments that we may not be able to explain but that we should consider.
The model used was:
Likelihood:
yjko∼dnorm(θjko, se
2
jko). (32)
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Model:
θjko=d½k, o (33)
d½k, o∼N(D½o, γ2o). (34)
Priors:
D½o∼N(0,0:001); γ21∼dunif (0, 2); γ22, γ23∼dunif (0,10). (35)
The parameter γ2o is the variance parameter defining the random effect across treatment. The priors differ
for outcome 1 because this is a log odds, while outcomes 2 and 3 are assumed continuous measures.
Within this modelling approach we explored potential heterogeneity in treatment effects using
metaregression (i.e. potential treatment effect modifiers). We did so by extended the modelling approach
in model A1 to include treatment effect interactions with baseline characteristics (centred on their means
when relevant). We have explored the inclusion of alternative covariates by evaluating the DIC associated
with alternative models.
Results of modelling approach A
The results of each modelling approach are shown in Table 154.
From model A5, drug-specific estimates can be retrieved (Table 155). Within this mode drug-specific
inferences will borrow strength from the common class effect and estimates are thus shrunken towards
the mean of this class effect (i.e. estimates are closer to the value reported for the class in Table 153).
Explorations of heterogeneity suggested only sex potentially modified the effect of anti-TNF treatment,
specifically for change in BASDAI as outcome; however, when sex is used together with all covariates, such
evidence on effect modification disappears (results not shown but available on request).
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TABLE 154 Modelling approach A: results
A1. Treatment:
independent;
studies: fixed
effect
A2. Treatment:
independent;
studies: random
effects
A3. Treatment:
common;
studies: fixed
effect
A4. Treatment:
common;
studies: random
effects
A5. Treatment:
exchangeable;
studies: fixed
effect
Outcome 1: OR on
BASDAI 50 score Median (SD) Median (SD) Median (SD) Median (SD) Median (SD)
Adalimumab 4.71 (1.00) 4.69 (6.11) 5.21 (0.72) 5.30 (0.98) 5.34 (9.79)a
Certolizumab 6.02 (3.33) 6.04 (22.87)
Etanercept 4.73 (1.43) 4.72 (3.32)
Golimumab 5.86 (1.81) 6.10 (7.45)
Infliximab 11.9 (11.94) 12.10 (44.00)
σ1 – 0.31 (0.30) – 0.15 (0.14) –
D1 – – – – 1.69 (0.23)
γ1 – – – – 0.27 (0.28)
Outcome 2: change
in BASDAI score Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Adalimumab –1.56 (0.16) –1.57 (0.27) –1.66 (0.11) –1.67 (0.15)
Certolizumab –1.45 (0.37) –1.46 (0.51)
Etanercept –1.76 (0.20) –1.73 (0.28) –1.70 (0.87)a
Golimumab N/A N/A
Infliximab –2.28 (0.46) –2.27 (–2.28)
σ2 – 0.25 (0.24) – 0.25 (0.19) –
D2 – – – – –1.63 (0.57)
γ2 – – – – 0.43 (0.63)
Outcome 3: change
in BASFI score Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Adalimumab –1.22 (0.18) –1.18 (0.29) –1.38 (0.11) –1.39 (0.13)
Certolizumab –1.10 (0.37) –1.11 (0.47)
Etanercept –1.48 (0.19) –1.50 (0.24) –1.41 (0.49)a
Golimumab –1.45 (0.20) –1.44 (0.29)
Infliximab –2.16 (0.53) –2.17 (0.56)
σ3 – 0.22 (0.19) – 0.14 (0.12) –
D3 – – – – –1.40 (0.22)
γ3 – – – – 0.28 (0.33)
DIC 52.4 57.0 39.1 44.3 43.6
N/A, not applicable.
a Predictive distribution.
Outcome: 1, logOR for BASDAI 50; 2, difference between treatment and placebo on change in BASDAI from baseline;
3, difference between treatment and placebo on change in BASFI from baseline; σ2 is the variance parameter for outcome
o of the random effect across studies; Do is the mean of the random effect for outcome o; γ3 is the variance parameter for
outcome o of the random effect across treatments.
DOI: 10.3310/hta20090 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 9
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
285
Modelling approach B
In the previous section the two outcomes based on BASDAI scores were synthesised separately; however,
BASDAI 50 is the probability of having a reduction in BASDAI score of 50%, and thus it should be possible
to relate the proportion of BASDAI 50 responders to the change in absolute BASDAI scores from baseline
observed in each study. Within this section, we use this structural relation within the synthesis, allowing
change scores from baseline to be informed not only from direct data on this quantity but also from data
on BASDAI 50.
Brief description of the data
The model implemented here pools the change in BASDAI score from baseline to evaluate the difference
between treatment and placebo, using evidence reported in trials directly on the change scores for each
arm and also data on BASDAI 50. The data modelled within this approach are shown in Table 156.
Description of synthesis methods
Consider we have available information on J trials comparing an individual treatment, k (out of the total
number of treatments T) to placebo. Study j may report yjk, the mean change in BASDAI from baseline,
alongside the SE for this measure, sejk. The likelihood for the data on change score was assumed normally
distributed and was expressed as:
yjk∼N(θjk, se
2
jk): (36)
The mean of this distribution was the treatment effects, θjk, defined as the sum of the change score for the
placebo arm plus the difference in change score for the treatments:
θjk=µj + δjk. (37)
Some studies also reported the number of responders to BASDAI 50 (a 50% reduction in BASDAI score),
rjk, out of the total number of individuals in the study, njk. The likelihood for the BASDAI 50 data was
binomially distributed and thus expressed as:
rjk∼Bin(pjk, njk): (38)
TABLE 155 Shrunken estimates of treatment effect from model A5
Model A5
Outcome 1: OR on
BASDAI 50 score,
median (SD)
Outcome 2: change
in BASDAI score,
median (SD)
Outcome 3: change
in BASFI score,
median (SD)
Adalimumab 5.05 (0.87) –1.60 (0.15) –1.31 (0.16)
Certolizumab 5.42 (1.71) –1.59 (0.26) –1.31 (0.23)
Etanercept 5.13 (1.08) –1.72 (0.17) –1.43 (0.15)
Golimumab 5.47 (1.25) –1.69 (0.84) –1.42 (0.16)
Infliximab 5.70 (3.30) –1.88 (0.34) –1.55 (0.33)
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TABLE 156 Data used in modelling approach B and C
s[] t[] n[] r[] b[] sd[] y[] y.se[] y.f[] y.f.se[]
1 1 20 N/A 6.2 1.1 –2 0.560 –1 0.34
1 2 26 N/A 5.9 1.4 –3.6 0.377 –1.9 0.29
2 1 115 19 6.2 1.4 –1.4 0.177 –0.47 0.15
2 2 229 114 6 1.4 –2.8 0.126 –1.75 0.13
3 1 44 N/A 6.5 1.6 N/A N/A N/A N/A
3 2 38 N/A 6.2 1.7 N/A N/A N/A N/A
4 1 107 17 6.3 1.7 –0.8 0.2 N/A N/A
4 2 208 94 6.3 1.7 –2.6 0.2 N/A N/A
5 1 57 8 6.4 1.9 –1.0 0.3 –0.6 0.30
5 3 121 50 6.36 1.54 –2.45 0.206 –1.7 0.21
6 1 20 1 5.46 1.74 –0.1 0.632 0.21 0.71
6 4 20 7 6.05 1.71 –1.97 0.645 –1.35 0.56
7 1 139 N/A 5.96 1.65 –0.45 0.18 –0.33 0.21
7 4 138 N/A 5.81 1.76 –2.36 0.19 –1.67 0.20
8 1 43 10 5.8 1.5 –1.4 0.305 –1 0.27
8 4 39 18 6.4 1.2 –2.6 0.320 –2.2 0.29
9 1 20 N/A N/A N/A N/A N/A –0.1 0.49
9 4 20 N/A N/A N/A N/A N/A –2.3 0.36
10 1 39 N/A 5.86 2.05 –0.85 0.35 –0.33 0.31
10 4 45 N/A 6.1 1.87 –2.72 0.34 –2.06 0.33
11 1 51 10 6.11 1.37 N/A N/A N/A N/A
11 4 305 180 6.09 1.69 N/A N/A N/A N/A
12 1 78 12 6.6 1.49 N/A N/A 0.1 0.19
12 5 138 61 6.6 1.49 N/A N/A –1.4 0.19
13 1 105 5 6.5 1.54 N/A N/A 0.11 0.20
13 5 108 37 6.6 1.31 N/A N/A –1.26 0.25
14 1 35 3 6.3 1.4 –0.6 0.478 –0.1 0.55
14 6 34 18 6.5 1.2 –3.2 0.495 –2.1 0.44
15 1 14 N/A 6.57 2.05 –1.38 0.564 0.1 0.88
15 6 28 N/A 6.45 1.87 –3.11 0.42 –1.72 0.49
16 1 12 N/A 5.27 2.05 –0.26 0.816 1.3 0.95
16 6 9 N/A 5.89 1.87 –3.23 0.961 –1.91 0.86
N/A, not applicable.
Outcome: 1, logOR for BASDAI 50; 2, difference between treatment and placebo on change in BASDAI from baseline;
3, difference between treatment and placebo on change in BASFI from baseline
s[]= study, t[]= treatment; 1= placebo, 2= adalimumab, 3= certolizumab pegol, 4= etanercept, 5= golimumab,
6= infliximab; n[]= total number of patients, r[]= number of patients showing a BASDAI 50 response, y[]= vector of results
from studies on change from baseline on BASDAI score; y.se[]= standard error associated with each y; y.f[]= vector of
results from studies on change from baseline on BASFI score; y.f.se[]= standard error associated with each y.f.
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Consider the BASDAI score at baseline for study j and treatment k, Xjk, as normally distributed, with a
mean score at baseline of νjk and variability on BASDAI score at baseline represented by σ
2
jk:
Xjk ∼ Nðνjk, σ2jk). (39)
The probability parameter of the binomial distribution can be expressed as a function of the baseline and
final BASDAI scores:
pjk=P
Yjk
Xjk
<−0:5
 
= P

Yjk+Xjk=2<0

: (40)
This can help us establish an algebraic relation between pjk and the change score Yjk, for a given baseline
value, Xjk. This requires some assumptions over the distribution of scores, which are described next.
Across individuals, the BASDAI scores at baseline and the change score are assumed correlated and are
described using a bivariate normal distribution:
X1 jk
Yjk
 
∼ N
ν1 jk
θjk
 
,
σ2jk ρσ
2
jk
ρσ2jk σ
2
jk
 !
:
 
(41)
For simplicity, the variability on BASDAI score at baseline, σ2jk, was assumed equal to that of the change
score. The correlation parameter is represented by ρ.
We would like to further explore the following relationship:
Pjk = P

Yjk+Xjk=2< 0

. (42)
To do so, first consider expressing Y by conditioning on the baseline value, Xjk= x (for simplicity we will
drop the jk subscript in the next few formulas):
YjX ∼N(θ+ρ(x−ν), (1−ρ2)σ2). (43)
So, we can standardise and relate this probability to a standard Normal distribution
pjX1¼x = P(Yjk + x=2 < 0X1=x) = Φ
−

x
2
+ θ + ρ(x−ν)

σ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð1− ρ2)
p
0
BB@
1
CCA: (44)
To obtain the joint distribution, one needs to average over Xjk ∼N(νjk, σ2jk), which means integrating over
this distribution with respect to x:
P jk=∫
+∞
−∞
Φ
−
x
2
+ θ + ρ(x− ν)
	 

σ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(1−ρ2)
p
0
B@
1
CAf x(x)dx. (45)
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Note that one can express the expectation over the cdf of a normal distribution as:
E½ΦðaX + bÞ=Φ

b + aνﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1−a2σ2
p

when x∼N(υ, σ2): (46)
Here, a = −(1=2+ρ)
σ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(1−ρ2)
p and b = −θ+ρν
σ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð1−ρ2)
p . Therefore:
pjk =Φ
−θ + ρν− (1=2 + ρ)ν
σ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(1− ρ2)
p ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1−
(1=2− ρ)2
ð1− ρ2)
s
0
BBBB@
1
CCCCA =Φ −
θ + ν=2
σ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
5=4 + ρ
p
 !
: (47)
The relations established above thus allow the probability parameter from BASDAI 50 data to be expressed
algebraically as a function of the change score:
probit(pjk) ¼
−θjk− νjk=2
σjk
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
5=4 + ρ
p . (48)
In computations, we used the mean score at baseline, vjk, and the associated SD, σjk, as reported in the
data (these were thus assumed known). The correlation between baseline and change score was estimated
within the model by assuming this quantity to be independent of study but assumed to differ between
placebo and anti-TNF treatments.
In what concerns the treatment effects, all trials in our evidence base compare against CC: δjk= dk. Our
preferred approach to model these was to assume a common class effect (i.e. exchangeable effects across
treatments, analogous assumption to model A5 above). This means:
dk
(
=0 if k = 1
∼N(D, σ2re) if k≠1
, (49)
where k= 1 is standard care.
The priors used to implement this model were:
D∼N(0,0:001), µj∼N(0,0:001), ρpla∼U(−1,1), ρanti−TNF∼U(−1,1): (50)
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WinBUGS code for modelling approach B 
model{ 
 for (i in 1:10) { 
  y[i] ~ dnorm(theta[i], y.prec[i])  #change in score 
  theta[i] <- mu[s[i]] + d[t[i]] 
  } 
 for (i in 11:18) { 
  r[i] ~ dbin(p[i], n[i]) 
  aux[i] <- equals(t[i],1)+1 
  probit(p[i]) <- -(b[i]*0.5 + theta[i])/(pow(prec[i],-
0.5)*pow(5/4+rho[aux[i]],0.5))   
  theta[i] <- mu[s[i]] + d[t[i]] 
  } 
 for (i in 19:28) { 
  r[i] ~ dbin(p[i], n[i]) 
  y[i] ~ dnorm(theta[i], prec[i])  #change in score 
  aux[i] <- equals(t[i],1)+1 
  probit(p[i]) <- -(b[i]*0.5 + theta[i])/(pow(prec[i],-
0.5)*pow(5/4+rho[aux[i]],0.5))   
  theta[i] <- mu[s[i]] + d[t[i]] 
 } 
 for (j in 1:14) { 
  mu[j] ~ dnorm(0,0.001) 
  } 
 d[1] <- 0 
 for (k in 2:6) { 
  d[k] ~ dnorm(re,intau) 
 } 
 re ~ dnorm(0, 0.01) 
 intau <- 1/tau 
 tau <- pow(sd,2) 
 sd ~ dunif(0,2)    
 re.pred ~ dnorm(re,intau)      
 rho[1] ~ dunif(-1,1) 
 rho[2] ~ dunif(-1,1) 
} 
 
FIGURE 26 WinBUGS code for modelling approach B.
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Results of modelling approach B
The summary results regarding relative treatment effects from this modelling approach are reported in
Table 157 for model B.
Drug-specific (shrunken) estimates from model B are shown in Table 158.
TABLE 157 Modelling approach B: results
Estimated Assumeda Predicted
Difference in change
score from baseline,
mean (SD)
Probability of having
a BASDAI 50
response, placebo,
mean (SD)
Probability of having
a BASDAI 50
response, anti-TNF,
mean (SD)
OR for BASDAI 50
response, anti-TNF
vs. placebo,
median (SD)
Anti-TNFs –1.91 (0.48)b 0.10 (–) 0.40 (0.08) 5.94 (4.06)
Other model summaries
D –1.91 (0.28) – – –
γ 0.30 (0.28) – – –
ρplacebo 0.26 (0.33) – – –
ρanti-TNF 0.69 (0.26) – – –
DIC 146.3 – – –
a This figure is based on a BASDAI baseline score of 6.11 (SD 1.56) and a placebo change score of –0.61 (SD 1.44),
which represent the average across trials (weighted by number of patients).
b Predictive distribution.
TABLE 158 Shrunken estimates of treatment effect from model B
Treatment Change in BASDAI score, mean (SD)
Adalimumab –1.77 (0.25)
Certolizumab –2.01 (0.37)
Etanercept –1.88 (0.18)
Golimumab –1.92 (0.30)
Infliximab –2.02 (0.32)
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Modelling approach C
The models implemented here extend those in the previous section by adding the syntheses of changes in
BASFI score. The data used are presented in Table 156.
Description of synthesis methods
Data on mean change in BASFI score reported in some of the studies available have been described as
normally distributed (the likelihood):
yBASFIjk ∼N θ
BASFI
jk , se
BASFI
jk
	 
2 
: (51)
The treatment effects over BASFI θBASFIjk were then defined as:
θBASFIjk = µ
BASFI
j + δ
BASFI
jk . (52)
Treatment effects on BASFI were assumed correlated to those on BASDAI across trials:
δBASDAIjk
δBASFIjk
 
∼N
 
dBASDAIk
dBASFIk
 
,
τ2BASDAI ρmτ
2
BASDAIτ
2
BASFI
ρmτ
2
BASDAIτ
2
BASFI τ
2
BASFI
 !
(53)
dok
(
=0 if k = 1
∼N(Do, σ2re, o) if k≠1
, (54)
with o= {BASDAI, BASFI} and k= 1 is placebo.
The additional priors used to implement this model were:
Do∼N (0,0:001), σ2re∼U (0,2) ρm∼U (−1,1) . (55)
The variation in treatment effects for both BASDAI and BASFI and the correlation parameter between
these were estimated from the data. As in model B, we assumed exchangeability across the effects of the
different treatments.
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WinBUGS code for modelling approach C 
model{ 
 for (i in 1:10) { 
  y[i] ~ dnorm(theta[i,1], y.prec[i])  #change in score 
  y.f[i] ~ dnorm(theta[i,2], y.prec.f[i])  #change in score BASFI 
  } 
 for (i in 11:14) { 
  r[i] ~ dbin(p[i], n[i]) 
  aux[i] <- equals(t[i],1)+1 
  probit(p[i]) <- -(b[i]*0.5 + theta[i,1])/(pow(prec[i],-
0.5)*pow(5/4+rho[aux[i]],0.5))   
  y.f[i] ~ dnorm(theta[i,2], y.prec.f[i])  #change in score BASFI 
  } 
 for (i in 15:16) { 
  r[i] ~ dbin(p[i], n[i]) 
  aux[i] <- equals(t[i],1)+1 
  probit(p[i]) <- -(b[i]*0.5 + theta[i,1])/(pow(prec[i],-
0.5)*pow(5/4+rho[aux[i]],0.5))   
  } 
 for (i in 17:26) { 
  r[i] ~ dbin(p[i], n[i]) 
  y[i] ~ dnorm(theta[i,1], prec[i])  #change in score 
  aux[i] <- equals(t[i],1)+1 
  probit(p[i]) <- -(b[i]*0.5 + theta[i,1])/(pow(prec[i],-
0.5)*pow(5/4+rho[aux[i]],0.5))   
  y.f[i] ~ dnorm(theta[i,2], y.prec.f[i])  #change in score BASFI 
 } 
 for (i in 27:28) { 
  y.f[i] ~ dnorm(theta[i,2], y.prec.f[i])  #change in score BASFI 
 } 
for (i in 29:30) { 
  r[i] ~ dbin(p[i], n[i]) 
  y[i] ~ dnorm(theta[i,1], prec[i])  #change in score 
  aux[i] <- equals(t[i],1)+1 
  probit(p[i]) <- -(b[i]*0.5 + theta[i,1])/(pow(prec[i],-
0.5)*pow(5/4+rho[aux[i]],0.5))  
 } 
 for (i in 1:30) { 
  theta[i,1:2] ~ dmnorm(delta[i,1:2],B[1:2,1:2])  
  delta[i,1] <- mu1[s[i]] + d1[t[i]] 
  delta[i,2] <- mu2[s[i]] + d2[t[i]] 
 } 
 d1[1] <- 0 
 d2[1] <- 0 
 for (k in 2:6) { 
  d1[k] ~ dnorm(re1,intau) 
  d2[k] ~ dnorm(re2,intau) 
 } 
 B[1,1]<- 1/(pow(sd[1],2)*(1-pow(cor,2))) 
 B[2,2]<- 1/(pow(sd[2],2)*(1-pow(cor,2))) 
 B[1,2]<- -cor/(sd[1]*sd[2]*(1-pow(cor,2))) 
 B[2,1]<- B[1,2] 
 sd[1] ~ dunif(0,5)         
FIGURE 27 WinBUGS code for modelling approach C. (continued )
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 sd[2] ~ dunif(0,5)  
 cor~dunif(0,1) 
 for (j in 1:15) { 
  mu1[j] ~ dnorm(0,0.01)I(-5,5) 
  mu2[j] ~ dnorm(0,0.01)I(-5,5) 
  } 
 re1 ~ dnorm(0, 0.01)I(-10,10) 
 re.pred1 ~ dnorm(re1,intau) 
 re2 ~ dnorm(0, 0.01)I(-10,10) 
 re.pred2 ~ dnorm(re2,intau) 
 intau <- 1/tau 
 tau <- pow(sd.re,2) 
 sd.re ~ dunif(0,2)    
 rho[1] ~ dunif(0,1) 
 rho[2] ~ dunif(0,1) 
 for (k in 2:6) { 
  d1.pred[k] ~ dnorm(re1,intau) 
 } 
} 
FIGURE 27 WinBUGS code for modelling approach C.
Results of modelling approach C
The results on differences between treatment and placebo on change score form baseline are reported in
Table 159, both for BASDAI and BASFI scores.
TABLE 159 Modelling approach C: results
Estimated Assumeda Predicted
Difference in change
score from baseline,
mean (SD)
Probability of having
a BASDAI 50
response, placebo,
mean (SD)
Probability of having
a BASDAI 50
response, anti-TNF,
mean (SD)
OR for BASDAI 50
response, anti-TNF
vs. placebo, mean
(SD)
Effect of anti-TNFs
on BASDAI
–1.95 (0.30) 0.10 (–) 0.41 (0.05) 6.30 (1.56)
Effect of anti-TNFs
on BASFI
–1.40 (0.28) – – –
Other model summaries
DBASDAI –1.99 (0.20) – – –
DBASFI –1.40 (0.16) – – –
γBASDAI 0.13 (0.10) – – –
γBASFI 0.11 (0.09) – – –
ρplacebo 0.42 (0.26) – – –
ρanti-TNF 0.71 (0.23) – – –
ρm 0.51 (0.29) – – –
σ2re 0.16 (0.14) – – –
DIC 181.9 – – –
a Based on a BASDAI baseline score of 6.11 (SD= 1.56) and a placebo change score of –0.61 (SD= 1.44), which represent
the average across trials (weighted by number of patients).
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Drug-specific (shrunken) estimates from model C are shown in Table 160.
TABLE 160 Shrunken estimates of treatment effect from model C
Treatment Change in BASDAI score, mean (SD) Change in BASFI score, mean (SD)
Adalimumab –1.89 (0.22) –1.34 (0.17)
Certolizumab –2.02 (0.28) –1.36 (0.21)
Etanercept –1.94 (0.18) –1.43 (0.16)
Golimumab –1.98 (0.25) –1.42 (0.17)
Infliximab –2.03 (0.27) –1.49 (0.25)
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Appendix 13 Synthesis of evidence on the
non-radiographic axial spondyloarthritis population
This section analyses the evidence on the effectiveness of anti-TNFs on the nr-AxSpA population.
Brief description of the data
On the nr-AxSpA population, five RCTs were considered directly relevant to the decision problem (studies
17–21 in Table 161). All studies reported BASFI outcomes and one study did not report BASDAI 50
(study 21).
The data on these five studies are shown in Table 162.
TABLE 162 Data on the nr-AxSpA population
s[] t[] n[] r[] b[] sd[] y[] y.se[] y.f[] y.f.se[]
1 1 24 5 6.20 0.59 –1.20 7.79 –0.80 6.87
1 2 22 11 6.50 0.69 –2.70 6.30 –2.40 7.24
2 1 73 10 6.38 0.44 –1.10 19.00 –0.63 22.78
2 2 69 27 6.43 0.42 –2.20 11.04 –1.28 16.91
3 1 50 8 6.40 0.44 –1.50 6.25 –0.40 6.25
3 3 97 47 6.55 0.43 –3.35 11.64 –2.30 12.21
4 1 109 26 6.00 0.28 –1.30 11.11 –0.80 25.00
4 4 106 46 6.00 0.31 –2.00 11.11 –1.40 25.00
5 1 20 N/A 5.76 0.28 –0.75 3.42 –0.47 3.95
5 5 20 N/A 5.85 0.31 –3.41 3.12 –2.70 3.59
N/A, not applicable.
s[]= study, t[]= treatment: 1= placebo, 2= adalimumab, 3= certolizumab pegol, 4= etanercept, 5= infliximab; n[]= total
number of patients, r[]= number of patients showing a BASDAI 50 response, y[]= vector of results from studies on change
from baseline on BASDAI score; y.se[]= standard error associated with each y; y.f[]= vector of results from studies on
change from baseline on BASFI score; y.f.se[]= standard error associated with each y.f.
TABLE 161 Evidence on BASDAI and BASFI-related outcomes for the nr-AxSpA population
Study
number Trial name Treatment
Number in
treatment
group
Number in
placebo
group
BASDAI
50 score
Change
BASDAI
score
Change
BASFI
score
17 Haibel 200852 Adalimumab 22 24 ✗ ✗ ✗
18 ABILITY-1 201358 Adalimumab 69 73 ✗ ✗ ✗
19 RAPID-axSpA
201464
Certolizumab
pegol
46+ 51 50 ✗ ✗ ✗
20 Dougados 201476 ETA50 106 109 ✗ ✗ ✗
21 Barkham 200950 Infliximab 20 20 ✗ ✗
DOI: 10.3310/hta20090 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 9
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
297
Description of approaches to the synthesis
To synthesise these data we used the same implementation and software specifications as described in
Appendix 12. Analyses explored two different scenarios to consider these data:
l scenario 1: data from nr-AxSpA trials were considered in isolation
l scenario 2: data from AS population were also used, no difference between the populations
was assumed.
All models implemented here jointly synthesise BASDAI and BASFI outcomes (our preferred modelling
approach, C).
Results of the synthesis
Results of the analysis are in Table 163.
TABLE 163 Non-radiographic axial spondyloarthritis population: results
Estimated Assumeda Predicted
Difference in change
score from baseline,
mean (SD)
Probability of having
a BASDAI 50
response, placebo,
mean (SD)
Probability of having
a BASDAI 50
response, anti-TNF,
mean (SD)
OR for BASDAI 50
response, anti-TNF
vs. placebo,
median (SD)
Scenario 1: data from nr-AxSpA trials
Effect of anti-TNFs
on BASDAI
–1.86 (0.79) 0.20 (–) 0.53 (0.13) 4.39 (6.59)
Effect of anti-TNFs
on BASFI
–1.30 (0.84) – – –
Other model summaries
DBASDAI –1.86 (0.53) – – –
DBASFI –1.30 (0.65) – – –
γBASDAI 0.41 (0.43) – – –
γBASFI 0.68 (0.53) – – –
ρplacebo 0.60 (0.27) – – –
ρanti-TNF 0.57 (0.28) – – –
ρm 0.51 (0.29) – – –
σ2re 0.55 (0.29) – – –
DIC 88.6 – – –
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TABLE 163 Non-radiographic axial spondyloarthritis population: results (continued )
Estimated Assumeda Predicted
Difference in change
score from baseline,
mean (SD)
Probability of having
a BASDAI 50
response, placebo,
mean (SD)
Probability of having
a BASDAI 50
response, anti-TNF,
mean (SD)
OR for BASDAI 50
response, anti-TNF
vs. placebo,
median (SD)
Scenario 2: data from AS and nr-AxSpA trials, no difference between the populations
Effect of anti-TNFs
on BASDAI
–1.97 (0.32) 0.20 (–) 0.55 (0.06) 4.94 (1.48)
Effect of anti-TNFs
on BASFI
–1.37 (0.3) – – –
Other model summaries
DBASDAI –1.97 (0.20) – – –
DBASFI –1.37 (0.18) – – –
γBASDAI 0.12 (0.09) – – –
γBASFI 0.18 (0.11) – – –
ρplacebo 0.50 (0.26) – – –
ρanti-TNF 0.74 (0.22) – – –
ρm 0.54 (0.29) – – –
σ2re 0.19 (0.16) – – –
DIC 269.0 – – –
a Based on a BASDAI baseline score of (AiC information has been removed) and a placebo change score of
(AiC information has been removed), which represent the results seen in the certolizumab trial (RAPID-axSpA64).
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Appendix 14 Utility review
In accordance with the NICE reference case,
238 utility values should be based on the EQ-5D instrument.
Therefore, a systematic review of utility studies was carried out to identify relevant studies which
(1) directly estimate EQ-5D utility values; and (2) establish the relationship between generic measures of
utility (in particular the EQ-5D) and measures of disease progression (including mapping studies). The
review of utility studies focuses on anti-TNFs for AS and AxSpA without radiographic evidence of AS
(nr-AxSpA).
Methods
Searches were undertaken in EMBASE and MEDLINE/MEDLINE In-Process & Other Non-Indexed Citations
(Ovid). A combination of disease terms and terms associated with the EQ-5D were used. Upon initial review,
it was evident that the results of the search did not identify the studies found in the cost-effectiveness
review that also reported on the quality of life of AS patients, for example Ara et al.161 Therefore, a separate
search in NHS EED, MEDLINE and EMBASE for published modelling studies was also subsequently
undertaken. No language and date limits were applied. Full details of the search strategy used are presented
in Appendix 1.
Studies that reported utility values consistent with the NICE reference case were included in the review,
that is studies reporting utilities for AS or nr-AxSpa patients generated using:
l the EQ-5D
l HRQoL or changes in HRQoL measured directly by patients
l changes in HRQoL should be valued using public preferences from a representative sample of the UK
population using a choice-based method (or this could be reasonably assumed from the publication).
When a mapping algorithm was reported, eligibility of studies was restricted to those that mapped from
BASDAI score and/or BASFI score to EQ-5D.
Results
Identified studies
The combined search retrieved 210 citations. After screening titles and abstracts, 28 citations were
retrieved for full review. The abstract by Pumford et al.239 was excluded, as the full publication by
Wade et al.240 reported on the same study. The abstract by Lee et al.241 was excluded as a more recent full
publication of the study (Lee et al.242) reported that a non-UK valuation set was used. Joore et al.243 was
also excluded, as primary data were reported in Van Tubergen et al.244 A further three studies were
excluded because the manuscripts were in a language other than English.
Kobelt et al. have reported costs/quality of life/cost-effectiveness of AS patients in multiple references
(e.g. Kobelt et al. 2004,152 Kobelt et al. 2006,245 Kobelt et al. 2007160 and Kobelt et al. 2008246). Kobelt
et al.152,160 are relevant to a UK population and are preferred to the other Kobelt publications that are
relevant to non-UK populations. Of these, Kobelt et al.152 reports utility data collected and used in the
analysis and is, therefore, included in this review.
In total, 12 studies were deemed to meet the NICE reference case238 and are summarised in Table 164.
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TABLE 164 Summary of utility studies that meet the NICE reference case
Study Population characteristics Interventions Utility assessment methods
Utilities reported,
mean (SD) [95% CI] Reviewer comments
Ara et al. (2007)161
The cost-effectiveness of
etanercept in patients
with severe ankylosing
spondylitis in the UK
(mapping algorithm to
EQ-5D values also
reported)
l AS, diagnosed using mNY
criteria defined by a VAS
for mean morning stiffness
≥ 30 units, and by at least
two of the following: VAS
score for patient global
assessment of disease
activity ≥ 30, average VAS
score for nocturnal and total
pain ≥ 30 or BASFI score of
≥ 30, patients from two
etanercept RCTs
l European RCT: 356 patients
randomised to receive
placebo (n= 51), etanercept
25mg twice weekly
(n= 150) and etanercept
50mg once weekly (n= 155)
for 12 weeks. Data from the
etanercept arms were
combined as no significant
differences in outcomes
were found
l Mainly US RCT: 277 patients
randomised to receive
placebo (n= 139) or
etanercept 25mg twice
weekly (n= 138) for
24 weeks plus a 3-year
open-label extension
l Age: 41 years (European
RCT), 42 years (US RCT)
l Disease duration: 9.3 years
(European RCT), 10.3 years
(US RCT)
l BASDAI score: 6.1 (European
RCT), 5.9 (US RCT)
l BASFI score: 5.9 (European
RCT), 5.4 (US RCT)
l Placebo
l Etanercept 25mg
twice weekly
l Etanercept 50mg
once weekly
EQ-5D
l Completed by patients in
11 European countries
(including the UK)
l UK population valuation
set is assumed to have
been used as this is a
UK study
l European RCT data were
used to derive an
algorithm between
BASDAI/BASFI and EQ-5D.
Methods were not
reported
European RCT week 12
(observed) for patient with a
BASDAI score of ≥ 4:
l Anti-TNF responder:
0.79 (NR)
l Anti-TNF non-responder:
0.48 (NR)
l Placebo responder:
0.74 (NR)
l Placebo non-responder:
0.46 (NR)
US RCT week 24 (predicted
using algorithm):
l Anti-TNF responder:
0.80 (NR)
l Anti-TNF non-responder:
0.46 (NR)
l Placebo responder:
0.79 (NR)
l Placebo non-responder:
0.42 (NR)
Algorithm % (BASDAI/BASFI
scores are on the 0–100 scale):
l Utility= 0.923
(0.0170) – 0.004
(0.0007) × BASFI –
0.004 (0.0008) ×
BASDAI
l R2= 0.52
l Observed values may be
generalisable to an AS
population that has been
treated with etanercept.
However, it is not clear
how generalisable the
outputs are to a UK
population
l Responders were
categorised using BSR
guidelines, that is
BASDAI 50
l Baseline values were
not reported
l The generalisability of the
algorithm is unclear as
the methods have not
been reported
l A UK population valuation
set is assumed to have
been used
A
P
P
E
N
D
IX
1
4
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
3
0
2
Study Population characteristics Interventions Utility assessment methods
Utilities reported,
mean (SD) [95% CI] Reviewer comments
Boonen et al. (2002)247
and (2003)248
2002: Work status and
productivity costs due to
ankylosing spondylitis:
comparison of three
European countries
2003: Costs of ankylosing
spondylitis in three
European countries: the
patient’s perspective
AS patients diagnosed using
mNY criteria
N/A EQ-5D
l Completed by patients in
Europe (not including the
UK)
It is assumed that the UK
population valuation set
was used as the authors’
reference. Dolan et al.249 and
Boonen et al.248 say the ‘York
weighting’ was used
Baseline:
l Netherlands 0.69 (0.16)
l France 0.63 (0.29)
l Belgium 0.67 (0.14)
l Results may be
generalisable to an AS
population; however,
generalisability to a UK
population is unknown
l A high proportion of
missing data (84% were
missing at least one
bimonthly questionnaire)
l UK population valuation
set is assumed to have
been used
There were 130 patients from
the Netherlands. Patients were
sampled from the Dutch
standard diagnosis register of
rheumatic diseases:
l Age: 46 years
l Disease duration since
diagnosis: 12 years
l BASDAI score: 3.7
l BASFI score: 3.9
Time averaged across 2-year
follow-up period:
l Netherlands 0.68 (0.16)
l France 0.63 (0.23)
l Belgium 0.67 (0.14)
l All patients 0.67 (0.19)
There were 53 patients from
France. Consecutive in- and
outpatients at a hospital
rheumatology department
l Age: 38 years
l Disease duration since
diagnosis: 9 years
l BASDAI score: 2.8
l BASFI score: 2.5
There were 26 patients from
Belgium. Consecutive
outpatients at a hospital
rheumatology department
l Age: 42 years
l Disease duration since
diagnosis: 11 years
l BASDAI score: 3.1
BASFI score: 2.6
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TABLE 164 Summary of utility studies that meet the NICE reference case (continued )
Study Population characteristics Interventions Utility assessment methods
Utilities reported,
mean (SD) [95% CI] Reviewer comments
Boonen et al. (2007)250
How do the EQ-5D,
SF-6D and the well-being
rating scale compare in
patients with ankylosing
spondylitis?
AS patients diagnosed using
mNY criteria
OASIS: N/A
(prevalence cohort)
EQ-5D
l Completed by patients in
Europe (not including
the UK)
l UK population valuation
set used
l Outputs from the EQ-5D
rating scale and SF-6D are
also reported in this study
but are not summarised
here
l Combined data sets
(n= 254): 0.64 (0.23)
l BASDAI score of < 4
(n= 125): 0.73 (0.16)
l BASDAI score of ≥ 4
(n= 137): 0.55 (0.26)
l BASFI score of < 4
(n= 121): 0.74 (0.16)
l BASFI score of ≥ 4
(n= 143): 0.55 (0.25)
l Results may be
generalisable to an AS
population; however,
generalisability to a UK
population is unknown
l It is not clear if the
utilities reported are
baseline values (baseline
and post intervention at
4 weeks EQ-5D results
were included in the RCT)
l EQ-5D discriminates more
between lower and
higher BASDAI patients
(and lower and higher
BASFI patients) than the
SF-6D. The authors
suggest there is a ceiling
effect between EQ-5D
values 0.6–0.8 (these
patients showed a wide
range of values on the
SF-6D and rating scale)
There were 134 patients from
the prevalence-based OASIS
cohort (Boonen et al.
2002/3)247,248
There were 120 patients from a
RCT comparing spa treatment
(n= 80) with usual care (n= 40)
(Van Tuburgen et al. 2002244)
RCT: spa treatment
(3 weeks) and usual
care
Both data sets were merged as
authors found that QoL
instruments provided similar
results in the two populations:
l Age: 48 years
l Disease duration since
diagnosis: 13 years
l BASDAI score: 4.2
l BASFI score: 4.2
A
P
P
E
N
D
IX
1
4
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
3
0
4
Study Population characteristics Interventions Utility assessment methods
Utilities reported,
mean (SD) [95% CI] Reviewer comments
Boonen et al. (2008)205
Rapid and sustained
improvement in health-
related quality of life and
utility for 72 weeks in
patients with ankylosing
spondylitis receiving
etanercept
In total 257 AS patients were
diagnosed using mNY criteria
who had completed 24 weeks of
treatment in a previous RCT (277
patients enrolled) comparing
etanercept with placebo.
Patients were treated with
etanercept in the open-label
extension study
l Age: 41 years
l Disease duration: 10.8 years
l BASDAI: not reported
l BASFI: not reported
l Etanercept 25mg
twice weekly
EQ-5D
l Completed by patients in
28 centres across Europe
and North America
l UK population valuation
set was used
Baseline (n= 232):
l Previously treated with
etanercept in the RCT
(n= 128): 0.69 (0.2)
l Previously treated with
placebo in the RCT
(n= 129): 0.49 (0.3)
Figure 3(a) in Boonen et al.205
shows that patients who were
previously on etanercept
maintained their baseline
utility up to week 72
(105 patients completed
72 weeks of treatment).
Patients who were previously
on placebo achieved a similar
utility to those patients
previously on etanercept by
week 12 and maintained this
to week 72 (115 patients
completed 72 weeks of
treatment)
l Results may be
generalisable to an AS
population, however,
generalisability to a UK
population is unknown
l Negative utility values
were imputed as 0
l Patients eligible for the
open-label study were
those who completed the
initial RCT, patients who
discontinued because of
lack of efficacy but
completed follow-up
evaluations and patients
who discontinued
because of AEs which
subsequently resolved
l Figure 3(a) in Boonen
et al.205 refers to
‘combined’ EQ-5D scores
but it is not clear what
‘combine’ denotes
continued
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TABLE 164 Summary of utility studies that meet the NICE reference case (continued )
Study Population characteristics Interventions Utility assessment methods
Utilities reported,
mean (SD) [95% CI] Reviewer comments
Braun et al. (2007)85
Improvement in patient-
reported outcomes for
patients with ankylosing
spondylitis treated with
etanercept 50mg
once-weekly and 25mg
twice-weekly
In total 356 active AS patients
were diagnosed using mNY
criteria defined by a VAS score
for mean morning stiffness ≥ 30,
and by at least two of the
following: VAS score for patient
global assessment of disease
activity ≥ 30, average VAS score
for nocturnal and total pain ≥ 30
or BASFI score of ≥ 30
l Age: 40 years
l Disease duration: 9 years
l BASDAI score: 6.1
l BASFI score: 6.0
l Placebo
l Etanercept 25mg
twice weekly
(12 weeks)
l Etanercept 50mg
once weekly
(12 weeks)
EQ-5D
l Completed by patients in
11 European countries
(including the UK)
l It is assumed that the UK
population valuation set
was used as the authors’
reference, Dolan et al.
(1997)249
Mean increase between 0 to
12 weeks reported in figure 2
in Braun et al.:205
l placebo, patient’s utility
increase at 12 weeks:
0.13
l etanercept 25mg,
patient’s utility increase at
12 weeks: 0.25
l etanercept 50mg, patient’s
utility increase at 12 weeks:
0.3
l Results may be
generalisable to an AS
population that has been
treated with etanercept.
However, it is not clear
how generalisable the
outputs are to a UK
population
l Baseline values were
not reported
l A rapid improvement in
utilities was seen within
2 weeks
l In total, 90% of patients
completed 12 weeks
of treatment
l A UK population
valuation set is assumed
to have been used
Gordeev et al. (2010)251
Role of contextual factors
in health-related quality
of life in ankylosing
spondylitis
In total 764 patients with AS
were diagnosed using mNY
criteria, in Canada and Australia
were sent a questionnaire in
the post. Overall, 522 (68%)
responded and were included in
the analysis
l Age: 43 years (Australian),
53 years (Canadian)
l Diagnosis duration: 13 years
(Australian), 19 years
(Canadian)
l BASDAI score: 3.5
(Australian), 4.1 (Canadian)
l BASFI score: 3.3 (Australian),
3.9 (Canadian)
l N/A EQ-5D
l Completed by patients in
Canada and Australia
l UK population valuation
set is used
l Australian cohort
(n= 105): 0.68 (0.27)
l Canadian cohort
(n= 417): 0.62 (0.29)
l This study may be
generalisable to patients
with AS. However,
generalisability to a UK
population is unknown
l Contextual factors
explained 37% of the
variance in EQ-5D
l Helplessness (measured
using the Rheumatoid
Attitudes Index
Helplessness Subscale),
employment and
education were the most
important contextual
factors. Their role was
independent of the
strong effect of BASDAI
and BASFI
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Study Population characteristics Interventions Utility assessment methods
Utilities reported,
mean (SD) [95% CI] Reviewer comments
Haywood et al. (2002)252
Generic measures of
health-related quality of
life in ankylosing
spondylitis: reliability,
validity and
responsiveness
A random sample of 451
patients with AS, diagnosed
using mNY criteria, were sent a
postal questionnaire
l n=349 (77%) patients
returned the questionnaire
at baseline
l n=349 patients returned the
questionnaire at baseline
l n=303 patients returned the
questionnaire at 2 weeks
l n=289 patients returned the
questionnaire at 6 months
l Age: 46 years
l Symptom duration: 20 years
l BASDAI: NR
l BASFI: NR
N/A EQ-5D
l Completed by patients in
the UK
l It is assumed that the UK
population valuation set
was used as the authors
reference Kind et al.
(1998)253
l Outputs from the EQ-5D
VAS and SF-12 are also
reported in this study but
are not summarised here
Reliability analysis using data
from patients whose health
remained the same at
2 weeks (n= 321): 0.53 (0.35)
Longitudinal construct validity
analysis at 6 months
l This study may be
generalisable to UK
patients with AS
l UK population valuation
set is assumed to have
been used
l BASDAI/BASFI values for
this cohort are
not reportedAS:
l Patients whose AS health
was better (n= 57):
improved by 0.30 (1.2)
l Patients whose AS health
stayed the same
(n= 120): –0.25 (1.5)
l Patients whose AS health
was worse (n= 77):
improved by –0.09 (1.6)
General health:
l Patients whose general
health was better
(n= 49): improved by
0.35 (1.3)
l Patients whose AS health
stayed the same
(n= 132): –0.21 (1.4)
l Patients whose AS health
was worse (n= 67):
–0.15 (1.7)
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TABLE 164 Summary of utility studies that meet the NICE reference case (continued )
Study Population characteristics Interventions Utility assessment methods
Utilities reported,
mean (SD) [95% CI] Reviewer comments
Healey et al. (2013)14
Patients with well-
established ankylosing
spondylitis show limited
deterioration in a ten-year
prospective cohort study
In total 269 patients with AS,
diagnosed using mNY criteria,
were invited to participate at a
rheumatology centre
159 patients participated at
baseline
69 patients participated at the
10 year assessment
l Age: 49 years
l Disease duration: 16 years
l BASDAI score: 4.1
l BASFI score: not reported
N/A EQ-5D
l Completed by patients in
the UK
l It is assumed that the UK
population valuation set
was used as this is a UK
study
Outputs from the SF-12 are
also reported in this study but
are not summarised here
Baseline assessment in 1998
(n= 159): 0.64 (0.28)
10-year follow-up assessment:
0.61 (0.30)
l This study may be
generalisable to UK
patients with AS
l Only 69 patients
participated in both
assessments
l A UK population
valuation set is assumed
to have been used
Kobelt et al. (2004)152
The burden of ankylosing
spondylitis and the
cost-effectiveness of
treatment with infliximab
(Remicade®)
Clinical trial, hospital cohort and
survey data for AS patients were
utilised in this study
Utilities were estimated from a
survey of 3000 patients. 1413
(57%) patients responded and
were included in the analysis
N/A EQ-5D
l Completed by patients in
the UK
l It is assumed that the UK
population valuation set
was used as the study
references Dolan et al.
(1995)254 and was
conducted in the UK
Survey mean: 0.67 (0.21) l This study may be
generalisable to UK
patients with AS
l Patients from across the
spectrum of possible
BASDAI/BASFI values
(0–10) responded to
the survey
l Measures of uncertainty
not reported
BASDAI subgroups:
l Patients with a BASDAI
score of < 3 (mean BASFI
score= 2.4): 0.8
l Patients with a BASDAI
3–3.99 (mean BASFI
score= 3.7): 0.7
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Study Population characteristics Interventions Utility assessment methods
Utilities reported,
mean (SD) [95% CI] Reviewer comments
Survey responders had the
following characteristics:
l Age: 57 years
l Disease duration: 30 years
l BASDAI score: 4.2
l BASFI score: 4.5
l UK population valuation
set is assumed to have
been used
l Patients with a BASDAI
4–4.99 (mean BASFI
score= 4.5): 0.64
l Patients with a BASDAI
5–5.99 (mean BASFI
score= 5.4): 0.60
l Patients with a BASDAI
6–6.99 (mean BASFI
score= 6.4): 0.51
l Patients with a BASDAI
score of > 7 (mean BASFI
score= 7.8): 0.39
BASFI subgroups:
l Patients with a BASFI
score of < 3 (mean
BASDAI score= 2.5): 0.8
l Patients with a BASFI
3–3.99 (mean BASDAI
score= 3.8): 0.71
l Patients with a BASFI
4–4.99 (mean BASDAI
score= 4.2): 0.67
l Patients with a BASFI
5–5.99 (mean BASDAI
score= 4.7): 0.57
l Patients with a BASFI
6–6.99 (mean BASDAI
score= 5.5): 0.53
l Patients with a BASFI
score of > 7 (mean
BASDAI score= 8.4): 0.47
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TABLE 164 Summary of utility studies that meet the NICE reference case (continued )
Study Population characteristics Interventions Utility assessment methods
Utilities reported,
mean (SD) [95% CI] Reviewer comments
McLeod et al. (2007)38
Adalimumab, etanercept
and infliximab for the
treatment of ankylosing
spondylitis: a systematic
review and economic
evaluation (mapping
algorithm to EQ-5D
values reported)
Utilities were estimated from a
reanalysis of the Kobelt et al.152
survey data by the manufacturer
of infliximab (n= 1144)
l Age: NR
l Disease duration: NR
l BASDAI: not reported
l BASFI: NR
N/A EQ-5D
l Completed by patients in
the UK
l It is assumed that the UK
population valuation set
was used as the study
references Dolan et al.254
and was conducted in
the UK
Methods for mapping
algorithm used by the
assessment group NR
Algorithm used in the
assessment group (LRiG)
model:
l Utility= 0.8772129 –
0.0384087 × BASDAI –
0.0322519 × BASFI –
0.0278913 ×Male+
0.0016809 ×Age
The algorithms used in the
manufacturer’s submissions
are also reported but not
reproduced here
l Generalisability of the
algorithm is unclear as
methods have not
been reported
l Report states that the
manufacturer analysis is
based on 1144 patients
from Kobelt et al.152
Utility values in Kobelt
et al.152 were calculated
using data from
1413 patients
l UK AS patients from
across the spectrum of
possible BASDAI/BASFI
values (0–10) are likely to
have been included in
the analysis
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Study Population characteristics Interventions Utility assessment methods
Utilities reported,
mean (SD) [95% CI] Reviewer comments
Van Tubergen et al.
(2002)244
Cost effectiveness of
combined spa-exercise
therapy in ankylosing
spondylitis: a randomized
controlled trial
120 AS patients, diagnosed
using mNY criteria
111 included in the analysis
l Age: 48 years
l Disease duration: 11 years
l BASDAI score: NR
l BASFI score: 4.4
l Spa treatment
(3 weeks)
l Usual care
EQ-5D
l Completed by patients in
Europe (not including
the UK)
l UK population valuation
set is assumed to have
been used as the study
references Dolan et al.
(1996)255
Outputs from the SF-6D are
also reported in this study but
are not summarised here
Spa treatment in Austria
(n= 36):
l Baseline (2 weeks before
treatment): 0.650 (0.22)
l Change at 4 weeks:
0.02 (0.2)
l Change at 16 weeks:
0.04 (0.21)
l Change at 28 weeks:
–0.03 (0.23)
l Change at 40 weeks:
–0.01 (0.27)
l Results may be
generalisable to an AS
population, however,
generalisability to a UK
population is unknown
l Patients were allowed to
continue taking their
usual medication
throughout the study
period. Medication could
be changed if needed.
This may bias the results
l A UK population
valuation set is assumed
to have been usedSpa treatment in
the Netherlands (n= 38):
l Baseline (2 weeks before
treatment): 0.64 (0.22)
l Change at 4 weeks:
0.1 (0.24)
l Change at 16 weeks:
0.12 (0.24)
l Change at 28 weeks:
0.1 (0.21)
l Change at 40 weeks:
0.03 (0.23)
Usual care (n= 37):
l Baseline (2 weeks before
treatment): 0.72 (0.1)
l Change at 4 weeks:
–0.06 (0.18)
l Change at 16 weeks:
–0.04 (0.19)
l Change at 28 weeks:
–0.08 (0.28)
l Change at 40 weeks:
–0.03 (0.19)
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TABLE 164 Summary of utility studies that meet the NICE reference case (continued )
Study Population characteristics Interventions Utility assessment methods
Utilities reported,
mean (SD) [95% CI] Reviewer comments
Wade et al. (2011)240
Baseline characteristics
and patient reported
outcome data of patients
prescribed etanercept:
web-based and telephone
evaluation
There were 43 patients
prescribed etanercept for
AS (diagnostic criteria not
reported)
RA, PsA and psoriasis patients
were also included in the study
l Age: 49 years
l Disease duration: NR
l BASDAI score: NR
l BASFI score: NR
l Etanercept EQ-5D
l Completed by patients in
the UK
l A UK population valuation
set is assumed to have
been used as this is a
UK study
Baseline: 0.37 (0.37)a l This study may be
generalisable to UK
patients with AS
l Overall, 23% of AS
patients were previously
treated with a TNF-α
inhibitor
l A UK population
valuation set is assumed
to have been used
l Differences in
characteristics between
telephone and web-based
responders were observed
for the entire sample
(for all conditions)
QoL, quality of life; mNY, modified New York criteria; N/A, not applicable; NR, not reported; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SF-6D, Short Form questionnaire-6 Dimensions.
a Only baseline reported in this study.
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The main reasons for excluding studies at the title/abstract and at full review stage were (1) utilities were
not reported (e.g. Haywood et al.256), (2) valuation set not reported or a non-UK valuation was used
(e.g. Kvamme et al.257), (3) utilities were reported for a mixed population with different inflammatory
arthropies or in a population not relevant to the decision problem (e.g. Osnes-Ringen et al.258).
Studies meeting the National Institute for Health and Care Excellence
reference case
The 12 studies meeting the reference case238 have been summarised in Table 164. The table includes a
primary study to Boonen et al.,250 reported in Boonen et al.247,248 The study by Boonen et al.250 has been
retained as it reports utility values for patients with a BASDAI score of ≥ 4.
Ankylosing spondylitis population
All studies included in Table 164 are of AS patients. Five studies reported utility values (or mapping
algorithms) generated from data specifically collected from the UK population (Haywood et al.,252
Healey et al.,14 Kobelt et al.,152 McLeod et al.38 and Wade et al.240). Four studies included interventions
specific to this appraisal, all of these studies were of etanercept (Ara et al.,161 Boonen et al.,205
Braun et al.87 and Wade et al.240). Utility values reported ranged from values at baseline to at
10 years’ follow-up.
Non-radiographic axial spondyloarthritis population
Two citations were identified in the review that reported utilities for nr-AxSpA patients (Dougados et al.78
and Lindstrom et al.259). However, these studies did not explicitly report which population valuation sets
were used and, therefore, were excluded from the review.
Mapping algorithms
Of the 12 studies in Table 164, two report mapping algorithms between disease-specific measures and
the EQ-5D (Ara et al.161 and McLeod et al.38). Both have been reported as part of a cost-effectiveness
analysis and provide limited information on methodology employed (e.g. covariates tested, correlation
considerations and goodness of fit). McLeod et al.38 reports on an algorithm generated using data from
UK AS patients.
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Appendix 15 Additional cost-effectiveness results
Following the consultation process to the NICE appraisal, additional analyses were undertaken to addresscomments received on Chapters 5 and 6. These focused on the conditional baseline BASDAI scores
used in Chapter 5 and on the existence of a biosimilar product for infliximab with a lower list price.
A. Truncated baseline Bath Ankylosing Spondylitis Disease
Activity Index scores
One of the consultees identified that the simulation procedure undertaken to evaluate conditional scores in
Chapter 5 was using a non-truncated distribution for the baseline BASDAI score. This meant that it was
possible for simulated individuals to have a baseline BASDAI score of < 4, which is inconsistent with clinical
practice for which treatment with anti-TNFs is only provided to patients with a baseline BASDAI score of
> 4. This was a result of assuming a normal distribution for baseline BASDAI scores. Together with the SD
applied, this resulted in the simulation model sampling population characteristics which we acknowledge
would subsequently fall outside of the decision problem. We have rerun our base-case results assuming a
truncated distribution (i.e. excluding the possibility of sampling patients with a baseline BASDAI score of
< 4). The results are presented in Table 165 and confirm only a minimal impact on the conditional scores.
Tables 166 and 167 report the revised base-case cost-effectiveness results for the AS population using a
truncated distribution for baseline BASDAI (the original base-case cost-effectiveness results are reported in
Tables 95 and 96 for the AS population).
These results demonstrate that the ICERs show only small variation using a truncated baseline BASDAI
distribution. The ICERs appear marginally less favourable than the original base-case results. Hence, any
potential bias in the original analysis appears to work in favour of the TNF-inhibitors. However, the
magnitude is small and could equally be a result of simulation error as opposed to any bias.
TABLE 165 Conditional scores predicted for the AS population using the synthesis model (truncated
baseline BASDAI)
Patient population
BASDAI BASFI
Control Treatment Control Treatment
BASDAI baseline score truncated to a minimum value of 4
% responders to BASDAI 50 0.08 0.45 – –
Change in score
Responders –2.93 –3.77 –1.49 –3.01
Non-responders –0.39 –1.56 –0.06 –0.39
All –0.60 –2.56 –0.18 –1.58
Baseline
Responders 4.52 4.86 3.92 4.24
Non-responders 6.30 7.23 5.40 6.15
All 6.15 6.15 5.28 5.28
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Non-radiographic axial spondyloarthritis population
We have rerun our base-case results assuming a truncated distribution (i.e. excluding the possibility of
sampling patients with a baseline BASDAI score of < 4) for the nr-AxSpA population. The results are
presented in Table 168 and confirm only a minimal impact on the conditional scores.
Tables 169 and 170 report the revised base-case cost-effectiveness results for the nr-AxSpA population
using a truncated distribution for baseline BASDAI (the original base-case cost-effectiveness results are
reported in Tables 97 and 98).
TABLE 166 Revised base-case cost-effectiveness results (truncated normal): AS (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£)
ICER
(£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.240 – 111,532 – – – –
Certolizumab pegol
PAS
8.249 1.009 131,909 20,377 20,195 0.482 0.877
Golimumab 8.249 1.009 133,543 22,011 21,814 0.381 0.830
Adalimumab 8.249 1.009 133,637 22,105 21,907 0.376 0.827
Etanercept 8.249 1.009 134,054 22,522 22,321 0.345 0.811
Certolizumab pegol 8.249 1.009 135,483 23,951 23,737 0.258 0.758
Infliximab 8.249 1.009 153,255 41,723 41,350 0.000 0.081
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 167 Revised base-case cost-effectiveness results (truncated normal): AS (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£)
ICER
(£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.251 – 111,666 – – – –
Certolizumab pegol
PAS
7.898 0.647 134,955 23,289 35,982 0.013 0.333
Golimumab 7.898 0.647 136,585 24,919 38,500 0.009 0.245
Adalimumab 7.898 0.647 136,679 25,013 38,646 0.008 0.239
Etanercept 7.898 0.647 137,100 25,434 39,296 0.006 0.222
Certolizumab pegol 7.898 0.647 138,528 26,862 41,503 0.004 0.172
Infliximab 7.898 0.647 156,420 44,754 69,146 0.000 0.000
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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TABLE 168 Conditional scores predicted for the nr-AxSpA population using the synthesis model (truncated
baseline BASDAI)
Patient population
BASDAI BASFI
Control Treatment Control Treatment
BASDAI baseline score truncated to a minimum value of 4
% responders to BASDAI 50 0.21 0.55 – –
Change in score
Responders –3.23 –4.29 –1.77 –3.23
Non-responders –1.05 –2.25 0.02 0.17
All –1.50 –3.37 –0.35 –1.70
Baseline
Responders 4.80 5.40 3.24 3.86
Non-responders 6.83 7.64 5.34 6.20
All 6.41 6.41 4.91 4.91
TABLE 169 Revised base-case cost-effectiveness results (truncated normal): nr-AxSpA (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.906 – 90,850 – – – –
Certolizumab
pegol PAS
11.291 1.386 130,974 40,124 28,958 0.102 0.576
Adalimumab 11.291 1.386 132,373 41,523 29,968 0.069 0.506
Etanercept 11.291 1.386 133,119 42,269 30,506 0.059 0.484
Certolizumab
pegol
11.291 1.386 134,547 43,696 31,536 0.045 0.454
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 170 Revised base-case cost-effectiveness results (truncated normal): nr-AxSpA (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.963 – 90,219 – – – –
Certolizumab
pegol PAS
11.200 1.237 131,714 41,495 33,555 0.057 0.396
Adalimumab 11.200 1.237 133,109 42,890 34,684 0.038 0.343
Etanercept 11.200 1.237 133,859 43,640 35,290 0.035 0.318
Certolizumab
pegol
11.200 1.237 135,286 45,067 36,444 0.029 0.284
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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As Tables 169 and 170 demonstrate, the ICERs show only small variation employing a truncated
distribution for baseline BASDAI. The ICERs appear marginally less favourable than the original base-case
results. Hence, any potential bias in the original analysis appears to work in favour of the TNF-inhibitors.
However, the magnitude is small and could equally be a result of simulation error as opposed to any bias.
B. Biosimilar
One of the consultees provided the list price for Remsima™, a biosimilar for infliximab marketed by
Celltrion Healthcare. In view of this, we updated the base-case analysis for the AS population using the list
price for Remsima. The results, of rerunning the analysis excluding infliximab and replacing it with Remsima
using the list price provided, are reported in Tables 171 and 172. Minor differences in the ICERs for the
other TNF inhibitors compared with the original base case are a result of sapling variation (i.e. all ICERs are
derived from the probabilistic analysis and rerunning the simulation results in minor differences each time).
TABLE 171 Revised base-case results using list price for Remsima: AS population (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.266 – 111,696 – – – –
Certolizumab
pegol PAS
8.179 0.913 129,281 17,586 19,257 0.551 0.899
Golimumab 8.179 0.913 130,969 19,274 21,106 0.428 0.848
Adalimumab 8.179 0.913 131,053 19,357 21,197 0.421 0.846
Etanercept 8.179 0.913 131,426 19,731 21,606 0.390 0.835
Certolizumab
pegol
8.179 0.913 132,855 21,159 23,171 0.295 0.762
Remsima™ 8.179 0.913 145,256 33,561 36,751 0.004 0.204
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 172 Revised base-case results using list price for Remsima: AS population (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.250 – 111,647 – – – –
Certolizumab
pegol PAS
7.854 0.604 131,922 20,275 33,578 0.040 0.397
Golimumab 7.854 0.604 133,605 21,958 36,366 0.016 0.307
Adalimumab 7.854 0.604 133,690 22,043 36,506 0.016 0.305
Etanercept 7.854 0.604 134,067 22,420 37,131 0.012 0.287
Certolizumab
pegol
7.854 0.604 135,496 23,849 39,497 0.007 0.215
Remsima™ 7.854 0.604 148,010 36,363 60,222 0.000 0.003
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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Appendix 16 Full incremental cost-effectiveness
ratio tables for scenarios
Ankylosing spondylitis population
TABLE 173 Summary of cost-effectiveness scenarios: AS population
Strategy
number Parameter/structural Approach in scenario Approach in base case
1 CC (‘placebo’) response No response to CC assumed at 12 weeks Response to CC included at
12 weeks
2 Different baselines
assumed for responders
and non-responders and
change in BASDAI/BASFI
scores
Separate baselines based on pooled estimates
provided by manufacturers. Changes in
BASDAI/BASFI score conditioned on response
also based on pooled estimates provided by
manufacturers
Separate baselines and
changes in BASDAI/BASFI
conditioned on responses
estimated via extended
synthesis model
3 BASFI progression No effect of anti-TNFs on BASFI progression Treatment effect applied from
year 4 onwards
4 BASFI progression Treatment effect of anti-TNFs applied from
start of model
Treatment effect applied from
year 4 onwards
5 Utilities Linear BASDAI/BASFI model (based on Kobelt
et al.152)
Non-linear BASDAI/BASFI
model (Pfizer submission36)
6 Baseline BASDAI score
truncated at 4
Baseline BASDAI scores used in the NMA are
limited to be between 4 and 10
Baseline BASDAI scores used
in the NMA are limited to
be between 0 and 10
7 Price of biosimilar
infliximab
The price of the biosimilar for infliximab
provided by the manufacturer was used in
the model
BNF price of infliximab
BNF, British National Formulary; NMA, network meta-analysis.
Ankylosing spondylitis scenario results: rebound equal to gain
TABLE 174 Ankylosing spondylitis: scenario 1 (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.262 – 111,702 – – – –
Certolizumab
pegol PAS
7.952 0.691 125,734 14,033 20,319 0.462 0.861
Golimumab 7.952 0.691 127,531 15,829 22,920 0.313 0.764
Adalimumab 7.952 0.691 127,594 15,893 23,013 0.308 0.761
Etanercept 7.952 0.691 127,879 16,178 23,425 0.292 0.741
Certolizumab
pegol
7.952 0.691 129,308 17,607 25,495 0.188 0.651
Infliximab 7.952 0.691 141,750 30,048 43,510 0.000 0.063
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
DOI: 10.3310/hta20090 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 9
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
319
TABLE 175 Ankylosing spondylitis: scenario 2 (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.100 – 112,768 – – – –
Certolizumab
pegol PAS
8.120 1.019 127,856 15,088 14,803 0.840 0.988
Golimumab 8.120 1.019 129,536 16,768 16,451 0.727 0.979
Adalimumab 8.120 1.019 129,621 16,853 16,535 0.720 0.977
Etanercept 8.120 1.019 130,001 17,233 16,907 0.696 0.975
Certolizumab
pegol
8.120 1.019 131,430 18,662 18,309 0.561 0.955
Infliximab 8.120 1.019 147,674 34,906 34,246 0.015 0.232
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 176 Ankylosing spondylitis: scenario 3 (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.253 – 109,379 – – – –
Certolizumab
pegol PAS
8.128 0.875 127,455 18,075 20,655 0.462 0.843
Golimumab 8.128 0.875 129,140 19,760 22,581 0.348 0.775
Adalimumab 8.128 0.875 129,224 19,845 22,677 0.341 0.771
Etanercept 8.128 0.875 129,600 20,220 23,106 0.319 0.760
Certolizumab
pegol
8.128 0.875 131,028 21,649 24,739 0.234 0.698
Infliximab 8.128 0.875 147,118 37,739 43,125 0.001 0.063
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
APPENDIX 16
NIHR Journals Library www.journalslibrary.nihr.ac.uk
320
TABLE 177 Ankylosing spondylitis: scenario 4 (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.239 – 111,036 – – – –
Certolizumab
pegol PAS
8.201 0.962 128,804 17,767 18,466 0.589 0.929
Golimumab 8.201 0.962 130,485 19,448 20,213 0.462 0.878
Adalimumab 8.201 0.962 130,570 19,533 20,301 0.453 0.875
Etanercept 8.201 0.962 130,949 19,912 20,695 0.429 0.862
Certolizumab
pegol
8.201 0.962 132,377 21,341 22,180 0.345 0.808
Infliximab 8.201 0.962 148,597 37,560 39,037 0.005 0.124
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 178 Ankylosing spondylitis: scenario 5 (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
10.272 – 111,187 – – – –
Certolizumab
pegol PAS
11.043 0.771 129,139 17,953 23,290 0.217 0.891
Golimumab 11.043 0.771 130,819 19,632 25,469 0.099 0.755
Adalimumab 11.043 0.771 130,904 19,717 25,579 0.094 0.750
Etanercept 11.043 0.771 131,285 20,098 26,073 0.074 0.724
Certolizumab
pegol
11.043 0.771 132,713 21,526 27,926 0.048 0.593
Infliximab 11.043 0.771 148,974 37,787 49,021 0.000 0.003
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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TABLE 179 Ankylosing spondylitis: scenario 6 (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.240 – 111,532 – – – –
Certolizumab
pegol PAS
8.249 1.009 131,909 20,377 20,195 0.482 0.877
Golimumab 8.249 1.009 133,543 22,011 21,814 0.381 0.830
Adalimumab 8.249 1.009 133,637 22,105 21,907 0.376 0.827
Etanercept 8.249 1.009 134,054 22,522 22,321 0.345 0.811
Certolizumab
pegol
8.249 1.009 135,483 23,951 23,737 0.258 0.758
Infliximab 8.249 1.009 153,255 41,723 41,350 0.000 0.081
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 180 Ankylosing spondylitis: scenario 7 (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.266 – 111,696 – – – –
Certolizumab
pegol PAS
8.179 0.913 129,281 17,586 19,257 0.551 0.899
Golimumab 8.179 0.913 130,969 19,274 21,106 0.428 0.848
Adalimumab 8.179 0.913 131,053 19,357 21,197 0.421 0.846
Etanercept 8.179 0.913 131,426 19,731 21,606 0.390 0.835
Certolizumab
pegol
8.179 0.913 132,855 21,159 23,171 0.295 0.762
Remsima 8.179 0.913 145,256 33,561 36,751 0.004 0.204
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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Ankylosing spondylitis scenario results: rebound to conventional care
TABLE 181 Ankylosing spondylitis: scenario 1 (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.295 – 112,675 – – – –
Certolizumab
pegol PAS
7.762 0.467 128,654 15,979 34,229 0.038 0.385
Golimumab 7.762 0.467 130,446 17,771 38,068 0.014 0.257
Adalimumab 7.762 0.467 130,511 17,836 38,207 0.013 0.256
Etanercept 7.762 0.467 130,799 18,124 38,824 0.010 0.245
Certolizumab
pegol
7.762 0.467 132,228 19,553 41,885 0.004 0.161
Infliximab 7.762 0.467 144,800 32,125 68,815 0.000 0.000
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 182 Ankylosing spondylitis: scenario 2 (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.092 – 114,772 – – – –
Certolizumab
pegol PAS
7.756 0.664 132,257 17,485 26,348 0.136 0.666
Golimumab 7.756 0.664 133,945 19,174 28,892 0.076 0.531
Adalimumab 7.756 0.664 134,029 19,257 29,018 0.075 0.521
Etanercept 7.756 0.664 134,402 19,631 29,580 0.068 0.493
Certolizumab
pegol
7.756 0.664 135,831 21,059 31,733 0.042 0.380
Infliximab 7.756 0.664 151,831 37,059 55,842 0.000 0.008
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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TABLE 183 Ankylosing spondylitis: scenario 3 (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.252 – 110,930 – – – –
Certolizumab
pegol PAS
7.818 0.566 131,610 20,679 36,518 0.021 0.339
Golimumab 7.818 0.566 133,289 22,359 39,483 0.009 0.249
Adalimumab 7.818 0.566 133,374 22,444 39,634 0.008 0.245
Etanercept 7.818 0.566 133,755 22,824 40,306 0.006 0.230
Certolizumab
pegol
7.818 0.566 135,183 24,253 42,828 0.003 0.166
Infliximab 7.818 0.566 151,457 40,526 71,565 0.000 0.000
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 184 Ankylosing spondylitis: scenario 4 (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.268 – 108,817 – – – –
Certolizumab
pegol PAS
7.894 0.626 128,999 20,182 32,222 0.047 0.429
Golimumab 7.894 0.626 130,683 21,866 34,910 0.022 0.341
Adalimumab 7.894 0.626 130,767 21,951 35,045 0.020 0.339
Etanercept 7.894 0.626 131,144 22,327 35,647 0.016 0.310
Certolizumab
pegol
7.894 0.626 132,573 23,756 37,928 0.008 0.234
Infliximab 7.894 0.626 148,706 39,889 63,684 0.000 0.000
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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TABLE 185 Ankylosing spondylitis: scenario 5 (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
10.272 – 112,648 – – – –
Certolizumab
pegol PAS
10.967 0.695 133,103 20,455 29,414 0.012 0.511
Golimumab 10.967 0.695 134,781 22,133 31,827 0.005 0.340
Adalimumab 10.967 0.695 134,866 22,218 31,950 0.005 0.333
Etanercept 10.967 0.695 135,248 22,600 32,499 0.004 0.300
Certolizumab
pegol
10.967 0.695 136,677 24,028 34,554 0.002 0.165
Infliximab 10.967 0.695 152,997 40,349 58,022 0.000 0.000
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 186 Ankylosing spondylitis: scenario 6 (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.251 – 111,666 – – – –
Certolizumab
pegol PAS
7.898 0.647 134,955 23,289 35,982 0.013 0.333
Golimumab 7.898 0.647 136,585 24,919 38,500 0.009 0.245
Adalimumab 7.898 0.647 136,679 25,013 38,646 0.008 0.239
Etanercept 7.898 0.647 137,100 25,434 39,296 0.006 0.222
Certolizumab
pegol
7.898 0.647 138,528 26,862 41,503 0.004 0.172
Infliximab 7.898 0.647 156,420 44,754 69,146 0.000 0.000
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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TABLE 187 Ankylosing spondylitis: scenario 7 (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.250 – 111,647 – – – –
Certolizumab
pegol PAS
7.854 0.604 131,922 20,275 33,578 0.040 0.397
Golimumab 7.854 0.604 133,605 21,958 36,366 0.016 0.307
Adalimumab 7.854 0.604 133,690 22,043 36,506 0.016 0.305
Etanercept 7.854 0.604 134,067 22,420 37,131 0.012 0.287
Certolizumab
pegol
7.854 0.604 135,496 23,849 39,497 0.007 0.215
Remsima 7.854 0.604 148,010 36,363 60,222 0.000 0.003
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
Non-radiographic axial spondyloarthritis population
TABLE 188 Summary of cost-effectiveness scenarios: nr-AxSpA population
Strategy
number Parameter/structural Approach in scenario Approach in base case
1 CC (‘placebo’) response No response to CC assumed at
12 weeks
Response to CC included at
12 weeks
2 Different baselines assumed for
responders and non-responders
and change in BASDAI/BASFI
scores
Separate baselines based on pooled
estimates provided by manufacturers.
Changes in BASDAI/BASFI score
conditioned on response also based
on pooled estimates provided by
manufacturers
Separate baselines and changes
in BASDAI/BASFI conditioned on
responses estimated via
extended synthesis model
3 BASFI progression No effect of anti-TNFs on BASFI
progression
Treatment effect applied from
year 4 onwards
4 BASFI progression Treatment effect of anti-TNFs applied
from start of model
Treatment effect applied from
year 4 onwards
5 Utilities Linear BASDAI/BASFI model (based on
Kobelt et al.152)
Non-linear BASDAI/BASFI model
(Pfizer submission36)
6 Treatment effect of anti-TNFs Trials in nr-AxSpA and AS populations
combined
Only trials in nr-AxSpA included
7 Baseline BASDAI score
truncated at 4
Baseline BASDAI scores used in the
NMA are limited to be between 4
and 10
Baseline BASDAI scores used in
the NMA are limited to be
between 0 and 10
NMA, network meta-analysis.
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Non-radiographic axial spondyloarthritis scenario results: rebound equal
to gain
TABLE 189 Non-radiographic axial spondyloarthritis: scenario 1 (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
10.012 – 87,215 – – – –
Certolizumab
pegol PAS
11.864 1.852 122,480 35,265 19,040 0.550 0.861
Adalimumab 11.864 1.852 123,883 36,668 19,797 0.500 0.844
Etanercept 11.864 1.852 124,625 37,410 20,198 0.481 0.838
Certolizumab
pegol
11.864 1.852 126,052 38,837 20,968 0.421 0.815
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 190 Non-radiographic axial spondyloarthritis: scenario 2 (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.988 – 87,947 – – – –
Certolizumab
pegol PAS
11.666 1.678 124,455 36,508 21,757 0.377 0.764
Adalimumab 11.666 1.678 125,858 37,910 22,593 0.337 0.739
Etanercept 11.666 1.678 126,600 38,653 23,036 0.317 0.722
Certolizumab
pegol
11.666 1.678 128,027 40,080 23,886 0.276 0.683
CE, cost-effectiveness.
Probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, when compared with CC, is a cost-effective
option at the stated threshold.
TABLE 191 Non-radiographic axial spondyloarthritis: scenario 3 (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.891 – 91,479 – – – –
Certolizumab
pegol PAS
11.262 1.370 130,734 39,254 28,643 0.138 0.576
Adalimumab 11.262 1.370 132,141 40,662 29,670 0.102 0.528
Etanercept 11.262 1.370 132,879 41,399 30,208 0.093 0.505
Certolizumab
pegol
11.262 1.370 134,306 42,827 31,250 0.076 0.460
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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TABLE 192 Non-radiographic axial spondyloarthritis: scenario 4 (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.923 – 90,625 – – – –
Certolizumab
pegol PAS
11.338 1.415 129,492 38,867 27,471 0.154 0.627
Adalimumab 11.338 1.415 130,899 40,274 28,466 0.127 0.574
Etanercept 11.338 1.415 131,637 41,012 28,988 0.116 0.549
Certolizumab
pegol
11.338 1.415 133,064 42,440 29,996 0.087 0.501
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 193 Non-radiographic axial spondyloarthritis: scenario 5 (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
10.973 – 89,400 – – – –
Certolizumab
pegol PAS
12.527 1.554 128,760 39,361 25,324 0.120 0.781
Adalimumab 12.527 1.554 130,165 40,765 26,227 0.086 0.725
Etanercept 12.527 1.554 130,905 41,506 26,704 0.071 0.692
Certolizumab
pegol
12.527 1.554 132,333 42,933 27,622 0.053 0.629
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 194 Non-radiographic axial spondyloarthritis: scenario 6 (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.944 – 88,563 – – – –
Certolizumab
pegol PAS
11.382 1.437 129,592 41,030 28,282 0.068 0.612
Adalimumab 11.382 1.437 130,978 42,415 29,228 0.040 0.570
Etanercept 11.382 1.437 131,737 43,175 29,753 0.032 0.546
Certolizumab
pegol
11.382 1.437 133,165 44,602 30,732 0.020 0.483
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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TABLE 195 Non-radiographic axial spondyloarthritis: scenario 7 (rebound equal to gain)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£)
ICER
(£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.906 – 90,850 – – – –
Certolizumab pegol
PAS
11.291 1.386 130,974 40,124 28,958 0.102 0.576
Adalimumab 11.291 1.386 132,373 41,523 29,968 0.069 0.506
Etanercept 11.291 1.386 133,119 42,269 30,506 0.059 0.484
Certolizumab pegol 11.291 1.386 134,547 43,696 31,536 0.045 0.454
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
Non-radiographic axial spondyloarthritis scenario results: rebound to
conventional care
TABLE 196 Non-radiographic axial spondyloarthritis: scenario 1 (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£)
ICER
(£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.998 – 88,600 – – – –
Certolizumab pegol
PAS
11.646 1.648 124,101 35,501 21,537 0.386 0.787
Adalimumab 11.646 1.648 125,519 36,919 22,397 0.342 0.746
Etanercept 11.646 1.648 126,246 37,646 22,839 0.318 0.733
Certolizumab pegol 11.646 1.648 127,674 39,074 23,705 0.267 0.712
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 197 Non-radiographic axial spondyloarthritis: scenario 2 (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£)
ICER
(£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.989 – 87,391 – – – –
Certolizumab pegol
PAS
11.460 1.472 124,660 37,268 25,326 0.230 0.618
Adalimumab 11.460 1.472 126,073 38,682 26,287 0.193 0.590
Etanercept 11.460 1.472 126,805 39,414 26,784 0.182 0.573
Certolizumab pegol 11.460 1.472 128,232 40,841 27,754 0.163 0.542
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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TABLE 198 Non-radiographic axial spondyloarthritis: scenario 3 (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.891 – 91,602 – – – –
Certolizumab
pegol PAS
11.066 1.175 132,047 40,445 34,416 0.052 0.396
Adalimumab 11.066 1.175 133,456 41,854 35,615 0.036 0.348
Etanercept 11.066 1.175 134,192 42,590 36,241 0.031 0.330
Certolizumab
pegol
11.066 1.175 135,620 44,017 37,456 0.026 0.290
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 199 Non-radiographic axial spondyloarthritis: scenario 4 (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.948 – 90,402 – – – –
Certolizumab
pegol PAS
11.223 1.275 131,015 40,613 31,841 0.063 0.456
Adalimumab 11.223 1.275 132,416 42,014 32,940 0.047 0.415
Etanercept 11.223 1.275 133,160 42,758 33,523 0.040 0.395
Certolizumab
pegol
11.223 1.275 134,587 44,185 34,642 0.027 0.337
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 200 Non-radiographic axial spondyloarthritis: scenario 5 (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
10.975 – 90,413 – – – –
Certolizumab
pegol PAS
12.462 1.487 130,404 39,991 26,900 0.069 0.678
Adalimumab 12.462 1.487 131,817 41,404 27,850 0.050 0.599
Etanercept 12.462 1.487 132,549 42,136 28,343 0.042 0.572
Certolizumab
pegol
12.462 1.487 133,976 43,563 29,303 0.028 0.498
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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TABLE 201 Non-radiographic axial spondyloarthritis: scenario 6 (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.953 – 89,196 – – – –
Certolizumab
pegol PAS
11.228 1.275 131,515 42,319 33,184 0.013 0.398
Adalimumab 11.228 1.275 132,901 43,704 34,270 0.007 0.353
Etanercept 11.228 1.275 133,661 44,464 34,866 0.002 0.332
Certolizumab
pegol
11.228 1.275 135,088 45,891 35,985 0.001 0.284
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 202 Non-radiographic axial spondyloarthritis: scenario 7 (rebound to CC)
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.963 – 90,219 – – – –
Certolizumab
pegol PAS
11.200 1.237 131,714 41,495 33,555 0.057 0.396
Adalimumab 11.200 1.237 133,109 42,890 34,684 0.038 0.343
Etanercept 11.200 1.237 133,859 43,640 35,290 0.035 0.318
Certolizumab
pegol
11.200 1.237 135,286 45,067 36,444 0.029 0.284
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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Additional validation scenarios assuming same baselines for
responders and non-responders
TABLE 203 Ankylosing spondylitis: rebound equal to gain
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.262 – 111,636 – – – –
Certolizumab
pegol PAS
8.317 1.054 126,238 14,601 13,851 0.803 0.975
Golimumab 8.317 1.054 127,917 16,281 15,444 0.732 0.958
Adalimumab 8.317 1.054 128,002 16,366 15,525 0.730 0.958
Etanercept 8.317 1.054 128,383 16,746 15,886 0.708 0.952
Certolizumab
pegol
8.317 1.054 129,811 18,175 17,241 0.645 0.931
Infliximab 8.317 1.054 146,079 34,443 32,673 0.044 0.376
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 204 Ankylosing spondylitis: rebound to CC
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
7.274 – 109,511 – – – –
Certolizumab
pegol PAS
7.958 0.684 127,164 17,654 25,809 0.277 0.632
Golimumab 7.958 0.684 128,850 19,339 28,273 0.183 0.554
Adalimumab 7.958 0.684 128,934 19,423 28,396 0.178 0.550
Etanercept 7.958 0.684 129,309 19,799 28,945 0.165 0.534
Certolizumab
pegol
7.958 0.684 130,738 21,227 31,034 0.107 0.473
Infliximab 7.958 0.684 146,808 37,298 54,528 0.000 0.010
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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TABLE 205 Non-radiographic axial spondyloarthritis: rebound equal to gain
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
9.977 – 88,692 – – – –
Certolizumab
pegol PAS
11.551 1.574 125,205 36,513 23,199 0.390 0.759
Adalimumab 11.551 1.574 126,606 37,914 24,089 0.341 0.733
Etanercept 11.551 1.574 127,350 38,658 24,562 0.319 0.720
Certolizumab
pegol
11.551 1.574 128,777 40,085 25,469 0.272 0.702
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
TABLE 206 Non-radiographic axial spondyloarthritis: rebound to CC
Strategy
Total
QALYs
Incremental
QALYs
Total
costs (£)
Incremental
costs (£) ICER (£)
Probability of
CE £20,000
Probability of
CE £30,000
Conventional
therapy
10.030 – 88,389 – – – –
Certolizumab
pegol PAS
11.391 1.361 126,116 37,727 27,721 0.218 0.617
Adalimumab 11.391 1.361 127,525 39,136 28,756 0.176 0.586
Etanercept 11.391 1.361 128,261 39,872 29,297 0.160 0.574
Certolizumab
pegol
11.391 1.361 129,689 41,299 30,345 0.133 0.537
CE, cost-effectiveness.
The probability of CE £20,000/30,000 is the probability that the TNF-α inhibitor, compared with CC, is a cost-effective
option at the stated threshold.
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